data_1w3d_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1w3d _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.825 0.345 . . . . 0.0 111.173 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 33.7 mtp -103.12 157.95 32.74 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.807 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 10.5 Cg_endo -53.6 -27.42 41.38 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.642 2.228 . . . . 0.0 112.192 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.6 t -80.06 -47.22 15.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.71 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 94.9 t -58.31 -31.31 42.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.822 179.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 6.6 mmm-85 -65.42 -52.74 51.22 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 11.0 tppt? -52.88 -39.5 62.71 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.532 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -54.33 -62.8 1.42 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.027 -0.988 . . . . 0.0 110.796 179.133 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -60.18 -24.67 64.97 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.601 -179.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 3.3 mmt85 -82.16 -27.6 32.59 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.69 0.281 . . . . 0.0 111.122 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -85.68 -29.39 24.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.973 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 3.7 mptp? -94.96 -24.45 16.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.172 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 98.66 14.27 38.07 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.613 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.418 HG11 ' CE1' ' A' ' 166' ' ' PHE . 34.4 t -94.19 160.13 2.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.713 0.292 . . . . 0.0 110.81 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.557 ' HB3' HD23 ' A' ' 148' ' ' LEU . 63.8 t0 -114.9 104.99 12.47 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.789 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.431 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 4.4 pt -45.5 -36.33 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.26 0.552 . . . . 0.0 111.818 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 6.8 mtt180 -48.29 -25.6 1.63 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.316 -0.856 . . . . 0.0 112.641 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . 0.574 ' N ' ' CD1' ' A' ' 148' ' ' LEU . 0.0 OUTLIER -125.49 30.02 5.87 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.662 0.268 . . . . 0.0 111.715 -179.433 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.431 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 58.1 t -94.63 155.65 3.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.862 0.363 . . . . 0.0 110.683 179.406 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -74.96 79.51 2.17 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.925 -179.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -73.32 110.52 3.16 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.433 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.328 -0.34 0 CA-C-O 120.585 0.231 . . . . 0.0 111.215 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.738 0.304 . . . . 0.0 110.931 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 5.1 mt -109.45 178.51 4.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.019 0.438 . . . . 0.0 111.311 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . 0.437 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 7.9 tttt -50.04 -47.69 53.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.688 179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -59.99 -33.63 72.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.752 179.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -67.66 -36.65 81.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.396 179.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' ILE . . . . . 0.532 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 3.5 mm -65.18 -50.09 75.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.174 179.114 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -58.62 -38.91 79.06 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.539 179.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.8 -42.08 97.77 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.787 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' PHE . . . . . 0.44 ' CZ ' HD22 ' A' ' 148' ' ' LEU . 45.8 t80 -59.67 -51.26 70.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.608 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 33.7 mt . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.959 179.91 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.863 0.363 . . . . 0.0 111.168 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 14.7 mtp -104.25 166.29 11.87 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.842 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -63.19 -27.59 72.75 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.556 2.171 . . . . 0.0 112.15 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 24.8 m -79.93 -44.92 19.46 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.772 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 59.5 t -59.46 -33.55 51.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.862 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.432 ' CD ' ' CD1' ' A' ' 146' ' ' ILE . 9.1 mmm-85 -63.89 -51.26 65.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.948 0.404 . . . . 0.0 109.921 179.312 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.68 -41.89 67.35 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 178.517 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.55 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -51.51 -61.99 1.9 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.755 179.066 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -62.76 -20.46 64.98 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.502 -179.751 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 -83.41 -27.88 29.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.526 -0.307 . . . . 0.0 110.968 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -85.63 -29.36 24.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.86 0.362 . . . . 0.0 110.856 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 4.9 tptt -95.26 -25.43 16.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.081 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 97.43 16.98 32.75 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.52 -179.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.415 HG11 ' CE1' ' A' ' 166' ' ' PHE . 43.9 t -91.1 158.85 2.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.805 0.336 . . . . 0.0 110.877 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 62.3 t0 -109.99 102.16 10.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.751 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.451 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 9.7 pt -48.61 -39.79 10.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.263 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 6.0 mtm-85 -48.97 -25.07 1.75 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.749 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . 0.45 ' CD1' ' CE2' ' A' ' 166' ' ' PHE . 0.5 OUTLIER -120.78 27.44 8.51 Favored 'General case' 0 N--CA 1.463 0.186 0 N-CA-C 111.647 0.24 . . . . 0.0 111.647 -179.78 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.451 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 51.2 t -96.01 152.23 3.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.979 0.419 . . . . 0.0 110.906 179.593 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -74.96 79.36 2.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.973 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -75.99 116.48 4.82 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.507 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.286 0 CA-C-O 120.803 0.335 . . . . 0.0 110.96 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 24.9 t . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.821 0.343 . . . . 0.0 110.952 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 3.2 mt -117.12 174.79 5.92 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.152 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . 0.429 ' HG2' ' CE2' ' A' ' 138' ' ' TYR . 0.0 OUTLIER -48.38 -48.97 36.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.875 179.946 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -58.03 -35.63 71.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.866 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -65.7 -38.8 90.23 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.35 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' ILE . . . . . 0.55 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 4.0 mm -62.64 -48.73 86.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.095 179.114 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -58.23 -39.93 80.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.63 179.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.5 -39.3 91.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.812 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' PHE . . . . . 0.45 ' CE2' ' CD1' ' A' ' 148' ' ' LEU . 21.9 t80 -64.15 -38.45 91.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.662 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 19.5 mt . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.144 179.98 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.107 0 CA-C-O 120.842 0.353 . . . . 0.0 111.217 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -88.93 166.32 22.74 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.849 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -61.44 -42.09 36.37 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.539 2.159 . . . . 0.0 112.227 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.03 -46.29 85.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.865 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.405 ' O ' ' HB3' ' A' ' 138' ' ' TYR . 57.9 t -58.48 -35.08 52.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.913 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 1.6 mmm180 -63.18 -48.07 79.92 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.03 -38.36 70.43 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 178.323 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.534 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -55.43 -63.06 1.28 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.879 179.127 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -62.79 -20.99 65.55 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.387 -179.529 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 12.9 tpt180 -83.54 -27.15 29.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.956 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -85.63 -28.86 24.5 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.888 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.83 -26.21 15.73 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.109 -179.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 100.02 15.59 30.47 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.588 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 49.0 t -93.71 159.28 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.881 0.372 . . . . 0.0 110.758 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.433 ' O ' ' HG ' ' A' ' 148' ' ' LEU . 41.6 t0 -110.91 107.71 17.25 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.747 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.435 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 6.7 pt -51.19 -39.63 20.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.104 0.478 . . . . 0.0 111.437 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 20.8 mtt180 -48.81 -26.19 2.26 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.832 -179.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . 0.433 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.0 OUTLIER -118.64 26.92 9.23 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 111.71 0.263 . . . . 0.0 111.71 -179.889 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.435 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 56.1 t -96.2 156.65 3.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.873 0.368 . . . . 0.0 110.702 179.468 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . 0.42 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.97 73.38 2.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.888 -179.738 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -69.13 133.67 26.57 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.477 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.273 0 CA-C-O 120.851 0.358 . . . . 0.0 110.812 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 22.8 t . . . . . 0 N--CA 1.458 -0.069 0 CA-C-O 120.883 0.373 . . . . 0.0 111.052 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.409 ' O ' ' HB2' ' A' ' 162' ' ' ASP . 16.3 mt -106.59 176.36 5.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.017 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . 0.428 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 0.1 OUTLIER -50.19 -45.71 53.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.645 179.784 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 50.5 mm-40 -61.35 -34.52 75.43 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.627 179.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . 0.409 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 60.8 m-20 -65.41 -39.55 92.28 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.249 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' ILE . . . . . 0.534 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 3.3 mm -64.47 -45.13 96.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.027 179.037 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -60.61 -35.71 76.8 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.284 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -67.83 -39.01 83.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.469 179.541 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' PHE . . . . . . . . . . . . . 20.2 t80 -68.53 -31.3 70.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.605 179.642 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 2.6 mt . . . . . 0 C--N 1.33 -0.266 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.978 179.968 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.78 0.324 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 64.2 mtp -80.07 157.34 73.68 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.946 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_exo -51.66 -42.58 55.8 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.576 2.184 . . . . 0.0 112.302 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.4 p -61.13 -42.64 98.91 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.956 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 59.2 t -59.46 -34.33 54.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.807 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.414 ' HD3' ' CD1' ' A' ' 146' ' ' ILE . 0.0 OUTLIER -66.8 -53.63 30.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.895 0.379 . . . . 0.0 110.034 179.329 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.4 tttt -55.38 -32.08 62.32 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 178.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.56 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -61.93 -61.97 2.12 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.344 179.149 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -61.46 -24.41 66.54 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.527 -179.645 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 9.5 mtp-105 -83.65 -29.05 27.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.795 0.331 . . . . 0.0 110.894 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -84.04 -26.94 28.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.112 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 5.4 mptt -97.45 -27.57 14.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.169 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.85 14.0 28.1 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.624 -179.783 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.431 HG11 ' CE1' ' A' ' 166' ' ' PHE . 47.3 t -95.46 160.8 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.862 0.363 . . . . 0.0 110.75 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -113.46 107.07 15.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.615 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.455 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 12.7 pt -50.03 -39.98 16.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.355 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 11.9 mtm105 -49.28 -24.06 1.66 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.854 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . 0.463 ' CD1' ' CE2' ' A' ' 166' ' ' PHE . 0.5 OUTLIER -120.45 27.15 8.74 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 120.65 0.262 . . . . 0.0 111.569 -179.83 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.455 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 55.6 t -96.4 158.19 3.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.957 0.408 . . . . 0.0 110.888 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . 0.425 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.4 OUTLIER -74.77 79.6 2.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.157 -179.653 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -69.63 96.61 0.51 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.315 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 70.2 p . . . . . 0 N--CA 1.452 -0.348 0 CA-C-O 120.785 0.326 . . . . 0.0 111.209 -179.724 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.788 0.327 . . . . 0.0 111.012 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.411 ' O ' ' HB2' ' A' ' 162' ' ' ASP . 1.3 mt -114.05 176.87 4.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.021 -179.811 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . 0.436 ' HG2' ' CE2' ' A' ' 138' ' ' TYR . 0.0 OUTLIER -49.37 -49.28 45.18 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.752 179.889 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -57.58 -34.48 69.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.796 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . 0.411 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 83.7 m-20 -67.54 -37.39 82.65 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.372 179.663 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' ILE . . . . . 0.56 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 4.0 mm -63.24 -47.99 89.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.168 179.23 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -59.33 -43.5 92.73 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.588 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -60.27 -40.4 90.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.814 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' PHE . . . . . 0.463 ' CE2' ' CD1' ' A' ' 148' ' ' LEU . 18.8 t80 -61.35 -50.07 74.38 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.631 179.727 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 37.6 mt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.843 179.979 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.839 0.352 . . . . 0.0 111.14 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 1.1 mtp -68.75 160.65 76.32 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.785 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -62.03 -18.18 60.2 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.602 2.201 . . . . 0.0 112.377 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 29.1 t -88.64 -41.37 12.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.994 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.438 ' O ' ' HB3' ' A' ' 138' ' ' TYR . 90.9 t -60.02 -40.19 82.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.099 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.418 ' HD2' ' CD1' ' A' ' 146' ' ' ILE . 4.3 mtm180 -63.11 -43.08 99.45 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 6.7 tttt -62.37 -34.34 76.49 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 178.376 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.544 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.9 OUTLIER -57.5 -60.95 2.89 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.304 179.005 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -60.73 -30.27 69.88 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.416 -179.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.53 -19.78 45.0 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.38 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -93.14 -22.43 19.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.674 0.273 . . . . 0.0 111.14 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -102.33 -21.38 14.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.343 -179.812 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.29 5.62 39.98 Favored Glycine 0 CA--C 1.519 0.314 0 C-N-CA 120.49 -0.862 . . . . 0.0 112.818 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.435 HG11 ' CE1' ' A' ' 166' ' ' PHE . 53.0 t -92.48 159.43 2.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.756 0.313 . . . . 0.0 110.695 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.417 ' HB3' ' CG ' ' A' ' 148' ' ' LEU . 62.6 t0 -109.1 108.34 18.98 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.798 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.476 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 0.2 OUTLIER -50.59 -41.52 20.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.519 179.927 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -49.9 -23.11 1.76 Allowed 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.907 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . 0.47 ' CD1' ' CE2' ' A' ' 166' ' ' PHE . 0.6 OUTLIER -120.27 25.69 9.68 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 111.819 0.303 . . . . 0.0 111.819 -179.605 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.476 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 63.2 t -92.64 151.96 3.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.929 0.395 . . . . 0.0 110.87 179.457 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -74.94 79.55 2.16 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.159 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.01 123.75 10.89 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.343 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.329 -0.318 0 CA-C-O 120.757 0.313 . . . . 0.0 111.177 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 14.9 t . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.83 0.348 . . . . 0.0 111.066 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.3 mp -118.61 173.08 7.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.09 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 11.1 tttt -50.37 -45.21 55.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.677 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -59.72 -35.54 74.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.561 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -66.67 -36.84 83.48 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.238 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' ILE . . . . . 0.544 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 8.6 mm -63.94 -48.78 84.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.181 179.216 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -58.71 -41.86 87.33 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.594 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.97 -42.03 98.67 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.674 179.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' PHE . . . . . 0.47 ' CE2' ' CD1' ' A' ' 148' ' ' LEU . 13.6 t80 -59.46 -47.34 85.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.489 179.691 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 19.9 mt . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.819 179.87 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.196 0 CA-C-O 120.779 0.323 . . . . 0.0 111.105 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -129.65 161.38 59.55 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.846 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -61.99 -24.69 77.06 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.613 2.208 . . . . 0.0 112.225 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.3 m -92.36 -42.02 10.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.854 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.423 ' O ' ' HB3' ' A' ' 138' ' ' TYR . 59.2 t -62.03 -37.31 78.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.943 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.412 ' CD ' HD11 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -63.94 -47.54 80.09 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.303 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.22 -40.86 78.36 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 178.36 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.526 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.9 OUTLIER -51.86 -61.1 2.47 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.491 178.973 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -59.89 -28.11 67.29 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.575 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 11.0 tpt180 -79.95 -24.45 40.98 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.623 0.249 . . . . 0.0 111.373 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 16.8 mm-40 -89.25 -26.34 21.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.047 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 13.9 mptt -96.55 -22.28 17.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.251 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 101.27 8.61 46.7 Favored Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.667 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.428 HG12 ' CD1' ' A' ' 166' ' ' PHE . 45.1 t -92.73 159.26 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.775 0.321 . . . . 0.0 110.86 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.51 ' HB3' HD23 ' A' ' 148' ' ' LEU . 66.5 t0 -112.67 111.39 22.16 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.807 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.447 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 0.0 OUTLIER -49.53 -37.25 11.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.145 0.498 . . . . 0.0 111.726 -179.884 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 4.0 mtm-85 -48.59 -24.02 1.19 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.463 -0.79 . . . . 0.0 112.697 -179.231 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . 0.598 ' N ' ' CD1' ' A' ' 148' ' ' LEU . 0.0 OUTLIER -127.92 31.75 5.05 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 111.893 0.331 . . . . 0.0 111.893 -179.25 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.447 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 76.5 t -94.75 157.08 3.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.841 0.353 . . . . 0.0 110.594 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -74.89 72.17 2.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.854 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.95 117.58 6.52 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.385 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.274 0 CA-C-O 120.876 0.37 . . . . 0.0 110.798 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 23.6 t . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.749 0.309 . . . . 0.0 111.059 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -112.19 173.56 6.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.048 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 2.0 tttt -49.15 -46.22 44.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.797 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 49.1 mm-40 -60.61 -35.62 76.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.659 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -65.52 -37.35 86.51 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.471 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' ILE . . . . . 0.526 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 4.0 mm -65.07 -49.48 79.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.207 179.193 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -58.55 -36.88 74.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.638 179.635 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -66.24 -41.98 89.26 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.918 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' PHE . . . . . 0.436 ' CZ ' HD22 ' A' ' 148' ' ' LEU . 37.0 t80 -60.21 -50.84 72.06 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.637 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' LEU . . . . . 0.409 ' CD2' ' CG2' ' A' ' 144' ' ' VAL . 49.7 mt . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.922 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.879 0.371 . . . . 0.0 111.088 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 1.4 mtp -95.33 157.36 36.45 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.9 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.79 -38.36 85.25 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.527 2.151 . . . . 0.0 112.393 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.2 t -80.06 -38.37 31.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.025 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 65.4 t -61.51 -36.49 73.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.051 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.42 ' CD ' ' CD1' ' A' ' 146' ' ' ILE . 1.4 mmt180 -68.05 -47.26 68.84 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.508 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.14 -36.94 78.63 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.462 ' CE2' ' CG2' ' A' ' 163' ' ' ILE . 1.2 t80 -55.95 -58.87 6.08 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.461 179.047 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -61.03 -28.73 69.26 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.21 -0.905 . . . . 0.0 111.262 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.55 -29.63 46.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.849 0.357 . . . . 0.0 111.161 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 64.7 mm-40 -85.59 -23.65 27.5 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.163 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -95.89 -24.35 16.47 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.398 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.36 4.17 40.81 Favored Glycine 0 CA--C 1.518 0.268 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.684 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.444 HG11 ' CE1' ' A' ' 166' ' ' PHE . 59.2 t -87.59 157.77 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 0.0 110.826 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.435 ' O ' ' HG ' ' A' ' 148' ' ' LEU . 62.3 t0 -106.79 105.48 15.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.73 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.459 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 4.3 pt -49.8 -42.16 17.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.49 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 80.3 mtp180 -48.65 -27.92 3.17 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.126 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . 0.435 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.0 OUTLIER -116.8 24.19 11.42 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 111.979 0.363 . . . . 0.0 111.979 -179.515 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.459 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 43.8 t -88.72 150.47 3.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.762 0.315 . . . . 0.0 110.588 179.37 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.97 78.78 2.17 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.994 -179.684 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -82.14 118.69 4.68 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.378 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 8.8 t . . . . . 0 C--N 1.329 -0.299 0 CA-C-O 120.823 0.344 . . . . 0.0 111.002 -179.956 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 26.5 t . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.799 0.333 . . . . 0.0 111.112 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 3.2 mt -95.83 172.78 7.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.955 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.7 tttt -49.72 -42.58 46.3 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.783 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 51.7 mm-40 -56.06 -40.56 73.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.48 179.566 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -64.76 -43.49 93.12 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.215 179.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' ILE . . . . . 0.462 ' CG2' ' CE2' ' A' ' 138' ' ' TYR . 10.7 mm -61.73 -38.78 81.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.167 179.152 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -62.37 -45.2 94.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.246 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -59.04 -42.9 91.35 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.418 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' PHE . . . . . 0.444 ' CE1' HG11 ' A' ' 144' ' ' VAL . 7.8 t80 -61.67 -48.99 78.31 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.297 179.308 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' LEU . . . . . 0.435 ' CD2' ' CG2' ' A' ' 144' ' ' VAL . 40.1 mt . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.859 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . 0.467 ' CB ' ' NE ' ' A' ' 136' ' ' ARG . . . . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.807 0.337 . . . . 0.0 110.987 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 26.8 mtp -99.6 165.21 15.12 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.951 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -58.67 -45.51 29.14 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.575 2.183 . . . . 0.0 112.183 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 66.7 m -69.85 -37.5 76.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.656 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.424 ' O ' ' HB3' ' A' ' 138' ' ' TYR . 64.8 t -64.05 -37.73 80.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.919 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.467 ' NE ' ' CB ' ' A' ' 131' ' ' ALA . 0.0 OUTLIER -64.21 -49.04 73.55 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.306 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 6.2 tttt -58.88 -32.9 69.91 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.544 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -58.42 -60.61 3.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.446 179.197 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -60.62 -29.52 69.29 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.665 -179.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 63.5 mtt180 -79.79 -27.39 40.39 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.271 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -86.6 -28.48 23.25 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.954 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -93.51 -23.58 18.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.097 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 99.53 10.78 46.49 Favored Glycine 0 CA--C 1.52 0.351 0 C-N-CA 120.596 -0.812 . . . . 0.0 112.56 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.429 HG11 ' CE1' ' A' ' 166' ' ' PHE . 48.5 t -89.95 158.67 2.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.757 0.313 . . . . 0.0 110.715 179.723 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.425 ' HB3' ' CG ' ' A' ' 148' ' ' LEU . 62.8 t0 -104.28 104.05 13.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.035 0.445 . . . . 0.0 110.966 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.461 HD11 ' HG3' ' A' ' 136' ' ' ARG . 3.9 pt -47.36 -44.57 9.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.716 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 7.2 mmt180 -50.0 -23.39 2.01 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.786 -0.643 . . . . 0.0 112.195 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . 0.461 ' CD1' ' CE2' ' A' ' 166' ' ' PHE . 0.7 OUTLIER -120.99 22.95 10.88 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -179.608 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.454 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 74.4 t -87.68 148.95 4.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.737 0.303 . . . . 0.0 110.497 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.91 79.32 2.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.904 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -85.68 115.33 4.15 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.41 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 3.7 t . . . . . 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.368 . . . . 0.0 111.041 -179.851 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 27.7 t . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.778 0.323 . . . . 0.0 110.945 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 5.6 mt -114.24 174.11 6.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.155 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.1 tttm -50.62 -44.39 57.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.734 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -60.43 -35.4 75.71 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.653 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 36.9 m-20 -66.33 -38.82 88.55 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.273 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' ILE . . . . . 0.544 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 5.0 mm -62.01 -50.16 81.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.256 179.054 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.6 -41.25 80.85 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.55 179.638 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.07 -41.25 96.29 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.67 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' PHE . . . . . 0.461 ' CE2' ' CD1' ' A' ' 148' ' ' LEU . 21.5 t80 -60.89 -48.07 83.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.477 179.618 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 41.8 mt . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.839 179.761 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.827 0.346 . . . . 0.0 111.173 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 10.6 mtp -120.94 161.86 38.12 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.888 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.2 -56.84 2.52 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.509 2.139 . . . . 0.0 112.413 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -59.49 -40.64 87.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.871 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 96.3 t -60.36 -34.42 57.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.917 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -65.85 -52.35 51.09 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.474 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -56.39 -32.79 65.13 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.577 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.53 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -59.02 -61.56 2.55 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.358 179.14 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -63.15 -23.08 67.27 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.364 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -82.74 -26.43 31.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.088 179.829 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -86.66 -26.72 24.18 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.05 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 2.9 mptt -98.05 -24.9 15.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.247 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 100.84 13.27 34.84 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.612 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.419 HG11 ' CE1' ' A' ' 166' ' ' PHE . 38.9 t -93.97 161.02 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.718 0.294 . . . . 0.0 110.774 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.516 ' HB3' HD23 ' A' ' 148' ' ' LEU . 47.9 t0 -116.06 104.62 11.75 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.89 0.376 . . . . 0.0 110.795 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.438 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 6.1 pt -44.55 -36.26 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.222 0.534 . . . . 0.0 111.805 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -47.64 -26.16 1.41 Allowed 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.251 -0.886 . . . . 0.0 112.644 -179.159 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . 0.577 ' N ' ' CD1' ' A' ' 148' ' ' LEU . 0.0 OUTLIER -125.21 29.87 5.98 Favored 'General case' 0 C--N 1.332 -0.161 0 C-N-CA 121.007 -0.277 . . . . 0.0 111.612 -179.36 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.438 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 54.5 t -94.26 157.73 2.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.839 0.352 . . . . 0.0 110.593 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . 0.412 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.91 75.1 2.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.906 -179.69 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -74.56 122.09 7.07 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.369 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.306 0 CA-C-O 120.928 0.394 . . . . 0.0 110.861 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 28.3 t . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.815 0.34 . . . . 0.0 110.998 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 5.0 mt -110.89 175.93 5.23 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.07 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 6.9 tttt -49.07 -45.75 43.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.816 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 -60.68 -36.12 77.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.696 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 73.3 m-20 -65.54 -36.3 83.39 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.298 179.663 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' ILE . . . . . 0.53 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 4.5 mm -64.79 -51.32 68.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.302 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.49 -38.03 73.91 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.638 179.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -64.83 -41.95 95.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.81 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' PHE . . . . . 0.432 ' CZ ' HD22 ' A' ' 148' ' ' LEU . 50.0 t80 -60.08 -48.88 79.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.622 179.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 39.6 mt . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.928 179.982 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.841 0.353 . . . . 0.0 111.335 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.88 157.2 41.25 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.766 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.91 -33.14 50.39 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.632 2.221 . . . . 0.0 112.099 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 9.4 p -76.99 -43.31 35.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.619 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.414 ' O ' ' HB3' ' A' ' 138' ' ' TYR . 73.0 t -58.5 -34.97 52.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.856 179.813 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -64.71 -49.78 69.54 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 179.206 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -57.58 -31.09 65.81 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 178.556 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.544 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -61.25 -62.36 1.89 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.369 179.032 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -59.92 -29.2 68.21 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.413 -179.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? -80.11 -26.29 39.58 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.212 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -86.59 -29.48 22.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.995 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 4.9 mptt -95.07 -22.19 18.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.256 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 97.16 12.82 47.83 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.609 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.422 HG11 ' CE1' ' A' ' 166' ' ' PHE . 54.0 t -94.3 159.32 2.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.706 0.288 . . . . 0.0 110.783 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.409 ' O ' ' HG ' ' A' ' 148' ' ' LEU . 67.0 t0 -110.06 111.48 22.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.868 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.425 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 7.9 pt -53.36 -39.95 37.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.402 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 1.2 mmm180 -49.23 -25.26 2.18 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.792 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . 0.42 HD13 ' CE2' ' A' ' 166' ' ' PHE . 0.3 OUTLIER -119.67 27.17 8.89 Favored 'General case' 0 C--N 1.332 -0.186 0 N-CA-C 111.659 0.244 . . . . 0.0 111.659 -179.827 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.425 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 40.5 t -95.04 150.3 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.867 0.365 . . . . 0.0 110.587 179.364 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -74.86 77.49 2.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.922 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -73.03 125.04 9.43 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.471 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 6.3 t . . . . . 0 C--N 1.328 -0.336 0 CA-C-O 120.766 0.317 . . . . 0.0 110.905 -179.997 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.691 0.282 . . . . 0.0 110.759 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -107.06 178.54 4.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.097 0.475 . . . . 0.0 111.371 -179.648 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . 0.442 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 2.8 tptt -50.59 -43.26 56.5 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.852 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -62.97 -34.62 77.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.794 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 26.8 m-20 -65.24 -42.69 93.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.407 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' ILE . . . . . 0.544 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 2.5 mm -62.15 -48.01 90.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.15 179.182 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.74 -37.42 73.56 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.472 179.44 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -64.77 -42.23 95.26 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.536 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' PHE . . . . . 0.422 ' CE1' HG11 ' A' ' 144' ' ' VAL . 28.2 t80 -62.3 -38.4 89.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.509 179.617 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 26.0 mt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.976 179.972 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.837 0.351 . . . . 0.0 111.079 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' MET . . . . . 0.408 ' CB ' ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -99.56 166.68 12.44 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.862 179.948 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . 0.408 ' HD2' ' CB ' ' A' ' 132' ' ' MET . 20.8 Cg_endo -60.91 -26.49 83.22 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.512 2.141 . . . . 0.0 112.282 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -81.47 -44.85 16.84 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.752 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 85.5 t -59.92 -31.49 47.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.862 179.798 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -67.28 -52.94 34.59 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 8.7 ttpt -56.37 -31.07 63.45 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 178.536 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.541 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -60.86 -62.57 1.76 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.413 179.103 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -61.78 -24.1 66.62 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.334 -179.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 20.2 mmm-85 -80.52 -32.51 36.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.903 0.383 . . . . 0.0 110.822 179.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -83.72 -29.28 27.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.662 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 11.5 mmtt -89.66 -25.74 21.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.05 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 96.33 13.58 47.95 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.439 -179.535 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.442 HG12 ' CD1' ' A' ' 166' ' ' PHE . 92.8 t -97.84 159.71 3.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.76 0.314 . . . . 0.0 110.783 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.423 ' O ' ' HG ' ' A' ' 148' ' ' LEU . 68.4 t0 -108.75 111.96 24.0 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.785 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.438 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 8.6 pt -53.6 -40.06 40.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.039 0.447 . . . . 0.0 111.32 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 91.4 mtt-85 -49.34 -25.67 2.61 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.765 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . 0.423 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.1 OUTLIER -118.81 27.32 8.96 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 111.721 0.267 . . . . 0.0 111.721 -179.878 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.438 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 38.8 t -94.0 154.5 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.851 0.358 . . . . 0.0 110.552 179.373 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.93 75.6 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.952 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -70.0 114.9 5.81 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.426 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.327 -0.375 0 CA-C-O 120.699 0.285 . . . . 0.0 111.167 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 30.8 t . . . . . 0 C--O 1.231 0.081 0 CA-C-O 120.748 0.309 . . . . 0.0 110.921 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.1 mt -113.19 177.42 4.64 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.072 0.463 . . . . 0.0 111.225 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . 0.44 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 1.8 tttt -50.68 -44.44 57.77 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.855 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 68.0 mm-40 -61.98 -34.11 75.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.695 179.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -67.11 -38.91 86.46 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.407 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' ILE . . . . . 0.541 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 4.4 mm -64.08 -48.93 83.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.294 179.263 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -58.37 -41.06 83.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.656 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.1 -41.71 99.43 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.921 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 166' ' ' PHE . . . . . 0.442 ' CD1' HG12 ' A' ' 144' ' ' VAL . 32.8 t80 -60.3 -50.45 73.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.827 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 50.8 mt . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.861 -179.98 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.797 0.332 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -69.95 162.75 66.44 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.86 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_endo -57.28 -24.45 59.78 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.627 2.218 . . . . 0.0 112.144 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.3 m -76.76 -44.86 31.34 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.89 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 93.0 t -59.8 -34.95 57.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.79 -51.38 56.39 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.325 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 2.5 tttt -56.75 -29.96 63.1 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 178.564 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.56 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -63.39 -62.74 1.48 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.496 179.301 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -63.11 -24.56 67.96 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.372 -179.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.63 -27.17 29.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.739 0.304 . . . . 0.0 110.957 179.746 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 8.2 mm-40 -85.82 -28.04 24.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.019 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 1.6 mmtm -97.66 -25.37 15.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.254 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 101.2 14.09 31.69 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.717 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.422 HG11 ' CE1' ' A' ' 166' ' ' PHE . 42.9 t -93.2 159.43 2.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.733 0.301 . . . . 0.0 110.826 179.731 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.434 ' O ' ' HG ' ' A' ' 148' ' ' LEU . 67.1 t0 -110.45 107.59 17.32 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.705 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.441 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 9.7 pt -52.05 -40.19 28.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 121.048 0.451 . . . . 0.0 111.217 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 92.0 mtt-85 -48.9 -26.33 2.41 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.931 -179.749 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . 0.434 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.1 OUTLIER -119.24 26.93 9.13 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.663 0.268 . . . . 0.0 111.668 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.441 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 40.5 t -93.97 157.63 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.782 0.325 . . . . 0.0 110.518 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . 0.431 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.95 76.21 2.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.967 -179.767 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -72.52 109.15 2.71 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.421 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.303 0 CA-C-O 120.607 0.241 . . . . 0.0 111.207 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.795 0.331 . . . . 0.0 110.999 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.2 mp -116.05 176.93 4.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.058 0.456 . . . . 0.0 111.183 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . 0.425 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 3.4 tttt -50.32 -46.48 55.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.787 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -59.69 -34.27 72.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.705 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 72.1 m-20 -67.69 -37.62 82.56 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.395 179.672 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' ILE . . . . . 0.56 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 4.9 mm -64.02 -49.01 83.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.339 179.271 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -58.8 -42.21 88.57 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.624 179.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.57 -40.83 96.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.81 179.8 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 166' ' ' PHE . . . . . 0.422 ' CE1' HG11 ' A' ' 144' ' ' VAL . 46.7 t80 -60.55 -51.31 69.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.65 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 29.4 mt . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.896 179.892 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.779 0.323 . . . . 0.0 111.199 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 2.6 mtm -71.98 166.22 42.66 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.816 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_endo -61.24 -32.64 90.59 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.513 2.142 . . . . 0.0 112.219 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -69.93 -45.54 67.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.782 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 84.7 t -60.16 -33.06 52.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.99 179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -65.9 -50.72 63.46 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.21 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.4 tttt -57.71 -31.71 66.67 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.536 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -60.27 -61.6 2.48 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.402 179.109 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -63.78 -21.67 66.54 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.299 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.79 -27.61 28.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.042 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -85.94 -25.81 25.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.059 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 2.1 tptt -98.61 -26.72 14.3 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.247 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 103.07 13.11 29.91 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.596 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.418 HG11 ' CE1' ' A' ' 166' ' ' PHE . 35.0 t -93.27 160.59 2.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.794 0.33 . . . . 0.0 110.831 179.737 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.502 ' HB3' HD23 ' A' ' 148' ' ' LEU . 51.9 t0 -115.22 105.66 13.15 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.952 0.406 . . . . 0.0 110.755 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.455 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 4.0 pt -45.13 -36.3 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.3 0.571 . . . . 0.0 111.867 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -48.24 -25.32 1.48 Allowed 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.332 -0.849 . . . . 0.0 112.643 -179.157 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . 0.571 ' N ' ' CD1' ' A' ' 148' ' ' LEU . 0.0 OUTLIER -126.82 31.07 5.37 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 111.817 0.303 . . . . 0.0 111.817 -179.33 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.455 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 54.1 t -92.88 157.45 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.821 0.344 . . . . 0.0 110.65 179.372 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . 0.419 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.84 69.77 1.87 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.999 -179.645 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -68.79 115.83 6.88 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.403 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.273 0 CA-C-O 120.617 0.246 . . . . 0.0 111.325 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 31.7 t . . . . . 0 N--CA 1.458 -0.072 0 CA-C-O 120.805 0.336 . . . . 0.0 110.776 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -115.13 176.67 4.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.027 0.442 . . . . 0.0 111.263 -179.69 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 14.3 tttm -49.84 -45.72 50.61 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.818 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 -60.03 -35.46 75.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.653 179.742 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -66.23 -37.94 86.73 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.368 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' ILE . . . . . 0.536 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 5.4 mm -63.14 -49.16 84.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.909 179.084 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -59.42 -36.49 75.97 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.508 179.459 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.6 -39.84 92.0 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.775 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 166' ' ' PHE . . . . . 0.429 ' CZ ' HD22 ' A' ' 148' ' ' LEU . 57.7 t80 -62.98 -47.27 83.88 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.536 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 5.8 mt . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.911 179.964 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.741 0.305 . . . . 0.0 111.101 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 77.6 mtp -100.8 162.04 21.93 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.953 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.42 -40.48 71.18 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.549 2.166 . . . . 0.0 112.254 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.22 -43.74 70.03 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.912 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 67.4 t -58.98 -36.48 62.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.942 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -66.14 -51.92 53.3 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 179.469 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.9 ttpt -56.72 -32.64 65.73 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 178.691 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.56 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.9 OUTLIER -59.73 -61.82 2.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.458 179.205 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -63.45 -23.31 67.34 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.297 -179.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -82.04 -28.22 32.58 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.951 179.78 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -86.35 -28.57 23.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.847 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 4.1 mptt -93.96 -24.58 17.61 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.04 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 98.07 13.94 41.03 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.6 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.428 HG11 ' CE1' ' A' ' 166' ' ' PHE . 45.6 t -92.74 159.11 2.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.799 0.333 . . . . 0.0 110.828 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 68.2 t0 -109.3 105.42 14.82 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.839 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.466 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 7.3 pt -49.33 -39.92 13.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.13 0.49 . . . . 0.0 111.389 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 8.4 mtt-85 -49.4 -24.73 2.09 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.746 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . 0.462 ' CD1' ' CE2' ' A' ' 166' ' ' PHE . 0.6 OUTLIER -120.32 27.99 8.28 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.586 0.231 . . . . 0.0 111.596 -179.846 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.466 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 43.4 t -95.31 155.56 3.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.934 0.397 . . . . 0.0 110.792 179.594 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . 0.407 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 8.6 tt0 -74.99 77.61 2.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.096 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.65 111.75 3.79 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.455 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.328 -0.333 0 CA-C-O 120.763 0.316 . . . . 0.0 111.042 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.89 0.376 . . . . 0.0 111.19 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 3.8 mp -112.96 175.91 5.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.911 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . 0.422 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 0.4 OUTLIER -50.91 -45.52 60.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.642 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 4.2 mm-40 -60.36 -34.25 73.6 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.603 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -67.64 -37.6 82.68 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.436 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' ILE . . . . . 0.56 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 5.4 mm -64.01 -47.93 88.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.169 179.164 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -58.76 -42.38 88.79 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.577 179.409 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.01 -40.94 95.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.653 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 166' ' ' PHE . . . . . 0.462 ' CE2' ' CD1' ' A' ' 148' ' ' LEU . 20.5 t80 -63.51 -38.94 93.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.513 179.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 12.7 mt . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.77 179.861 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.786 0.327 . . . . 0.0 111.196 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.3 mtp -91.47 160.37 36.97 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.851 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.65 -23.49 76.05 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.591 2.194 . . . . 0.0 112.242 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.2 m -90.65 -41.48 11.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.898 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.459 ' O ' ' HB3' ' A' ' 138' ' ' TYR . 59.5 t -59.91 -39.7 80.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.033 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.452 ' CD ' ' CD1' ' A' ' 146' ' ' ILE . 0.0 OUTLIER -62.48 -43.44 98.8 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.63 -0.508 . . . . 0.0 109.63 179.364 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.3 -33.32 74.43 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 178.331 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.55 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.9 OUTLIER -57.7 -60.87 3.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.375 179.052 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -61.29 -29.61 69.97 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.377 -179.649 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 11.3 mmm180 -79.19 -23.03 44.13 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.339 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -89.67 -26.57 20.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.802 0.334 . . . . 0.0 111.032 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -96.06 -22.31 17.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.288 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.46 7.09 46.44 Favored Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.573 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.44 HG11 ' CE1' ' A' ' 166' ' ' PHE . 59.2 t -89.44 155.24 3.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 120.722 0.296 . . . . 0.0 110.67 179.65 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.412 ' HB3' ' CG ' ' A' ' 148' ' ' LEU . 66.5 t0 -102.34 109.19 20.77 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.14 0.495 . . . . 0.0 110.89 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.466 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 5.4 pt -51.07 -43.78 27.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.63 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 11.6 mtt180 -49.72 -24.62 2.4 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.941 -0.572 . . . . 0.0 112.11 -179.437 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . 0.412 ' CG ' ' HB3' ' A' ' 145' ' ' ASP . 0.1 OUTLIER -119.2 23.97 11.01 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 112.111 0.412 . . . . 0.0 112.111 -179.645 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.466 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 48.9 t -86.64 156.18 3.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.733 0.301 . . . . 0.0 110.555 179.209 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . 0.405 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 4.2 tt0 -74.79 74.24 2.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.067 -179.73 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -72.07 107.38 2.17 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.403 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.299 0 CA-C-O 120.871 0.367 . . . . 0.0 110.988 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.865 0.364 . . . . 0.0 111.083 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 14.5 mt -112.37 175.12 5.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.05 -179.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . 0.424 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 1.0 OUTLIER -50.77 -44.98 58.77 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.673 179.903 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -61.11 -34.41 74.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.637 179.587 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -66.82 -37.22 84.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.457 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' ILE . . . . . 0.55 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 8.2 mm -65.11 -49.23 80.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.186 179.167 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -58.82 -38.42 78.6 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.572 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.49 -41.08 93.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.836 179.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 166' ' ' PHE . . . . . 0.44 ' CE1' HG11 ' A' ' 144' ' ' VAL . 24.6 t80 -61.1 -45.69 93.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.591 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 167' ' ' LEU . . . . . 0.408 ' CD2' ' CG2' ' A' ' 144' ' ' VAL . 16.4 mt . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.805 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.801 0.334 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.42 166.06 11.75 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.864 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -52.89 -37.62 77.73 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.505 2.137 . . . . 0.0 112.381 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.66 -48.25 55.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.88 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 73.9 t -58.06 -33.06 45.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.848 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.12 -52.88 36.29 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 179.341 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 3.8 tttp -55.96 -30.3 61.53 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 178.634 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.548 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -62.86 -62.78 1.49 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.442 179.295 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -63.71 -23.91 67.56 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.243 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 3.8 tpt180 -82.97 -25.92 31.81 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.943 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -87.55 -26.59 23.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.945 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -97.52 -25.18 15.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.188 -179.779 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 100.85 13.27 34.82 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.674 -0.775 . . . . 0.0 112.584 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.42 HG11 ' CE1' ' A' ' 166' ' ' PHE . 44.3 t -94.55 160.03 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.788 0.327 . . . . 0.0 110.743 179.716 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.424 ' O ' ' HG ' ' A' ' 148' ' ' LEU . 42.9 t0 -111.17 109.6 19.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.733 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.439 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 9.7 pt -52.03 -39.84 27.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.389 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 2.2 ptt180 -48.99 -25.92 2.24 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.794 -179.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . 0.424 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.2 OUTLIER -119.43 26.96 9.07 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 111.645 0.239 . . . . 0.0 111.645 -179.809 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.439 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 43.6 t -95.05 157.53 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.837 0.351 . . . . 0.0 110.586 179.305 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . 0.425 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 2.1 tt0 -74.74 77.55 2.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.067 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -72.91 106.11 1.89 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.447 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 120.605 0.24 . . . . 0.0 111.24 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.854 0.359 . . . . 0.0 110.949 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 2.1 mt -121.85 172.46 8.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.219 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . 0.432 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 4.9 tttm -47.8 -50.41 25.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.053 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -57.18 -35.38 69.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.781 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -67.56 -34.75 77.69 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.38 179.678 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' ILE . . . . . 0.548 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 5.7 mm -64.98 -50.65 73.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.068 179.106 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -59.57 -37.72 79.23 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.571 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.9 -40.5 91.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.712 179.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 166' ' ' PHE . . . . . 0.42 ' CE1' HG11 ' A' ' 144' ' ' VAL . 37.2 t80 -60.91 -48.32 82.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.567 179.675 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 16.5 mt . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.955 179.813 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.897 0.379 . . . . 0.0 111.016 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 24.5 mmm -88.79 161.19 42.27 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.93 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -52.22 -28.18 32.96 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.587 2.191 . . . . 0.0 112.257 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 58.2 m -87.31 -38.6 16.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.906 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.436 ' O ' ' HB3' ' A' ' 138' ' ' TYR . 61.4 t -62.68 -40.48 88.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.022 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.481 ' HD2' ' CD1' ' A' ' 146' ' ' ILE . 25.1 mmm-85 -65.52 -47.74 74.9 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.35 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 2.0 tttm -60.72 -29.81 69.58 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.537 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -60.95 -60.66 3.43 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.481 179.213 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -62.69 -27.76 69.47 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.78 -0.645 . . . . 0.0 111.516 -179.544 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.4 -21.18 33.08 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.301 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -91.95 -22.22 20.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.069 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 1.1 mmtt -103.22 -24.47 13.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.346 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.58 9.6 32.82 Favored Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.875 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.427 HG11 ' CE1' ' A' ' 166' ' ' PHE . 46.3 t -89.24 155.06 3.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.748 0.309 . . . . 0.0 110.59 179.545 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.447 ' HB3' ' CG ' ' A' ' 148' ' ' LEU . 61.4 t0 -100.79 104.97 16.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.11 0.481 . . . . 0.0 111.023 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.481 ' CD1' ' HD2' ' A' ' 136' ' ' ARG . 3.1 pt -47.44 -45.51 9.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.73 179.564 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.67 -22.09 1.9 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.332 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . 0.463 ' CD1' ' CE2' ' A' ' 166' ' ' PHE . 0.9 OUTLIER -121.44 22.27 10.77 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 112.053 0.39 . . . . 0.0 112.053 -179.592 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.438 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 76.0 t -85.96 152.49 3.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.864 0.364 . . . . 0.0 110.574 179.251 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.94 78.98 2.16 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.919 -179.776 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -80.92 106.85 2.6 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.42 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.329 -0.286 0 CA-C-O 120.925 0.393 . . . . 0.0 110.879 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 22.6 t . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.807 0.337 . . . . 0.0 110.977 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 2.3 mt -122.96 170.93 9.63 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.122 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 29.6 tttm -50.61 -44.75 57.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.622 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -60.31 -35.37 75.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.501 179.704 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -66.26 -38.28 87.45 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.328 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' ILE . . . . . 0.537 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 6.1 mm -63.22 -49.78 81.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.248 179.351 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -58.08 -41.04 82.58 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.621 179.719 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.13 -40.72 98.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.764 179.704 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 166' ' ' PHE . . . . . 0.463 ' CE2' ' CD1' ' A' ' 148' ' ' LEU . 17.9 t80 -60.82 -45.57 93.95 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.486 179.725 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 167' ' ' LEU . . . . . 0.409 ' CD2' ' CG2' ' A' ' 144' ' ' VAL . 21.1 mt . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.849 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.876 0.37 . . . . 0.0 111.246 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 1.3 mmt -85.97 161.35 50.16 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.822 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_endo -61.15 -30.81 89.53 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.575 2.183 . . . . 0.0 112.221 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -82.1 -37.39 26.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.736 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 62.6 t -61.7 -34.63 63.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -65.91 -52.85 46.45 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.439 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.14 -34.34 63.67 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 178.671 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.567 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.9 OUTLIER -59.08 -61.79 2.37 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.442 179.21 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -62.01 -23.88 66.7 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.517 -179.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 3.2 mmm-85 -82.6 -28.81 30.61 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.717 0.294 . . . . 0.0 111.116 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -84.22 -27.69 27.81 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.123 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 2.1 mptp? -96.06 -26.9 15.34 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.124 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.09 13.34 31.63 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.619 -179.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.429 HG12 ' CD1' ' A' ' 166' ' ' PHE . 47.7 t -94.91 159.88 2.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-O 120.689 0.28 . . . . 0.0 110.738 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.431 ' O ' ' HG ' ' A' ' 148' ' ' LEU . 66.9 t0 -111.99 111.17 21.91 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.811 179.817 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.424 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 7.8 pt -52.16 -39.77 28.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.457 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -48.94 -25.75 2.12 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.754 -179.762 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . 0.431 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.2 OUTLIER -119.65 28.12 8.34 Favored 'General case' 0 N--CA 1.462 0.138 0 N-CA-C 111.679 0.251 . . . . 0.0 111.679 -179.832 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.424 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 55.6 t -98.25 155.64 3.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.79 0.329 . . . . 0.0 110.659 179.269 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.94 79.3 2.16 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.96 -179.736 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -76.48 114.83 4.24 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.328 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.33 -0.281 0 CA-C-O 120.694 0.283 . . . . 0.0 111.085 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 22.2 t . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.749 0.309 . . . . 0.0 110.79 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -117.6 174.69 6.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.094 0.474 . . . . 0.0 111.291 -179.621 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . 0.444 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 2.1 tptt -50.16 -45.8 53.6 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.784 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -60.11 -34.86 74.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.681 179.663 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -67.17 -36.69 82.33 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.332 179.57 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' ILE . . . . . 0.567 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 5.2 mm -64.01 -50.3 77.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.093 179.179 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -58.62 -39.65 81.08 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.484 179.675 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -62.54 -41.34 98.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.771 179.664 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 166' ' ' PHE . . . . . 0.429 ' CD1' HG12 ' A' ' 144' ' ' VAL . 40.9 t80 -60.61 -51.81 67.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.568 179.659 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 23.7 mt . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.833 179.847 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.858 0.361 . . . . 0.0 111.304 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -114.42 158.88 38.77 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.843 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.08 -54.82 4.79 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.682 2.255 . . . . 0.0 112.159 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.1 m -60.33 -40.97 92.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.624 179.736 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.407 ' O ' ' HB3' ' A' ' 138' ' ' TYR . 81.6 t -60.53 -34.24 57.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.716 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.402 ' HD3' ' CD1' ' A' ' 146' ' ' ILE . 0.2 OUTLIER -64.04 -53.16 54.28 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.201 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -56.84 -30.71 64.05 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 178.536 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.521 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -62.26 -61.32 2.54 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.581 179.313 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -62.45 -27.1 68.88 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.49 -179.466 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 31.0 mmm180 -83.18 -24.06 32.63 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.708 0.289 . . . . 0.0 111.084 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -88.71 -22.84 23.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.25 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 4.3 mmtt -102.65 -25.38 13.58 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.288 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.75 9.99 31.64 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.64 -179.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.425 HG11 ' CE1' ' A' ' 166' ' ' PHE . 25.1 t -94.98 162.05 2.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.632 0.253 . . . . 0.0 110.656 179.628 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.501 ' HB3' ' CD1' ' A' ' 148' ' ' LEU . 55.5 t0 -117.53 109.09 16.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.946 0.403 . . . . 0.0 110.845 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.457 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 5.1 pt -46.45 -37.3 3.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.125 0.488 . . . . 0.0 111.807 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -47.58 -25.35 1.11 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.53 -0.759 . . . . 0.0 112.616 -179.196 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . 0.581 ' N ' ' CD1' ' A' ' 148' ' ' LEU . 0.0 OUTLIER -127.12 30.24 5.46 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 111.736 0.273 . . . . 0.0 111.736 -179.22 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.457 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 58.3 t -93.92 158.57 2.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.804 0.335 . . . . 0.0 110.609 179.514 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . 0.423 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.7 OUTLIER -74.8 77.13 2.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.975 -179.659 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.59 90.64 0.47 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.393 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 11.2 t . . . . . 0 C--N 1.329 -0.295 0 CA-C-O 120.823 0.344 . . . . 0.0 111.058 -179.944 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 N--CA 1.457 -0.092 0 CA-C-O 120.795 0.331 . . . . 0.0 110.939 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -124.04 174.02 7.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.121 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . 0.426 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 64.5 tttt -48.54 -50.19 33.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.901 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -56.27 -35.37 67.39 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.824 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -67.24 -38.22 84.85 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.434 179.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' ILE . . . . . 0.521 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 4.2 mm -61.98 -47.28 93.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.064 0.459 . . . . 0.0 109.929 179.114 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -60.23 -40.92 91.89 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.475 179.413 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -62.08 -40.89 97.38 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.798 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 166' ' ' PHE . . . . . 0.425 ' CE1' HG11 ' A' ' 144' ' ' VAL . 44.5 t80 -60.49 -50.6 72.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.429 179.62 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 167' ' ' LEU . . . . . 0.405 ' CD2' ' CG2' ' A' ' 144' ' ' VAL . 14.8 mt . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.855 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.861 0.363 . . . . 0.0 111.112 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.3 mmm -106.72 161.55 22.52 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.884 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -56.15 -23.6 45.65 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.582 2.188 . . . . 0.0 112.126 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 45.9 p -81.05 -46.18 15.39 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.79 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 86.2 t -58.68 -33.25 48.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.986 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 4.8 mmm180 -64.35 -51.21 64.5 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.263 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -53.96 -38.8 65.36 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 178.467 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.532 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -55.02 -62.6 1.55 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.93 179.183 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -61.09 -23.28 65.37 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.782 -179.33 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 38.2 mtt-85 -84.08 -28.11 27.78 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.765 0.317 . . . . 0.0 111.123 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -84.05 -27.09 28.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.172 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.27 -27.88 13.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.158 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.28 16.01 24.06 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.578 -179.831 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.434 HG12 ' CD1' ' A' ' 166' ' ' PHE . 46.4 t -95.91 160.67 2.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.772 0.32 . . . . 0.0 110.756 179.766 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -113.9 108.99 17.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.888 179.665 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.433 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 7.1 pt -50.5 -39.83 18.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.433 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -48.9 -24.84 1.62 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.773 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . 0.405 ' CD1' ' CE2' ' A' ' 166' ' ' PHE . 0.4 OUTLIER -120.36 28.09 8.22 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.652 0.263 . . . . 0.0 111.612 -179.715 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.433 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 55.2 t -99.31 153.6 4.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.928 0.394 . . . . 0.0 110.771 179.456 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -74.96 79.16 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.161 -179.629 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -73.64 120.0 6.75 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.399 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.318 0 CA-C-O 120.643 0.259 . . . . 0.0 111.227 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 N--CA 1.457 -0.083 0 CA-C-O 120.844 0.354 . . . . 0.0 110.847 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.4 mt -111.87 175.98 5.21 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.107 0.479 . . . . 0.0 111.167 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 49.5 tttt -49.43 -48.19 47.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.806 179.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -59.03 -34.48 71.96 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.714 179.778 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -67.35 -36.06 80.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.452 179.721 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' ILE . . . . . 0.532 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 4.2 mm -65.2 -50.22 74.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.169 179.226 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -58.52 -39.61 80.61 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.601 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.78 -40.57 97.0 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.628 179.737 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 166' ' ' PHE . . . . . 0.434 ' CD1' HG12 ' A' ' 144' ' ' VAL . 26.9 t80 -60.32 -48.98 79.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.425 179.678 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 6.1 mt . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.911 179.807 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.486 1.357 0 CA-C-O 120.822 0.344 . . . . 0.0 111.21 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.5 mtp180 -175.54 82.64 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.858 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -71.28 147.26 48.32 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.863 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 25.4 t -106.37 150.31 9.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.136 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 20.5 mt -92.34 68.72 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.895 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -126.86 166.85 16.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.173 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 33.7 mtp -103.12 157.95 32.74 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.807 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 10.5 Cg_endo -53.6 -27.42 41.38 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.642 2.228 . . . . 0.0 112.192 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.6 t -80.06 -47.22 15.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.71 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 94.9 t -58.31 -31.31 42.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.822 179.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 6.6 mmm-85 -65.42 -52.74 51.22 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 11.0 tppt? -52.88 -39.5 62.71 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.532 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -54.33 -62.8 1.42 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.027 -0.988 . . . . 0.0 110.796 179.133 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -60.18 -24.67 64.97 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.601 -179.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 3.3 mmt85 -82.16 -27.6 32.59 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.69 0.281 . . . . 0.0 111.122 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -85.68 -29.39 24.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.973 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 3.7 mptp? -94.96 -24.45 16.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.172 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 98.66 14.27 38.07 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.613 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.418 HG11 ' CE1' ' A' ' 166' ' ' PHE . 34.4 t -94.19 160.13 2.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.713 0.292 . . . . 0.0 110.81 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.557 ' HB3' HD23 ' A' ' 148' ' ' LEU . 63.8 t0 -114.9 104.99 12.47 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.789 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.431 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 4.4 pt -45.5 -36.33 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.26 0.552 . . . . 0.0 111.818 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 6.8 mtt180 -48.29 -25.6 1.63 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.316 -0.856 . . . . 0.0 112.641 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.574 ' N ' ' CD1' ' A' ' 148' ' ' LEU . 0.0 OUTLIER -125.49 30.02 5.87 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.662 0.268 . . . . 0.0 111.715 -179.433 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.431 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 58.1 t -94.63 155.65 3.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.862 0.363 . . . . 0.0 110.683 179.406 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -74.96 79.51 2.17 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.925 -179.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -73.32 110.52 3.16 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.433 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -103.37 -17.8 15.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.585 0.231 . . . . 0.0 111.215 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -52.64 173.89 0.27 Allowed Glycine 0 C--N 1.331 0.291 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.624 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 14.5 tptt -50.31 123.87 9.35 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.791 0.329 . . . . 0.0 111.195 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 80.6 m-20 61.25 44.5 9.77 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.876 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 58.8 57.55 19.25 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.398 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -98.0 121.16 39.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.77 0.319 . . . . 0.0 111.03 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 21.8 t -78.04 110.34 13.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.931 179.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 5.1 mt -109.45 178.51 4.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.019 0.438 . . . . 0.0 111.311 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . 0.437 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 7.9 tttt -50.04 -47.69 53.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.688 179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -59.99 -33.63 72.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.752 179.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -67.66 -36.65 81.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.396 179.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' ILE . . . . . 0.532 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 3.5 mm -65.18 -50.09 75.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.174 179.114 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -58.62 -38.91 79.06 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.539 179.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.8 -42.08 97.77 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.787 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' PHE . . . . . 0.44 ' CZ ' HD22 ' A' ' 148' ' ' LEU . 45.8 t80 -59.67 -51.26 70.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.608 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 33.7 mt -70.91 -30.31 66.61 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.959 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -87.52 179.35 6.57 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.122 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 120.92 105.99 2.02 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.592 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 114.63 141.78 7.71 Favored Glycine 0 C--O 1.248 1.001 0 CA-C-O 118.377 -1.235 . . . . 0.0 112.573 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.782 0 CA-C-N 118.34 1.07 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 67.6 m-20 . . . . . 0 N--CA 1.486 1.369 0 CA-C-O 120.807 0.337 . . . . 0.0 111.159 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -134.01 145.63 49.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.878 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 51.8 ttt180 -71.35 123.31 22.03 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.955 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 20.1 t -98.77 154.61 3.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.123 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 18.8 mt -97.37 62.82 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.99 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -128.32 177.16 7.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.168 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 14.7 mtp -104.25 166.29 11.87 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.842 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -63.19 -27.59 72.75 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.556 2.171 . . . . 0.0 112.15 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 24.8 m -79.93 -44.92 19.46 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.772 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 59.5 t -59.46 -33.55 51.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.862 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.432 ' CD ' ' CD1' ' A' ' 146' ' ' ILE . 9.1 mmm-85 -63.89 -51.26 65.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.948 0.404 . . . . 0.0 109.921 179.312 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.68 -41.89 67.35 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 178.517 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.55 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -51.51 -61.99 1.9 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.755 179.066 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -62.76 -20.46 64.98 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.502 -179.751 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 -83.41 -27.88 29.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.526 -0.307 . . . . 0.0 110.968 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -85.63 -29.36 24.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.86 0.362 . . . . 0.0 110.856 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 4.9 tptt -95.26 -25.43 16.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.081 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 97.43 16.98 32.75 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.52 -179.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.415 HG11 ' CE1' ' A' ' 166' ' ' PHE . 43.9 t -91.1 158.85 2.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.805 0.336 . . . . 0.0 110.877 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 62.3 t0 -109.99 102.16 10.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.751 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.451 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 9.7 pt -48.61 -39.79 10.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.263 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 6.0 mtm-85 -48.97 -25.07 1.75 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.749 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.45 ' CD1' ' CE2' ' A' ' 166' ' ' PHE . 0.5 OUTLIER -120.78 27.44 8.51 Favored 'General case' 0 N--CA 1.463 0.186 0 N-CA-C 111.647 0.24 . . . . 0.0 111.647 -179.78 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.451 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 51.2 t -96.01 152.23 3.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.979 0.419 . . . . 0.0 110.906 179.593 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -74.96 79.36 2.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.973 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -75.99 116.48 4.82 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.507 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -114.43 28.35 8.8 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.803 0.335 . . . . 0.0 110.96 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -98.08 -174.28 33.11 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.349 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 7.9 tttt -45.42 111.07 0.3 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.784 0.326 . . . . 0.0 111.433 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 4.9 t30 62.78 52.85 2.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.89 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 57.12 54.15 39.2 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.459 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 28.9 ttm-85 -96.15 139.8 31.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.82 0.343 . . . . 0.0 110.995 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 24.9 t -89.97 120.59 39.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.952 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 3.2 mt -117.12 174.79 5.92 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.152 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . 0.429 ' HG2' ' CE2' ' A' ' 138' ' ' TYR . 0.0 OUTLIER -48.38 -48.97 36.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.875 179.946 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -58.03 -35.63 71.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.866 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -65.7 -38.8 90.23 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.35 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' ILE . . . . . 0.55 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 4.0 mm -62.64 -48.73 86.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.095 179.114 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -58.23 -39.93 80.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.63 179.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.5 -39.3 91.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.812 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' PHE . . . . . 0.45 ' CE2' ' CD1' ' A' ' 148' ' ' LEU . 21.9 t80 -64.15 -38.45 91.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.662 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 19.5 mt -86.88 -76.39 0.36 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.144 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -66.69 -45.06 80.06 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.393 -179.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -59.06 -27.53 62.57 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.511 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -128.09 -91.56 0.71 Allowed Glycine 0 C--O 1.249 1.048 0 CA-C-O 118.407 -1.218 . . . . 0.0 112.494 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.779 0 CA-C-N 118.365 1.082 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.487 1.417 0 CA-C-O 120.853 0.359 . . . . 0.0 111.14 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -66.58 107.01 1.95 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.911 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 4.6 mtt85 -135.57 -178.21 5.02 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.913 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 22.0 t -108.85 155.94 9.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.171 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 6.0 mt -79.97 68.69 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.804 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -139.97 155.21 47.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.217 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -88.93 166.32 22.74 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.849 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -61.44 -42.09 36.37 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.539 2.159 . . . . 0.0 112.227 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.03 -46.29 85.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.865 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.405 ' O ' ' HB3' ' A' ' 138' ' ' TYR . 57.9 t -58.48 -35.08 52.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.913 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 1.6 mmm180 -63.18 -48.07 79.92 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.03 -38.36 70.43 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 178.323 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.534 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -55.43 -63.06 1.28 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.879 179.127 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -62.79 -20.99 65.55 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.387 -179.529 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 12.9 tpt180 -83.54 -27.15 29.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.956 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -85.63 -28.86 24.5 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.888 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.83 -26.21 15.73 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.109 -179.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 100.02 15.59 30.47 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.588 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 49.0 t -93.71 159.28 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.881 0.372 . . . . 0.0 110.758 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.433 ' O ' ' HG ' ' A' ' 148' ' ' LEU . 41.6 t0 -110.91 107.71 17.25 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.747 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.435 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 6.7 pt -51.19 -39.63 20.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.104 0.478 . . . . 0.0 111.437 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 20.8 mtt180 -48.81 -26.19 2.26 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.832 -179.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.433 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.0 OUTLIER -118.64 26.92 9.23 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 111.71 0.263 . . . . 0.0 111.71 -179.889 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.435 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 56.1 t -96.2 156.65 3.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.873 0.368 . . . . 0.0 110.702 179.468 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . 0.42 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.97 73.38 2.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.888 -179.738 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -69.13 133.67 26.57 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.477 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.19 30.09 0.87 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.851 0.358 . . . . 0.0 110.812 -179.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -96.66 105.13 3.17 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.696 -0.764 . . . . 0.0 113.009 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . 0.527 ' HG3' ' N ' ' A' ' 155' ' ' ASN . 0.0 OUTLIER 73.55 -49.73 0.69 Allowed 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 179.509 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.527 ' N ' ' HG3' ' A' ' 154' ' ' LYS . 9.4 m-20 -155.5 27.12 0.4 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.892 0.377 . . . . 0.0 110.338 179.829 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 108.49 16.1 12.59 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.489 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 1.3 ttt180 -68.55 128.92 38.36 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.748 0.309 . . . . 0.0 110.618 179.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 22.8 t -74.97 106.66 4.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.052 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.409 ' O ' ' HB2' ' A' ' 162' ' ' ASP . 16.3 mt -106.59 176.36 5.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.017 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . 0.428 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 0.1 OUTLIER -50.19 -45.71 53.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.645 179.784 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 50.5 mm-40 -61.35 -34.52 75.43 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.627 179.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . 0.409 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 60.8 m-20 -65.41 -39.55 92.28 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.249 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' ILE . . . . . 0.534 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 3.3 mm -64.47 -45.13 96.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.027 179.037 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -60.61 -35.71 76.8 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.284 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -67.83 -39.01 83.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.469 179.541 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' PHE . . . . . . . . . . . . . 20.2 t80 -68.53 -31.3 70.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.605 179.642 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 2.6 mt -105.69 -80.1 0.55 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.978 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . 53.41 100.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.314 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -166.19 -94.63 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.494 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -165.75 6.42 0.06 OUTLIER Glycine 0 C--O 1.25 1.108 0 CA-C-O 118.317 -1.268 . . . . 0.0 112.468 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.818 0 CA-C-N 118.432 1.116 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 6.9 m120 . . . . . 0 N--CA 1.485 1.315 0 CA-C-O 120.896 0.379 . . . . 0.0 111.187 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -103.73 157.67 16.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.891 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.0 141.57 33.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.907 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 14.6 t -132.18 161.55 41.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.948 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 3.4 mt -79.96 69.78 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.915 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -142.83 153.35 43.12 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.123 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 64.2 mtp -80.07 157.34 73.68 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.946 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_exo -51.66 -42.58 55.8 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.576 2.184 . . . . 0.0 112.302 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.4 p -61.13 -42.64 98.91 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.956 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 59.2 t -59.46 -34.33 54.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.807 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.414 ' HD3' ' CD1' ' A' ' 146' ' ' ILE . 0.0 OUTLIER -66.8 -53.63 30.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.895 0.379 . . . . 0.0 110.034 179.329 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.4 tttt -55.38 -32.08 62.32 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 178.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.56 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -61.93 -61.97 2.12 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.344 179.149 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -61.46 -24.41 66.54 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.527 -179.645 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 9.5 mtp-105 -83.65 -29.05 27.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.795 0.331 . . . . 0.0 110.894 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -84.04 -26.94 28.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.112 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 5.4 mptt -97.45 -27.57 14.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.169 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.85 14.0 28.1 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.624 -179.783 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.431 HG11 ' CE1' ' A' ' 166' ' ' PHE . 47.3 t -95.46 160.8 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.862 0.363 . . . . 0.0 110.75 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -113.46 107.07 15.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.615 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.455 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 12.7 pt -50.03 -39.98 16.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.355 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 11.9 mtm105 -49.28 -24.06 1.66 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.854 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.463 ' CD1' ' CE2' ' A' ' 166' ' ' PHE . 0.5 OUTLIER -120.45 27.15 8.74 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 120.65 0.262 . . . . 0.0 111.569 -179.83 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.455 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 55.6 t -96.4 158.19 3.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.957 0.408 . . . . 0.0 110.888 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . 0.425 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.4 OUTLIER -74.77 79.6 2.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.157 -179.653 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -69.63 96.61 0.51 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.315 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 70.2 p -84.98 -23.25 28.79 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-O 120.785 0.326 . . . . 0.0 111.209 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -54.18 167.88 1.78 Allowed Glycine 0 C--N 1.332 0.307 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.566 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 3.4 tttt -55.0 138.44 43.81 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.82 0.343 . . . . 0.0 111.08 -179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 10.4 m-20 60.5 31.07 20.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 64.56 53.6 34.3 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.379 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 38.4 ttp180 -95.04 128.13 41.63 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.847 0.356 . . . . 0.0 111.032 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 25.2 t -87.59 118.56 33.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.012 179.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.411 ' O ' ' HB2' ' A' ' 162' ' ' ASP . 1.3 mt -114.05 176.87 4.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.021 -179.811 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . 0.436 ' HG2' ' CE2' ' A' ' 138' ' ' TYR . 0.0 OUTLIER -49.37 -49.28 45.18 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.752 179.889 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -57.58 -34.48 69.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.796 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . 0.411 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 83.7 m-20 -67.54 -37.39 82.65 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.372 179.663 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' ILE . . . . . 0.56 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 4.0 mm -63.24 -47.99 89.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.168 179.23 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -59.33 -43.5 92.73 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.588 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -60.27 -40.4 90.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.814 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' PHE . . . . . 0.463 ' CE2' ' CD1' ' A' ' 148' ' ' LEU . 18.8 t80 -61.35 -50.07 74.38 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.631 179.727 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 37.6 mt -70.72 -33.18 70.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.843 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -83.14 147.02 28.32 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.169 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -151.81 50.78 0.52 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.564 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 58.76 -176.02 2.5 Favored Glycine 0 C--O 1.249 1.064 0 CA-C-O 118.367 -1.24 . . . . 0.0 112.578 -179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.801 0 CA-C-N 118.466 1.133 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 23.5 p30 . . . . . 0 N--CA 1.487 1.381 0 CA-C-O 120.86 0.362 . . . . 0.0 111.198 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.54 104.22 7.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.871 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.99 156.18 3.09 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.16 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 24.2 t -135.09 149.72 29.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.109 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 4.9 mt -79.99 63.09 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.769 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -141.22 155.78 45.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.14 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 1.1 mtp -68.75 160.65 76.32 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.785 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -62.03 -18.18 60.2 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.602 2.201 . . . . 0.0 112.377 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 29.1 t -88.64 -41.37 12.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.994 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.438 ' O ' ' HB3' ' A' ' 138' ' ' TYR . 90.9 t -60.02 -40.19 82.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.099 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.418 ' HD2' ' CD1' ' A' ' 146' ' ' ILE . 4.3 mtm180 -63.11 -43.08 99.45 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 6.7 tttt -62.37 -34.34 76.49 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 178.376 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.544 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.9 OUTLIER -57.5 -60.95 2.89 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.304 179.005 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -60.73 -30.27 69.88 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.416 -179.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.53 -19.78 45.0 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.38 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -93.14 -22.43 19.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.674 0.273 . . . . 0.0 111.14 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -102.33 -21.38 14.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.343 -179.812 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.29 5.62 39.98 Favored Glycine 0 CA--C 1.519 0.314 0 C-N-CA 120.49 -0.862 . . . . 0.0 112.818 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.435 HG11 ' CE1' ' A' ' 166' ' ' PHE . 53.0 t -92.48 159.43 2.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.756 0.313 . . . . 0.0 110.695 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.417 ' HB3' ' CG ' ' A' ' 148' ' ' LEU . 62.6 t0 -109.1 108.34 18.98 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.798 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.476 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 0.2 OUTLIER -50.59 -41.52 20.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.519 179.927 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -49.9 -23.11 1.76 Allowed 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.907 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.47 ' CD1' ' CE2' ' A' ' 166' ' ' PHE . 0.6 OUTLIER -120.27 25.69 9.68 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 111.819 0.303 . . . . 0.0 111.819 -179.605 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.476 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 63.2 t -92.64 151.96 3.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.929 0.395 . . . . 0.0 110.87 179.457 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -74.94 79.55 2.16 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.159 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.01 123.75 10.89 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.343 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -99.28 -25.3 14.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.757 0.313 . . . . 0.0 111.177 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -52.77 168.9 0.8 Allowed Glycine 0 C--N 1.331 0.264 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.716 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 1.2 ttmm -58.18 142.47 47.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.768 0.318 . . . . 0.0 110.99 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 59.73 31.21 20.71 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.915 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 66.16 55.01 20.87 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.416 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -91.28 131.57 36.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.829 0.347 . . . . 0.0 110.926 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 14.9 t -91.6 123.91 43.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.066 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.3 mp -118.61 173.08 7.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.09 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 11.1 tttt -50.37 -45.21 55.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.677 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -59.72 -35.54 74.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.561 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -66.67 -36.84 83.48 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.238 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' ILE . . . . . 0.544 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 8.6 mm -63.94 -48.78 84.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.181 179.216 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -58.71 -41.86 87.33 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.594 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.97 -42.03 98.67 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.674 179.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' PHE . . . . . 0.47 ' CE2' ' CD1' ' A' ' 148' ' ' LEU . 13.6 t80 -59.46 -47.34 85.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.489 179.691 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 19.9 mt -75.81 -73.6 0.26 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.819 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -82.75 118.12 23.15 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.048 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -101.87 -44.78 1.87 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.562 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -100.68 -58.44 0.85 Allowed Glycine 0 C--O 1.249 1.046 0 CA-C-O 118.406 -1.219 . . . . 0.0 112.479 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.25 -3.757 0 CA-C-N 118.349 1.075 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 . . . . . 0 N--CA 1.486 1.356 0 CA-C-O 120.828 0.346 . . . . 0.0 111.163 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.1 ttm180 -152.37 100.4 2.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.927 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -116.45 176.32 5.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.82 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.7 t -133.26 159.26 43.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.017 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 3.3 mp -79.9 67.07 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.065 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -113.15 -169.86 1.57 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.105 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -129.65 161.38 59.55 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.846 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -61.99 -24.69 77.06 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.613 2.208 . . . . 0.0 112.225 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.3 m -92.36 -42.02 10.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.854 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.423 ' O ' ' HB3' ' A' ' 138' ' ' TYR . 59.2 t -62.03 -37.31 78.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.943 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.412 ' CD ' HD11 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -63.94 -47.54 80.09 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.303 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.22 -40.86 78.36 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 178.36 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.526 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.9 OUTLIER -51.86 -61.1 2.47 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.491 178.973 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -59.89 -28.11 67.29 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.575 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 11.0 tpt180 -79.95 -24.45 40.98 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.623 0.249 . . . . 0.0 111.373 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 16.8 mm-40 -89.25 -26.34 21.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.047 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 13.9 mptt -96.55 -22.28 17.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.251 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 101.27 8.61 46.7 Favored Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.667 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.428 HG12 ' CD1' ' A' ' 166' ' ' PHE . 45.1 t -92.73 159.26 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.775 0.321 . . . . 0.0 110.86 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.51 ' HB3' HD23 ' A' ' 148' ' ' LEU . 66.5 t0 -112.67 111.39 22.16 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.807 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.447 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 0.0 OUTLIER -49.53 -37.25 11.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.145 0.498 . . . . 0.0 111.726 -179.884 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 4.0 mtm-85 -48.59 -24.02 1.19 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.463 -0.79 . . . . 0.0 112.697 -179.231 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.598 ' N ' ' CD1' ' A' ' 148' ' ' LEU . 0.0 OUTLIER -127.92 31.75 5.05 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 111.893 0.331 . . . . 0.0 111.893 -179.25 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.447 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 76.5 t -94.75 157.08 3.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.841 0.353 . . . . 0.0 110.594 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -74.89 72.17 2.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.854 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.95 117.58 6.52 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.385 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -130.94 31.48 4.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.876 0.37 . . . . 0.0 110.798 -179.835 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -91.79 101.97 2.86 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.566 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 11.3 tttp 63.48 -78.69 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.712 0.292 . . . . 0.0 111.143 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 7.3 t30 -113.23 31.42 6.46 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.852 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 92.11 29.57 11.31 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.536 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 61.2 ttm-85 -77.02 130.98 38.18 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.87 0.367 . . . . 0.0 110.884 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 23.6 t -74.96 112.04 11.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.059 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -112.19 173.56 6.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.048 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 2.0 tttt -49.15 -46.22 44.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.797 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 49.1 mm-40 -60.61 -35.62 76.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.659 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -65.52 -37.35 86.51 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.471 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' ILE . . . . . 0.526 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 4.0 mm -65.07 -49.48 79.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.207 179.193 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -58.55 -36.88 74.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.638 179.635 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -66.24 -41.98 89.26 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.918 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' PHE . . . . . 0.436 ' CZ ' HD22 ' A' ' 148' ' ' LEU . 37.0 t80 -60.21 -50.84 72.06 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.637 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . 0.409 ' CD2' ' CG2' ' A' ' 144' ' ' VAL . 49.7 mt -71.95 -75.66 0.13 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.922 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -59.39 149.57 28.86 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.133 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 131.5 63.85 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.513 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -104.06 54.0 0.68 Allowed Glycine 0 C--O 1.249 1.047 0 CA-C-O 118.387 -1.23 . . . . 0.0 112.556 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.774 0 CA-C-N 118.387 1.094 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 9.0 t30 . . . . . 0 N--CA 1.487 1.414 0 CA-C-O 120.826 0.346 . . . . 0.0 111.195 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 2.2 mtt180 -145.14 -178.49 6.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.886 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 10.0 ttm105 -100.49 158.83 15.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 29.2 t -78.06 147.43 7.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.075 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 4.3 mt -108.34 52.98 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.125 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -100.58 168.08 9.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.088 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 1.4 mtp -95.33 157.36 36.45 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.9 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.79 -38.36 85.25 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.527 2.151 . . . . 0.0 112.393 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.2 t -80.06 -38.37 31.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.025 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 65.4 t -61.51 -36.49 73.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.051 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.42 ' CD ' ' CD1' ' A' ' 146' ' ' ILE . 1.4 mmt180 -68.05 -47.26 68.84 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.508 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.14 -36.94 78.63 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.462 ' CE2' ' CG2' ' A' ' 163' ' ' ILE . 1.2 t80 -55.95 -58.87 6.08 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.461 179.047 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -61.03 -28.73 69.26 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.21 -0.905 . . . . 0.0 111.262 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.55 -29.63 46.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.849 0.357 . . . . 0.0 111.161 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 64.7 mm-40 -85.59 -23.65 27.5 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.163 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -95.89 -24.35 16.47 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.398 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.36 4.17 40.81 Favored Glycine 0 CA--C 1.518 0.268 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.684 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.444 HG11 ' CE1' ' A' ' 166' ' ' PHE . 59.2 t -87.59 157.77 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 0.0 110.826 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.435 ' O ' ' HG ' ' A' ' 148' ' ' LEU . 62.3 t0 -106.79 105.48 15.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.73 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.459 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 4.3 pt -49.8 -42.16 17.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.49 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 80.3 mtp180 -48.65 -27.92 3.17 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.126 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.435 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.0 OUTLIER -116.8 24.19 11.42 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 111.979 0.363 . . . . 0.0 111.979 -179.515 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.459 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 43.8 t -88.72 150.47 3.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.762 0.315 . . . . 0.0 110.588 179.37 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.97 78.78 2.17 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.994 -179.684 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -82.14 118.69 4.68 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.378 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 8.8 t -137.83 34.87 2.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.823 0.344 . . . . 0.0 111.002 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -81.08 92.75 1.48 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.487 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 7.8 tttt 64.83 -75.08 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.716 0.293 . . . . 0.0 111.078 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.4 t30 -110.3 24.88 12.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.102 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 96.82 29.68 7.99 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.72 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 3.2 mtt180 -79.96 121.93 26.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.787 0.327 . . . . 0.0 110.771 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 26.5 t -75.02 92.79 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.112 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 3.2 mt -95.83 172.78 7.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.955 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.7 tttt -49.72 -42.58 46.3 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.783 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 51.7 mm-40 -56.06 -40.56 73.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.48 179.566 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -64.76 -43.49 93.12 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.215 179.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' ILE . . . . . 0.462 ' CG2' ' CE2' ' A' ' 138' ' ' TYR . 10.7 mm -61.73 -38.78 81.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.167 179.152 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -62.37 -45.2 94.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.246 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -59.04 -42.9 91.35 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.418 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' PHE . . . . . 0.444 ' CE1' HG11 ' A' ' 144' ' ' VAL . 7.8 t80 -61.67 -48.99 78.31 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.297 179.308 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . 0.435 ' CD2' ' CG2' ' A' ' 144' ' ' VAL . 40.1 mt -72.52 -76.21 0.12 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.859 180.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -67.12 -78.45 0.06 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.104 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 88.87 49.35 3.6 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.525 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -133.82 4.68 4.7 Favored Glycine 0 C--O 1.25 1.097 0 CA-C-O 118.306 -1.274 . . . . 0.0 112.426 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.812 0 CA-C-N 118.394 1.097 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.487 1.384 0 CA-C-O 120.809 0.338 . . . . 0.0 111.172 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 4.4 mtt180 -91.95 161.56 14.76 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.931 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.33 176.06 6.87 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.901 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 18.4 t -101.14 159.63 3.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.127 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 18.1 mt -80.02 59.94 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.022 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . 0.467 ' CB ' ' NE ' ' A' ' 136' ' ' ARG . . . -120.23 169.91 9.82 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.987 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 26.8 mtp -99.6 165.21 15.12 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.951 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -58.67 -45.51 29.14 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.575 2.183 . . . . 0.0 112.183 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 66.7 m -69.85 -37.5 76.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.656 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.424 ' O ' ' HB3' ' A' ' 138' ' ' TYR . 64.8 t -64.05 -37.73 80.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.919 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.467 ' NE ' ' CB ' ' A' ' 131' ' ' ALA . 0.0 OUTLIER -64.21 -49.04 73.55 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.306 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 6.2 tttt -58.88 -32.9 69.91 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.544 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -58.42 -60.61 3.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.446 179.197 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -60.62 -29.52 69.29 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.665 -179.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 63.5 mtt180 -79.79 -27.39 40.39 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.271 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -86.6 -28.48 23.25 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.954 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -93.51 -23.58 18.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.097 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 99.53 10.78 46.49 Favored Glycine 0 CA--C 1.52 0.351 0 C-N-CA 120.596 -0.812 . . . . 0.0 112.56 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.429 HG11 ' CE1' ' A' ' 166' ' ' PHE . 48.5 t -89.95 158.67 2.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.757 0.313 . . . . 0.0 110.715 179.723 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.425 ' HB3' ' CG ' ' A' ' 148' ' ' LEU . 62.8 t0 -104.28 104.05 13.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.035 0.445 . . . . 0.0 110.966 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.461 HD11 ' HG3' ' A' ' 136' ' ' ARG . 3.9 pt -47.36 -44.57 9.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.716 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 7.2 mmt180 -50.0 -23.39 2.01 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.786 -0.643 . . . . 0.0 112.195 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.461 ' CD1' ' CE2' ' A' ' 166' ' ' PHE . 0.7 OUTLIER -120.99 22.95 10.88 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -179.608 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.454 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 74.4 t -87.68 148.95 4.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.737 0.303 . . . . 0.0 110.497 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.91 79.32 2.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.904 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -85.68 115.33 4.15 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.41 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 3.7 t -140.67 42.81 1.86 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.368 . . . . 0.0 111.041 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -114.05 101.27 1.1 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.494 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 12.9 tttm 55.69 102.62 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.864 0.364 . . . . 0.0 111.074 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 65.64 14.22 9.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.345 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 81.61 46.99 6.54 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.792 179.789 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -96.92 130.97 44.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.781 0.324 . . . . 0.0 110.752 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 27.7 t -74.95 116.67 17.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.945 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 5.6 mt -114.24 174.11 6.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.155 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.1 tttm -50.62 -44.39 57.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.734 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -60.43 -35.4 75.71 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.653 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 36.9 m-20 -66.33 -38.82 88.55 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.273 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' ILE . . . . . 0.544 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 5.0 mm -62.01 -50.16 81.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.256 179.054 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.6 -41.25 80.85 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.55 179.638 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.07 -41.25 96.29 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.67 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' PHE . . . . . 0.461 ' CE2' ' CD1' ' A' ' 148' ' ' LEU . 21.5 t80 -60.89 -48.07 83.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.477 179.618 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 41.8 mt -74.61 -71.9 0.32 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.839 179.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -60.11 141.88 55.1 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.071 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 126.01 91.74 0.84 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.534 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 127.88 -33.67 3.17 Favored Glycine 0 C--O 1.249 1.047 0 CA-C-O 118.396 -1.224 . . . . 0.0 112.49 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.791 0 CA-C-N 118.386 1.093 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 . . . . . 0 N--CA 1.486 1.334 0 CA-C-O 120.851 0.358 . . . . 0.0 111.21 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.89 163.15 14.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.84 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.95 170.1 17.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.783 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 27.6 t -83.07 136.13 23.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.053 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 2.6 mt -83.42 64.43 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.064 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -116.72 -177.7 3.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.173 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 10.6 mtp -120.94 161.86 38.12 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.888 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.2 -56.84 2.52 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.509 2.139 . . . . 0.0 112.413 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -59.49 -40.64 87.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.871 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 96.3 t -60.36 -34.42 57.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.917 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -65.85 -52.35 51.09 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.474 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -56.39 -32.79 65.13 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.577 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.53 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -59.02 -61.56 2.55 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.358 179.14 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -63.15 -23.08 67.27 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.364 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -82.74 -26.43 31.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.088 179.829 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -86.66 -26.72 24.18 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.05 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 2.9 mptt -98.05 -24.9 15.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.247 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 100.84 13.27 34.84 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.612 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.419 HG11 ' CE1' ' A' ' 166' ' ' PHE . 38.9 t -93.97 161.02 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.718 0.294 . . . . 0.0 110.774 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.516 ' HB3' HD23 ' A' ' 148' ' ' LEU . 47.9 t0 -116.06 104.62 11.75 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.89 0.376 . . . . 0.0 110.795 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.438 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 6.1 pt -44.55 -36.26 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.222 0.534 . . . . 0.0 111.805 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -47.64 -26.16 1.41 Allowed 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.251 -0.886 . . . . 0.0 112.644 -179.159 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.577 ' N ' ' CD1' ' A' ' 148' ' ' LEU . 0.0 OUTLIER -125.21 29.87 5.98 Favored 'General case' 0 C--N 1.332 -0.161 0 C-N-CA 121.007 -0.277 . . . . 0.0 111.612 -179.36 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.438 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 54.5 t -94.26 157.73 2.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.839 0.352 . . . . 0.0 110.593 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . 0.412 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.91 75.1 2.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.906 -179.69 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -74.56 122.09 7.07 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.369 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -137.79 31.36 2.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.928 0.394 . . . . 0.0 110.861 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -92.27 106.05 3.36 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.622 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 5.0 tptp 67.16 -70.88 0.11 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.686 0.279 . . . . 0.0 111.204 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -131.73 36.69 3.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.821 0.343 . . . . 0.0 111.006 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 96.58 27.52 9.71 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.603 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 13.9 ttm180 -80.11 125.1 29.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.77 0.319 . . . . 0.0 110.833 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 28.3 t -75.03 111.9 11.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.998 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 5.0 mt -110.89 175.93 5.23 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.07 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 6.9 tttt -49.07 -45.75 43.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.816 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 -60.68 -36.12 77.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.696 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 73.3 m-20 -65.54 -36.3 83.39 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.298 179.663 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' ILE . . . . . 0.53 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 4.5 mm -64.79 -51.32 68.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.302 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.49 -38.03 73.91 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.638 179.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -64.83 -41.95 95.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.81 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' PHE . . . . . 0.432 ' CZ ' HD22 ' A' ' 148' ' ' LEU . 50.0 t80 -60.08 -48.88 79.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.622 179.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 39.6 mt -74.98 -31.54 61.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.928 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -91.32 102.62 15.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.03 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 93.82 -46.27 2.3 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.544 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 129.45 138.19 4.39 Favored Glycine 0 C--O 1.249 1.073 0 CA-C-O 118.379 -1.234 . . . . 0.0 112.554 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.785 0 CA-C-N 118.446 1.123 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 8.2 m120 . . . . . 0 N--CA 1.486 1.362 0 CA-C-O 120.806 0.336 . . . . 0.0 111.154 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 5.5 mtt180 -66.24 159.53 26.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.904 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -114.06 114.89 26.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.807 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 19.5 t -139.67 154.18 24.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.241 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 20.3 mt -93.37 67.17 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.863 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -129.8 -173.16 2.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.335 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.88 157.2 41.25 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.766 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.91 -33.14 50.39 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.632 2.221 . . . . 0.0 112.099 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 9.4 p -76.99 -43.31 35.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.619 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.414 ' O ' ' HB3' ' A' ' 138' ' ' TYR . 73.0 t -58.5 -34.97 52.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.856 179.813 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -64.71 -49.78 69.54 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 179.206 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -57.58 -31.09 65.81 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 178.556 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.544 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -61.25 -62.36 1.89 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.369 179.032 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -59.92 -29.2 68.21 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.413 -179.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? -80.11 -26.29 39.58 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.212 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -86.59 -29.48 22.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.995 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 4.9 mptt -95.07 -22.19 18.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.256 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 97.16 12.82 47.83 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.609 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.422 HG11 ' CE1' ' A' ' 166' ' ' PHE . 54.0 t -94.3 159.32 2.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.706 0.288 . . . . 0.0 110.783 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.409 ' O ' ' HG ' ' A' ' 148' ' ' LEU . 67.0 t0 -110.06 111.48 22.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.868 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.425 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 7.9 pt -53.36 -39.95 37.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.402 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 1.2 mmm180 -49.23 -25.26 2.18 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.792 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.42 HD13 ' CE2' ' A' ' 166' ' ' PHE . 0.3 OUTLIER -119.67 27.17 8.89 Favored 'General case' 0 C--N 1.332 -0.186 0 N-CA-C 111.659 0.244 . . . . 0.0 111.659 -179.827 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.425 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 40.5 t -95.04 150.3 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.867 0.365 . . . . 0.0 110.587 179.364 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -74.86 77.49 2.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.922 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -73.03 125.04 9.43 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.471 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 6.3 t -135.52 28.36 3.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.766 0.317 . . . . 0.0 110.905 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . 0.431 ' O ' ' N ' ' A' ' 155' ' ' ASN . . . -84.04 97.27 2.05 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.507 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 42.72 -90.55 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 122.451 0.301 . . . . 0.0 111.765 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.431 ' N ' ' O ' ' A' ' 153' ' ' GLY . 4.0 t-20 -89.14 51.16 2.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.993 0.425 . . . . 0.0 111.083 -179.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 58.96 56.48 25.09 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.465 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.57 125.96 54.48 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.797 0.332 . . . . 0.0 110.98 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 21.9 t -80.02 109.41 14.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.759 179.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -107.06 178.54 4.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.097 0.475 . . . . 0.0 111.371 -179.648 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . 0.442 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 2.8 tptt -50.59 -43.26 56.5 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.852 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -62.97 -34.62 77.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.794 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 26.8 m-20 -65.24 -42.69 93.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.407 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' ILE . . . . . 0.544 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 2.5 mm -62.15 -48.01 90.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.15 179.182 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.74 -37.42 73.56 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.472 179.44 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -64.77 -42.23 95.26 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.536 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' PHE . . . . . 0.422 ' CE1' HG11 ' A' ' 144' ' ' VAL . 28.2 t80 -62.3 -38.4 89.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.509 179.617 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 26.0 mt -90.44 -77.8 0.39 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.976 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -73.33 -80.71 0.07 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.192 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 169.62 -32.02 0.16 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.571 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 136.95 -24.97 3.09 Favored Glycine 0 C--O 1.249 1.053 0 CA-C-O 118.396 -1.224 . . . . 0.0 112.475 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.25 -3.758 0 CA-C-N 118.377 1.089 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 5.5 m-80 . . . . . 0 N--CA 1.486 1.369 0 CA-C-O 120.869 0.366 . . . . 0.0 111.24 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -139.94 140.23 36.31 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.91 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 9.6 mtt180 -87.56 149.2 24.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.861 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.4 t -82.52 151.64 4.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.171 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 3.3 mp -98.82 66.09 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.858 179.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -122.61 164.26 18.52 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.079 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' MET . . . . . 0.408 ' CB ' ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -99.56 166.68 12.44 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.862 179.948 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . 0.408 ' HD2' ' CB ' ' A' ' 132' ' ' MET . 20.8 Cg_endo -60.91 -26.49 83.22 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.512 2.141 . . . . 0.0 112.282 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -81.47 -44.85 16.84 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.752 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 85.5 t -59.92 -31.49 47.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.862 179.798 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -67.28 -52.94 34.59 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 8.7 ttpt -56.37 -31.07 63.45 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 178.536 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.541 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -60.86 -62.57 1.76 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.413 179.103 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -61.78 -24.1 66.62 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.334 -179.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 20.2 mmm-85 -80.52 -32.51 36.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.903 0.383 . . . . 0.0 110.822 179.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -83.72 -29.28 27.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.662 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 11.5 mmtt -89.66 -25.74 21.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.05 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 96.33 13.58 47.95 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.439 -179.535 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.442 HG12 ' CD1' ' A' ' 166' ' ' PHE . 92.8 t -97.84 159.71 3.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.76 0.314 . . . . 0.0 110.783 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.423 ' O ' ' HG ' ' A' ' 148' ' ' LEU . 68.4 t0 -108.75 111.96 24.0 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.785 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.438 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 8.6 pt -53.6 -40.06 40.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.039 0.447 . . . . 0.0 111.32 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 91.4 mtt-85 -49.34 -25.67 2.61 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.765 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.423 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.1 OUTLIER -118.81 27.32 8.96 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 111.721 0.267 . . . . 0.0 111.721 -179.878 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.438 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 38.8 t -94.0 154.5 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.851 0.358 . . . . 0.0 110.552 179.373 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.93 75.6 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.952 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -70.0 114.9 5.81 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.426 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -102.66 -21.01 14.19 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.699 0.285 . . . . 0.0 111.167 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -55.15 172.13 1.22 Allowed Glycine 0 C--N 1.332 0.33 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.629 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 16.0 tttp -52.91 134.72 37.31 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.798 0.332 . . . . 0.0 111.141 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.9 m-20 59.35 34.75 22.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.732 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 63.99 45.15 94.72 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.304 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 10.9 ttm-85 -82.95 128.14 34.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.86 0.362 . . . . 0.0 110.976 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 30.8 t -87.87 117.98 32.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.921 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.1 mt -113.19 177.42 4.64 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.072 0.463 . . . . 0.0 111.225 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . 0.44 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 1.8 tttt -50.68 -44.44 57.77 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.855 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 68.0 mm-40 -61.98 -34.11 75.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.695 179.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -67.11 -38.91 86.46 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.407 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' ILE . . . . . 0.541 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 4.4 mm -64.08 -48.93 83.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.294 179.263 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -58.37 -41.06 83.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.656 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.1 -41.71 99.43 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.921 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' PHE . . . . . 0.442 ' CD1' HG12 ' A' ' 144' ' ' VAL . 32.8 t80 -60.3 -50.45 73.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.827 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 50.8 mt -73.45 -33.8 65.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.861 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -102.15 86.35 2.84 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.088 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -96.3 28.05 14.61 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.488 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 176.33 98.49 0.11 Allowed Glycine 0 C--O 1.248 1.028 0 CA-C-O 118.347 -1.252 . . . . 0.0 112.497 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.815 0 CA-C-N 118.342 1.071 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 62.3 t30 . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 120.751 0.31 . . . . 0.0 111.219 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.31 175.68 9.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.862 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -94.88 -178.47 4.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.5 t -98.55 159.51 3.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.04 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.412 HD11 HG22 ' A' ' 130' ' ' ILE . 28.2 mm -79.9 68.87 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.791 179.81 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -141.6 142.67 33.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.123 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -69.95 162.75 66.44 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.86 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_endo -57.28 -24.45 59.78 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.627 2.218 . . . . 0.0 112.144 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.3 m -76.76 -44.86 31.34 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.89 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 93.0 t -59.8 -34.95 57.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.79 -51.38 56.39 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.325 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 2.5 tttt -56.75 -29.96 63.1 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 178.564 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.56 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -63.39 -62.74 1.48 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.496 179.301 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -63.11 -24.56 67.96 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.372 -179.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.63 -27.17 29.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.739 0.304 . . . . 0.0 110.957 179.746 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 8.2 mm-40 -85.82 -28.04 24.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.019 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 1.6 mmtm -97.66 -25.37 15.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.254 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 101.2 14.09 31.69 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.717 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.422 HG11 ' CE1' ' A' ' 166' ' ' PHE . 42.9 t -93.2 159.43 2.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.733 0.301 . . . . 0.0 110.826 179.731 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.434 ' O ' ' HG ' ' A' ' 148' ' ' LEU . 67.1 t0 -110.45 107.59 17.32 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.705 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.441 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 9.7 pt -52.05 -40.19 28.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 121.048 0.451 . . . . 0.0 111.217 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 92.0 mtt-85 -48.9 -26.33 2.41 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.931 -179.749 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.434 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.1 OUTLIER -119.24 26.93 9.13 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.663 0.268 . . . . 0.0 111.668 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.441 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 40.5 t -93.97 157.63 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.782 0.325 . . . . 0.0 110.518 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . 0.431 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.95 76.21 2.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.967 -179.767 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -72.52 109.15 2.71 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.421 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -97.65 -18.99 18.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.607 0.241 . . . . 0.0 111.207 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -56.36 168.13 3.48 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.508 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.13 136.95 41.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.925 0.393 . . . . 0.0 111.144 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 59.33 33.63 22.56 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.817 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 66.15 42.03 94.62 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.404 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 49.9 ttp180 -82.25 121.63 26.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.853 0.359 . . . . 0.0 110.878 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 21.5 t -85.38 122.94 38.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.999 179.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.2 mp -116.05 176.93 4.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.058 0.456 . . . . 0.0 111.183 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . 0.425 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 3.4 tttt -50.32 -46.48 55.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.787 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -59.69 -34.27 72.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.705 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 72.1 m-20 -67.69 -37.62 82.56 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.395 179.672 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' ILE . . . . . 0.56 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 4.9 mm -64.02 -49.01 83.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.339 179.271 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -58.8 -42.21 88.57 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.624 179.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.57 -40.83 96.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.81 179.8 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' PHE . . . . . 0.422 ' CE1' HG11 ' A' ' 144' ' ' VAL . 46.7 t80 -60.55 -51.31 69.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.65 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 29.4 mt -70.44 -30.95 67.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.896 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -75.14 176.61 7.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.08 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -81.39 -30.64 36.31 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.5 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 79.79 66.59 1.65 Allowed Glycine 0 C--O 1.248 1.03 0 CA-C-O 118.472 -1.182 . . . . 0.0 112.477 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.768 0 CA-C-N 118.309 1.054 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 38.2 t30 . . . . . 0 N--CA 1.486 1.344 0 CA-C-O 120.86 0.362 . . . . 0.0 111.205 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 18.2 ttm-85 -114.73 156.38 24.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.912 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -117.38 172.43 7.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.845 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.4 t -132.42 145.45 34.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.173 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 2.6 mp -83.75 65.86 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.997 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -132.74 142.24 48.94 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.199 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 2.6 mtm -71.98 166.22 42.66 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.816 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_endo -61.24 -32.64 90.59 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.513 2.142 . . . . 0.0 112.219 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -69.93 -45.54 67.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.782 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 84.7 t -60.16 -33.06 52.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.99 179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -65.9 -50.72 63.46 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.21 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.4 tttt -57.71 -31.71 66.67 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.536 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -60.27 -61.6 2.48 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.402 179.109 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -63.78 -21.67 66.54 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.299 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.79 -27.61 28.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.042 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -85.94 -25.81 25.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.059 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 2.1 tptt -98.61 -26.72 14.3 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.247 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 103.07 13.11 29.91 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.596 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.418 HG11 ' CE1' ' A' ' 166' ' ' PHE . 35.0 t -93.27 160.59 2.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.794 0.33 . . . . 0.0 110.831 179.737 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.502 ' HB3' HD23 ' A' ' 148' ' ' LEU . 51.9 t0 -115.22 105.66 13.15 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.952 0.406 . . . . 0.0 110.755 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.455 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 4.0 pt -45.13 -36.3 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.3 0.571 . . . . 0.0 111.867 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -48.24 -25.32 1.48 Allowed 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.332 -0.849 . . . . 0.0 112.643 -179.157 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.571 ' N ' ' CD1' ' A' ' 148' ' ' LEU . 0.0 OUTLIER -126.82 31.07 5.37 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 111.817 0.303 . . . . 0.0 111.817 -179.33 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.455 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 54.1 t -92.88 157.45 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.821 0.344 . . . . 0.0 110.65 179.372 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . 0.419 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.84 69.77 1.87 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.999 -179.645 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -68.79 115.83 6.88 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.403 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -116.79 13.81 15.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.617 0.246 . . . . 0.0 111.325 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -83.06 175.2 52.93 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.298 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.27 117.9 2.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.789 0.328 . . . . 0.0 111.147 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 3.5 m120 62.49 52.72 2.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.938 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 56.66 48.55 76.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.536 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 5.9 ttm180 -90.6 114.94 27.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.781 0.325 . . . . 0.0 110.982 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 31.7 t -81.29 118.19 28.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.776 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -115.13 176.67 4.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.027 0.442 . . . . 0.0 111.263 -179.69 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 14.3 tttm -49.84 -45.72 50.61 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.818 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 -60.03 -35.46 75.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.653 179.742 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -66.23 -37.94 86.73 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.368 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' ILE . . . . . 0.536 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 5.4 mm -63.14 -49.16 84.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.909 179.084 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -59.42 -36.49 75.97 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.508 179.459 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.6 -39.84 92.0 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.775 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' PHE . . . . . 0.429 ' CZ ' HD22 ' A' ' 148' ' ' LEU . 57.7 t80 -62.98 -47.27 83.88 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.536 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 5.8 mt -82.33 -69.79 0.6 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.911 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -58.12 -74.39 0.06 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.256 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 119.33 86.51 1.03 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.54 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 166.49 -41.03 0.26 Allowed Glycine 0 C--O 1.249 1.072 0 CA-C-O 118.407 -1.219 . . . . 0.0 112.521 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.818 0 CA-C-N 118.382 1.091 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 120.802 0.334 . . . . 0.0 111.188 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 5.8 ttm180 -118.26 108.4 15.08 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.874 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.16 174.18 5.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.911 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 33.9 t -114.9 158.56 15.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.019 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 3.5 mp -80.01 64.27 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.996 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -135.76 176.53 8.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.101 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 77.6 mtp -100.8 162.04 21.93 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.953 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.42 -40.48 71.18 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.549 2.166 . . . . 0.0 112.254 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.22 -43.74 70.03 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.912 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 67.4 t -58.98 -36.48 62.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.942 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -66.14 -51.92 53.3 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 179.469 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.9 ttpt -56.72 -32.64 65.73 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 178.691 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.56 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.9 OUTLIER -59.73 -61.82 2.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.458 179.205 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -63.45 -23.31 67.34 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.297 -179.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -82.04 -28.22 32.58 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.951 179.78 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -86.35 -28.57 23.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.847 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 4.1 mptt -93.96 -24.58 17.61 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.04 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 98.07 13.94 41.03 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.6 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.428 HG11 ' CE1' ' A' ' 166' ' ' PHE . 45.6 t -92.74 159.11 2.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.799 0.333 . . . . 0.0 110.828 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 68.2 t0 -109.3 105.42 14.82 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.839 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.466 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 7.3 pt -49.33 -39.92 13.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.13 0.49 . . . . 0.0 111.389 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 8.4 mtt-85 -49.4 -24.73 2.09 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.746 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.462 ' CD1' ' CE2' ' A' ' 166' ' ' PHE . 0.6 OUTLIER -120.32 27.99 8.28 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.586 0.231 . . . . 0.0 111.596 -179.846 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.466 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 43.4 t -95.31 155.56 3.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.934 0.397 . . . . 0.0 110.792 179.594 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . 0.407 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 8.6 tt0 -74.99 77.61 2.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.096 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.65 111.75 3.79 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.455 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -87.38 -27.09 23.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.763 0.316 . . . . 0.0 111.042 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -57.73 173.19 2.72 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.556 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 3.9 tttp -57.78 140.06 52.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.839 0.352 . . . . 0.0 110.944 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 59.83 30.93 20.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.831 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 69.87 42.34 69.98 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.482 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.45 127.23 32.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.772 0.32 . . . . 0.0 110.844 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 25.9 t -94.41 117.2 37.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.19 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 3.8 mp -112.96 175.91 5.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.911 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . 0.422 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 0.4 OUTLIER -50.91 -45.52 60.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.642 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 4.2 mm-40 -60.36 -34.25 73.6 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.603 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -67.64 -37.6 82.68 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.436 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' ILE . . . . . 0.56 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 5.4 mm -64.01 -47.93 88.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.169 179.164 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -58.76 -42.38 88.79 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.577 179.409 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.01 -40.94 95.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.653 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' PHE . . . . . 0.462 ' CE2' ' CD1' ' A' ' 148' ' ' LEU . 20.5 t80 -63.51 -38.94 93.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.513 179.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 12.7 mt -96.33 -83.18 0.38 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.77 179.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . 50.45 -177.64 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.377 179.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -169.2 -61.62 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.452 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 85.74 12.5 71.84 Favored Glycine 0 C--O 1.249 1.077 0 CA-C-O 118.338 -1.257 . . . . 0.0 112.469 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.832 0 CA-C-N 118.387 1.094 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 34.4 m120 . . . . . 0 N--CA 1.487 1.385 0 CA-C-O 120.772 0.32 . . . . 0.0 111.205 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.87 149.3 40.74 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.797 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 11.8 ttt180 -58.64 168.54 1.16 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.014 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.2 t -77.42 139.98 17.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.066 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 6.4 mt -80.11 68.22 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.987 0.423 . . . . 0.0 110.974 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -130.19 171.31 13.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.196 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.3 mtp -91.47 160.37 36.97 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.851 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.65 -23.49 76.05 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.591 2.194 . . . . 0.0 112.242 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.2 m -90.65 -41.48 11.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.898 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.459 ' O ' ' HB3' ' A' ' 138' ' ' TYR . 59.5 t -59.91 -39.7 80.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.033 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.452 ' CD ' ' CD1' ' A' ' 146' ' ' ILE . 0.0 OUTLIER -62.48 -43.44 98.8 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.63 -0.508 . . . . 0.0 109.63 179.364 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.3 -33.32 74.43 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 178.331 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.55 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.9 OUTLIER -57.7 -60.87 3.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.375 179.052 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -61.29 -29.61 69.97 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.377 -179.649 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 11.3 mmm180 -79.19 -23.03 44.13 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.339 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -89.67 -26.57 20.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.802 0.334 . . . . 0.0 111.032 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -96.06 -22.31 17.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.288 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.46 7.09 46.44 Favored Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.573 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.44 HG11 ' CE1' ' A' ' 166' ' ' PHE . 59.2 t -89.44 155.24 3.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 120.722 0.296 . . . . 0.0 110.67 179.65 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.412 ' HB3' ' CG ' ' A' ' 148' ' ' LEU . 66.5 t0 -102.34 109.19 20.77 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.14 0.495 . . . . 0.0 110.89 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.466 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 5.4 pt -51.07 -43.78 27.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.63 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 11.6 mtt180 -49.72 -24.62 2.4 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.941 -0.572 . . . . 0.0 112.11 -179.437 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.412 ' CG ' ' HB3' ' A' ' 145' ' ' ASP . 0.1 OUTLIER -119.2 23.97 11.01 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 112.111 0.412 . . . . 0.0 112.111 -179.645 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.466 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 48.9 t -86.64 156.18 3.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.733 0.301 . . . . 0.0 110.555 179.209 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . 0.405 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 4.2 tt0 -74.79 74.24 2.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.067 -179.73 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -72.07 107.38 2.17 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.403 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -129.06 27.8 5.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.871 0.367 . . . . 0.0 110.988 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -106.09 107.03 2.68 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.426 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 14.5 tptm 56.17 97.94 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.756 0.313 . . . . 0.0 110.809 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 70.16 -66.15 0.29 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.784 -179.767 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 178.54 58.71 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.429 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 43.2 ttm-85 -108.98 138.87 44.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.861 0.363 . . . . 0.0 110.894 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 21.9 t -82.76 114.39 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.083 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 14.5 mt -112.37 175.12 5.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.05 -179.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . 0.424 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 1.0 OUTLIER -50.77 -44.98 58.77 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.673 179.903 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -61.11 -34.41 74.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.637 179.587 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -66.82 -37.22 84.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.457 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' ILE . . . . . 0.55 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 8.2 mm -65.11 -49.23 80.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.186 179.167 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -58.82 -38.42 78.6 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.572 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.49 -41.08 93.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.836 179.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' PHE . . . . . 0.44 ' CE1' HG11 ' A' ' 144' ' ' VAL . 24.6 t80 -61.1 -45.69 93.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.591 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . 0.408 ' CD2' ' CG2' ' A' ' 144' ' ' VAL . 16.4 mt -78.68 -65.56 0.97 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.805 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -85.51 131.82 34.3 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.038 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -93.06 -103.64 1.6 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.539 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -177.99 128.16 1.26 Allowed Glycine 0 C--O 1.249 1.091 0 CA-C-O 118.389 -1.228 . . . . 0.0 112.493 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.77 0 CA-C-N 118.369 1.084 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 . . . . . 0 N--CA 1.487 1.417 0 CA-C-O 120.737 0.303 . . . . 0.0 111.253 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.9 mtt85 -141.8 153.36 44.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.841 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -64.7 -177.35 0.32 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.846 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.3 t -124.88 149.16 29.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.169 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 28.4 mt -87.41 68.93 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.048 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -133.5 -177.11 4.39 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.123 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.42 166.06 11.75 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.864 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -52.89 -37.62 77.73 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.505 2.137 . . . . 0.0 112.381 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.66 -48.25 55.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.88 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 73.9 t -58.06 -33.06 45.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.848 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.12 -52.88 36.29 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 179.341 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 3.8 tttp -55.96 -30.3 61.53 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 178.634 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.548 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -62.86 -62.78 1.49 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.442 179.295 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -63.71 -23.91 67.56 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.243 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 3.8 tpt180 -82.97 -25.92 31.81 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.943 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -87.55 -26.59 23.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.945 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -97.52 -25.18 15.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.188 -179.779 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 100.85 13.27 34.82 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.674 -0.775 . . . . 0.0 112.584 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.42 HG11 ' CE1' ' A' ' 166' ' ' PHE . 44.3 t -94.55 160.03 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.788 0.327 . . . . 0.0 110.743 179.716 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.424 ' O ' ' HG ' ' A' ' 148' ' ' LEU . 42.9 t0 -111.17 109.6 19.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.733 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.439 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 9.7 pt -52.03 -39.84 27.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.389 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 2.2 ptt180 -48.99 -25.92 2.24 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.794 -179.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.424 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.2 OUTLIER -119.43 26.96 9.07 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 111.645 0.239 . . . . 0.0 111.645 -179.809 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.439 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 43.6 t -95.05 157.53 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.837 0.351 . . . . 0.0 110.586 179.305 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . 0.425 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 2.1 tt0 -74.74 77.55 2.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.067 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -72.91 106.11 1.89 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.447 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -93.03 -17.52 23.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.605 0.24 . . . . 0.0 111.24 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -53.25 161.84 2.94 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.649 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.2 138.19 26.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.795 0.331 . . . . 0.0 111.168 -179.897 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 61.68 31.64 18.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.802 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 61.57 68.22 1.76 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.482 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 34.7 ttm180 -112.04 133.7 54.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.813 0.339 . . . . 0.0 110.987 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 21.9 t -85.3 124.18 39.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.949 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 2.1 mt -121.85 172.46 8.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.219 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . 0.432 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 4.9 tttm -47.8 -50.41 25.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.053 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -57.18 -35.38 69.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.781 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -67.56 -34.75 77.69 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.38 179.678 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' ILE . . . . . 0.548 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 5.7 mm -64.98 -50.65 73.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.068 179.106 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -59.57 -37.72 79.23 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.571 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.9 -40.5 91.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.712 179.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' PHE . . . . . 0.42 ' CE1' HG11 ' A' ' 144' ' ' VAL . 37.2 t80 -60.91 -48.32 82.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.567 179.675 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 16.5 mt -75.06 -30.5 61.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.955 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -106.4 103.44 12.9 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.038 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -176.98 41.54 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.516 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -106.32 -159.45 22.16 Favored Glycine 0 C--O 1.249 1.04 0 CA-C-O 118.348 -1.251 . . . . 0.0 112.447 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.25 -3.745 0 CA-C-N 118.402 1.101 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 . . . . . 0 N--CA 1.487 1.396 0 CA-C-O 120.711 0.291 . . . . 0.0 111.272 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.45 149.85 50.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.982 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -115.41 -175.46 2.71 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.832 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.5 t -127.21 137.0 59.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.17 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 32.2 mt -87.29 60.05 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.082 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -120.47 163.44 17.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.016 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 24.5 mmm -88.79 161.19 42.27 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.93 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -52.22 -28.18 32.96 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.587 2.191 . . . . 0.0 112.257 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 58.2 m -87.31 -38.6 16.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.906 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.436 ' O ' ' HB3' ' A' ' 138' ' ' TYR . 61.4 t -62.68 -40.48 88.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.022 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.481 ' HD2' ' CD1' ' A' ' 146' ' ' ILE . 25.1 mmm-85 -65.52 -47.74 74.9 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.35 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 2.0 tttm -60.72 -29.81 69.58 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.537 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -60.95 -60.66 3.43 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.481 179.213 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -62.69 -27.76 69.47 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.78 -0.645 . . . . 0.0 111.516 -179.544 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.4 -21.18 33.08 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.301 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -91.95 -22.22 20.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.069 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 1.1 mmtt -103.22 -24.47 13.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.346 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.58 9.6 32.82 Favored Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.875 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.427 HG11 ' CE1' ' A' ' 166' ' ' PHE . 46.3 t -89.24 155.06 3.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.748 0.309 . . . . 0.0 110.59 179.545 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.447 ' HB3' ' CG ' ' A' ' 148' ' ' LEU . 61.4 t0 -100.79 104.97 16.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.11 0.481 . . . . 0.0 111.023 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.481 ' CD1' ' HD2' ' A' ' 136' ' ' ARG . 3.1 pt -47.44 -45.51 9.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.73 179.564 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.67 -22.09 1.9 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.332 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.463 ' CD1' ' CE2' ' A' ' 166' ' ' PHE . 0.9 OUTLIER -121.44 22.27 10.77 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 112.053 0.39 . . . . 0.0 112.053 -179.592 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.438 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 76.0 t -85.96 152.49 3.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.864 0.364 . . . . 0.0 110.574 179.251 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.94 78.98 2.16 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.919 -179.776 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -80.92 106.85 2.6 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.42 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -112.12 31.14 6.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.925 0.393 . . . . 0.0 110.879 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . 0.426 ' O ' ' N ' ' A' ' 155' ' ' ASN . . . -86.59 95.48 2.05 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.519 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . 0.421 ' CD ' ' N ' ' A' ' 154' ' ' LYS . 0.0 OUTLIER 38.97 -90.9 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 122.606 0.362 . . . . 0.0 111.861 179.92 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.426 ' N ' ' O ' ' A' ' 153' ' ' GLY . 3.2 m-20 -87.49 54.67 3.22 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.887 0.375 . . . . 0.0 111.028 -179.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 57.63 52.46 51.82 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.508 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -106.75 121.46 44.41 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.804 0.335 . . . . 0.0 110.892 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 22.6 t -74.96 129.09 37.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.977 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 2.3 mt -122.96 170.93 9.63 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.122 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 29.6 tttm -50.61 -44.75 57.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.622 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -60.31 -35.37 75.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.501 179.704 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -66.26 -38.28 87.45 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.328 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' ILE . . . . . 0.537 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 6.1 mm -63.22 -49.78 81.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.248 179.351 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -58.08 -41.04 82.58 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.621 179.719 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.13 -40.72 98.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.764 179.704 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' PHE . . . . . 0.463 ' CE2' ' CD1' ' A' ' 148' ' ' LEU . 17.9 t80 -60.82 -45.57 93.95 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.486 179.725 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . 0.409 ' CD2' ' CG2' ' A' ' 144' ' ' VAL . 21.1 mt -75.69 -31.85 59.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.849 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -91.42 -177.68 4.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.042 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 88.33 29.37 19.77 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.517 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -161.81 88.35 0.11 Allowed Glycine 0 C--O 1.25 1.126 0 CA-C-O 118.399 -1.223 . . . . 0.0 112.513 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.837 0 CA-C-N 118.42 1.11 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 . . . . . 0 N--CA 1.486 1.332 0 CA-C-O 120.78 0.324 . . . . 0.0 111.226 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -119.43 63.12 0.8 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.857 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 1.6 mtm-85 -134.43 -178.58 5.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.888 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 17.0 t -124.51 151.73 30.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.177 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 3.0 mp -81.6 70.73 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.847 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -124.85 158.05 34.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.246 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 1.3 mmt -85.97 161.35 50.16 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.822 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_endo -61.15 -30.81 89.53 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.575 2.183 . . . . 0.0 112.221 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -82.1 -37.39 26.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.736 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 62.6 t -61.7 -34.63 63.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -65.91 -52.85 46.45 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.439 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.14 -34.34 63.67 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 178.671 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.567 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.9 OUTLIER -59.08 -61.79 2.37 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.442 179.21 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -62.01 -23.88 66.7 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.517 -179.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 3.2 mmm-85 -82.6 -28.81 30.61 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.717 0.294 . . . . 0.0 111.116 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -84.22 -27.69 27.81 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.123 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 2.1 mptp? -96.06 -26.9 15.34 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.124 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.09 13.34 31.63 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.619 -179.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.429 HG12 ' CD1' ' A' ' 166' ' ' PHE . 47.7 t -94.91 159.88 2.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-O 120.689 0.28 . . . . 0.0 110.738 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.431 ' O ' ' HG ' ' A' ' 148' ' ' LEU . 66.9 t0 -111.99 111.17 21.91 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.811 179.817 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.424 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 7.8 pt -52.16 -39.77 28.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.457 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -48.94 -25.75 2.12 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.754 -179.762 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.431 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.2 OUTLIER -119.65 28.12 8.34 Favored 'General case' 0 N--CA 1.462 0.138 0 N-CA-C 111.679 0.251 . . . . 0.0 111.679 -179.832 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.424 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 55.6 t -98.25 155.64 3.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.79 0.329 . . . . 0.0 110.659 179.269 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.94 79.3 2.16 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.96 -179.736 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -76.48 114.83 4.24 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.328 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -110.74 26.17 10.99 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.694 0.283 . . . . 0.0 111.085 -179.866 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -99.05 179.56 31.2 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.354 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -51.27 118.28 3.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.782 0.325 . . . . 0.0 111.178 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 59.72 54.62 4.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.936 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 57.22 48.76 77.62 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.361 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.93 120.04 28.88 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.808 0.337 . . . . 0.0 111.024 -179.808 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 22.2 t -84.0 122.84 38.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.79 179.751 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -117.6 174.69 6.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.094 0.474 . . . . 0.0 111.291 -179.621 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . 0.444 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 2.1 tptt -50.16 -45.8 53.6 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.784 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -60.11 -34.86 74.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.681 179.663 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -67.17 -36.69 82.33 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.332 179.57 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' ILE . . . . . 0.567 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 5.2 mm -64.01 -50.3 77.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.093 179.179 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -58.62 -39.65 81.08 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.484 179.675 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -62.54 -41.34 98.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.771 179.664 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' PHE . . . . . 0.429 ' CD1' HG12 ' A' ' 144' ' ' VAL . 40.9 t80 -60.61 -51.81 67.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.568 179.659 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 23.7 mt -71.15 -72.53 0.21 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.833 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -66.68 168.62 9.11 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.03 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -173.79 57.69 0.14 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.498 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -78.2 -60.74 2.63 Favored Glycine 0 C--O 1.25 1.109 0 CA-C-O 118.432 -1.204 . . . . 0.0 112.518 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.762 0 CA-C-N 118.419 1.109 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 8.5 m-80 . . . . . 0 N--CA 1.486 1.358 0 CA-C-O 120.788 0.327 . . . . 0.0 111.214 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.39 55.52 1.27 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.854 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.06 175.8 0.11 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.835 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 35.1 t -121.23 115.35 46.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.13 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 4.4 mt -93.79 50.03 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.726 179.757 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -97.48 178.24 5.26 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.304 -179.799 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -114.42 158.88 38.77 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.843 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.08 -54.82 4.79 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.682 2.255 . . . . 0.0 112.159 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.1 m -60.33 -40.97 92.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.624 179.736 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.407 ' O ' ' HB3' ' A' ' 138' ' ' TYR . 81.6 t -60.53 -34.24 57.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.716 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.402 ' HD3' ' CD1' ' A' ' 146' ' ' ILE . 0.2 OUTLIER -64.04 -53.16 54.28 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.201 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -56.84 -30.71 64.05 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 178.536 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.521 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -62.26 -61.32 2.54 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.581 179.313 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -62.45 -27.1 68.88 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.49 -179.466 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 31.0 mmm180 -83.18 -24.06 32.63 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.708 0.289 . . . . 0.0 111.084 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -88.71 -22.84 23.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.25 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 4.3 mmtt -102.65 -25.38 13.58 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.288 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.75 9.99 31.64 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.64 -179.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.425 HG11 ' CE1' ' A' ' 166' ' ' PHE . 25.1 t -94.98 162.05 2.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.632 0.253 . . . . 0.0 110.656 179.628 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.501 ' HB3' ' CD1' ' A' ' 148' ' ' LEU . 55.5 t0 -117.53 109.09 16.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.946 0.403 . . . . 0.0 110.845 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.457 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 5.1 pt -46.45 -37.3 3.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.125 0.488 . . . . 0.0 111.807 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -47.58 -25.35 1.11 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.53 -0.759 . . . . 0.0 112.616 -179.196 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.581 ' N ' ' CD1' ' A' ' 148' ' ' LEU . 0.0 OUTLIER -127.12 30.24 5.46 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 111.736 0.273 . . . . 0.0 111.736 -179.22 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.457 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 58.3 t -93.92 158.57 2.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.804 0.335 . . . . 0.0 110.609 179.514 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . 0.423 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.7 OUTLIER -74.8 77.13 2.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.975 -179.659 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.59 90.64 0.47 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.393 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 11.2 t -99.14 26.9 5.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.823 0.344 . . . . 0.0 111.058 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -92.45 170.9 33.03 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.429 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -49.95 122.58 6.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.864 0.364 . . . . 0.0 111.081 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 62.0 t30 64.87 40.44 5.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.837 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 59.78 56.76 23.02 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.484 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 17.3 ttm180 -106.05 135.5 47.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.754 0.312 . . . . 0.0 110.999 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 21.8 t -89.27 126.64 42.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.939 179.783 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -124.04 174.02 7.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.121 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . 0.426 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 64.5 tttt -48.54 -50.19 33.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.901 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -56.27 -35.37 67.39 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.824 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -67.24 -38.22 84.85 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.434 179.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' ILE . . . . . 0.521 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 4.2 mm -61.98 -47.28 93.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.064 0.459 . . . . 0.0 109.929 179.114 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -60.23 -40.92 91.89 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.475 179.413 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -62.08 -40.89 97.38 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.798 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' PHE . . . . . 0.425 ' CE1' HG11 ' A' ' 144' ' ' VAL . 44.5 t80 -60.49 -50.6 72.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.429 179.62 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . 0.405 ' CD2' ' CG2' ' A' ' 144' ' ' VAL . 14.8 mt -71.92 -29.72 64.6 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.855 179.856 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -91.0 96.51 10.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.111 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 149.73 44.73 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.489 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -113.93 146.5 18.61 Favored Glycine 0 C--O 1.249 1.09 0 CA-C-O 118.349 -1.251 . . . . 0.0 112.485 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.805 0 CA-C-N 118.377 1.089 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.488 1.427 0 CA-C-O 120.775 0.321 . . . . 0.0 111.147 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.35 126.28 36.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.901 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 6.4 mtt180 -176.38 166.42 2.78 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.796 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.4 t -101.67 146.21 10.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.134 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 24.0 mt -84.24 62.87 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.035 179.823 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -133.3 -174.71 3.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.112 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.3 mmm -106.72 161.55 22.52 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.884 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -56.15 -23.6 45.65 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.582 2.188 . . . . 0.0 112.126 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 45.9 p -81.05 -46.18 15.39 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.79 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 86.2 t -58.68 -33.25 48.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.986 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 4.8 mmm180 -64.35 -51.21 64.5 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.263 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -53.96 -38.8 65.36 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 178.467 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.532 ' CE2' ' HB ' ' A' ' 163' ' ' ILE . 0.8 OUTLIER -55.02 -62.6 1.55 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.93 179.183 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -61.09 -23.28 65.37 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.782 -179.33 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 38.2 mtt-85 -84.08 -28.11 27.78 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.765 0.317 . . . . 0.0 111.123 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -84.05 -27.09 28.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.172 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.27 -27.88 13.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.158 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.28 16.01 24.06 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.578 -179.831 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.434 HG12 ' CD1' ' A' ' 166' ' ' PHE . 46.4 t -95.91 160.67 2.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.772 0.32 . . . . 0.0 110.756 179.766 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -113.9 108.99 17.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.888 179.665 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.433 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 7.1 pt -50.5 -39.83 18.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.433 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -48.9 -24.84 1.62 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.773 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.405 ' CD1' ' CE2' ' A' ' 166' ' ' PHE . 0.4 OUTLIER -120.36 28.09 8.22 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.652 0.263 . . . . 0.0 111.612 -179.715 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.433 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 55.2 t -99.31 153.6 4.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.928 0.394 . . . . 0.0 110.771 179.456 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -74.96 79.16 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.161 -179.629 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -73.64 120.0 6.75 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.399 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -104.55 -21.26 13.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.643 0.259 . . . . 0.0 111.227 -179.848 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -50.13 176.21 0.04 OUTLIER Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.729 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 16.5 tptt -53.72 125.01 16.81 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.806 0.336 . . . . 0.0 111.13 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 60.46 47.45 8.68 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.859 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 58.8 55.14 32.52 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.418 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.87 120.97 32.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.864 0.364 . . . . 0.0 110.922 -179.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 25.9 t -79.99 111.93 17.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.847 179.791 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.4 mt -111.87 175.98 5.21 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.107 0.479 . . . . 0.0 111.167 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 49.5 tttt -49.43 -48.19 47.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.806 179.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -59.03 -34.48 71.96 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.714 179.778 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -67.35 -36.06 80.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.452 179.721 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' ILE . . . . . 0.532 ' HB ' ' CE2' ' A' ' 138' ' ' TYR . 4.2 mm -65.2 -50.22 74.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.169 179.226 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -58.52 -39.61 80.61 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.601 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.78 -40.57 97.0 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.628 179.737 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' PHE . . . . . 0.434 ' CD1' HG12 ' A' ' 144' ' ' VAL . 26.9 t80 -60.32 -48.98 79.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.425 179.678 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' LEU . . . . . . . . . . . . . 6.1 mt -72.63 -31.17 64.93 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.911 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -75.71 149.37 38.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.158 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 109.08 29.83 3.88 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.499 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 150.82 109.83 0.47 Allowed Glycine 0 C--O 1.249 1.07 0 CA-C-O 118.385 -1.231 . . . . 0.0 112.526 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.782 0 CA-C-N 118.371 1.086 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.825 0.345 . . . . 0.0 111.173 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 33.7 mtp -103.12 157.95 32.74 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.807 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 10.5 Cg_endo -53.6 -27.42 41.38 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.642 2.228 . . . . 0.0 112.192 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.6 t -80.06 -47.22 15.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.71 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.735 ' CG1' HD11 ' A' ' 163' ' ' ILE . 94.9 t -58.31 -31.31 42.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.822 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.469 ' HD3' HD11 ' A' ' 146' ' ' ILE . 6.6 mmm-85 -65.42 -52.74 51.22 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.281 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 11.0 tppt? -52.88 -39.5 62.71 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.478 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.689 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -54.33 -62.8 1.42 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.027 -0.988 . . . . 0.0 110.796 179.133 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.873 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -60.18 -24.67 64.97 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.601 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 3.3 mmt85 -82.16 -27.6 32.59 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.69 0.281 . . . . 0.0 111.122 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -85.68 -29.39 24.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.973 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 3.7 mptp? -94.96 -24.45 16.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.172 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 98.66 14.27 38.07 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.613 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.873 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 34.4 t -94.19 160.13 2.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.713 0.292 . . . . 0.0 110.81 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.772 ' HB3' HD11 ' A' ' 148' ' ' LEU . 63.8 t0 -114.9 104.99 12.47 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.789 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.469 HD11 ' HD3' ' A' ' 136' ' ' ARG . 4.4 pt -45.5 -36.33 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.26 0.552 . . . . 0.0 111.818 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 6.8 mtt180 -48.29 -25.6 1.63 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.316 -0.856 . . . . 0.0 112.641 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.852 ' N ' HD13 ' A' ' 148' ' ' LEU . 0.0 OUTLIER -125.49 30.02 5.87 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.662 0.268 . . . . 0.0 111.715 -179.433 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.46 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 58.1 t -94.63 155.65 3.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.862 0.363 . . . . 0.0 110.683 179.406 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.408 ' N ' HG12 ' A' ' 149' ' ' VAL . 0.5 OUTLIER -74.96 79.51 2.17 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.925 -179.749 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -73.32 110.52 3.16 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.433 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.328 -0.34 0 CA-C-O 120.585 0.231 . . . . 0.0 111.215 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.463 ' O ' HG21 ' A' ' 135' ' ' VAL . 21.8 t . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.738 0.304 . . . . 0.0 110.931 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.608 ' HA ' HG21 ' A' ' 135' ' ' VAL . 5.1 mt -109.45 178.51 4.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.019 0.438 . . . . 0.0 111.311 -179.754 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 160' ' ' LYS . . . . . 0.452 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 7.9 tttt -50.04 -47.69 53.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.688 179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -59.99 -33.63 72.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.752 179.712 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 162' ' ' ASP . . . . . 0.402 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 70.1 m-20 -67.66 -36.65 81.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.396 179.757 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 163' ' ' ILE . . . . . 0.735 HD11 ' CG1' ' A' ' 135' ' ' VAL . 3.5 mm -65.18 -50.09 75.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.174 179.114 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -58.62 -38.91 79.06 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.539 179.635 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.8 -42.08 97.77 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.787 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 166' ' ' PHE . . . . . 0.571 ' CE1' HG13 ' A' ' 144' ' ' VAL . 45.8 t80 -59.67 -51.26 70.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.608 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 167' ' ' LEU . . . . . 0.714 HD21 ' CG2' ' A' ' 144' ' ' VAL . 33.7 mt . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.959 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.863 0.363 . . . . 0.0 111.168 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 14.7 mtp -104.25 166.29 11.87 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.842 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -63.19 -27.59 72.75 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.556 2.171 . . . . 0.0 112.15 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 24.8 m -79.93 -44.92 19.46 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.772 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.637 HG21 ' HA ' ' A' ' 159' ' ' LEU . 59.5 t -59.46 -33.55 51.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.862 179.807 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.432 ' CD ' ' CD1' ' A' ' 146' ' ' ILE . 9.1 mmm-85 -63.89 -51.26 65.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.948 0.404 . . . . 0.0 109.921 179.312 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.401 ' CE ' ' HG3' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -53.68 -41.89 67.35 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 178.517 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.7 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -51.51 -61.99 1.9 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.755 179.066 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.814 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -62.76 -20.46 64.98 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.502 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 -83.41 -27.88 29.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.526 -0.307 . . . . 0.0 110.968 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.401 ' HG3' ' CE ' ' A' ' 137' ' ' LYS . 14.9 mt-10 -85.63 -29.36 24.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.86 0.362 . . . . 0.0 110.856 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 142' ' ' LYS . . . . . 0.521 ' HG2' HD13 ' A' ' 167' ' ' LEU . 4.9 tptt -95.26 -25.43 16.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.081 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 97.43 16.98 32.75 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.52 -179.709 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.814 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 43.9 t -91.1 158.85 2.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.805 0.336 . . . . 0.0 110.877 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.49 ' N ' HG12 ' A' ' 144' ' ' VAL . 62.3 t0 -109.99 102.16 10.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.751 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.475 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 9.7 pt -48.61 -39.79 10.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.263 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 6.0 mtm-85 -48.97 -25.07 1.75 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.749 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.526 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.5 OUTLIER -120.78 27.44 8.51 Favored 'General case' 0 N--CA 1.463 0.186 0 N-CA-C 111.647 0.24 . . . . 0.0 111.647 -179.78 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.475 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 51.2 t -96.01 152.23 3.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.979 0.419 . . . . 0.0 110.906 179.593 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -74.96 79.36 2.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.973 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -75.99 116.48 4.82 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.507 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.286 0 CA-C-O 120.803 0.335 . . . . 0.0 110.96 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.424 ' O ' HG21 ' A' ' 135' ' ' VAL . 24.9 t . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.821 0.343 . . . . 0.0 110.952 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.637 ' HA ' HG21 ' A' ' 135' ' ' VAL . 3.2 mt -117.12 174.79 5.92 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.152 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 160' ' ' LYS . . . . . 0.442 ' HG2' ' CE2' ' A' ' 138' ' ' TYR . 0.0 OUTLIER -48.38 -48.97 36.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.875 179.946 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -58.03 -35.63 71.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.866 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -65.7 -38.8 90.23 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.35 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 163' ' ' ILE . . . . . 0.7 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.0 mm -62.64 -48.73 86.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.095 179.114 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -58.23 -39.93 80.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.63 179.541 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.5 -39.3 91.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.812 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 166' ' ' PHE . . . . . 0.62 ' CE1' HG13 ' A' ' 144' ' ' VAL . 21.9 t80 -64.15 -38.45 91.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.662 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 167' ' ' LEU . . . . . 0.779 HD21 ' CG2' ' A' ' 144' ' ' VAL . 19.5 mt . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.144 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.107 0 CA-C-O 120.842 0.353 . . . . 0.0 111.217 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 132' ' ' MET . . . . . 0.407 ' CB ' ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -88.93 166.32 22.74 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.849 179.947 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 133' ' ' PRO . . . . . 0.407 ' HD2' ' CB ' ' A' ' 132' ' ' MET . 22.6 Cg_endo -61.44 -42.09 36.37 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.539 2.159 . . . . 0.0 112.227 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.03 -46.29 85.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.865 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.677 HG21 ' HA ' ' A' ' 159' ' ' LEU . 57.9 t -58.48 -35.08 52.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.913 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.625 ' HD3' HD11 ' A' ' 146' ' ' ILE . 1.6 mmm180 -63.18 -48.07 79.92 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.298 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.03 -38.36 70.43 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 178.323 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.679 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -55.43 -63.06 1.28 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.879 179.127 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.85 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -62.79 -20.99 65.55 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.387 -179.529 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 12.9 tpt180 -83.54 -27.15 29.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.956 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -85.63 -28.86 24.5 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.888 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' LYS . . . . . 0.444 ' HE2' HD13 ' A' ' 167' ' ' LEU . 0.0 OUTLIER -95.83 -26.21 15.73 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.109 -179.864 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 100.02 15.59 30.47 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.588 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.85 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 49.0 t -93.71 159.28 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.881 0.372 . . . . 0.0 110.758 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.51 ' N ' HG12 ' A' ' 144' ' ' VAL . 41.6 t0 -110.91 107.71 17.25 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.747 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.625 HD11 ' HD3' ' A' ' 136' ' ' ARG . 6.7 pt -51.19 -39.63 20.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.104 0.478 . . . . 0.0 111.437 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 20.8 mtt180 -48.81 -26.19 2.26 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.832 -179.744 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.447 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.0 OUTLIER -118.64 26.92 9.23 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 111.71 0.263 . . . . 0.0 111.71 -179.889 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.455 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 56.1 t -96.2 156.65 3.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.873 0.368 . . . . 0.0 110.702 179.468 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.42 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.97 73.38 2.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.888 -179.738 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -69.13 133.67 26.57 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.477 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.273 0 CA-C-O 120.851 0.358 . . . . 0.0 110.812 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.493 ' O ' HG21 ' A' ' 135' ' ' VAL . 22.8 t . . . . . 0 N--CA 1.458 -0.069 0 CA-C-O 120.883 0.373 . . . . 0.0 111.052 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.677 ' HA ' HG21 ' A' ' 135' ' ' VAL . 16.3 mt -106.59 176.36 5.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.017 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 160' ' ' LYS . . . . . 0.443 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 0.1 OUTLIER -50.19 -45.71 53.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.645 179.784 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 50.5 mm-40 -61.35 -34.52 75.43 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.627 179.694 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 162' ' ' ASP . . . . . 0.413 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 60.8 m-20 -65.41 -39.55 92.28 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.249 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 163' ' ' ILE . . . . . 0.679 HG21 ' CD1' ' A' ' 138' ' ' TYR . 3.3 mm -64.47 -45.13 96.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.027 179.037 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -60.61 -35.71 76.8 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.284 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -67.83 -39.01 83.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.469 179.541 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 166' ' ' PHE . . . . . 0.458 ' CE1' HG13 ' A' ' 144' ' ' VAL . 20.2 t80 -68.53 -31.3 70.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.605 179.642 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 167' ' ' LEU . . . . . 0.844 HD21 ' CG2' ' A' ' 144' ' ' VAL . 2.6 mt . . . . . 0 C--N 1.33 -0.266 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.978 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.78 0.324 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 64.2 mtp -80.07 157.34 73.68 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.946 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_exo -51.66 -42.58 55.8 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.576 2.184 . . . . 0.0 112.302 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.4 p -61.13 -42.64 98.91 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.956 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.621 ' CG1' HD11 ' A' ' 163' ' ' ILE . 59.2 t -59.46 -34.33 54.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.807 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.415 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -66.8 -53.63 30.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.895 0.379 . . . . 0.0 110.034 179.329 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.4 tttt -55.38 -32.08 62.32 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 178.696 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.715 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -61.93 -61.97 2.12 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.344 179.149 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.867 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -61.46 -24.41 66.54 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.527 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 9.5 mtp-105 -83.65 -29.05 27.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.795 0.331 . . . . 0.0 110.894 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -84.04 -26.94 28.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.112 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 5.4 mptt -97.45 -27.57 14.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.169 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.85 14.0 28.1 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.624 -179.783 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.867 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 47.3 t -95.46 160.8 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.862 0.363 . . . . 0.0 110.75 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.52 ' N ' HG12 ' A' ' 144' ' ' VAL . 45.5 t0 -113.46 107.07 15.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.615 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.48 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 12.7 pt -50.03 -39.98 16.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.355 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 11.9 mtm105 -49.28 -24.06 1.66 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.854 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.495 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.5 OUTLIER -120.45 27.15 8.74 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 120.65 0.262 . . . . 0.0 111.569 -179.83 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.48 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 55.6 t -96.4 158.19 3.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.957 0.408 . . . . 0.0 110.888 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.425 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.4 OUTLIER -74.77 79.6 2.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.157 -179.653 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -69.63 96.61 0.51 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.315 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 70.2 p . . . . . 0 N--CA 1.452 -0.348 0 CA-C-O 120.785 0.326 . . . . 0.0 111.209 -179.724 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.424 HG13 ' CG1' ' A' ' 149' ' ' VAL . 25.2 t . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.788 0.327 . . . . 0.0 111.012 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.525 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.3 mt -114.05 176.87 4.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.021 -179.811 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 160' ' ' LYS . . . . . 0.444 ' HG2' ' CE2' ' A' ' 138' ' ' TYR . 0.0 OUTLIER -49.37 -49.28 45.18 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.752 179.889 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -57.58 -34.48 69.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.796 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 162' ' ' ASP . . . . . 0.415 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 83.7 m-20 -67.54 -37.39 82.65 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.372 179.663 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 163' ' ' ILE . . . . . 0.715 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.0 mm -63.24 -47.99 89.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.168 179.23 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -59.33 -43.5 92.73 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.588 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -60.27 -40.4 90.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.814 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 166' ' ' PHE . . . . . 0.58 ' CE1' HG13 ' A' ' 144' ' ' VAL . 18.8 t80 -61.35 -50.07 74.38 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.631 179.727 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 167' ' ' LEU . . . . . 0.718 HD21 ' CG2' ' A' ' 144' ' ' VAL . 37.6 mt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.843 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.839 0.352 . . . . 0.0 111.14 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 1.1 mtp -68.75 160.65 76.32 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.785 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -62.03 -18.18 60.2 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.602 2.201 . . . . 0.0 112.377 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 29.1 t -88.64 -41.37 12.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.994 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.678 HG21 ' HA ' ' A' ' 159' ' ' LEU . 90.9 t -60.02 -40.19 82.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.099 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.627 ' HA ' HG21 ' A' ' 146' ' ' ILE . 4.3 mtm180 -63.11 -43.08 99.45 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 6.7 tttt -62.37 -34.34 76.49 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 178.376 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.75 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.9 OUTLIER -57.5 -60.95 2.89 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.304 179.005 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.78 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -60.73 -30.27 69.88 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.416 -179.708 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.53 -19.78 45.0 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.38 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -93.14 -22.43 19.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.674 0.273 . . . . 0.0 111.14 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' LYS . . . . . 0.477 ' HD2' HD13 ' A' ' 167' ' ' LEU . 0.2 OUTLIER -102.33 -21.38 14.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.343 -179.812 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.29 5.62 39.98 Favored Glycine 0 CA--C 1.519 0.314 0 C-N-CA 120.49 -0.862 . . . . 0.0 112.818 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.78 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 53.0 t -92.48 159.43 2.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.756 0.313 . . . . 0.0 110.695 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.498 ' N ' HG12 ' A' ' 144' ' ' VAL . 62.6 t0 -109.1 108.34 18.98 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.798 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.644 HG23 ' HB3' ' A' ' 139' ' ' ALA . 0.2 OUTLIER -50.59 -41.52 20.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.519 179.927 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -49.9 -23.11 1.76 Allowed 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.907 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.47 ' CD1' ' CE2' ' A' ' 166' ' ' PHE . 0.6 OUTLIER -120.27 25.69 9.68 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 111.819 0.303 . . . . 0.0 111.819 -179.605 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.501 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 63.2 t -92.64 151.96 3.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.929 0.395 . . . . 0.0 110.87 179.457 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -74.94 79.55 2.16 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.159 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.01 123.75 10.89 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.343 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.329 -0.318 0 CA-C-O 120.757 0.313 . . . . 0.0 111.177 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.45 ' O ' HG21 ' A' ' 135' ' ' VAL . 14.9 t . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.83 0.348 . . . . 0.0 111.066 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.678 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.3 mp -118.61 173.08 7.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.09 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 11.1 tttt -50.37 -45.21 55.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.677 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -59.72 -35.54 74.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.561 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -66.67 -36.84 83.48 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.238 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 163' ' ' ILE . . . . . 0.75 HG21 ' CD1' ' A' ' 138' ' ' TYR . 8.6 mm -63.94 -48.78 84.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.181 179.216 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -58.71 -41.86 87.33 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.594 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.97 -42.03 98.67 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.674 179.701 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 166' ' ' PHE . . . . . 0.608 ' CE1' HG13 ' A' ' 144' ' ' VAL . 13.6 t80 -59.46 -47.34 85.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.489 179.691 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 167' ' ' LEU . . . . . 0.744 HD21 ' CG2' ' A' ' 144' ' ' VAL . 19.9 mt . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.819 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.196 0 CA-C-O 120.779 0.323 . . . . 0.0 111.105 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 132' ' ' MET . . . . . 0.462 ' HB2' HG23 ' A' ' 135' ' ' VAL . 1.0 OUTLIER -129.65 161.38 59.55 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.846 179.969 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -61.99 -24.69 77.06 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.613 2.208 . . . . 0.0 112.225 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.3 m -92.36 -42.02 10.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.854 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.691 HG21 ' HA ' ' A' ' 159' ' ' LEU . 59.2 t -62.03 -37.31 78.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.943 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.67 ' HD3' HD12 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -63.94 -47.54 80.09 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.303 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.22 -40.86 78.36 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 178.36 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.722 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.9 OUTLIER -51.86 -61.1 2.47 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.491 178.973 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.805 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -59.89 -28.11 67.29 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.575 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 11.0 tpt180 -79.95 -24.45 40.98 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.623 0.249 . . . . 0.0 111.373 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 16.8 mm-40 -89.25 -26.34 21.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.047 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 13.9 mptt -96.55 -22.28 17.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.251 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 101.27 8.61 46.7 Favored Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.667 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.805 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 45.1 t -92.73 159.26 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.775 0.321 . . . . 0.0 110.86 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.811 ' HB3' HD11 ' A' ' 148' ' ' LEU . 66.5 t0 -112.67 111.39 22.16 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.807 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.67 HD12 ' HD3' ' A' ' 136' ' ' ARG . 0.0 OUTLIER -49.53 -37.25 11.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.145 0.498 . . . . 0.0 111.726 -179.884 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 4.0 mtm-85 -48.59 -24.02 1.19 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.463 -0.79 . . . . 0.0 112.697 -179.231 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.871 ' N ' HD13 ' A' ' 148' ' ' LEU . 0.0 OUTLIER -127.92 31.75 5.05 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 111.893 0.331 . . . . 0.0 111.893 -179.25 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.478 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 76.5 t -94.75 157.08 3.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.841 0.353 . . . . 0.0 110.594 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.443 ' N ' HG12 ' A' ' 149' ' ' VAL . 1.2 mt-30 -74.89 72.17 2.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.854 -179.717 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.95 117.58 6.52 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.385 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.274 0 CA-C-O 120.876 0.37 . . . . 0.0 110.798 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.645 HG12 HG11 ' A' ' 135' ' ' VAL . 23.6 t . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.749 0.309 . . . . 0.0 111.059 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.691 ' HA ' HG21 ' A' ' 135' ' ' VAL . 0.9 OUTLIER -112.19 173.56 6.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.048 -179.867 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 2.0 tttt -49.15 -46.22 44.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.797 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 49.1 mm-40 -60.61 -35.62 76.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.659 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -65.52 -37.35 86.51 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.471 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 163' ' ' ILE . . . . . 0.722 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.0 mm -65.07 -49.48 79.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.207 179.193 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -58.55 -36.88 74.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.638 179.635 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -66.24 -41.98 89.26 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.918 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 166' ' ' PHE . . . . . 0.584 ' CE2' HD23 ' A' ' 148' ' ' LEU . 37.0 t80 -60.21 -50.84 72.06 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.637 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 167' ' ' LEU . . . . . 0.691 HD21 ' CG2' ' A' ' 144' ' ' VAL . 49.7 mt . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.922 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.879 0.371 . . . . 0.0 111.088 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 132' ' ' MET . . . . . 0.673 ' HB2' HG23 ' A' ' 135' ' ' VAL . 1.4 mtp -95.33 157.36 36.45 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.9 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.79 -38.36 85.25 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.527 2.151 . . . . 0.0 112.393 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.2 t -80.06 -38.37 31.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.025 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.722 HG21 ' HA ' ' A' ' 159' ' ' LEU . 65.4 t -61.51 -36.49 73.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.051 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.901 ' HD3' HD12 ' A' ' 146' ' ' ILE . 1.4 mmt180 -68.05 -47.26 68.84 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.508 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.14 -36.94 78.63 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.642 ' CD2' HG21 ' A' ' 163' ' ' ILE . 1.2 t80 -55.95 -58.87 6.08 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.461 179.047 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.709 ' HB3' HG23 ' A' ' 146' ' ' ILE . . . -61.03 -28.73 69.26 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.21 -0.905 . . . . 0.0 111.262 -179.863 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.55 -29.63 46.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.849 0.357 . . . . 0.0 111.161 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 64.7 mm-40 -85.59 -23.65 27.5 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.163 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -95.89 -24.35 16.47 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.398 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.36 4.17 40.81 Favored Glycine 0 CA--C 1.518 0.268 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.684 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.741 ' CG2' HD21 ' A' ' 167' ' ' LEU . 59.2 t -87.59 157.77 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 0.0 110.826 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.667 ' OD2' HD21 ' A' ' 148' ' ' LEU . 62.3 t0 -106.79 105.48 15.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.73 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.901 HD12 ' HD3' ' A' ' 136' ' ' ARG . 4.3 pt -49.8 -42.16 17.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.49 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 80.3 mtp180 -48.65 -27.92 3.17 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.126 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.667 HD21 ' OD2' ' A' ' 145' ' ' ASP . 0.0 OUTLIER -116.8 24.19 11.42 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 111.979 0.363 . . . . 0.0 111.979 -179.515 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.532 HG21 HD13 ' A' ' 163' ' ' ILE . 43.8 t -88.72 150.47 3.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.762 0.315 . . . . 0.0 110.588 179.37 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.97 78.78 2.17 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.994 -179.684 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 151' ' ' GLY . . . . . 0.591 ' HA3' HG22 ' A' ' 158' ' ' VAL . . . -82.14 118.69 4.68 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.378 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' THR . . . . . 0.501 HG22 ' OD1' ' A' ' 162' ' ' ASP . 8.8 t . . . . . 0 C--N 1.329 -0.299 0 CA-C-O 120.823 0.344 . . . . 0.0 111.002 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.681 ' O ' HG11 ' A' ' 135' ' ' VAL . 26.5 t . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.799 0.333 . . . . 0.0 111.112 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.722 ' HA ' HG21 ' A' ' 135' ' ' VAL . 3.2 mt -95.83 172.78 7.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.955 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.7 tttt -49.72 -42.58 46.3 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.783 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 51.7 mm-40 -56.06 -40.56 73.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.48 179.566 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 162' ' ' ASP . . . . . 0.501 ' OD1' HG22 ' A' ' 152' ' ' THR . 76.7 m-20 -64.76 -43.49 93.12 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.215 179.293 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 163' ' ' ILE . . . . . 0.658 ' CG1' HG13 ' A' ' 135' ' ' VAL . 10.7 mm -61.73 -38.78 81.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.167 179.152 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -62.37 -45.2 94.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.246 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -59.04 -42.9 91.35 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.418 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 166' ' ' PHE . . . . . 0.704 ' CE1' HG13 ' A' ' 144' ' ' VAL . 7.8 t80 -61.67 -48.99 78.31 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.297 179.308 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 167' ' ' LEU . . . . . 0.741 HD21 ' CG2' ' A' ' 144' ' ' VAL . 40.1 mt . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.859 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.845 ' HB3' ' NE ' ' A' ' 136' ' ' ARG . . . . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.807 0.337 . . . . 0.0 110.987 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 26.8 mtp -99.6 165.21 15.12 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.951 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -58.67 -45.51 29.14 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.575 2.183 . . . . 0.0 112.183 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 66.7 m -69.85 -37.5 76.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.656 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.65 HG21 ' HA ' ' A' ' 159' ' ' LEU . 64.8 t -64.05 -37.73 80.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.919 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.845 ' NE ' ' HB3' ' A' ' 131' ' ' ALA . 0.0 OUTLIER -64.21 -49.04 73.55 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.306 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 6.2 tttt -58.88 -32.9 69.91 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.747 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -58.42 -60.61 3.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.446 179.197 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.69 ' HB3' HG23 ' A' ' 146' ' ' ILE . . . -60.62 -29.52 69.29 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.665 -179.453 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 63.5 mtt180 -79.79 -27.39 40.39 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.271 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -86.6 -28.48 23.25 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.954 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -93.51 -23.58 18.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.097 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 99.53 10.78 46.49 Favored Glycine 0 CA--C 1.52 0.351 0 C-N-CA 120.596 -0.812 . . . . 0.0 112.56 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.705 ' CG2' HD21 ' A' ' 167' ' ' LEU . 48.5 t -89.95 158.67 2.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.757 0.313 . . . . 0.0 110.715 179.723 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.485 ' N ' HG12 ' A' ' 144' ' ' VAL . 62.8 t0 -104.28 104.05 13.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.035 0.445 . . . . 0.0 110.966 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.738 HD12 ' HD2' ' A' ' 136' ' ' ARG . 3.9 pt -47.36 -44.57 9.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.716 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 7.2 mmt180 -50.0 -23.39 2.01 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.786 -0.643 . . . . 0.0 112.195 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.516 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.7 OUTLIER -120.99 22.95 10.88 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -179.608 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.485 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 74.4 t -87.68 148.95 4.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.737 0.303 . . . . 0.0 110.497 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.91 79.32 2.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.904 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 151' ' ' GLY . . . . . 0.672 ' HA3' HG22 ' A' ' 158' ' ' VAL . . . -85.68 115.33 4.15 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.41 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 3.7 t . . . . . 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.368 . . . . 0.0 111.041 -179.851 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.672 HG22 ' HA3' ' A' ' 151' ' ' GLY . 27.7 t . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.778 0.323 . . . . 0.0 110.945 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.65 ' HA ' HG21 ' A' ' 135' ' ' VAL . 5.6 mt -114.24 174.11 6.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.155 -179.772 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.1 tttm -50.62 -44.39 57.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.734 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -60.43 -35.4 75.71 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.653 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 36.9 m-20 -66.33 -38.82 88.55 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.273 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 163' ' ' ILE . . . . . 0.747 HG21 ' CD1' ' A' ' 138' ' ' TYR . 5.0 mm -62.01 -50.16 81.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.256 179.054 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.6 -41.25 80.85 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.55 179.638 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.07 -41.25 96.29 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.67 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 166' ' ' PHE . . . . . 0.618 ' CE1' HG13 ' A' ' 144' ' ' VAL . 21.5 t80 -60.89 -48.07 83.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.477 179.618 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 167' ' ' LEU . . . . . 0.705 HD21 ' CG2' ' A' ' 144' ' ' VAL . 41.8 mt . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.839 179.761 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.827 0.346 . . . . 0.0 111.173 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 132' ' ' MET . . . . . 0.44 ' HB2' HG23 ' A' ' 135' ' ' VAL . 10.6 mtp -120.94 161.86 38.12 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.888 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.2 -56.84 2.52 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.509 2.139 . . . . 0.0 112.413 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -59.49 -40.64 87.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.871 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.631 ' CG1' HD11 ' A' ' 163' ' ' ILE . 96.3 t -60.36 -34.42 57.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.917 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.567 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.9 OUTLIER -65.85 -52.35 51.09 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.474 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -56.39 -32.79 65.13 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.577 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.718 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -59.02 -61.56 2.55 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.358 179.14 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.856 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -63.15 -23.08 67.27 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.364 -179.776 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -82.74 -26.43 31.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.088 179.829 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -86.66 -26.72 24.18 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.05 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 2.9 mptt -98.05 -24.9 15.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.247 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 100.84 13.27 34.84 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.612 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.856 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 38.9 t -93.97 161.02 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.718 0.294 . . . . 0.0 110.774 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.79 ' HB3' HD11 ' A' ' 148' ' ' LEU . 47.9 t0 -116.06 104.62 11.75 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.89 0.376 . . . . 0.0 110.795 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.567 HD11 ' HD3' ' A' ' 136' ' ' ARG . 6.1 pt -44.55 -36.26 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.222 0.534 . . . . 0.0 111.805 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -47.64 -26.16 1.41 Allowed 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.251 -0.886 . . . . 0.0 112.644 -179.159 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.853 ' N ' HD13 ' A' ' 148' ' ' LEU . 0.0 OUTLIER -125.21 29.87 5.98 Favored 'General case' 0 C--N 1.332 -0.161 0 C-N-CA 121.007 -0.277 . . . . 0.0 111.612 -179.36 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.468 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 54.5 t -94.26 157.73 2.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.839 0.352 . . . . 0.0 110.593 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.433 ' N ' HG12 ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.91 75.1 2.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.906 -179.69 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -74.56 122.09 7.07 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.369 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.306 0 CA-C-O 120.928 0.394 . . . . 0.0 110.861 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.431 ' O ' HG21 ' A' ' 135' ' ' VAL . 28.3 t . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.815 0.34 . . . . 0.0 110.998 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.528 ' HA ' HG21 ' A' ' 135' ' ' VAL . 5.0 mt -110.89 175.93 5.23 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.07 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 6.9 tttt -49.07 -45.75 43.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.816 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 -60.68 -36.12 77.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.696 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 73.3 m-20 -65.54 -36.3 83.39 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.298 179.663 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 163' ' ' ILE . . . . . 0.718 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.5 mm -64.79 -51.32 68.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.302 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.49 -38.03 73.91 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.638 179.591 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -64.83 -41.95 95.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.81 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 166' ' ' PHE . . . . . 0.552 ' CE1' HG13 ' A' ' 144' ' ' VAL . 50.0 t80 -60.08 -48.88 79.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.622 179.76 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 167' ' ' LEU . . . . . 0.715 HD21 ' CG2' ' A' ' 144' ' ' VAL . 39.6 mt . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.928 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.841 0.353 . . . . 0.0 111.335 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 132' ' ' MET . . . . . 0.509 ' HE3' ' O ' ' A' ' 158' ' ' VAL . 0.0 OUTLIER -112.88 157.2 41.25 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.766 -179.991 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.91 -33.14 50.39 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.632 2.221 . . . . 0.0 112.099 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 9.4 p -76.99 -43.31 35.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.619 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.627 HG21 ' HA ' ' A' ' 159' ' ' LEU . 73.0 t -58.5 -34.97 52.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.856 179.813 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.466 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.2 OUTLIER -64.71 -49.78 69.54 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 179.206 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -57.58 -31.09 65.81 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 178.556 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.688 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -61.25 -62.36 1.89 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.369 179.032 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.833 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -59.92 -29.2 68.21 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.413 -179.578 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? -80.11 -26.29 39.58 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.212 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -86.59 -29.48 22.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.995 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 4.9 mptt -95.07 -22.19 18.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.256 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 97.16 12.82 47.83 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.609 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.833 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 54.0 t -94.3 159.32 2.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.706 0.288 . . . . 0.0 110.783 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.495 ' N ' HG12 ' A' ' 144' ' ' VAL . 67.0 t0 -110.06 111.48 22.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.868 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.466 HD11 ' HD3' ' A' ' 136' ' ' ARG . 7.9 pt -53.36 -39.95 37.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.402 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 1.2 mmm180 -49.23 -25.26 2.18 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.792 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.552 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.3 OUTLIER -119.67 27.17 8.89 Favored 'General case' 0 C--N 1.332 -0.186 0 N-CA-C 111.659 0.244 . . . . 0.0 111.659 -179.827 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.447 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 40.5 t -95.04 150.3 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.867 0.365 . . . . 0.0 110.587 179.364 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -74.86 77.49 2.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.922 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -73.03 125.04 9.43 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.471 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' THR . . . . . 0.706 HG22 ' OD1' ' A' ' 162' ' ' ASP . 6.3 t . . . . . 0 C--N 1.328 -0.336 0 CA-C-O 120.766 0.317 . . . . 0.0 110.905 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.53 ' O ' HG21 ' A' ' 135' ' ' VAL . 21.9 t . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.691 0.282 . . . . 0.0 110.759 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.627 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.0 OUTLIER -107.06 178.54 4.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.097 0.475 . . . . 0.0 111.371 -179.648 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 160' ' ' LYS . . . . . 0.457 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 2.8 tptt -50.59 -43.26 56.5 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.852 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -62.97 -34.62 77.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.794 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 162' ' ' ASP . . . . . 0.706 ' OD1' HG22 ' A' ' 152' ' ' THR . 26.8 m-20 -65.24 -42.69 93.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.407 179.687 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 163' ' ' ILE . . . . . 0.688 HG21 ' CD1' ' A' ' 138' ' ' TYR . 2.5 mm -62.15 -48.01 90.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.15 179.182 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.74 -37.42 73.56 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.472 179.44 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -64.77 -42.23 95.26 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.536 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 166' ' ' PHE . . . . . 0.552 ' CE2' HD12 ' A' ' 148' ' ' LEU . 28.2 t80 -62.3 -38.4 89.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.509 179.617 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 167' ' ' LEU . . . . . 0.709 HD21 ' CG2' ' A' ' 144' ' ' VAL . 26.0 mt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.976 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.837 0.351 . . . . 0.0 111.079 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 132' ' ' MET . . . . . 0.414 ' CB ' ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -99.56 166.68 12.44 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.862 179.948 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 133' ' ' PRO . . . . . 0.414 ' HD2' ' CB ' ' A' ' 132' ' ' MET . 20.8 Cg_endo -60.91 -26.49 83.22 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.512 2.141 . . . . 0.0 112.282 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -81.47 -44.85 16.84 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.752 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.543 HG21 ' HA ' ' A' ' 159' ' ' LEU . 85.5 t -59.92 -31.49 47.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.862 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -67.28 -52.94 34.59 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 8.7 ttpt -56.37 -31.07 63.45 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 178.536 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.736 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -60.86 -62.57 1.76 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.413 179.103 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.857 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -61.78 -24.1 66.62 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.334 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 20.2 mmm-85 -80.52 -32.51 36.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.903 0.383 . . . . 0.0 110.822 179.707 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -83.72 -29.28 27.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.662 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' LYS . . . . . 0.666 ' HE3' HD13 ' A' ' 167' ' ' LEU . 11.5 mmtt -89.66 -25.74 21.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.05 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 96.33 13.58 47.95 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.439 -179.535 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.857 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 92.8 t -97.84 159.71 3.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.76 0.314 . . . . 0.0 110.783 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.498 ' N ' HG12 ' A' ' 144' ' ' VAL . 68.4 t0 -108.75 111.96 24.0 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.785 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.46 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 8.6 pt -53.6 -40.06 40.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.039 0.447 . . . . 0.0 111.32 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 91.4 mtt-85 -49.34 -25.67 2.61 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.765 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.434 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.1 OUTLIER -118.81 27.32 8.96 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 111.721 0.267 . . . . 0.0 111.721 -179.878 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.46 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 38.8 t -94.0 154.5 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.851 0.358 . . . . 0.0 110.552 179.373 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.93 75.6 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.952 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -70.0 114.9 5.81 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.426 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.327 -0.375 0 CA-C-O 120.699 0.285 . . . . 0.0 111.167 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.441 HG13 ' CG1' ' A' ' 149' ' ' VAL . 30.8 t . . . . . 0 C--O 1.231 0.081 0 CA-C-O 120.748 0.309 . . . . 0.0 110.921 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.543 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.1 mt -113.19 177.42 4.64 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.072 0.463 . . . . 0.0 111.225 -179.719 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 160' ' ' LYS . . . . . 0.452 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 1.8 tttt -50.68 -44.44 57.77 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.855 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 68.0 mm-40 -61.98 -34.11 75.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.695 179.795 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -67.11 -38.91 86.46 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.407 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 163' ' ' ILE . . . . . 0.736 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.4 mm -64.08 -48.93 83.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.294 179.263 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -58.37 -41.06 83.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.656 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.1 -41.71 99.43 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.921 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 166' ' ' PHE . . . . . 0.547 ' CE1' HG13 ' A' ' 144' ' ' VAL . 32.8 t80 -60.3 -50.45 73.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.827 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 167' ' ' LEU . . . . . 0.691 HD21 ' CG2' ' A' ' 144' ' ' VAL . 50.8 mt . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.861 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.797 0.332 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -69.95 162.75 66.44 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.86 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_endo -57.28 -24.45 59.78 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.627 2.218 . . . . 0.0 112.144 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.3 m -76.76 -44.86 31.34 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.89 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.572 HG21 ' HA ' ' A' ' 159' ' ' LEU . 93.0 t -59.8 -34.95 57.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.79 -51.38 56.39 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.325 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.403 ' HG3' ' HG3' ' A' ' 141' ' ' GLU . 2.5 tttt -56.75 -29.96 63.1 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 178.564 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.722 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -63.39 -62.74 1.48 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.496 179.301 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.861 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -63.11 -24.56 67.96 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.372 -179.648 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.63 -27.17 29.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.739 0.304 . . . . 0.0 110.957 179.746 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.403 ' HG3' ' HG3' ' A' ' 137' ' ' LYS . 8.2 mm-40 -85.82 -28.04 24.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.019 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 1.6 mmtm -97.66 -25.37 15.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.254 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 101.2 14.09 31.69 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.717 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.861 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 42.9 t -93.2 159.43 2.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.733 0.301 . . . . 0.0 110.826 179.731 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.499 ' N ' HG12 ' A' ' 144' ' ' VAL . 67.1 t0 -110.45 107.59 17.32 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.705 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.459 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 9.7 pt -52.05 -40.19 28.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 121.048 0.451 . . . . 0.0 111.217 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 92.0 mtt-85 -48.9 -26.33 2.41 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.931 -179.749 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.447 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.1 OUTLIER -119.24 26.93 9.13 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.663 0.268 . . . . 0.0 111.668 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.459 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 40.5 t -93.97 157.63 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.782 0.325 . . . . 0.0 110.518 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.431 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.95 76.21 2.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.967 -179.767 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -72.52 109.15 2.71 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.421 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.303 0 CA-C-O 120.607 0.241 . . . . 0.0 111.207 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.425 ' O ' HG21 ' A' ' 135' ' ' VAL . 21.5 t . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.795 0.331 . . . . 0.0 110.999 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.572 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.2 mp -116.05 176.93 4.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.058 0.456 . . . . 0.0 111.183 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 160' ' ' LYS . . . . . 0.439 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 3.4 tttt -50.32 -46.48 55.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.787 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -59.69 -34.27 72.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.705 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 72.1 m-20 -67.69 -37.62 82.56 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.395 179.672 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 163' ' ' ILE . . . . . 0.722 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.9 mm -64.02 -49.01 83.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.339 179.271 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -58.8 -42.21 88.57 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.624 179.601 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.57 -40.83 96.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.81 179.8 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 166' ' ' PHE . . . . . 0.583 ' CE1' HG13 ' A' ' 144' ' ' VAL . 46.7 t80 -60.55 -51.31 69.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.65 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 167' ' ' LEU . . . . . 0.738 HD21 ' CG2' ' A' ' 144' ' ' VAL . 29.4 mt . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.896 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.779 0.323 . . . . 0.0 111.199 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 132' ' ' MET . . . . . 0.4 ' CB ' ' HD2' ' A' ' 133' ' ' PRO . 2.6 mtm -71.98 166.22 42.66 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.816 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 133' ' ' PRO . . . . . 0.4 ' HD2' ' CB ' ' A' ' 132' ' ' MET . 22.8 Cg_endo -61.24 -32.64 90.59 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.513 2.142 . . . . 0.0 112.219 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -69.93 -45.54 67.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.782 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.654 ' CG1' HD11 ' A' ' 163' ' ' ILE . 84.7 t -60.16 -33.06 52.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.99 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.436 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.5 OUTLIER -65.9 -50.72 63.46 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.21 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.4 tttt -57.71 -31.71 66.67 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.551 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.716 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -60.27 -61.6 2.48 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.402 179.109 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.851 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -63.78 -21.67 66.54 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.299 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.79 -27.61 28.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.042 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -85.94 -25.81 25.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.059 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' LYS . . . . . 0.493 ' HG2' HD13 ' A' ' 167' ' ' LEU . 2.1 tptt -98.61 -26.72 14.3 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.247 -179.822 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 103.07 13.11 29.91 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.596 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.851 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 35.0 t -93.27 160.59 2.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.794 0.33 . . . . 0.0 110.831 179.737 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.802 ' HB3' HD11 ' A' ' 148' ' ' LEU . 51.9 t0 -115.22 105.66 13.15 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.952 0.406 . . . . 0.0 110.755 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.479 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 4.0 pt -45.13 -36.3 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.3 0.571 . . . . 0.0 111.867 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -48.24 -25.32 1.48 Allowed 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.332 -0.849 . . . . 0.0 112.643 -179.157 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.845 ' N ' HD13 ' A' ' 148' ' ' LEU . 0.0 OUTLIER -126.82 31.07 5.37 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 111.817 0.303 . . . . 0.0 111.817 -179.33 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.479 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 54.1 t -92.88 157.45 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.821 0.344 . . . . 0.0 110.65 179.372 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.426 ' N ' HG12 ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.84 69.77 1.87 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.999 -179.645 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -68.79 115.83 6.88 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.403 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.273 0 CA-C-O 120.617 0.246 . . . . 0.0 111.325 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.464 ' O ' HG21 ' A' ' 135' ' ' VAL . 31.7 t . . . . . 0 N--CA 1.458 -0.072 0 CA-C-O 120.805 0.336 . . . . 0.0 110.776 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.601 ' HA ' HG21 ' A' ' 135' ' ' VAL . 0.9 OUTLIER -115.13 176.67 4.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.027 0.442 . . . . 0.0 111.263 -179.69 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 14.3 tttm -49.84 -45.72 50.61 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.818 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 -60.03 -35.46 75.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.653 179.742 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -66.23 -37.94 86.73 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.368 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 163' ' ' ILE . . . . . 0.716 HG21 ' CD1' ' A' ' 138' ' ' TYR . 5.4 mm -63.14 -49.16 84.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.909 179.084 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -59.42 -36.49 75.97 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.508 179.459 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.6 -39.84 92.0 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.775 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 166' ' ' PHE . . . . . 0.536 ' CE1' HG13 ' A' ' 144' ' ' VAL . 57.7 t80 -62.98 -47.27 83.88 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.536 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 167' ' ' LEU . . . . . 0.795 HD21 ' CG2' ' A' ' 144' ' ' VAL . 5.8 mt . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.911 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.741 0.305 . . . . 0.0 111.101 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 77.6 mtp -100.8 162.04 21.93 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.953 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.42 -40.48 71.18 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.549 2.166 . . . . 0.0 112.254 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.22 -43.74 70.03 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.912 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.621 HG21 ' HA ' ' A' ' 159' ' ' LEU . 67.4 t -58.98 -36.48 62.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.942 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.453 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.2 OUTLIER -66.14 -51.92 53.3 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 179.469 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.9 ttpt -56.72 -32.64 65.73 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 178.691 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.734 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.9 OUTLIER -59.73 -61.82 2.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.458 179.205 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.745 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -63.45 -23.31 67.34 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.297 -179.772 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -82.04 -28.22 32.58 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.951 179.78 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -86.35 -28.57 23.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.847 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 4.1 mptt -93.96 -24.58 17.61 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.04 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 98.07 13.94 41.03 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.6 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.749 HG21 HD11 ' A' ' 167' ' ' LEU . 45.6 t -92.74 159.11 2.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.799 0.333 . . . . 0.0 110.828 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.488 ' N ' HG12 ' A' ' 144' ' ' VAL . 68.2 t0 -109.3 105.42 14.82 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.839 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.489 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 7.3 pt -49.33 -39.92 13.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.13 0.49 . . . . 0.0 111.389 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 8.4 mtt-85 -49.4 -24.73 2.09 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.746 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.463 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.6 OUTLIER -120.32 27.99 8.28 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.586 0.231 . . . . 0.0 111.596 -179.846 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.545 ' CG1' HG13 ' A' ' 158' ' ' VAL . 43.4 t -95.31 155.56 3.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.934 0.397 . . . . 0.0 110.792 179.594 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.407 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 8.6 tt0 -74.99 77.61 2.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.096 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.65 111.75 3.79 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.455 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.328 -0.333 0 CA-C-O 120.763 0.316 . . . . 0.0 111.042 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.545 HG13 ' CG1' ' A' ' 149' ' ' VAL . 25.9 t . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.89 0.376 . . . . 0.0 111.19 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.621 ' HA ' HG21 ' A' ' 135' ' ' VAL . 3.8 mp -112.96 175.91 5.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.911 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 160' ' ' LYS . . . . . 0.441 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 0.4 OUTLIER -50.91 -45.52 60.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.642 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 4.2 mm-40 -60.36 -34.25 73.6 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.603 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -67.64 -37.6 82.68 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.436 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 163' ' ' ILE . . . . . 0.734 HG21 ' CD1' ' A' ' 138' ' ' TYR . 5.4 mm -64.01 -47.93 88.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.169 179.164 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -58.76 -42.38 88.79 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.577 179.409 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.01 -40.94 95.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.653 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 166' ' ' PHE . . . . . 0.58 ' CE1' HG13 ' A' ' 144' ' ' VAL . 20.5 t80 -63.51 -38.94 93.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.513 179.61 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 167' ' ' LEU . . . . . 0.749 HD11 HG21 ' A' ' 144' ' ' VAL . 12.7 mt . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.77 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.786 0.327 . . . . 0.0 111.196 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 132' ' ' MET . . . . . 0.549 ' HB2' HG23 ' A' ' 135' ' ' VAL . 3.3 mtp -91.47 160.37 36.97 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.851 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.65 -23.49 76.05 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.591 2.194 . . . . 0.0 112.242 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.2 m -90.65 -41.48 11.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.898 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.772 HG21 ' HA ' ' A' ' 159' ' ' LEU . 59.5 t -59.91 -39.7 80.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.033 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.75 ' HD3' HD12 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -62.48 -43.44 98.8 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.63 -0.508 . . . . 0.0 109.63 179.364 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.3 -33.32 74.43 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 178.331 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.758 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.9 OUTLIER -57.7 -60.87 3.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.375 179.052 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.711 ' HB3' HG23 ' A' ' 146' ' ' ILE . . . -61.29 -29.61 69.97 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.377 -179.649 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 11.3 mmm180 -79.19 -23.03 44.13 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.339 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -89.67 -26.57 20.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.802 0.334 . . . . 0.0 111.032 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -96.06 -22.31 17.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.288 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.46 7.09 46.44 Favored Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.573 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.797 ' CG2' HD21 ' A' ' 167' ' ' LEU . 59.2 t -89.44 155.24 3.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 120.722 0.296 . . . . 0.0 110.67 179.65 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.489 ' HB3' HD11 ' A' ' 148' ' ' LEU . 66.5 t0 -102.34 109.19 20.77 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.14 0.495 . . . . 0.0 110.89 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.75 HD12 ' HD3' ' A' ' 136' ' ' ARG . 5.4 pt -51.07 -43.78 27.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.63 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 147' ' ' ARG . . . . . 0.418 HH11 ' HD2' ' A' ' 147' ' ' ARG . 11.6 mtt180 -49.72 -24.62 2.4 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.941 -0.572 . . . . 0.0 112.11 -179.437 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.489 HD11 ' HB3' ' A' ' 145' ' ' ASP . 0.1 OUTLIER -119.2 23.97 11.01 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 112.111 0.412 . . . . 0.0 112.111 -179.645 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.539 ' CG1' HG13 ' A' ' 158' ' ' VAL . 48.9 t -86.64 156.18 3.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.733 0.301 . . . . 0.0 110.555 179.209 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.405 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 4.2 tt0 -74.79 74.24 2.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.067 -179.73 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -72.07 107.38 2.17 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.403 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.299 0 CA-C-O 120.871 0.367 . . . . 0.0 110.988 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.539 HG13 ' CG1' ' A' ' 149' ' ' VAL . 21.9 t . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.865 0.364 . . . . 0.0 111.083 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.772 ' HA ' HG21 ' A' ' 135' ' ' VAL . 14.5 mt -112.37 175.12 5.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.05 -179.803 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 160' ' ' LYS . . . . . 0.44 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 1.0 OUTLIER -50.77 -44.98 58.77 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.673 179.903 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -61.11 -34.41 74.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.637 179.587 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -66.82 -37.22 84.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.457 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 163' ' ' ILE . . . . . 0.758 HG21 ' CD1' ' A' ' 138' ' ' TYR . 8.2 mm -65.11 -49.23 80.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.186 179.167 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -58.82 -38.42 78.6 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.572 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.49 -41.08 93.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.836 179.748 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 166' ' ' PHE . . . . . 0.593 ' CE1' HG13 ' A' ' 144' ' ' VAL . 24.6 t80 -61.1 -45.69 93.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.591 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 167' ' ' LEU . . . . . 0.797 HD21 ' CG2' ' A' ' 144' ' ' VAL . 16.4 mt . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.805 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.801 0.334 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.42 166.06 11.75 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.864 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -52.89 -37.62 77.73 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.505 2.137 . . . . 0.0 112.381 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.66 -48.25 55.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.88 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.593 ' CG1' HD11 ' A' ' 163' ' ' ILE . 73.9 t -58.06 -33.06 45.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.848 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.12 -52.88 36.29 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 179.341 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 3.8 tttp -55.96 -30.3 61.53 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 178.634 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.725 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -62.86 -62.78 1.49 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.442 179.295 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.834 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -63.71 -23.91 67.56 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.243 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 3.8 tpt180 -82.97 -25.92 31.81 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.943 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -87.55 -26.59 23.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.945 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -97.52 -25.18 15.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.188 -179.779 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 100.85 13.27 34.82 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.674 -0.775 . . . . 0.0 112.584 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.834 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 44.3 t -94.55 160.03 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.788 0.327 . . . . 0.0 110.743 179.716 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.509 ' N ' HG12 ' A' ' 144' ' ' VAL . 42.9 t0 -111.17 109.6 19.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.733 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.461 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 9.7 pt -52.03 -39.84 27.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.389 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 147' ' ' ARG . . . . . 0.538 ' HG2' HD23 ' A' ' 148' ' ' LEU . 2.2 ptt180 -48.99 -25.92 2.24 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.794 -179.731 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.538 HD23 ' HG2' ' A' ' 147' ' ' ARG . 0.2 OUTLIER -119.43 26.96 9.07 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 111.645 0.239 . . . . 0.0 111.645 -179.809 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.461 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 43.6 t -95.05 157.53 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.837 0.351 . . . . 0.0 110.586 179.305 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.425 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 2.1 tt0 -74.74 77.55 2.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.067 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -72.91 106.11 1.89 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.447 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 120.605 0.24 . . . . 0.0 111.24 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.446 HG13 ' CG1' ' A' ' 149' ' ' VAL . 21.9 t . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.854 0.359 . . . . 0.0 110.949 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.556 ' HA ' HG21 ' A' ' 135' ' ' VAL . 2.1 mt -121.85 172.46 8.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.219 -179.81 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 160' ' ' LYS . . . . . 0.442 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 4.9 tttm -47.8 -50.41 25.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.053 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -57.18 -35.38 69.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.781 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -67.56 -34.75 77.69 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.38 179.678 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 163' ' ' ILE . . . . . 0.725 HG21 ' CD1' ' A' ' 138' ' ' TYR . 5.7 mm -64.98 -50.65 73.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.068 179.106 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -59.57 -37.72 79.23 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.571 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.9 -40.5 91.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.712 179.759 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 166' ' ' PHE . . . . . 0.552 ' CE1' HG13 ' A' ' 144' ' ' VAL . 37.2 t80 -60.91 -48.32 82.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.567 179.675 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 167' ' ' LEU . . . . . 0.777 HD21 ' CG2' ' A' ' 144' ' ' VAL . 16.5 mt . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.955 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.912 ' HB3' ' HD3' ' A' ' 136' ' ' ARG . . . . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.897 0.379 . . . . 0.0 111.016 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 132' ' ' MET . . . . . 0.564 ' HB2' HG23 ' A' ' 135' ' ' VAL . 24.5 mmm -88.79 161.19 42.27 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.93 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -52.22 -28.18 32.96 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.587 2.191 . . . . 0.0 112.257 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 58.2 m -87.31 -38.6 16.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.906 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.619 HG21 ' HA ' ' A' ' 159' ' ' LEU . 61.4 t -62.68 -40.48 88.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.022 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.912 ' HD3' ' HB3' ' A' ' 131' ' ' ALA . 25.1 mmm-85 -65.52 -47.74 74.9 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.35 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 2.0 tttm -60.72 -29.81 69.58 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.755 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -60.95 -60.66 3.43 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.481 179.213 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.767 ' HB3' HG23 ' A' ' 146' ' ' ILE . . . -62.69 -27.76 69.47 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.78 -0.645 . . . . 0.0 111.516 -179.544 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.4 -21.18 33.08 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.301 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -91.95 -22.22 20.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.069 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 1.1 mmtt -103.22 -24.47 13.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.346 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.58 9.6 32.82 Favored Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.875 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.798 ' CG2' HD21 ' A' ' 167' ' ' LEU . 46.3 t -89.24 155.06 3.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.748 0.309 . . . . 0.0 110.59 179.545 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.445 ' HB3' ' CG ' ' A' ' 148' ' ' LEU . 61.4 t0 -100.79 104.97 16.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.11 0.481 . . . . 0.0 111.023 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.767 HG23 ' HB3' ' A' ' 139' ' ' ALA . 3.1 pt -47.44 -45.51 9.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.73 179.564 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.67 -22.09 1.9 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.332 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.512 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.9 OUTLIER -121.44 22.27 10.77 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 112.053 0.39 . . . . 0.0 112.053 -179.592 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.468 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 76.0 t -85.96 152.49 3.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.864 0.364 . . . . 0.0 110.574 179.251 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.94 78.98 2.16 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.919 -179.776 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -80.92 106.85 2.6 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.42 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.329 -0.286 0 CA-C-O 120.925 0.393 . . . . 0.0 110.879 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.605 HG12 HG11 ' A' ' 135' ' ' VAL . 22.6 t . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.807 0.337 . . . . 0.0 110.977 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.619 ' HA ' HG21 ' A' ' 135' ' ' VAL . 2.3 mt -122.96 170.93 9.63 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.122 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 29.6 tttm -50.61 -44.75 57.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.622 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -60.31 -35.37 75.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.501 179.704 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -66.26 -38.28 87.45 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.328 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 163' ' ' ILE . . . . . 0.755 HG21 ' CD1' ' A' ' 138' ' ' TYR . 6.1 mm -63.22 -49.78 81.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.248 179.351 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -58.08 -41.04 82.58 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.621 179.719 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.13 -40.72 98.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.764 179.704 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 166' ' ' PHE . . . . . 0.63 ' CE1' HG13 ' A' ' 144' ' ' VAL . 17.9 t80 -60.82 -45.57 93.95 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.486 179.725 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 167' ' ' LEU . . . . . 0.798 HD21 ' CG2' ' A' ' 144' ' ' VAL . 21.1 mt . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.849 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.876 0.37 . . . . 0.0 111.246 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 132' ' ' MET . . . . . 0.589 ' HB2' HG23 ' A' ' 135' ' ' VAL . 1.3 mmt -85.97 161.35 50.16 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.822 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_endo -61.15 -30.81 89.53 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.575 2.183 . . . . 0.0 112.221 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -82.1 -37.39 26.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.736 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.643 ' CG1' HD11 ' A' ' 163' ' ' ILE . 62.6 t -61.7 -34.63 63.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.41 ' HD3' HD13 ' A' ' 146' ' ' ILE . 0.4 OUTLIER -65.91 -52.85 46.45 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.439 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.14 -34.34 63.67 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 178.671 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.719 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.9 OUTLIER -59.08 -61.79 2.37 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.442 179.21 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.853 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -62.01 -23.88 66.7 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.517 -179.747 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 3.2 mmm-85 -82.6 -28.81 30.61 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.717 0.294 . . . . 0.0 111.116 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -84.22 -27.69 27.81 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.123 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 2.1 mptp? -96.06 -26.9 15.34 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.124 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.09 13.34 31.63 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.619 -179.747 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.853 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 47.7 t -94.91 159.88 2.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-O 120.689 0.28 . . . . 0.0 110.738 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.507 ' N ' HG12 ' A' ' 144' ' ' VAL . 66.9 t0 -111.99 111.17 21.91 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.811 179.817 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.448 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 7.8 pt -52.16 -39.77 28.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.457 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -48.94 -25.75 2.12 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.754 -179.762 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.44 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.2 OUTLIER -119.65 28.12 8.34 Favored 'General case' 0 N--CA 1.462 0.138 0 N-CA-C 111.679 0.251 . . . . 0.0 111.679 -179.832 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.448 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 55.6 t -98.25 155.64 3.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.79 0.329 . . . . 0.0 110.659 179.269 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.94 79.3 2.16 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.96 -179.736 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -76.48 114.83 4.24 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.328 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.33 -0.281 0 CA-C-O 120.694 0.283 . . . . 0.0 111.085 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.462 ' O ' HG21 ' A' ' 135' ' ' VAL . 22.2 t . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.749 0.309 . . . . 0.0 110.79 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.619 ' HA ' HG21 ' A' ' 135' ' ' VAL . 0.8 OUTLIER -117.6 174.69 6.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.094 0.474 . . . . 0.0 111.291 -179.621 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 160' ' ' LYS . . . . . 0.456 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 2.1 tptt -50.16 -45.8 53.6 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.784 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -60.11 -34.86 74.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.681 179.663 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -67.17 -36.69 82.33 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.332 179.57 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 163' ' ' ILE . . . . . 0.719 HG21 ' CD1' ' A' ' 138' ' ' TYR . 5.2 mm -64.01 -50.3 77.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.093 179.179 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -58.62 -39.65 81.08 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.484 179.675 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -62.54 -41.34 98.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.771 179.664 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 166' ' ' PHE . . . . . 0.541 ' CE1' HG13 ' A' ' 144' ' ' VAL . 40.9 t80 -60.61 -51.81 67.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.568 179.659 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 167' ' ' LEU . . . . . 0.766 HD21 ' CG2' ' A' ' 144' ' ' VAL . 23.7 mt . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.833 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.858 0.361 . . . . 0.0 111.304 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 132' ' ' MET . . . . . 0.528 ' HB2' HG23 ' A' ' 135' ' ' VAL . 0.7 OUTLIER -114.42 158.88 38.77 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.843 -179.991 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.08 -54.82 4.79 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.682 2.255 . . . . 0.0 112.159 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.1 m -60.33 -40.97 92.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.624 179.736 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.769 ' CG1' HD11 ' A' ' 163' ' ' ILE . 81.6 t -60.53 -34.24 57.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.716 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.525 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.2 OUTLIER -64.04 -53.16 54.28 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.201 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -56.84 -30.71 64.05 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 178.536 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.678 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -62.26 -61.32 2.54 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.581 179.313 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.835 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -62.45 -27.1 68.88 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.49 -179.466 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 31.0 mmm180 -83.18 -24.06 32.63 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.708 0.289 . . . . 0.0 111.084 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -88.71 -22.84 23.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.25 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 142' ' ' LYS . . . . . 0.46 ' HD2' HD13 ' A' ' 167' ' ' LEU . 4.3 mmtt -102.65 -25.38 13.58 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.288 -179.716 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.75 9.99 31.64 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.64 -179.86 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.835 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 25.1 t -94.98 162.05 2.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.632 0.253 . . . . 0.0 110.656 179.628 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.815 ' HB3' HD11 ' A' ' 148' ' ' LEU . 55.5 t0 -117.53 109.09 16.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.946 0.403 . . . . 0.0 110.845 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.525 HD11 ' HD3' ' A' ' 136' ' ' ARG . 5.1 pt -46.45 -37.3 3.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.125 0.488 . . . . 0.0 111.807 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -47.58 -25.35 1.11 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.53 -0.759 . . . . 0.0 112.616 -179.196 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.859 ' N ' HD13 ' A' ' 148' ' ' LEU . 0.0 OUTLIER -127.12 30.24 5.46 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 111.736 0.273 . . . . 0.0 111.736 -179.22 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.486 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 58.3 t -93.92 158.57 2.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.804 0.335 . . . . 0.0 110.609 179.514 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.452 ' N ' HG12 ' A' ' 149' ' ' VAL . 0.7 OUTLIER -74.8 77.13 2.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.975 -179.659 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.59 90.64 0.47 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.393 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 152' ' ' THR . . . . . 0.779 HG22 ' OD1' ' A' ' 162' ' ' ASP . 11.2 t . . . . . 0 C--N 1.329 -0.295 0 CA-C-O 120.823 0.344 . . . . 0.0 111.058 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 N--CA 1.457 -0.092 0 CA-C-O 120.795 0.331 . . . . 0.0 110.939 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.503 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.0 OUTLIER -124.04 174.02 7.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.121 -179.773 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 160' ' ' LYS . . . . . 0.443 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 64.5 tttt -48.54 -50.19 33.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.901 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -56.27 -35.37 67.39 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.824 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 162' ' ' ASP . . . . . 0.779 ' OD1' HG22 ' A' ' 152' ' ' THR . 89.7 m-20 -67.24 -38.22 84.85 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.434 179.769 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 163' ' ' ILE . . . . . 0.769 HD11 ' CG1' ' A' ' 135' ' ' VAL . 4.2 mm -61.98 -47.28 93.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.064 0.459 . . . . 0.0 109.929 179.114 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -60.23 -40.92 91.89 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.475 179.413 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -62.08 -40.89 97.38 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.798 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 166' ' ' PHE . . . . . 0.568 ' CE1' HG13 ' A' ' 144' ' ' VAL . 44.5 t80 -60.49 -50.6 72.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.429 179.62 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 167' ' ' LEU . . . . . 0.798 HD21 ' CG2' ' A' ' 144' ' ' VAL . 14.8 mt . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.855 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.419 ' HB2' ' HB ' ' A' ' 158' ' ' VAL . . . . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.861 0.363 . . . . 0.0 111.112 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.3 mmm -106.72 161.55 22.52 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.884 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -56.15 -23.6 45.65 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.582 2.188 . . . . 0.0 112.126 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 45.9 p -81.05 -46.18 15.39 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.79 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.713 ' CG1' HD11 ' A' ' 163' ' ' ILE . 86.2 t -58.68 -33.25 48.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.986 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.532 ' HD3' HD11 ' A' ' 146' ' ' ILE . 4.8 mmm180 -64.35 -51.21 64.5 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.263 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -53.96 -38.8 65.36 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 178.467 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.708 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -55.02 -62.6 1.55 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.93 179.183 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.895 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -61.09 -23.28 65.37 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.782 -179.33 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 38.2 mtt-85 -84.08 -28.11 27.78 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.765 0.317 . . . . 0.0 111.123 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -84.05 -27.09 28.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.172 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.27 -27.88 13.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.158 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.28 16.01 24.06 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.578 -179.831 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.895 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 46.4 t -95.91 160.67 2.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.772 0.32 . . . . 0.0 110.756 179.766 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.524 ' N ' HG12 ' A' ' 144' ' ' VAL . 67.2 t0 -113.9 108.99 17.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.888 179.665 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.532 HD11 ' HD3' ' A' ' 136' ' ' ARG . 7.1 pt -50.5 -39.83 18.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.433 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -48.9 -24.84 1.62 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.773 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.558 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.4 OUTLIER -120.36 28.09 8.22 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.652 0.263 . . . . 0.0 111.612 -179.715 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.456 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 55.2 t -99.31 153.6 4.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.928 0.394 . . . . 0.0 110.771 179.456 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -74.96 79.16 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.161 -179.629 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -73.64 120.0 6.75 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.399 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.318 0 CA-C-O 120.643 0.259 . . . . 0.0 111.227 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.487 ' O ' HG21 ' A' ' 135' ' ' VAL . 25.9 t . . . . . 0 N--CA 1.457 -0.083 0 CA-C-O 120.844 0.354 . . . . 0.0 110.847 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.649 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.4 mt -111.87 175.98 5.21 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.107 0.479 . . . . 0.0 111.167 -179.744 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 49.5 tttt -49.43 -48.19 47.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.806 179.793 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -59.03 -34.48 71.96 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.714 179.778 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -67.35 -36.06 80.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.452 179.721 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 163' ' ' ILE . . . . . 0.713 HD11 ' CG1' ' A' ' 135' ' ' VAL . 4.2 mm -65.2 -50.22 74.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.169 179.226 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -58.52 -39.61 80.61 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.601 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.78 -40.57 97.0 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.628 179.737 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 166' ' ' PHE . . . . . 0.576 ' CE1' HG13 ' A' ' 144' ' ' VAL . 26.9 t80 -60.32 -48.98 79.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.425 179.678 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 167' ' ' LEU . . . . . 0.81 HD21 ' CG2' ' A' ' 144' ' ' VAL . 6.1 mt . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.911 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.486 1.357 0 CA-C-O 120.822 0.344 . . . . 0.0 111.21 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.5 mtp180 -175.54 82.64 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.858 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -71.28 147.26 48.32 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.863 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.718 HG21 ' HG2' ' A' ' 147' ' ' ARG . 25.4 t -106.37 150.31 9.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.136 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.613 HG22 ' CG ' ' A' ' 157' ' ' ARG . 20.5 mt -92.34 68.72 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.895 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -126.86 166.85 16.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.173 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 33.7 mtp -103.12 157.95 32.74 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.807 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 10.5 Cg_endo -53.6 -27.42 41.38 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.642 2.228 . . . . 0.0 112.192 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.6 t -80.06 -47.22 15.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.71 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.735 ' CG1' HD11 ' A' ' 163' ' ' ILE . 94.9 t -58.31 -31.31 42.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.822 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.469 ' HD3' HD11 ' A' ' 146' ' ' ILE . 6.6 mmm-85 -65.42 -52.74 51.22 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.281 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 11.0 tppt? -52.88 -39.5 62.71 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.478 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.689 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -54.33 -62.8 1.42 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.027 -0.988 . . . . 0.0 110.796 179.133 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.873 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -60.18 -24.67 64.97 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.601 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 3.3 mmt85 -82.16 -27.6 32.59 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.69 0.281 . . . . 0.0 111.122 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -85.68 -29.39 24.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.973 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 3.7 mptp? -94.96 -24.45 16.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.172 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 98.66 14.27 38.07 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.613 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.873 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 34.4 t -94.19 160.13 2.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.713 0.292 . . . . 0.0 110.81 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.772 ' HB3' HD11 ' A' ' 148' ' ' LEU . 63.8 t0 -114.9 104.99 12.47 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.789 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.469 HD11 ' HD3' ' A' ' 136' ' ' ARG . 4.4 pt -45.5 -36.33 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.26 0.552 . . . . 0.0 111.818 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' ARG . . . . . 0.718 ' HG2' HG21 ' A' ' 129' ' ' VAL . 6.8 mtt180 -48.29 -25.6 1.63 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.316 -0.856 . . . . 0.0 112.641 -179.253 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.852 ' N ' HD13 ' A' ' 148' ' ' LEU . 0.0 OUTLIER -125.49 30.02 5.87 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.662 0.268 . . . . 0.0 111.715 -179.433 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.46 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 58.1 t -94.63 155.65 3.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.862 0.363 . . . . 0.0 110.683 179.406 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.408 ' N ' HG12 ' A' ' 149' ' ' VAL . 0.5 OUTLIER -74.96 79.51 2.17 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.925 -179.749 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -73.32 110.52 3.16 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.433 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -103.37 -17.8 15.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.585 0.231 . . . . 0.0 111.215 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -52.64 173.89 0.27 Allowed Glycine 0 C--N 1.331 0.291 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.624 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 14.5 tptt -50.31 123.87 9.35 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.791 0.329 . . . . 0.0 111.195 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.552 ' O ' HD13 ' A' ' 130' ' ' ILE . 80.6 m-20 61.25 44.5 9.77 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.876 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 58.8 57.55 19.25 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.398 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.613 ' CG ' HG22 ' A' ' 130' ' ' ILE . 0.0 OUTLIER -98.0 121.16 39.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.77 0.319 . . . . 0.0 111.03 -179.918 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.463 ' O ' HG21 ' A' ' 135' ' ' VAL . 21.8 t -78.04 110.34 13.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.931 179.753 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.608 ' HA ' HG21 ' A' ' 135' ' ' VAL . 5.1 mt -109.45 178.51 4.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.019 0.438 . . . . 0.0 111.311 -179.754 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 160' ' ' LYS . . . . . 0.452 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 7.9 tttt -50.04 -47.69 53.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.688 179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -59.99 -33.63 72.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.752 179.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' ASP . . . . . 0.402 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 70.1 m-20 -67.66 -36.65 81.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.396 179.757 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 163' ' ' ILE . . . . . 0.735 HD11 ' CG1' ' A' ' 135' ' ' VAL . 3.5 mm -65.18 -50.09 75.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.174 179.114 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -58.62 -38.91 79.06 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.539 179.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.8 -42.08 97.77 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.787 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 166' ' ' PHE . . . . . 0.571 ' CE1' HG13 ' A' ' 144' ' ' VAL . 45.8 t80 -59.67 -51.26 70.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.608 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 167' ' ' LEU . . . . . 0.714 HD21 ' CG2' ' A' ' 144' ' ' VAL . 33.7 mt -70.91 -30.31 66.61 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.959 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -87.52 179.35 6.57 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.122 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 120.92 105.99 2.02 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.592 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 114.63 141.78 7.71 Favored Glycine 0 C--O 1.248 1.001 0 CA-C-O 118.377 -1.235 . . . . 0.0 112.573 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.782 0 CA-C-N 118.34 1.07 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 67.6 m-20 . . . . . 0 N--CA 1.486 1.369 0 CA-C-O 120.807 0.337 . . . . 0.0 111.159 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -134.01 145.63 49.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.878 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 51.8 ttt180 -71.35 123.31 22.03 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.955 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.538 HG21 ' HG2' ' A' ' 147' ' ' ARG . 20.1 t -98.77 154.61 3.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.123 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.765 HG22 ' HG3' ' A' ' 157' ' ' ARG . 18.8 mt -97.37 62.82 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.99 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -128.32 177.16 7.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.168 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 14.7 mtp -104.25 166.29 11.87 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.842 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -63.19 -27.59 72.75 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.556 2.171 . . . . 0.0 112.15 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 24.8 m -79.93 -44.92 19.46 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.772 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.637 HG21 ' HA ' ' A' ' 159' ' ' LEU . 59.5 t -59.46 -33.55 51.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.862 179.807 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.432 ' CD ' ' CD1' ' A' ' 146' ' ' ILE . 9.1 mmm-85 -63.89 -51.26 65.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.948 0.404 . . . . 0.0 109.921 179.312 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.401 ' CE ' ' HG3' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -53.68 -41.89 67.35 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 178.517 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.7 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -51.51 -61.99 1.9 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.755 179.066 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.814 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -62.76 -20.46 64.98 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.502 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 -83.41 -27.88 29.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.526 -0.307 . . . . 0.0 110.968 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.401 ' HG3' ' CE ' ' A' ' 137' ' ' LYS . 14.9 mt-10 -85.63 -29.36 24.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.86 0.362 . . . . 0.0 110.856 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' LYS . . . . . 0.521 ' HG2' HD13 ' A' ' 167' ' ' LEU . 4.9 tptt -95.26 -25.43 16.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.081 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 97.43 16.98 32.75 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.52 -179.709 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.814 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 43.9 t -91.1 158.85 2.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.805 0.336 . . . . 0.0 110.877 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.49 ' N ' HG12 ' A' ' 144' ' ' VAL . 62.3 t0 -109.99 102.16 10.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.751 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.475 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 9.7 pt -48.61 -39.79 10.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.263 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' ARG . . . . . 0.538 ' HG2' HG21 ' A' ' 129' ' ' VAL . 6.0 mtm-85 -48.97 -25.07 1.75 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.749 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.526 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.5 OUTLIER -120.78 27.44 8.51 Favored 'General case' 0 N--CA 1.463 0.186 0 N-CA-C 111.647 0.24 . . . . 0.0 111.647 -179.78 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.475 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 51.2 t -96.01 152.23 3.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.979 0.419 . . . . 0.0 110.906 179.593 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -74.96 79.36 2.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.973 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -75.99 116.48 4.82 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.507 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -114.43 28.35 8.8 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.803 0.335 . . . . 0.0 110.96 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -98.08 -174.28 33.11 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.349 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 7.9 tttt -45.42 111.07 0.3 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.784 0.326 . . . . 0.0 111.433 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 4.9 t30 62.78 52.85 2.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.89 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 57.12 54.15 39.2 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.459 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.765 ' HG3' HG22 ' A' ' 130' ' ' ILE . 28.9 ttm-85 -96.15 139.8 31.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.82 0.343 . . . . 0.0 110.995 -179.812 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.424 ' O ' HG21 ' A' ' 135' ' ' VAL . 24.9 t -89.97 120.59 39.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.952 179.849 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.637 ' HA ' HG21 ' A' ' 135' ' ' VAL . 3.2 mt -117.12 174.79 5.92 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.152 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 160' ' ' LYS . . . . . 0.442 ' HG2' ' CE2' ' A' ' 138' ' ' TYR . 0.0 OUTLIER -48.38 -48.97 36.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.875 179.946 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -58.03 -35.63 71.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.866 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -65.7 -38.8 90.23 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.35 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 163' ' ' ILE . . . . . 0.7 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.0 mm -62.64 -48.73 86.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.095 179.114 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -58.23 -39.93 80.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.63 179.541 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.5 -39.3 91.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.812 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 166' ' ' PHE . . . . . 0.62 ' CE1' HG13 ' A' ' 144' ' ' VAL . 21.9 t80 -64.15 -38.45 91.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.662 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 167' ' ' LEU . . . . . 0.779 HD21 ' CG2' ' A' ' 144' ' ' VAL . 19.5 mt -86.88 -76.39 0.36 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.144 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -66.69 -45.06 80.06 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.393 -179.784 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -59.06 -27.53 62.57 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.511 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -128.09 -91.56 0.71 Allowed Glycine 0 C--O 1.249 1.048 0 CA-C-O 118.407 -1.218 . . . . 0.0 112.494 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.779 0 CA-C-N 118.365 1.082 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.487 1.417 0 CA-C-O 120.853 0.359 . . . . 0.0 111.14 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -66.58 107.01 1.95 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.911 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 4.6 mtt85 -135.57 -178.21 5.02 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.913 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.865 HG21 ' HG2' ' A' ' 147' ' ' ARG . 22.0 t -108.85 155.94 9.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.171 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.567 HG22 ' HA ' ' A' ' 157' ' ' ARG . 6.0 mt -79.97 68.69 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.804 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -139.97 155.21 47.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.217 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' MET . . . . . 0.407 ' CB ' ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -88.93 166.32 22.74 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.849 179.947 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 133' ' ' PRO . . . . . 0.407 ' HD2' ' CB ' ' A' ' 132' ' ' MET . 22.6 Cg_endo -61.44 -42.09 36.37 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.539 2.159 . . . . 0.0 112.227 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.03 -46.29 85.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.865 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.677 HG21 ' HA ' ' A' ' 159' ' ' LEU . 57.9 t -58.48 -35.08 52.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.913 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.625 ' HD3' HD11 ' A' ' 146' ' ' ILE . 1.6 mmm180 -63.18 -48.07 79.92 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.298 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.03 -38.36 70.43 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 178.323 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.679 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -55.43 -63.06 1.28 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.879 179.127 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.85 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -62.79 -20.99 65.55 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.387 -179.529 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 12.9 tpt180 -83.54 -27.15 29.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.956 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -85.63 -28.86 24.5 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.888 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' LYS . . . . . 0.444 ' HE2' HD13 ' A' ' 167' ' ' LEU . 0.0 OUTLIER -95.83 -26.21 15.73 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.109 -179.864 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 100.02 15.59 30.47 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.588 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.85 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 49.0 t -93.71 159.28 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.881 0.372 . . . . 0.0 110.758 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.51 ' N ' HG12 ' A' ' 144' ' ' VAL . 41.6 t0 -110.91 107.71 17.25 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.747 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.625 HD11 ' HD3' ' A' ' 136' ' ' ARG . 6.7 pt -51.19 -39.63 20.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.104 0.478 . . . . 0.0 111.437 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' ARG . . . . . 0.865 ' HG2' HG21 ' A' ' 129' ' ' VAL . 20.8 mtt180 -48.81 -26.19 2.26 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.832 -179.744 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.447 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.0 OUTLIER -118.64 26.92 9.23 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 111.71 0.263 . . . . 0.0 111.71 -179.889 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.455 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 56.1 t -96.2 156.65 3.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.873 0.368 . . . . 0.0 110.702 179.468 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.42 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.97 73.38 2.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.888 -179.738 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -69.13 133.67 26.57 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.477 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.19 30.09 0.87 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.851 0.358 . . . . 0.0 110.812 -179.833 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -96.66 105.13 3.17 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.696 -0.764 . . . . 0.0 113.009 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' LYS . . . . . 0.522 ' HG3' ' N ' ' A' ' 155' ' ' ASN . 0.0 OUTLIER 73.55 -49.73 0.69 Allowed 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 179.509 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.522 ' N ' ' HG3' ' A' ' 154' ' ' LYS . 9.4 m-20 -155.5 27.12 0.4 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.892 0.377 . . . . 0.0 110.338 179.829 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 108.49 16.1 12.59 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.489 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.567 ' HA ' HG22 ' A' ' 130' ' ' ILE . 1.3 ttt180 -68.55 128.92 38.36 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.748 0.309 . . . . 0.0 110.618 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.493 ' O ' HG21 ' A' ' 135' ' ' VAL . 22.8 t -74.97 106.66 4.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.052 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.677 ' HA ' HG21 ' A' ' 135' ' ' VAL . 16.3 mt -106.59 176.36 5.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.017 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 160' ' ' LYS . . . . . 0.443 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 0.1 OUTLIER -50.19 -45.71 53.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.645 179.784 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 50.5 mm-40 -61.35 -34.52 75.43 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.627 179.694 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 162' ' ' ASP . . . . . 0.413 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 60.8 m-20 -65.41 -39.55 92.28 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.249 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 163' ' ' ILE . . . . . 0.679 HG21 ' CD1' ' A' ' 138' ' ' TYR . 3.3 mm -64.47 -45.13 96.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.027 179.037 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 164' ' ' ASP . . . . . 0.507 ' O ' ' HB2' ' A' ' 168' ' ' ALA . 4.5 m-20 -60.61 -35.71 76.8 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.284 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -67.83 -39.01 83.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.469 179.541 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 166' ' ' PHE . . . . . 0.458 ' CE1' HG13 ' A' ' 144' ' ' VAL . 20.2 t80 -68.53 -31.3 70.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.605 179.642 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 167' ' ' LEU . . . . . 0.844 HD21 ' CG2' ' A' ' 144' ' ' VAL . 2.6 mt -105.69 -80.1 0.55 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.978 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 168' ' ' ALA . . . . . 0.507 ' HB2' ' O ' ' A' ' 164' ' ' ASP . . . 53.41 100.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.314 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -166.19 -94.63 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.494 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -165.75 6.42 0.06 OUTLIER Glycine 0 C--O 1.25 1.108 0 CA-C-O 118.317 -1.268 . . . . 0.0 112.468 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.818 0 CA-C-N 118.432 1.116 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 6.9 m120 . . . . . 0 N--CA 1.485 1.315 0 CA-C-O 120.896 0.379 . . . . 0.0 111.187 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -103.73 157.67 16.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.891 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.0 141.57 33.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.907 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.664 HG21 ' HG2' ' A' ' 147' ' ' ARG . 14.6 t -132.18 161.55 41.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.948 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.489 ' N ' HG12 ' A' ' 129' ' ' VAL . 3.4 mt -79.96 69.78 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.915 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -142.83 153.35 43.12 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.123 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 64.2 mtp -80.07 157.34 73.68 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.946 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_exo -51.66 -42.58 55.8 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.576 2.184 . . . . 0.0 112.302 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.4 p -61.13 -42.64 98.91 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.956 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.621 ' CG1' HD11 ' A' ' 163' ' ' ILE . 59.2 t -59.46 -34.33 54.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.807 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.415 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -66.8 -53.63 30.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.895 0.379 . . . . 0.0 110.034 179.329 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.4 tttt -55.38 -32.08 62.32 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 178.696 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.715 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -61.93 -61.97 2.12 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.344 179.149 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.867 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -61.46 -24.41 66.54 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.527 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 9.5 mtp-105 -83.65 -29.05 27.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.795 0.331 . . . . 0.0 110.894 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -84.04 -26.94 28.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.112 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 5.4 mptt -97.45 -27.57 14.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.169 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.85 14.0 28.1 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.624 -179.783 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.867 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 47.3 t -95.46 160.8 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.862 0.363 . . . . 0.0 110.75 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.52 ' N ' HG12 ' A' ' 144' ' ' VAL . 45.5 t0 -113.46 107.07 15.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.615 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.48 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 12.7 pt -50.03 -39.98 16.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.355 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 147' ' ' ARG . . . . . 0.664 ' HG2' HG21 ' A' ' 129' ' ' VAL . 11.9 mtm105 -49.28 -24.06 1.66 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.854 -179.766 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.495 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.5 OUTLIER -120.45 27.15 8.74 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 120.65 0.262 . . . . 0.0 111.569 -179.83 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.48 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 55.6 t -96.4 158.19 3.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.957 0.408 . . . . 0.0 110.888 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.425 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.4 OUTLIER -74.77 79.6 2.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.157 -179.653 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -69.63 96.61 0.51 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.315 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 70.2 p -84.98 -23.25 28.79 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-O 120.785 0.326 . . . . 0.0 111.209 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -54.18 167.88 1.78 Allowed Glycine 0 C--N 1.332 0.307 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.566 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 3.4 tttt -55.0 138.44 43.81 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.82 0.343 . . . . 0.0 111.08 -179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 10.4 m-20 60.5 31.07 20.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 64.56 53.6 34.3 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.379 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.555 ' CZ ' HD21 ' A' ' 159' ' ' LEU . 38.4 ttp180 -95.04 128.13 41.63 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.847 0.356 . . . . 0.0 111.032 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.424 HG13 ' CG1' ' A' ' 149' ' ' VAL . 25.2 t -87.59 118.56 33.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.012 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.555 HD21 ' CZ ' ' A' ' 157' ' ' ARG . 1.3 mt -114.05 176.87 4.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.021 -179.811 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 160' ' ' LYS . . . . . 0.444 ' HG2' ' CE2' ' A' ' 138' ' ' TYR . 0.0 OUTLIER -49.37 -49.28 45.18 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.752 179.889 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -57.58 -34.48 69.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.796 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 162' ' ' ASP . . . . . 0.415 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 83.7 m-20 -67.54 -37.39 82.65 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.372 179.663 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 163' ' ' ILE . . . . . 0.715 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.0 mm -63.24 -47.99 89.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.168 179.23 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -59.33 -43.5 92.73 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.588 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -60.27 -40.4 90.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.814 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 166' ' ' PHE . . . . . 0.58 ' CE1' HG13 ' A' ' 144' ' ' VAL . 18.8 t80 -61.35 -50.07 74.38 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.631 179.727 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 167' ' ' LEU . . . . . 0.718 HD21 ' CG2' ' A' ' 144' ' ' VAL . 37.6 mt -70.72 -33.18 70.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.843 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -83.14 147.02 28.32 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.169 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -151.81 50.78 0.52 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.564 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 58.76 -176.02 2.5 Favored Glycine 0 C--O 1.249 1.064 0 CA-C-O 118.367 -1.24 . . . . 0.0 112.578 -179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.801 0 CA-C-N 118.466 1.133 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 126' ' ' ASN . . . . . 0.578 ' N ' HD21 ' A' ' 126' ' ' ASN . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.381 0 CA-C-O 120.86 0.362 . . . . 0.0 111.198 . . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.54 104.22 7.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.871 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.99 156.18 3.09 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.16 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.628 HG21 ' HG3' ' A' ' 147' ' ' ARG . 24.2 t -135.09 149.72 29.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.109 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.438 HG22 ' HG2' ' A' ' 157' ' ' ARG . 4.9 mt -79.99 63.09 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.769 179.785 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -141.22 155.78 45.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.14 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 1.1 mtp -68.75 160.65 76.32 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.785 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -62.03 -18.18 60.2 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.602 2.201 . . . . 0.0 112.377 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 29.1 t -88.64 -41.37 12.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.994 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.678 HG21 ' HA ' ' A' ' 159' ' ' LEU . 90.9 t -60.02 -40.19 82.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.099 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.627 ' HA ' HG21 ' A' ' 146' ' ' ILE . 4.3 mtm180 -63.11 -43.08 99.45 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 6.7 tttt -62.37 -34.34 76.49 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 178.376 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.75 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.9 OUTLIER -57.5 -60.95 2.89 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.304 179.005 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.78 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -60.73 -30.27 69.88 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.416 -179.708 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.53 -19.78 45.0 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.38 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -93.14 -22.43 19.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.674 0.273 . . . . 0.0 111.14 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' LYS . . . . . 0.477 ' HD2' HD13 ' A' ' 167' ' ' LEU . 0.2 OUTLIER -102.33 -21.38 14.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.343 -179.812 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.29 5.62 39.98 Favored Glycine 0 CA--C 1.519 0.314 0 C-N-CA 120.49 -0.862 . . . . 0.0 112.818 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.78 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 53.0 t -92.48 159.43 2.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.756 0.313 . . . . 0.0 110.695 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.498 ' N ' HG12 ' A' ' 144' ' ' VAL . 62.6 t0 -109.1 108.34 18.98 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.798 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.644 HG23 ' HB3' ' A' ' 139' ' ' ALA . 0.2 OUTLIER -50.59 -41.52 20.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.519 179.927 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 147' ' ' ARG . . . . . 0.628 ' HG3' HG21 ' A' ' 129' ' ' VAL . 0.7 OUTLIER -49.9 -23.11 1.76 Allowed 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.907 -179.853 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.47 ' CD1' ' CE2' ' A' ' 166' ' ' PHE . 0.6 OUTLIER -120.27 25.69 9.68 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 111.819 0.303 . . . . 0.0 111.819 -179.605 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.501 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 63.2 t -92.64 151.96 3.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.929 0.395 . . . . 0.0 110.87 179.457 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -74.94 79.55 2.16 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.159 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.01 123.75 10.89 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.343 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -99.28 -25.3 14.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.757 0.313 . . . . 0.0 111.177 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -52.77 168.9 0.8 Allowed Glycine 0 C--N 1.331 0.264 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.716 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 1.2 ttmm -58.18 142.47 47.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.768 0.318 . . . . 0.0 110.99 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 59.73 31.21 20.71 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.915 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 66.16 55.01 20.87 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.416 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.438 ' HG2' HG22 ' A' ' 130' ' ' ILE . 0.2 OUTLIER -91.28 131.57 36.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.829 0.347 . . . . 0.0 110.926 179.913 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.45 ' O ' HG21 ' A' ' 135' ' ' VAL . 14.9 t -91.6 123.91 43.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.066 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.678 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.3 mp -118.61 173.08 7.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.09 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 11.1 tttt -50.37 -45.21 55.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.677 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -59.72 -35.54 74.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.561 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -66.67 -36.84 83.48 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.238 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 163' ' ' ILE . . . . . 0.75 HG21 ' CD1' ' A' ' 138' ' ' TYR . 8.6 mm -63.94 -48.78 84.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.181 179.216 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -58.71 -41.86 87.33 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.594 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.97 -42.03 98.67 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.674 179.701 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 166' ' ' PHE . . . . . 0.608 ' CE1' HG13 ' A' ' 144' ' ' VAL . 13.6 t80 -59.46 -47.34 85.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.489 179.691 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 167' ' ' LEU . . . . . 0.744 HD21 ' CG2' ' A' ' 144' ' ' VAL . 19.9 mt -75.81 -73.6 0.26 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.819 179.87 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -82.75 118.12 23.15 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.048 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -101.87 -44.78 1.87 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.562 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -100.68 -58.44 0.85 Allowed Glycine 0 C--O 1.249 1.046 0 CA-C-O 118.406 -1.219 . . . . 0.0 112.479 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.25 -3.757 0 CA-C-N 118.349 1.075 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 . . . . . 0 N--CA 1.486 1.356 0 CA-C-O 120.828 0.346 . . . . 0.0 111.163 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.1 ttm180 -152.37 100.4 2.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.927 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -116.45 176.32 5.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.82 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.622 HG21 ' HG2' ' A' ' 147' ' ' ARG . 21.7 t -133.26 159.26 43.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.017 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.583 HG22 ' HG3' ' A' ' 157' ' ' ARG . 3.3 mp -79.9 67.07 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.065 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -113.15 -169.86 1.57 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.105 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' MET . . . . . 0.462 ' HB2' HG23 ' A' ' 135' ' ' VAL . 1.0 OUTLIER -129.65 161.38 59.55 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.846 179.969 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -61.99 -24.69 77.06 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.613 2.208 . . . . 0.0 112.225 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.3 m -92.36 -42.02 10.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.854 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.691 HG21 ' HA ' ' A' ' 159' ' ' LEU . 59.2 t -62.03 -37.31 78.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.943 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.67 ' HD3' HD12 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -63.94 -47.54 80.09 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.303 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.22 -40.86 78.36 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 178.36 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.722 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.9 OUTLIER -51.86 -61.1 2.47 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.491 178.973 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.805 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -59.89 -28.11 67.29 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.575 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 11.0 tpt180 -79.95 -24.45 40.98 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.623 0.249 . . . . 0.0 111.373 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 16.8 mm-40 -89.25 -26.34 21.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.047 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 13.9 mptt -96.55 -22.28 17.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.251 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 101.27 8.61 46.7 Favored Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.667 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.805 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 45.1 t -92.73 159.26 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.775 0.321 . . . . 0.0 110.86 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.811 ' HB3' HD11 ' A' ' 148' ' ' LEU . 66.5 t0 -112.67 111.39 22.16 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.807 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.67 HD12 ' HD3' ' A' ' 136' ' ' ARG . 0.0 OUTLIER -49.53 -37.25 11.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.145 0.498 . . . . 0.0 111.726 -179.884 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 147' ' ' ARG . . . . . 0.622 ' HG2' HG21 ' A' ' 129' ' ' VAL . 4.0 mtm-85 -48.59 -24.02 1.19 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.463 -0.79 . . . . 0.0 112.697 -179.231 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.871 ' N ' HD13 ' A' ' 148' ' ' LEU . 0.0 OUTLIER -127.92 31.75 5.05 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 111.893 0.331 . . . . 0.0 111.893 -179.25 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.478 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 76.5 t -94.75 157.08 3.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.841 0.353 . . . . 0.0 110.594 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.443 ' N ' HG12 ' A' ' 149' ' ' VAL . 1.2 mt-30 -74.89 72.17 2.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.854 -179.717 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.95 117.58 6.52 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.385 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -130.94 31.48 4.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.876 0.37 . . . . 0.0 110.798 -179.835 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 153' ' ' GLY . . . . . 0.699 ' HA3' HD11 ' A' ' 159' ' ' LEU . . . -91.79 101.97 2.86 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.566 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 11.3 tttp 63.48 -78.69 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.712 0.292 . . . . 0.0 111.143 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 7.3 t30 -113.23 31.42 6.46 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.852 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 92.11 29.57 11.31 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.536 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.583 ' HG3' HG22 ' A' ' 130' ' ' ILE . 61.2 ttm-85 -77.02 130.98 38.18 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.87 0.367 . . . . 0.0 110.884 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.645 HG12 HG11 ' A' ' 135' ' ' VAL . 23.6 t -74.96 112.04 11.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.059 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.699 HD11 ' HA3' ' A' ' 153' ' ' GLY . 0.9 OUTLIER -112.19 173.56 6.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.048 -179.867 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 2.0 tttt -49.15 -46.22 44.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.797 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 49.1 mm-40 -60.61 -35.62 76.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.659 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -65.52 -37.35 86.51 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.471 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 163' ' ' ILE . . . . . 0.722 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.0 mm -65.07 -49.48 79.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.207 179.193 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -58.55 -36.88 74.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.638 179.635 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -66.24 -41.98 89.26 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.918 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 166' ' ' PHE . . . . . 0.584 ' CE2' HD23 ' A' ' 148' ' ' LEU . 37.0 t80 -60.21 -50.84 72.06 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.637 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 167' ' ' LEU . . . . . 0.691 HD21 ' CG2' ' A' ' 144' ' ' VAL . 49.7 mt -71.95 -75.66 0.13 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.922 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -59.39 149.57 28.86 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.133 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 131.5 63.85 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.513 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -104.06 54.0 0.68 Allowed Glycine 0 C--O 1.249 1.047 0 CA-C-O 118.387 -1.23 . . . . 0.0 112.556 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.774 0 CA-C-N 118.387 1.094 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 9.0 t30 . . . . . 0 N--CA 1.487 1.414 0 CA-C-O 120.826 0.346 . . . . 0.0 111.195 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 2.2 mtt180 -145.14 -178.49 6.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.886 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 10.0 ttm105 -100.49 158.83 15.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.465 HG21 ' HG2' ' A' ' 147' ' ' ARG . 29.2 t -78.06 147.43 7.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.075 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.592 HG22 ' HG2' ' A' ' 157' ' ' ARG . 4.3 mt -108.34 52.98 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.125 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -100.58 168.08 9.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.088 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' MET . . . . . 0.673 ' HB2' HG23 ' A' ' 135' ' ' VAL . 1.4 mtp -95.33 157.36 36.45 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.9 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.79 -38.36 85.25 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.527 2.151 . . . . 0.0 112.393 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.2 t -80.06 -38.37 31.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.025 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.722 HG21 ' HA ' ' A' ' 159' ' ' LEU . 65.4 t -61.51 -36.49 73.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.051 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.901 ' HD3' HD12 ' A' ' 146' ' ' ILE . 1.4 mmt180 -68.05 -47.26 68.84 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.508 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.14 -36.94 78.63 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.642 ' CD2' HG21 ' A' ' 163' ' ' ILE . 1.2 t80 -55.95 -58.87 6.08 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.461 179.047 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.709 ' HB3' HG23 ' A' ' 146' ' ' ILE . . . -61.03 -28.73 69.26 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.21 -0.905 . . . . 0.0 111.262 -179.863 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.55 -29.63 46.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.849 0.357 . . . . 0.0 111.161 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 64.7 mm-40 -85.59 -23.65 27.5 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.163 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -95.89 -24.35 16.47 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.398 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.36 4.17 40.81 Favored Glycine 0 CA--C 1.518 0.268 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.684 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.741 ' CG2' HD21 ' A' ' 167' ' ' LEU . 59.2 t -87.59 157.77 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 0.0 110.826 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.667 ' OD2' HD21 ' A' ' 148' ' ' LEU . 62.3 t0 -106.79 105.48 15.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.73 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.901 HD12 ' HD3' ' A' ' 136' ' ' ARG . 4.3 pt -49.8 -42.16 17.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.49 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 147' ' ' ARG . . . . . 0.465 ' HG2' HG21 ' A' ' 129' ' ' VAL . 80.3 mtp180 -48.65 -27.92 3.17 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.126 -179.601 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.667 HD21 ' OD2' ' A' ' 145' ' ' ASP . 0.0 OUTLIER -116.8 24.19 11.42 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 111.979 0.363 . . . . 0.0 111.979 -179.515 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.532 HG21 HD13 ' A' ' 163' ' ' ILE . 43.8 t -88.72 150.47 3.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.762 0.315 . . . . 0.0 110.588 179.37 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.97 78.78 2.17 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.994 -179.684 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 151' ' ' GLY . . . . . 0.591 ' HA3' HG22 ' A' ' 158' ' ' VAL . . . -82.14 118.69 4.68 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.378 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' THR . . . . . 0.501 HG22 ' OD1' ' A' ' 162' ' ' ASP . 8.8 t -137.83 34.87 2.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.823 0.344 . . . . 0.0 111.002 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -81.08 92.75 1.48 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.487 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 7.8 tttt 64.83 -75.08 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.716 0.293 . . . . 0.0 111.078 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.4 t30 -110.3 24.88 12.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.102 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 96.82 29.68 7.99 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.72 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.592 ' HG2' HG22 ' A' ' 130' ' ' ILE . 3.2 mtt180 -79.96 121.93 26.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.787 0.327 . . . . 0.0 110.771 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.681 ' O ' HG11 ' A' ' 135' ' ' VAL . 26.5 t -75.02 92.79 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.112 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.722 ' HA ' HG21 ' A' ' 135' ' ' VAL . 3.2 mt -95.83 172.78 7.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.955 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.7 tttt -49.72 -42.58 46.3 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.783 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 51.7 mm-40 -56.06 -40.56 73.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.48 179.566 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 162' ' ' ASP . . . . . 0.501 ' OD1' HG22 ' A' ' 152' ' ' THR . 76.7 m-20 -64.76 -43.49 93.12 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.215 179.293 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 163' ' ' ILE . . . . . 0.658 ' CG1' HG13 ' A' ' 135' ' ' VAL . 10.7 mm -61.73 -38.78 81.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.167 179.152 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -62.37 -45.2 94.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.246 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -59.04 -42.9 91.35 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.418 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 166' ' ' PHE . . . . . 0.704 ' CE1' HG13 ' A' ' 144' ' ' VAL . 7.8 t80 -61.67 -48.99 78.31 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.297 179.308 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 167' ' ' LEU . . . . . 0.741 HD21 ' CG2' ' A' ' 144' ' ' VAL . 40.1 mt -72.52 -76.21 0.12 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.859 180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -67.12 -78.45 0.06 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.104 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 88.87 49.35 3.6 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.525 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -133.82 4.68 4.7 Favored Glycine 0 C--O 1.25 1.097 0 CA-C-O 118.306 -1.274 . . . . 0.0 112.426 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.812 0 CA-C-N 118.394 1.097 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.487 1.384 0 CA-C-O 120.809 0.338 . . . . 0.0 111.172 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 4.4 mtt180 -91.95 161.56 14.76 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.931 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.33 176.06 6.87 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.901 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.489 HG21 ' HG2' ' A' ' 147' ' ' ARG . 18.4 t -101.14 159.63 3.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.127 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.633 HG22 ' HG3' ' A' ' 157' ' ' ARG . 18.1 mt -80.02 59.94 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.022 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.845 ' HB3' ' NE ' ' A' ' 136' ' ' ARG . . . -120.23 169.91 9.82 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.987 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 26.8 mtp -99.6 165.21 15.12 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.951 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -58.67 -45.51 29.14 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.575 2.183 . . . . 0.0 112.183 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 66.7 m -69.85 -37.5 76.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.656 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.65 HG21 ' HA ' ' A' ' 159' ' ' LEU . 64.8 t -64.05 -37.73 80.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.919 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.845 ' NE ' ' HB3' ' A' ' 131' ' ' ALA . 0.0 OUTLIER -64.21 -49.04 73.55 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.306 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 6.2 tttt -58.88 -32.9 69.91 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.747 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -58.42 -60.61 3.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.446 179.197 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.69 ' HB3' HG23 ' A' ' 146' ' ' ILE . . . -60.62 -29.52 69.29 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.665 -179.453 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 63.5 mtt180 -79.79 -27.39 40.39 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.271 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -86.6 -28.48 23.25 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.954 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -93.51 -23.58 18.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.097 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 99.53 10.78 46.49 Favored Glycine 0 CA--C 1.52 0.351 0 C-N-CA 120.596 -0.812 . . . . 0.0 112.56 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.705 ' CG2' HD21 ' A' ' 167' ' ' LEU . 48.5 t -89.95 158.67 2.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.757 0.313 . . . . 0.0 110.715 179.723 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.485 ' N ' HG12 ' A' ' 144' ' ' VAL . 62.8 t0 -104.28 104.05 13.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.035 0.445 . . . . 0.0 110.966 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.738 HD12 ' HD2' ' A' ' 136' ' ' ARG . 3.9 pt -47.36 -44.57 9.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.716 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' ARG . . . . . 0.489 ' HG2' HG21 ' A' ' 129' ' ' VAL . 7.2 mmt180 -50.0 -23.39 2.01 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.786 -0.643 . . . . 0.0 112.195 -179.484 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.516 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.7 OUTLIER -120.99 22.95 10.88 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -179.608 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.485 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 74.4 t -87.68 148.95 4.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.737 0.303 . . . . 0.0 110.497 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.91 79.32 2.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.904 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 151' ' ' GLY . . . . . 0.672 ' HA3' HG22 ' A' ' 158' ' ' VAL . . . -85.68 115.33 4.15 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.41 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 3.7 t -140.67 42.81 1.86 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.368 . . . . 0.0 111.041 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -114.05 101.27 1.1 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.494 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 12.9 tttm 55.69 102.62 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.864 0.364 . . . . 0.0 111.074 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 65.64 14.22 9.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.345 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 81.61 46.99 6.54 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.792 179.789 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.633 ' HG3' HG22 ' A' ' 130' ' ' ILE . 0.3 OUTLIER -96.92 130.97 44.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.781 0.324 . . . . 0.0 110.752 179.903 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.672 HG22 ' HA3' ' A' ' 151' ' ' GLY . 27.7 t -74.95 116.67 17.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.945 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.65 ' HA ' HG21 ' A' ' 135' ' ' VAL . 5.6 mt -114.24 174.11 6.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.155 -179.772 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.1 tttm -50.62 -44.39 57.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.734 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -60.43 -35.4 75.71 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.653 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 36.9 m-20 -66.33 -38.82 88.55 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.273 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 163' ' ' ILE . . . . . 0.747 HG21 ' CD1' ' A' ' 138' ' ' TYR . 5.0 mm -62.01 -50.16 81.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.256 179.054 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.6 -41.25 80.85 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.55 179.638 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.07 -41.25 96.29 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.67 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 166' ' ' PHE . . . . . 0.618 ' CE1' HG13 ' A' ' 144' ' ' VAL . 21.5 t80 -60.89 -48.07 83.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.477 179.618 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 167' ' ' LEU . . . . . 0.705 HD21 ' CG2' ' A' ' 144' ' ' VAL . 41.8 mt -74.61 -71.9 0.32 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.839 179.761 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -60.11 141.88 55.1 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.071 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 126.01 91.74 0.84 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.534 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 127.88 -33.67 3.17 Favored Glycine 0 C--O 1.249 1.047 0 CA-C-O 118.396 -1.224 . . . . 0.0 112.49 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.791 0 CA-C-N 118.386 1.093 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 . . . . . 0 N--CA 1.486 1.334 0 CA-C-O 120.851 0.358 . . . . 0.0 111.21 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.89 163.15 14.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.84 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.95 170.1 17.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.783 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.445 HG21 ' HG3' ' A' ' 147' ' ' ARG . 27.6 t -83.07 136.13 23.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.053 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.664 HG22 ' HG3' ' A' ' 157' ' ' ARG . 2.6 mt -83.42 64.43 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.064 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -116.72 -177.7 3.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.173 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' MET . . . . . 0.44 ' HB2' HG23 ' A' ' 135' ' ' VAL . 10.6 mtp -120.94 161.86 38.12 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.888 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.2 -56.84 2.52 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.509 2.139 . . . . 0.0 112.413 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -59.49 -40.64 87.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.871 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.631 ' CG1' HD11 ' A' ' 163' ' ' ILE . 96.3 t -60.36 -34.42 57.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.917 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.567 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.9 OUTLIER -65.85 -52.35 51.09 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.474 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -56.39 -32.79 65.13 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.577 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.718 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -59.02 -61.56 2.55 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.358 179.14 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.856 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -63.15 -23.08 67.27 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.364 -179.776 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -82.74 -26.43 31.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.088 179.829 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -86.66 -26.72 24.18 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.05 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 2.9 mptt -98.05 -24.9 15.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.247 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 100.84 13.27 34.84 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.612 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.856 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 38.9 t -93.97 161.02 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.718 0.294 . . . . 0.0 110.774 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.79 ' HB3' HD11 ' A' ' 148' ' ' LEU . 47.9 t0 -116.06 104.62 11.75 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.89 0.376 . . . . 0.0 110.795 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.567 HD11 ' HD3' ' A' ' 136' ' ' ARG . 6.1 pt -44.55 -36.26 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.222 0.534 . . . . 0.0 111.805 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 147' ' ' ARG . . . . . 0.445 ' HG3' HG21 ' A' ' 129' ' ' VAL . 0.0 OUTLIER -47.64 -26.16 1.41 Allowed 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.251 -0.886 . . . . 0.0 112.644 -179.159 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.853 ' N ' HD13 ' A' ' 148' ' ' LEU . 0.0 OUTLIER -125.21 29.87 5.98 Favored 'General case' 0 C--N 1.332 -0.161 0 C-N-CA 121.007 -0.277 . . . . 0.0 111.612 -179.36 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.468 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 54.5 t -94.26 157.73 2.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.839 0.352 . . . . 0.0 110.593 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.433 ' N ' HG12 ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.91 75.1 2.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.906 -179.69 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -74.56 122.09 7.07 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.369 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -137.79 31.36 2.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.928 0.394 . . . . 0.0 110.861 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -92.27 106.05 3.36 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.622 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 5.0 tptp 67.16 -70.88 0.11 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.686 0.279 . . . . 0.0 111.204 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -131.73 36.69 3.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.821 0.343 . . . . 0.0 111.006 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 96.58 27.52 9.71 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.603 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.664 ' HG3' HG22 ' A' ' 130' ' ' ILE . 13.9 ttm180 -80.11 125.1 29.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.77 0.319 . . . . 0.0 110.833 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.431 ' O ' HG21 ' A' ' 135' ' ' VAL . 28.3 t -75.03 111.9 11.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.998 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.528 ' HA ' HG21 ' A' ' 135' ' ' VAL . 5.0 mt -110.89 175.93 5.23 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.07 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 6.9 tttt -49.07 -45.75 43.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.816 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 -60.68 -36.12 77.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.696 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 73.3 m-20 -65.54 -36.3 83.39 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.298 179.663 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 163' ' ' ILE . . . . . 0.718 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.5 mm -64.79 -51.32 68.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.302 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.49 -38.03 73.91 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.638 179.591 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -64.83 -41.95 95.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.81 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 166' ' ' PHE . . . . . 0.552 ' CE1' HG13 ' A' ' 144' ' ' VAL . 50.0 t80 -60.08 -48.88 79.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.622 179.76 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 167' ' ' LEU . . . . . 0.715 HD21 ' CG2' ' A' ' 144' ' ' VAL . 39.6 mt -74.98 -31.54 61.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.928 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -91.32 102.62 15.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.03 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 93.82 -46.27 2.3 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.544 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 129.45 138.19 4.39 Favored Glycine 0 C--O 1.249 1.073 0 CA-C-O 118.379 -1.234 . . . . 0.0 112.554 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.785 0 CA-C-N 118.446 1.123 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 8.2 m120 . . . . . 0 N--CA 1.486 1.362 0 CA-C-O 120.806 0.336 . . . . 0.0 111.154 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 5.5 mtt180 -66.24 159.53 26.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.904 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -114.06 114.89 26.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.807 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.404 HG12 ' N ' ' A' ' 130' ' ' ILE . 19.5 t -139.67 154.18 24.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.241 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.661 HG22 ' CG ' ' A' ' 157' ' ' ARG . 20.3 mt -93.37 67.17 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.863 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -129.8 -173.16 2.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.335 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' MET . . . . . 0.489 ' SD ' HD23 ' A' ' 159' ' ' LEU . 0.0 OUTLIER -112.88 157.2 41.25 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.766 -179.991 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.91 -33.14 50.39 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.632 2.221 . . . . 0.0 112.099 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 9.4 p -76.99 -43.31 35.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.619 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.627 HG21 ' HA ' ' A' ' 159' ' ' LEU . 73.0 t -58.5 -34.97 52.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.856 179.813 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.466 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.2 OUTLIER -64.71 -49.78 69.54 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 179.206 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -57.58 -31.09 65.81 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 178.556 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.688 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -61.25 -62.36 1.89 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.369 179.032 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.833 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -59.92 -29.2 68.21 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.413 -179.578 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? -80.11 -26.29 39.58 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.212 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -86.59 -29.48 22.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.995 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 4.9 mptt -95.07 -22.19 18.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.256 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 97.16 12.82 47.83 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.609 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.833 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 54.0 t -94.3 159.32 2.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.706 0.288 . . . . 0.0 110.783 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.495 ' N ' HG12 ' A' ' 144' ' ' VAL . 67.0 t0 -110.06 111.48 22.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.868 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.466 HD11 ' HD3' ' A' ' 136' ' ' ARG . 7.9 pt -53.36 -39.95 37.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.402 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 1.2 mmm180 -49.23 -25.26 2.18 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.792 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.552 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.3 OUTLIER -119.67 27.17 8.89 Favored 'General case' 0 C--N 1.332 -0.186 0 N-CA-C 111.659 0.244 . . . . 0.0 111.659 -179.827 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.447 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 40.5 t -95.04 150.3 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.867 0.365 . . . . 0.0 110.587 179.364 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -74.86 77.49 2.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.922 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -73.03 125.04 9.43 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.471 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' THR . . . . . 0.706 HG22 ' OD1' ' A' ' 162' ' ' ASP . 6.3 t -135.52 28.36 3.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.766 0.317 . . . . 0.0 110.905 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 153' ' ' GLY . . . . . 0.541 ' HA3' HD11 ' A' ' 159' ' ' LEU . . . -84.04 97.27 2.05 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.507 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 42.72 -90.55 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 122.451 0.301 . . . . 0.0 111.765 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.431 ' N ' ' O ' ' A' ' 153' ' ' GLY . 4.0 t-20 -89.14 51.16 2.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.993 0.425 . . . . 0.0 111.083 -179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 58.96 56.48 25.09 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.465 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.661 ' CG ' HG22 ' A' ' 130' ' ' ILE . 0.0 OUTLIER -111.57 125.96 54.48 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.797 0.332 . . . . 0.0 110.98 179.971 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.53 ' O ' HG21 ' A' ' 135' ' ' VAL . 21.9 t -80.02 109.41 14.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.759 179.789 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.627 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.0 OUTLIER -107.06 178.54 4.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.097 0.475 . . . . 0.0 111.371 -179.648 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 160' ' ' LYS . . . . . 0.457 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 2.8 tptt -50.59 -43.26 56.5 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.852 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -62.97 -34.62 77.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.794 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 162' ' ' ASP . . . . . 0.706 ' OD1' HG22 ' A' ' 152' ' ' THR . 26.8 m-20 -65.24 -42.69 93.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.407 179.687 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 163' ' ' ILE . . . . . 0.688 HG21 ' CD1' ' A' ' 138' ' ' TYR . 2.5 mm -62.15 -48.01 90.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.15 179.182 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.74 -37.42 73.56 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.472 179.44 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -64.77 -42.23 95.26 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.536 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 166' ' ' PHE . . . . . 0.552 ' CE2' HD12 ' A' ' 148' ' ' LEU . 28.2 t80 -62.3 -38.4 89.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.509 179.617 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 167' ' ' LEU . . . . . 0.709 HD21 ' CG2' ' A' ' 144' ' ' VAL . 26.0 mt -90.44 -77.8 0.39 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.976 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -73.33 -80.71 0.07 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.192 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 169.62 -32.02 0.16 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.571 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 136.95 -24.97 3.09 Favored Glycine 0 C--O 1.249 1.053 0 CA-C-O 118.396 -1.224 . . . . 0.0 112.475 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.25 -3.758 0 CA-C-N 118.377 1.089 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 5.5 m-80 . . . . . 0 N--CA 1.486 1.369 0 CA-C-O 120.869 0.366 . . . . 0.0 111.24 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -139.94 140.23 36.31 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.91 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 9.6 mtt180 -87.56 149.2 24.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.861 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.467 HG21 ' HG2' ' A' ' 147' ' ' ARG . 21.4 t -82.52 151.64 4.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.171 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.679 HG22 ' HG3' ' A' ' 157' ' ' ARG . 3.3 mp -98.82 66.09 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.858 179.804 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -122.61 164.26 18.52 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.079 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' MET . . . . . 0.414 ' CB ' ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -99.56 166.68 12.44 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.862 179.948 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 133' ' ' PRO . . . . . 0.414 ' HD2' ' CB ' ' A' ' 132' ' ' MET . 20.8 Cg_endo -60.91 -26.49 83.22 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.512 2.141 . . . . 0.0 112.282 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -81.47 -44.85 16.84 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.752 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.543 HG21 ' HA ' ' A' ' 159' ' ' LEU . 85.5 t -59.92 -31.49 47.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.862 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -67.28 -52.94 34.59 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 8.7 ttpt -56.37 -31.07 63.45 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 178.536 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.736 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -60.86 -62.57 1.76 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.413 179.103 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.857 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -61.78 -24.1 66.62 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.334 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 20.2 mmm-85 -80.52 -32.51 36.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.903 0.383 . . . . 0.0 110.822 179.707 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -83.72 -29.28 27.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.662 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' LYS . . . . . 0.666 ' HE3' HD13 ' A' ' 167' ' ' LEU . 11.5 mmtt -89.66 -25.74 21.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.05 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 96.33 13.58 47.95 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.439 -179.535 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.857 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 92.8 t -97.84 159.71 3.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.76 0.314 . . . . 0.0 110.783 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.498 ' N ' HG12 ' A' ' 144' ' ' VAL . 68.4 t0 -108.75 111.96 24.0 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.785 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.46 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 8.6 pt -53.6 -40.06 40.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.039 0.447 . . . . 0.0 111.32 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 147' ' ' ARG . . . . . 0.467 ' HG2' HG21 ' A' ' 129' ' ' VAL . 91.4 mtt-85 -49.34 -25.67 2.61 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.765 -179.777 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.434 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.1 OUTLIER -118.81 27.32 8.96 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 111.721 0.267 . . . . 0.0 111.721 -179.878 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.46 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 38.8 t -94.0 154.5 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.851 0.358 . . . . 0.0 110.552 179.373 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.93 75.6 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.952 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -70.0 114.9 5.81 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.426 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -102.66 -21.01 14.19 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.699 0.285 . . . . 0.0 111.167 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -55.15 172.13 1.22 Allowed Glycine 0 C--N 1.332 0.33 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.629 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 16.0 tttp -52.91 134.72 37.31 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.798 0.332 . . . . 0.0 111.141 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.9 m-20 59.35 34.75 22.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.732 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 63.99 45.15 94.72 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.304 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.679 ' HG3' HG22 ' A' ' 130' ' ' ILE . 10.9 ttm-85 -82.95 128.14 34.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.86 0.362 . . . . 0.0 110.976 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.441 HG13 ' CG1' ' A' ' 149' ' ' VAL . 30.8 t -87.87 117.98 32.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.921 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.543 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.1 mt -113.19 177.42 4.64 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.072 0.463 . . . . 0.0 111.225 -179.719 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 160' ' ' LYS . . . . . 0.452 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 1.8 tttt -50.68 -44.44 57.77 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.855 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 68.0 mm-40 -61.98 -34.11 75.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.695 179.795 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -67.11 -38.91 86.46 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.407 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 163' ' ' ILE . . . . . 0.736 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.4 mm -64.08 -48.93 83.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.294 179.263 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -58.37 -41.06 83.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.656 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.1 -41.71 99.43 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.921 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 166' ' ' PHE . . . . . 0.547 ' CE1' HG13 ' A' ' 144' ' ' VAL . 32.8 t80 -60.3 -50.45 73.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.827 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 167' ' ' LEU . . . . . 0.691 HD21 ' CG2' ' A' ' 144' ' ' VAL . 50.8 mt -73.45 -33.8 65.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.861 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -102.15 86.35 2.84 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.088 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -96.3 28.05 14.61 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.488 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 176.33 98.49 0.11 Allowed Glycine 0 C--O 1.248 1.028 0 CA-C-O 118.347 -1.252 . . . . 0.0 112.497 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.815 0 CA-C-N 118.342 1.071 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 62.3 t30 . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 120.751 0.31 . . . . 0.0 111.219 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.31 175.68 9.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.862 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -94.88 -178.47 4.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.483 HG12 ' N ' ' A' ' 130' ' ' ILE . 21.5 t -98.55 159.51 3.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.04 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.483 ' N ' HG12 ' A' ' 129' ' ' VAL . 28.2 mm -79.9 68.87 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.791 179.81 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -141.6 142.67 33.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.123 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -69.95 162.75 66.44 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.86 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_endo -57.28 -24.45 59.78 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.627 2.218 . . . . 0.0 112.144 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.3 m -76.76 -44.86 31.34 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.89 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.572 HG21 ' HA ' ' A' ' 159' ' ' LEU . 93.0 t -59.8 -34.95 57.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.79 -51.38 56.39 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.325 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.403 ' HG3' ' HG3' ' A' ' 141' ' ' GLU . 2.5 tttt -56.75 -29.96 63.1 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 178.564 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.722 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -63.39 -62.74 1.48 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.496 179.301 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.861 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -63.11 -24.56 67.96 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.372 -179.648 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.63 -27.17 29.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.739 0.304 . . . . 0.0 110.957 179.746 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.403 ' HG3' ' HG3' ' A' ' 137' ' ' LYS . 8.2 mm-40 -85.82 -28.04 24.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.019 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 1.6 mmtm -97.66 -25.37 15.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.254 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 101.2 14.09 31.69 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.717 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.861 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 42.9 t -93.2 159.43 2.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.733 0.301 . . . . 0.0 110.826 179.731 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.499 ' N ' HG12 ' A' ' 144' ' ' VAL . 67.1 t0 -110.45 107.59 17.32 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.705 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.459 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 9.7 pt -52.05 -40.19 28.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 121.048 0.451 . . . . 0.0 111.217 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 92.0 mtt-85 -48.9 -26.33 2.41 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.931 -179.749 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.447 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.1 OUTLIER -119.24 26.93 9.13 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.663 0.268 . . . . 0.0 111.668 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.459 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 40.5 t -93.97 157.63 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.782 0.325 . . . . 0.0 110.518 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.431 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.95 76.21 2.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.967 -179.767 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -72.52 109.15 2.71 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.421 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -97.65 -18.99 18.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.607 0.241 . . . . 0.0 111.207 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -56.36 168.13 3.48 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.508 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.13 136.95 41.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.925 0.393 . . . . 0.0 111.144 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 59.33 33.63 22.56 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.817 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 66.15 42.03 94.62 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.404 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 49.9 ttp180 -82.25 121.63 26.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.853 0.359 . . . . 0.0 110.878 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.425 ' O ' HG21 ' A' ' 135' ' ' VAL . 21.5 t -85.38 122.94 38.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.999 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.572 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.2 mp -116.05 176.93 4.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.058 0.456 . . . . 0.0 111.183 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 160' ' ' LYS . . . . . 0.439 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 3.4 tttt -50.32 -46.48 55.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.787 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -59.69 -34.27 72.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.705 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 72.1 m-20 -67.69 -37.62 82.56 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.395 179.672 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 163' ' ' ILE . . . . . 0.722 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.9 mm -64.02 -49.01 83.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.339 179.271 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -58.8 -42.21 88.57 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.624 179.601 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.57 -40.83 96.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.81 179.8 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 166' ' ' PHE . . . . . 0.583 ' CE1' HG13 ' A' ' 144' ' ' VAL . 46.7 t80 -60.55 -51.31 69.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.65 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 167' ' ' LEU . . . . . 0.738 HD21 ' CG2' ' A' ' 144' ' ' VAL . 29.4 mt -70.44 -30.95 67.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.896 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -75.14 176.61 7.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.08 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -81.39 -30.64 36.31 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.5 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 79.79 66.59 1.65 Allowed Glycine 0 C--O 1.248 1.03 0 CA-C-O 118.472 -1.182 . . . . 0.0 112.477 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.768 0 CA-C-N 118.309 1.054 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 38.2 t30 . . . . . 0 N--CA 1.486 1.344 0 CA-C-O 120.86 0.362 . . . . 0.0 111.205 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 18.2 ttm-85 -114.73 156.38 24.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.912 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -117.38 172.43 7.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.845 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.552 HG21 ' HG3' ' A' ' 147' ' ' ARG . 21.4 t -132.42 145.45 34.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.173 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.576 HG22 ' HG3' ' A' ' 157' ' ' ARG . 2.6 mp -83.75 65.86 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.997 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -132.74 142.24 48.94 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.199 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' MET . . . . . 0.406 ' HE2' ' HD3' ' A' ' 157' ' ' ARG . 2.6 mtm -71.98 166.22 42.66 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.816 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 133' ' ' PRO . . . . . 0.4 ' HD2' ' CB ' ' A' ' 132' ' ' MET . 22.8 Cg_endo -61.24 -32.64 90.59 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.513 2.142 . . . . 0.0 112.219 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -69.93 -45.54 67.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.782 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.654 ' CG1' HD11 ' A' ' 163' ' ' ILE . 84.7 t -60.16 -33.06 52.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.99 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.436 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.5 OUTLIER -65.9 -50.72 63.46 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.21 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.4 tttt -57.71 -31.71 66.67 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.551 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.716 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -60.27 -61.6 2.48 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.402 179.109 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.851 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -63.78 -21.67 66.54 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.299 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.79 -27.61 28.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.042 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -85.94 -25.81 25.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.059 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 142' ' ' LYS . . . . . 0.493 ' HG2' HD13 ' A' ' 167' ' ' LEU . 2.1 tptt -98.61 -26.72 14.3 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.247 -179.822 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 103.07 13.11 29.91 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.596 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.851 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 35.0 t -93.27 160.59 2.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.794 0.33 . . . . 0.0 110.831 179.737 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.802 ' HB3' HD11 ' A' ' 148' ' ' LEU . 51.9 t0 -115.22 105.66 13.15 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.952 0.406 . . . . 0.0 110.755 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.479 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 4.0 pt -45.13 -36.3 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.3 0.571 . . . . 0.0 111.867 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 147' ' ' ARG . . . . . 0.552 ' HG3' HG21 ' A' ' 129' ' ' VAL . 0.0 OUTLIER -48.24 -25.32 1.48 Allowed 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.332 -0.849 . . . . 0.0 112.643 -179.157 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.845 ' N ' HD13 ' A' ' 148' ' ' LEU . 0.0 OUTLIER -126.82 31.07 5.37 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 111.817 0.303 . . . . 0.0 111.817 -179.33 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.479 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 54.1 t -92.88 157.45 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.821 0.344 . . . . 0.0 110.65 179.372 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.426 ' N ' HG12 ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.84 69.77 1.87 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.999 -179.645 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -68.79 115.83 6.88 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.403 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -116.79 13.81 15.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.617 0.246 . . . . 0.0 111.325 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -83.06 175.2 52.93 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.298 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.27 117.9 2.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.789 0.328 . . . . 0.0 111.147 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 3.5 m120 62.49 52.72 2.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.938 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 56.66 48.55 76.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.536 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.576 ' HG3' HG22 ' A' ' 130' ' ' ILE . 5.9 ttm180 -90.6 114.94 27.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.781 0.325 . . . . 0.0 110.982 -179.834 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.464 ' O ' HG21 ' A' ' 135' ' ' VAL . 31.7 t -81.29 118.19 28.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.776 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.601 ' HA ' HG21 ' A' ' 135' ' ' VAL . 0.9 OUTLIER -115.13 176.67 4.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.027 0.442 . . . . 0.0 111.263 -179.69 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 14.3 tttm -49.84 -45.72 50.61 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.818 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 -60.03 -35.46 75.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.653 179.742 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -66.23 -37.94 86.73 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.368 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 163' ' ' ILE . . . . . 0.716 HG21 ' CD1' ' A' ' 138' ' ' TYR . 5.4 mm -63.14 -49.16 84.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.909 179.084 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 164' ' ' ASP . . . . . 0.504 ' O ' ' HB3' ' A' ' 168' ' ' ALA . 4.4 m-20 -59.42 -36.49 75.97 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.508 179.459 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.6 -39.84 92.0 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.775 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 166' ' ' PHE . . . . . 0.536 ' CE1' HG13 ' A' ' 144' ' ' VAL . 57.7 t80 -62.98 -47.27 83.88 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.536 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 167' ' ' LEU . . . . . 0.795 HD21 ' CG2' ' A' ' 144' ' ' VAL . 5.8 mt -82.33 -69.79 0.6 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.911 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 168' ' ' ALA . . . . . 0.504 ' HB3' ' O ' ' A' ' 164' ' ' ASP . . . -58.12 -74.39 0.06 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.256 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 119.33 86.51 1.03 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.54 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 166.49 -41.03 0.26 Allowed Glycine 0 C--O 1.249 1.072 0 CA-C-O 118.407 -1.219 . . . . 0.0 112.521 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.818 0 CA-C-N 118.382 1.091 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 120.802 0.334 . . . . 0.0 111.188 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 5.8 ttm180 -118.26 108.4 15.08 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.874 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.16 174.18 5.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.911 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.502 HG21 ' HG3' ' A' ' 147' ' ' ARG . 33.9 t -114.9 158.56 15.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.019 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.734 HG22 ' HG2' ' A' ' 157' ' ' ARG . 3.5 mp -80.01 64.27 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.996 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -135.76 176.53 8.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.101 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 77.6 mtp -100.8 162.04 21.93 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.953 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.42 -40.48 71.18 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.549 2.166 . . . . 0.0 112.254 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.22 -43.74 70.03 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.912 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.621 HG21 ' HA ' ' A' ' 159' ' ' LEU . 67.4 t -58.98 -36.48 62.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.942 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.453 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.2 OUTLIER -66.14 -51.92 53.3 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 179.469 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.9 ttpt -56.72 -32.64 65.73 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 178.691 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.734 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.9 OUTLIER -59.73 -61.82 2.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.458 179.205 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.745 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -63.45 -23.31 67.34 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.297 -179.772 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -82.04 -28.22 32.58 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.951 179.78 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -86.35 -28.57 23.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.847 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 4.1 mptt -93.96 -24.58 17.61 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.04 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 98.07 13.94 41.03 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.6 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.749 HG21 HD11 ' A' ' 167' ' ' LEU . 45.6 t -92.74 159.11 2.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.799 0.333 . . . . 0.0 110.828 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.488 ' N ' HG12 ' A' ' 144' ' ' VAL . 68.2 t0 -109.3 105.42 14.82 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.839 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.489 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 7.3 pt -49.33 -39.92 13.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.13 0.49 . . . . 0.0 111.389 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' ARG . . . . . 0.502 ' HG3' HG21 ' A' ' 129' ' ' VAL . 8.4 mtt-85 -49.4 -24.73 2.09 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.746 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.463 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.6 OUTLIER -120.32 27.99 8.28 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.586 0.231 . . . . 0.0 111.596 -179.846 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.545 ' CG1' HG13 ' A' ' 158' ' ' VAL . 43.4 t -95.31 155.56 3.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.934 0.397 . . . . 0.0 110.792 179.594 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.407 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 8.6 tt0 -74.99 77.61 2.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.096 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.65 111.75 3.79 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.455 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -87.38 -27.09 23.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.763 0.316 . . . . 0.0 111.042 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -57.73 173.19 2.72 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.556 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 3.9 tttp -57.78 140.06 52.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.839 0.352 . . . . 0.0 110.944 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 59.83 30.93 20.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.831 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 69.87 42.34 69.98 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.482 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.734 ' HG2' HG22 ' A' ' 130' ' ' ILE . 0.0 OUTLIER -70.45 127.23 32.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.772 0.32 . . . . 0.0 110.844 -179.993 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.545 HG13 ' CG1' ' A' ' 149' ' ' VAL . 25.9 t -94.41 117.2 37.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.19 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.621 ' HA ' HG21 ' A' ' 135' ' ' VAL . 3.8 mp -112.96 175.91 5.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.911 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 160' ' ' LYS . . . . . 0.441 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 0.4 OUTLIER -50.91 -45.52 60.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.642 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 4.2 mm-40 -60.36 -34.25 73.6 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.603 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -67.64 -37.6 82.68 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.436 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 163' ' ' ILE . . . . . 0.734 HG21 ' CD1' ' A' ' 138' ' ' TYR . 5.4 mm -64.01 -47.93 88.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.169 179.164 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -58.76 -42.38 88.79 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.577 179.409 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.01 -40.94 95.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.653 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 166' ' ' PHE . . . . . 0.58 ' CE1' HG13 ' A' ' 144' ' ' VAL . 20.5 t80 -63.51 -38.94 93.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.513 179.61 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 167' ' ' LEU . . . . . 0.749 HD11 HG21 ' A' ' 144' ' ' VAL . 12.7 mt -96.33 -83.18 0.38 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.77 179.861 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . 50.45 -177.64 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.377 179.784 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -169.2 -61.62 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.452 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 85.74 12.5 71.84 Favored Glycine 0 C--O 1.249 1.077 0 CA-C-O 118.338 -1.257 . . . . 0.0 112.469 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.832 0 CA-C-N 118.387 1.094 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 34.4 m120 . . . . . 0 N--CA 1.487 1.385 0 CA-C-O 120.772 0.32 . . . . 0.0 111.205 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.87 149.3 40.74 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.797 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 11.8 ttt180 -58.64 168.54 1.16 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.014 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.452 HG21 ' HG3' ' A' ' 147' ' ' ARG . 21.2 t -77.42 139.98 17.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.066 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.775 HG22 ' HG3' ' A' ' 157' ' ' ARG . 6.4 mt -80.11 68.22 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.987 0.423 . . . . 0.0 110.974 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -130.19 171.31 13.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.196 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' MET . . . . . 0.549 ' HB2' HG23 ' A' ' 135' ' ' VAL . 3.3 mtp -91.47 160.37 36.97 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.851 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.65 -23.49 76.05 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.591 2.194 . . . . 0.0 112.242 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.2 m -90.65 -41.48 11.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.898 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.772 HG21 ' HA ' ' A' ' 159' ' ' LEU . 59.5 t -59.91 -39.7 80.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.033 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.75 ' HD3' HD12 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -62.48 -43.44 98.8 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.63 -0.508 . . . . 0.0 109.63 179.364 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.3 -33.32 74.43 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 178.331 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.758 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.9 OUTLIER -57.7 -60.87 3.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.375 179.052 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.711 ' HB3' HG23 ' A' ' 146' ' ' ILE . . . -61.29 -29.61 69.97 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.377 -179.649 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 11.3 mmm180 -79.19 -23.03 44.13 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.339 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -89.67 -26.57 20.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.802 0.334 . . . . 0.0 111.032 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -96.06 -22.31 17.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.288 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.46 7.09 46.44 Favored Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.573 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.797 ' CG2' HD21 ' A' ' 167' ' ' LEU . 59.2 t -89.44 155.24 3.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 120.722 0.296 . . . . 0.0 110.67 179.65 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.489 ' HB3' HD11 ' A' ' 148' ' ' LEU . 66.5 t0 -102.34 109.19 20.77 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.14 0.495 . . . . 0.0 110.89 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.75 HD12 ' HD3' ' A' ' 136' ' ' ARG . 5.4 pt -51.07 -43.78 27.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.63 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 147' ' ' ARG . . . . . 0.452 ' HG3' HG21 ' A' ' 129' ' ' VAL . 11.6 mtt180 -49.72 -24.62 2.4 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.941 -0.572 . . . . 0.0 112.11 -179.437 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.489 HD11 ' HB3' ' A' ' 145' ' ' ASP . 0.1 OUTLIER -119.2 23.97 11.01 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 112.111 0.412 . . . . 0.0 112.111 -179.645 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.539 ' CG1' HG13 ' A' ' 158' ' ' VAL . 48.9 t -86.64 156.18 3.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.733 0.301 . . . . 0.0 110.555 179.209 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.405 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 4.2 tt0 -74.79 74.24 2.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.067 -179.73 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -72.07 107.38 2.17 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.403 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -129.06 27.8 5.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.871 0.367 . . . . 0.0 110.988 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 153' ' ' GLY . . . . . 0.406 ' HA3' ' CD1' ' A' ' 159' ' ' LEU . . . -106.09 107.03 2.68 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.426 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 14.5 tptm 56.17 97.94 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.756 0.313 . . . . 0.0 110.809 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 70.16 -66.15 0.29 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.784 -179.767 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 178.54 58.71 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.429 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.775 ' HG3' HG22 ' A' ' 130' ' ' ILE . 43.2 ttm-85 -108.98 138.87 44.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.861 0.363 . . . . 0.0 110.894 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.539 HG13 ' CG1' ' A' ' 149' ' ' VAL . 21.9 t -82.76 114.39 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.083 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.772 ' HA ' HG21 ' A' ' 135' ' ' VAL . 14.5 mt -112.37 175.12 5.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.05 -179.803 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 160' ' ' LYS . . . . . 0.44 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 1.0 OUTLIER -50.77 -44.98 58.77 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.673 179.903 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -61.11 -34.41 74.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.637 179.587 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -66.82 -37.22 84.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.457 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 163' ' ' ILE . . . . . 0.758 HG21 ' CD1' ' A' ' 138' ' ' TYR . 8.2 mm -65.11 -49.23 80.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.186 179.167 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -58.82 -38.42 78.6 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.572 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.49 -41.08 93.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.836 179.748 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 166' ' ' PHE . . . . . 0.593 ' CE1' HG13 ' A' ' 144' ' ' VAL . 24.6 t80 -61.1 -45.69 93.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.591 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 167' ' ' LEU . . . . . 0.797 HD21 ' CG2' ' A' ' 144' ' ' VAL . 16.4 mt -78.68 -65.56 0.97 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.805 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -85.51 131.82 34.3 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.038 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -93.06 -103.64 1.6 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.539 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -177.99 128.16 1.26 Allowed Glycine 0 C--O 1.249 1.091 0 CA-C-O 118.389 -1.228 . . . . 0.0 112.493 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.77 0 CA-C-N 118.369 1.084 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 . . . . . 0 N--CA 1.487 1.417 0 CA-C-O 120.737 0.303 . . . . 0.0 111.253 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.9 mtt85 -141.8 153.36 44.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.841 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -64.7 -177.35 0.32 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.846 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.3 t -124.88 149.16 29.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.169 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.604 HG22 ' HG3' ' A' ' 157' ' ' ARG . 28.4 mt -87.41 68.93 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.048 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -133.5 -177.11 4.39 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.123 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.42 166.06 11.75 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.864 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -52.89 -37.62 77.73 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.505 2.137 . . . . 0.0 112.381 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.66 -48.25 55.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.88 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.593 ' CG1' HD11 ' A' ' 163' ' ' ILE . 73.9 t -58.06 -33.06 45.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.848 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.12 -52.88 36.29 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 179.341 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 3.8 tttp -55.96 -30.3 61.53 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 178.634 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.725 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -62.86 -62.78 1.49 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.442 179.295 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.834 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -63.71 -23.91 67.56 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.243 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 3.8 tpt180 -82.97 -25.92 31.81 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.943 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -87.55 -26.59 23.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.945 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -97.52 -25.18 15.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.188 -179.779 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 100.85 13.27 34.82 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.674 -0.775 . . . . 0.0 112.584 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.834 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 44.3 t -94.55 160.03 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.788 0.327 . . . . 0.0 110.743 179.716 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.509 ' N ' HG12 ' A' ' 144' ' ' VAL . 42.9 t0 -111.17 109.6 19.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.733 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.461 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 9.7 pt -52.03 -39.84 27.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.389 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 147' ' ' ARG . . . . . 0.538 ' HG2' HD23 ' A' ' 148' ' ' LEU . 2.2 ptt180 -48.99 -25.92 2.24 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.794 -179.731 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.538 HD23 ' HG2' ' A' ' 147' ' ' ARG . 0.2 OUTLIER -119.43 26.96 9.07 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 111.645 0.239 . . . . 0.0 111.645 -179.809 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.461 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 43.6 t -95.05 157.53 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.837 0.351 . . . . 0.0 110.586 179.305 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.425 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 2.1 tt0 -74.74 77.55 2.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.067 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -72.91 106.11 1.89 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.447 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -93.03 -17.52 23.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.605 0.24 . . . . 0.0 111.24 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -53.25 161.84 2.94 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.649 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.2 138.19 26.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.795 0.331 . . . . 0.0 111.168 -179.897 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 61.68 31.64 18.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.802 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 61.57 68.22 1.76 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.482 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.604 ' HG3' HG22 ' A' ' 130' ' ' ILE . 34.7 ttm180 -112.04 133.7 54.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.813 0.339 . . . . 0.0 110.987 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.446 HG13 ' CG1' ' A' ' 149' ' ' VAL . 21.9 t -85.3 124.18 39.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.949 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.556 ' HA ' HG21 ' A' ' 135' ' ' VAL . 2.1 mt -121.85 172.46 8.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.219 -179.81 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 160' ' ' LYS . . . . . 0.442 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 4.9 tttm -47.8 -50.41 25.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.053 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -57.18 -35.38 69.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.781 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -67.56 -34.75 77.69 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.38 179.678 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 163' ' ' ILE . . . . . 0.725 HG21 ' CD1' ' A' ' 138' ' ' TYR . 5.7 mm -64.98 -50.65 73.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.068 179.106 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -59.57 -37.72 79.23 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.571 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.9 -40.5 91.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.712 179.759 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 166' ' ' PHE . . . . . 0.552 ' CE1' HG13 ' A' ' 144' ' ' VAL . 37.2 t80 -60.91 -48.32 82.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.567 179.675 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 167' ' ' LEU . . . . . 0.777 HD21 ' CG2' ' A' ' 144' ' ' VAL . 16.5 mt -75.06 -30.5 61.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.955 179.813 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -106.4 103.44 12.9 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.038 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -176.98 41.54 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.516 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -106.32 -159.45 22.16 Favored Glycine 0 C--O 1.249 1.04 0 CA-C-O 118.348 -1.251 . . . . 0.0 112.447 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.25 -3.745 0 CA-C-N 118.402 1.101 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 . . . . . 0 N--CA 1.487 1.396 0 CA-C-O 120.711 0.291 . . . . 0.0 111.272 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.45 149.85 50.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.982 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -115.41 -175.46 2.71 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.832 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.642 HG22 ' HG2' ' A' ' 147' ' ' ARG . 21.5 t -127.21 137.0 59.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.17 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.559 HG22 ' HG2' ' A' ' 157' ' ' ARG . 32.2 mt -87.29 60.05 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.082 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.912 ' HB3' ' HD3' ' A' ' 136' ' ' ARG . . . -120.47 163.44 17.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.016 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' MET . . . . . 0.564 ' HB2' HG23 ' A' ' 135' ' ' VAL . 24.5 mmm -88.79 161.19 42.27 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.93 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -52.22 -28.18 32.96 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.587 2.191 . . . . 0.0 112.257 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 58.2 m -87.31 -38.6 16.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.906 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.619 HG21 ' HA ' ' A' ' 159' ' ' LEU . 61.4 t -62.68 -40.48 88.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.022 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.912 ' HD3' ' HB3' ' A' ' 131' ' ' ALA . 25.1 mmm-85 -65.52 -47.74 74.9 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.35 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 2.0 tttm -60.72 -29.81 69.58 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.755 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -60.95 -60.66 3.43 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.481 179.213 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.767 ' HB3' HG23 ' A' ' 146' ' ' ILE . . . -62.69 -27.76 69.47 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.78 -0.645 . . . . 0.0 111.516 -179.544 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.4 -21.18 33.08 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.301 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -91.95 -22.22 20.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.069 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 1.1 mmtt -103.22 -24.47 13.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.346 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.58 9.6 32.82 Favored Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.875 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.798 ' CG2' HD21 ' A' ' 167' ' ' LEU . 46.3 t -89.24 155.06 3.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.748 0.309 . . . . 0.0 110.59 179.545 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.445 ' HB3' ' CG ' ' A' ' 148' ' ' LEU . 61.4 t0 -100.79 104.97 16.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.11 0.481 . . . . 0.0 111.023 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.767 HG23 ' HB3' ' A' ' 139' ' ' ALA . 3.1 pt -47.44 -45.51 9.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.73 179.564 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 147' ' ' ARG . . . . . 0.642 ' HG2' HG22 ' A' ' 129' ' ' VAL . 0.0 OUTLIER -50.67 -22.09 1.9 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.332 -179.266 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.512 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.9 OUTLIER -121.44 22.27 10.77 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 112.053 0.39 . . . . 0.0 112.053 -179.592 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.468 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 76.0 t -85.96 152.49 3.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.864 0.364 . . . . 0.0 110.574 179.251 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.94 78.98 2.16 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.919 -179.776 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -80.92 106.85 2.6 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.42 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -112.12 31.14 6.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.925 0.393 . . . . 0.0 110.879 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 153' ' ' GLY . . . . . 0.426 ' O ' ' N ' ' A' ' 155' ' ' ASN . . . -86.59 95.48 2.05 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.519 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 154' ' ' LYS . . . . . 0.421 ' N ' ' CD ' ' A' ' 154' ' ' LYS . 0.0 OUTLIER 38.97 -90.9 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 122.606 0.362 . . . . 0.0 111.861 179.92 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.426 ' N ' ' O ' ' A' ' 153' ' ' GLY . 3.2 m-20 -87.49 54.67 3.22 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.887 0.375 . . . . 0.0 111.028 -179.87 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 57.63 52.46 51.82 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.508 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.559 ' HG2' HG22 ' A' ' 130' ' ' ILE . 0.0 OUTLIER -106.75 121.46 44.41 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.804 0.335 . . . . 0.0 110.892 -179.98 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.605 HG12 HG11 ' A' ' 135' ' ' VAL . 22.6 t -74.96 129.09 37.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.977 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.619 ' HA ' HG21 ' A' ' 135' ' ' VAL . 2.3 mt -122.96 170.93 9.63 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.122 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 29.6 tttm -50.61 -44.75 57.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.622 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -60.31 -35.37 75.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.501 179.704 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -66.26 -38.28 87.45 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.328 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 163' ' ' ILE . . . . . 0.755 HG21 ' CD1' ' A' ' 138' ' ' TYR . 6.1 mm -63.22 -49.78 81.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.248 179.351 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -58.08 -41.04 82.58 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.621 179.719 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.13 -40.72 98.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.764 179.704 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 166' ' ' PHE . . . . . 0.63 ' CE1' HG13 ' A' ' 144' ' ' VAL . 17.9 t80 -60.82 -45.57 93.95 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.486 179.725 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 167' ' ' LEU . . . . . 0.798 HD21 ' CG2' ' A' ' 144' ' ' VAL . 21.1 mt -75.69 -31.85 59.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.849 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -91.42 -177.68 4.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.042 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 88.33 29.37 19.77 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.517 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -161.81 88.35 0.11 Allowed Glycine 0 C--O 1.25 1.126 0 CA-C-O 118.399 -1.223 . . . . 0.0 112.513 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.837 0 CA-C-N 118.42 1.11 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 . . . . . 0 N--CA 1.486 1.332 0 CA-C-O 120.78 0.324 . . . . 0.0 111.226 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -119.43 63.12 0.8 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.857 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 1.6 mtm-85 -134.43 -178.58 5.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.888 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.528 HG21 ' CG ' ' A' ' 147' ' ' ARG . 17.0 t -124.51 151.73 30.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.177 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.763 HG22 ' HG2' ' A' ' 157' ' ' ARG . 3.0 mp -81.6 70.73 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.847 179.819 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -124.85 158.05 34.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.246 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' MET . . . . . 0.589 ' HB2' HG23 ' A' ' 135' ' ' VAL . 1.3 mmt -85.97 161.35 50.16 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.822 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_endo -61.15 -30.81 89.53 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.575 2.183 . . . . 0.0 112.221 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -82.1 -37.39 26.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.736 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.643 ' CG1' HD11 ' A' ' 163' ' ' ILE . 62.6 t -61.7 -34.63 63.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.41 ' HD3' HD13 ' A' ' 146' ' ' ILE . 0.4 OUTLIER -65.91 -52.85 46.45 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.439 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.14 -34.34 63.67 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 178.671 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.719 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.9 OUTLIER -59.08 -61.79 2.37 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.442 179.21 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.853 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -62.01 -23.88 66.7 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.517 -179.747 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 3.2 mmm-85 -82.6 -28.81 30.61 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.717 0.294 . . . . 0.0 111.116 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -84.22 -27.69 27.81 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.123 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 2.1 mptp? -96.06 -26.9 15.34 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.124 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.09 13.34 31.63 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.619 -179.747 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.853 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 47.7 t -94.91 159.88 2.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-O 120.689 0.28 . . . . 0.0 110.738 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.507 ' N ' HG12 ' A' ' 144' ' ' VAL . 66.9 t0 -111.99 111.17 21.91 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.811 179.817 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.448 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 7.8 pt -52.16 -39.77 28.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.457 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 147' ' ' ARG . . . . . 0.528 ' CG ' HG21 ' A' ' 129' ' ' VAL . 0.1 OUTLIER -48.94 -25.75 2.12 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.754 -179.762 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.44 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.2 OUTLIER -119.65 28.12 8.34 Favored 'General case' 0 N--CA 1.462 0.138 0 N-CA-C 111.679 0.251 . . . . 0.0 111.679 -179.832 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.448 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 55.6 t -98.25 155.64 3.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.79 0.329 . . . . 0.0 110.659 179.269 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.94 79.3 2.16 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.96 -179.736 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -76.48 114.83 4.24 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.328 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -110.74 26.17 10.99 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.694 0.283 . . . . 0.0 111.085 -179.866 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -99.05 179.56 31.2 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.354 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -51.27 118.28 3.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.782 0.325 . . . . 0.0 111.178 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 59.72 54.62 4.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.936 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 57.22 48.76 77.62 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.361 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.763 ' HG2' HG22 ' A' ' 130' ' ' ILE . 0.0 OUTLIER -87.93 120.04 28.88 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.808 0.337 . . . . 0.0 111.024 -179.808 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.462 ' O ' HG21 ' A' ' 135' ' ' VAL . 22.2 t -84.0 122.84 38.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.79 179.751 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.619 ' HA ' HG21 ' A' ' 135' ' ' VAL . 0.8 OUTLIER -117.6 174.69 6.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.094 0.474 . . . . 0.0 111.291 -179.621 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 160' ' ' LYS . . . . . 0.456 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 2.1 tptt -50.16 -45.8 53.6 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.784 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -60.11 -34.86 74.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.681 179.663 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -67.17 -36.69 82.33 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.332 179.57 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 163' ' ' ILE . . . . . 0.719 HG21 ' CD1' ' A' ' 138' ' ' TYR . 5.2 mm -64.01 -50.3 77.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.093 179.179 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -58.62 -39.65 81.08 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.484 179.675 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -62.54 -41.34 98.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.771 179.664 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 166' ' ' PHE . . . . . 0.541 ' CE1' HG13 ' A' ' 144' ' ' VAL . 40.9 t80 -60.61 -51.81 67.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.568 179.659 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 167' ' ' LEU . . . . . 0.766 HD21 ' CG2' ' A' ' 144' ' ' VAL . 23.7 mt -71.15 -72.53 0.21 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.833 179.847 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -66.68 168.62 9.11 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.03 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -173.79 57.69 0.14 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.498 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -78.2 -60.74 2.63 Favored Glycine 0 C--O 1.25 1.109 0 CA-C-O 118.432 -1.204 . . . . 0.0 112.518 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.762 0 CA-C-N 118.419 1.109 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 8.5 m-80 . . . . . 0 N--CA 1.486 1.358 0 CA-C-O 120.788 0.327 . . . . 0.0 111.214 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.39 55.52 1.27 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.854 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.06 175.8 0.11 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.835 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.606 HG22 ' HG2' ' A' ' 147' ' ' ARG . 35.1 t -121.23 115.35 46.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.13 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.539 HG22 ' O ' ' A' ' 130' ' ' ILE . 4.4 mt -93.79 50.03 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.726 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -97.48 178.24 5.26 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.304 -179.799 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' MET . . . . . 0.528 ' HB2' HG23 ' A' ' 135' ' ' VAL . 0.7 OUTLIER -114.42 158.88 38.77 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.843 -179.991 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.08 -54.82 4.79 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.682 2.255 . . . . 0.0 112.159 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.1 m -60.33 -40.97 92.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.624 179.736 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.769 ' CG1' HD11 ' A' ' 163' ' ' ILE . 81.6 t -60.53 -34.24 57.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.716 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.525 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.2 OUTLIER -64.04 -53.16 54.28 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.201 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -56.84 -30.71 64.05 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 178.536 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.678 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -62.26 -61.32 2.54 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.581 179.313 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.835 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -62.45 -27.1 68.88 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.49 -179.466 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 31.0 mmm180 -83.18 -24.06 32.63 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.708 0.289 . . . . 0.0 111.084 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -88.71 -22.84 23.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.25 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 142' ' ' LYS . . . . . 0.46 ' HD2' HD13 ' A' ' 167' ' ' LEU . 4.3 mmtt -102.65 -25.38 13.58 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.288 -179.716 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.75 9.99 31.64 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.64 -179.86 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.835 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 25.1 t -94.98 162.05 2.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.632 0.253 . . . . 0.0 110.656 179.628 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.815 ' HB3' HD11 ' A' ' 148' ' ' LEU . 55.5 t0 -117.53 109.09 16.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.946 0.403 . . . . 0.0 110.845 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.525 HD11 ' HD3' ' A' ' 136' ' ' ARG . 5.1 pt -46.45 -37.3 3.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.125 0.488 . . . . 0.0 111.807 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 147' ' ' ARG . . . . . 0.606 ' HG2' HG22 ' A' ' 129' ' ' VAL . 0.1 OUTLIER -47.58 -25.35 1.11 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.53 -0.759 . . . . 0.0 112.616 -179.196 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.859 ' N ' HD13 ' A' ' 148' ' ' LEU . 0.0 OUTLIER -127.12 30.24 5.46 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 111.736 0.273 . . . . 0.0 111.736 -179.22 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.486 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 58.3 t -93.92 158.57 2.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.804 0.335 . . . . 0.0 110.609 179.514 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.452 ' N ' HG12 ' A' ' 149' ' ' VAL . 0.7 OUTLIER -74.8 77.13 2.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.975 -179.659 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.59 90.64 0.47 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.393 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 152' ' ' THR . . . . . 0.779 HG22 ' OD1' ' A' ' 162' ' ' ASP . 11.2 t -99.14 26.9 5.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.823 0.344 . . . . 0.0 111.058 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -92.45 170.9 33.03 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.429 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -49.95 122.58 6.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.864 0.364 . . . . 0.0 111.081 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 62.0 t30 64.87 40.44 5.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.837 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 59.78 56.76 23.02 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.484 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 17.3 ttm180 -106.05 135.5 47.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.754 0.312 . . . . 0.0 110.999 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 21.8 t -89.27 126.64 42.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.939 179.783 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.503 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.0 OUTLIER -124.04 174.02 7.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.121 -179.773 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 160' ' ' LYS . . . . . 0.443 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 64.5 tttt -48.54 -50.19 33.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.901 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -56.27 -35.37 67.39 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.824 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 162' ' ' ASP . . . . . 0.779 ' OD1' HG22 ' A' ' 152' ' ' THR . 89.7 m-20 -67.24 -38.22 84.85 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.434 179.769 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 163' ' ' ILE . . . . . 0.769 HD11 ' CG1' ' A' ' 135' ' ' VAL . 4.2 mm -61.98 -47.28 93.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.064 0.459 . . . . 0.0 109.929 179.114 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -60.23 -40.92 91.89 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.475 179.413 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -62.08 -40.89 97.38 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.798 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 166' ' ' PHE . . . . . 0.568 ' CE1' HG13 ' A' ' 144' ' ' VAL . 44.5 t80 -60.49 -50.6 72.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.429 179.62 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 167' ' ' LEU . . . . . 0.798 HD21 ' CG2' ' A' ' 144' ' ' VAL . 14.8 mt -71.92 -29.72 64.6 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.855 179.856 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -91.0 96.51 10.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.111 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 149.73 44.73 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.489 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -113.93 146.5 18.61 Favored Glycine 0 C--O 1.249 1.09 0 CA-C-O 118.349 -1.251 . . . . 0.0 112.485 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.805 0 CA-C-N 118.377 1.089 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.488 1.427 0 CA-C-O 120.775 0.321 . . . . 0.0 111.147 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.35 126.28 36.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.901 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 6.4 mtt180 -176.38 166.42 2.78 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.796 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.778 HG22 ' HG2' ' A' ' 147' ' ' ARG . 21.4 t -101.67 146.21 10.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.134 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.918 HG22 ' HG2' ' A' ' 157' ' ' ARG . 24.0 mt -84.24 62.87 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.035 179.823 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.419 ' HB2' ' HB ' ' A' ' 158' ' ' VAL . . . -133.3 -174.71 3.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.112 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.3 mmm -106.72 161.55 22.52 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.884 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -56.15 -23.6 45.65 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.582 2.188 . . . . 0.0 112.126 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 45.9 p -81.05 -46.18 15.39 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.79 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.713 ' CG1' HD11 ' A' ' 163' ' ' ILE . 86.2 t -58.68 -33.25 48.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.986 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.532 ' HD3' HD11 ' A' ' 146' ' ' ILE . 4.8 mmm180 -64.35 -51.21 64.5 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.263 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -53.96 -38.8 65.36 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 178.467 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.708 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -55.02 -62.6 1.55 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.93 179.183 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.895 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -61.09 -23.28 65.37 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.782 -179.33 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 38.2 mtt-85 -84.08 -28.11 27.78 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.765 0.317 . . . . 0.0 111.123 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -84.05 -27.09 28.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.172 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.27 -27.88 13.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.158 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.28 16.01 24.06 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.578 -179.831 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.895 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 46.4 t -95.91 160.67 2.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.772 0.32 . . . . 0.0 110.756 179.766 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.524 ' N ' HG12 ' A' ' 144' ' ' VAL . 67.2 t0 -113.9 108.99 17.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.888 179.665 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.532 HD11 ' HD3' ' A' ' 136' ' ' ARG . 7.1 pt -50.5 -39.83 18.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.433 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 147' ' ' ARG . . . . . 0.778 ' HG2' HG22 ' A' ' 129' ' ' VAL . 0.5 OUTLIER -48.9 -24.84 1.62 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.773 -179.89 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.558 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.4 OUTLIER -120.36 28.09 8.22 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.652 0.263 . . . . 0.0 111.612 -179.715 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.456 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 55.2 t -99.31 153.6 4.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.928 0.394 . . . . 0.0 110.771 179.456 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -74.96 79.16 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.161 -179.629 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -73.64 120.0 6.75 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.399 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -104.55 -21.26 13.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.643 0.259 . . . . 0.0 111.227 -179.848 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -50.13 176.21 0.04 OUTLIER Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.729 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 16.5 tptt -53.72 125.01 16.81 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.806 0.336 . . . . 0.0 111.13 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 60.46 47.45 8.68 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.859 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 58.8 55.14 32.52 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.418 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.918 ' HG2' HG22 ' A' ' 130' ' ' ILE . 0.0 OUTLIER -90.87 120.97 32.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.864 0.364 . . . . 0.0 110.922 -179.86 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.487 ' O ' HG21 ' A' ' 135' ' ' VAL . 25.9 t -79.99 111.93 17.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.847 179.791 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.649 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.4 mt -111.87 175.98 5.21 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.107 0.479 . . . . 0.0 111.167 -179.744 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 49.5 tttt -49.43 -48.19 47.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.806 179.793 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -59.03 -34.48 71.96 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.714 179.778 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -67.35 -36.06 80.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.452 179.721 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 163' ' ' ILE . . . . . 0.713 HD11 ' CG1' ' A' ' 135' ' ' VAL . 4.2 mm -65.2 -50.22 74.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.169 179.226 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -58.52 -39.61 80.61 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.601 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.78 -40.57 97.0 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.628 179.737 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 166' ' ' PHE . . . . . 0.576 ' CE1' HG13 ' A' ' 144' ' ' VAL . 26.9 t80 -60.32 -48.98 79.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.425 179.678 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 167' ' ' LEU . . . . . 0.81 HD21 ' CG2' ' A' ' 144' ' ' VAL . 6.1 mt -72.63 -31.17 64.93 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.911 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -75.71 149.37 38.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.158 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 109.08 29.83 3.88 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.499 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 150.82 109.83 0.47 Allowed Glycine 0 C--O 1.249 1.07 0 CA-C-O 118.385 -1.231 . . . . 0.0 112.526 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.782 0 CA-C-N 118.371 1.086 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.825 0.345 . . . . 0.0 111.173 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 33.7 mtp -103.12 157.95 32.74 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.807 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 10.5 Cg_endo -53.6 -27.42 41.38 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.642 2.228 . . . . 0.0 112.192 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.6 t -80.06 -47.22 15.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.71 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.735 ' CG1' HD11 ' A' ' 163' ' ' ILE . 94.9 t -58.31 -31.31 42.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.822 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.469 ' HD3' HD11 ' A' ' 146' ' ' ILE . 6.6 mmm-85 -65.42 -52.74 51.22 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.281 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 11.0 tppt? -52.88 -39.5 62.71 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.478 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.689 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -54.33 -62.8 1.42 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.027 -0.988 . . . . 0.0 110.796 179.133 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.873 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -60.18 -24.67 64.97 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.601 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 3.3 mmt85 -82.16 -27.6 32.59 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.69 0.281 . . . . 0.0 111.122 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -85.68 -29.39 24.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.973 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 3.7 mptp? -94.96 -24.45 16.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.172 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 98.66 14.27 38.07 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.613 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.873 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 34.4 t -94.19 160.13 2.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.713 0.292 . . . . 0.0 110.81 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.772 ' HB3' HD11 ' A' ' 148' ' ' LEU . 63.8 t0 -114.9 104.99 12.47 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.789 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.469 HD11 ' HD3' ' A' ' 136' ' ' ARG . 4.4 pt -45.5 -36.33 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.26 0.552 . . . . 0.0 111.818 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 6.8 mtt180 -48.29 -25.6 1.63 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.316 -0.856 . . . . 0.0 112.641 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.852 ' N ' HD13 ' A' ' 148' ' ' LEU . 0.0 OUTLIER -125.49 30.02 5.87 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.662 0.268 . . . . 0.0 111.715 -179.433 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.46 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 58.1 t -94.63 155.65 3.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.862 0.363 . . . . 0.0 110.683 179.406 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.408 ' N ' HG12 ' A' ' 149' ' ' VAL . 0.5 OUTLIER -74.96 79.51 2.17 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.925 -179.749 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -73.32 110.52 3.16 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.433 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.328 -0.34 0 CA-C-O 120.585 0.231 . . . . 0.0 111.215 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.463 ' O ' HG21 ' A' ' 135' ' ' VAL . 21.8 t . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.738 0.304 . . . . 0.0 110.931 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.608 ' HA ' HG21 ' A' ' 135' ' ' VAL . 5.1 mt -109.45 178.51 4.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.019 0.438 . . . . 0.0 111.311 -179.754 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . 0.452 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 7.9 tttt -50.04 -47.69 53.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.688 179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -59.99 -33.63 72.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.752 179.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . 0.402 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 70.1 m-20 -67.66 -36.65 81.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.396 179.757 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' ILE . . . . . 0.735 HD11 ' CG1' ' A' ' 135' ' ' VAL . 3.5 mm -65.18 -50.09 75.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.174 179.114 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -58.62 -38.91 79.06 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.539 179.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.8 -42.08 97.77 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.787 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' PHE . . . . . 0.571 ' CE1' HG13 ' A' ' 144' ' ' VAL . 45.8 t80 -59.67 -51.26 70.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.608 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' LEU . . . . . 0.714 HD21 ' CG2' ' A' ' 144' ' ' VAL . 33.7 mt . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.959 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.863 0.363 . . . . 0.0 111.168 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 14.7 mtp -104.25 166.29 11.87 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.842 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -63.19 -27.59 72.75 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.556 2.171 . . . . 0.0 112.15 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 24.8 m -79.93 -44.92 19.46 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.772 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.637 HG21 ' HA ' ' A' ' 159' ' ' LEU . 59.5 t -59.46 -33.55 51.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.862 179.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.432 ' CD ' ' CD1' ' A' ' 146' ' ' ILE . 9.1 mmm-85 -63.89 -51.26 65.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.948 0.404 . . . . 0.0 109.921 179.312 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.401 ' CE ' ' HG3' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -53.68 -41.89 67.35 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 178.517 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.7 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -51.51 -61.99 1.9 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.755 179.066 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.814 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -62.76 -20.46 64.98 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.502 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 -83.41 -27.88 29.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.526 -0.307 . . . . 0.0 110.968 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.401 ' HG3' ' CE ' ' A' ' 137' ' ' LYS . 14.9 mt-10 -85.63 -29.36 24.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.86 0.362 . . . . 0.0 110.856 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . 0.521 ' HG2' HD13 ' A' ' 167' ' ' LEU . 4.9 tptt -95.26 -25.43 16.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.081 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 97.43 16.98 32.75 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.52 -179.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.814 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 43.9 t -91.1 158.85 2.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.805 0.336 . . . . 0.0 110.877 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.49 ' N ' HG12 ' A' ' 144' ' ' VAL . 62.3 t0 -109.99 102.16 10.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.751 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.475 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 9.7 pt -48.61 -39.79 10.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.263 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 6.0 mtm-85 -48.97 -25.07 1.75 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.749 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.526 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.5 OUTLIER -120.78 27.44 8.51 Favored 'General case' 0 N--CA 1.463 0.186 0 N-CA-C 111.647 0.24 . . . . 0.0 111.647 -179.78 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.475 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 51.2 t -96.01 152.23 3.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.979 0.419 . . . . 0.0 110.906 179.593 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -74.96 79.36 2.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.973 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -75.99 116.48 4.82 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.507 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.286 0 CA-C-O 120.803 0.335 . . . . 0.0 110.96 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.424 ' O ' HG21 ' A' ' 135' ' ' VAL . 24.9 t . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.821 0.343 . . . . 0.0 110.952 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.637 ' HA ' HG21 ' A' ' 135' ' ' VAL . 3.2 mt -117.12 174.79 5.92 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.152 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . 0.442 ' HG2' ' CE2' ' A' ' 138' ' ' TYR . 0.0 OUTLIER -48.38 -48.97 36.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.875 179.946 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -58.03 -35.63 71.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.866 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -65.7 -38.8 90.23 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.35 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' ILE . . . . . 0.7 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.0 mm -62.64 -48.73 86.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.095 179.114 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -58.23 -39.93 80.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.63 179.541 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.5 -39.3 91.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.812 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' PHE . . . . . 0.62 ' CE1' HG13 ' A' ' 144' ' ' VAL . 21.9 t80 -64.15 -38.45 91.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.662 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' LEU . . . . . 0.779 HD21 ' CG2' ' A' ' 144' ' ' VAL . 19.5 mt . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.144 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.107 0 CA-C-O 120.842 0.353 . . . . 0.0 111.217 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . 0.407 ' CB ' ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -88.93 166.32 22.74 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.849 179.947 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . 0.407 ' HD2' ' CB ' ' A' ' 132' ' ' MET . 22.6 Cg_endo -61.44 -42.09 36.37 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.539 2.159 . . . . 0.0 112.227 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.03 -46.29 85.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.865 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.677 HG21 ' HA ' ' A' ' 159' ' ' LEU . 57.9 t -58.48 -35.08 52.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.913 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.625 ' HD3' HD11 ' A' ' 146' ' ' ILE . 1.6 mmm180 -63.18 -48.07 79.92 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.298 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.03 -38.36 70.43 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 178.323 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.679 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -55.43 -63.06 1.28 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.879 179.127 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.85 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -62.79 -20.99 65.55 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.387 -179.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 12.9 tpt180 -83.54 -27.15 29.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.956 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -85.63 -28.86 24.5 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.888 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . 0.444 ' HE2' HD13 ' A' ' 167' ' ' LEU . 0.0 OUTLIER -95.83 -26.21 15.73 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.109 -179.864 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 100.02 15.59 30.47 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.588 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.85 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 49.0 t -93.71 159.28 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.881 0.372 . . . . 0.0 110.758 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.51 ' N ' HG12 ' A' ' 144' ' ' VAL . 41.6 t0 -110.91 107.71 17.25 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.747 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.625 HD11 ' HD3' ' A' ' 136' ' ' ARG . 6.7 pt -51.19 -39.63 20.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.104 0.478 . . . . 0.0 111.437 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 20.8 mtt180 -48.81 -26.19 2.26 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.832 -179.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.447 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.0 OUTLIER -118.64 26.92 9.23 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 111.71 0.263 . . . . 0.0 111.71 -179.889 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.455 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 56.1 t -96.2 156.65 3.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.873 0.368 . . . . 0.0 110.702 179.468 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.42 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.97 73.38 2.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.888 -179.738 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -69.13 133.67 26.57 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.477 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.273 0 CA-C-O 120.851 0.358 . . . . 0.0 110.812 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.493 ' O ' HG21 ' A' ' 135' ' ' VAL . 22.8 t . . . . . 0 N--CA 1.458 -0.069 0 CA-C-O 120.883 0.373 . . . . 0.0 111.052 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.677 ' HA ' HG21 ' A' ' 135' ' ' VAL . 16.3 mt -106.59 176.36 5.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.017 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . 0.443 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 0.1 OUTLIER -50.19 -45.71 53.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.645 179.784 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 50.5 mm-40 -61.35 -34.52 75.43 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.627 179.694 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . 0.413 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 60.8 m-20 -65.41 -39.55 92.28 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.249 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' ILE . . . . . 0.679 HG21 ' CD1' ' A' ' 138' ' ' TYR . 3.3 mm -64.47 -45.13 96.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.027 179.037 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -60.61 -35.71 76.8 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.284 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -67.83 -39.01 83.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.469 179.541 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' PHE . . . . . 0.458 ' CE1' HG13 ' A' ' 144' ' ' VAL . 20.2 t80 -68.53 -31.3 70.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.605 179.642 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' LEU . . . . . 0.844 HD21 ' CG2' ' A' ' 144' ' ' VAL . 2.6 mt . . . . . 0 C--N 1.33 -0.266 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.978 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.78 0.324 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 64.2 mtp -80.07 157.34 73.68 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.946 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_exo -51.66 -42.58 55.8 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.576 2.184 . . . . 0.0 112.302 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.4 p -61.13 -42.64 98.91 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.956 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.621 ' CG1' HD11 ' A' ' 163' ' ' ILE . 59.2 t -59.46 -34.33 54.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.807 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.415 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -66.8 -53.63 30.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.895 0.379 . . . . 0.0 110.034 179.329 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.4 tttt -55.38 -32.08 62.32 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 178.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.715 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -61.93 -61.97 2.12 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.344 179.149 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.867 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -61.46 -24.41 66.54 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.527 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 9.5 mtp-105 -83.65 -29.05 27.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.795 0.331 . . . . 0.0 110.894 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -84.04 -26.94 28.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.112 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 5.4 mptt -97.45 -27.57 14.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.169 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.85 14.0 28.1 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.624 -179.783 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.867 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 47.3 t -95.46 160.8 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.862 0.363 . . . . 0.0 110.75 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.52 ' N ' HG12 ' A' ' 144' ' ' VAL . 45.5 t0 -113.46 107.07 15.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.615 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.48 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 12.7 pt -50.03 -39.98 16.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.355 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 11.9 mtm105 -49.28 -24.06 1.66 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.854 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.495 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.5 OUTLIER -120.45 27.15 8.74 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 120.65 0.262 . . . . 0.0 111.569 -179.83 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.48 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 55.6 t -96.4 158.19 3.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.957 0.408 . . . . 0.0 110.888 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.425 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.4 OUTLIER -74.77 79.6 2.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.157 -179.653 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -69.63 96.61 0.51 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.315 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 70.2 p . . . . . 0 N--CA 1.452 -0.348 0 CA-C-O 120.785 0.326 . . . . 0.0 111.209 -179.724 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.424 HG13 ' CG1' ' A' ' 149' ' ' VAL . 25.2 t . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.788 0.327 . . . . 0.0 111.012 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.525 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.3 mt -114.05 176.87 4.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.021 -179.811 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . 0.444 ' HG2' ' CE2' ' A' ' 138' ' ' TYR . 0.0 OUTLIER -49.37 -49.28 45.18 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.752 179.889 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -57.58 -34.48 69.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.796 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . 0.415 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 83.7 m-20 -67.54 -37.39 82.65 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.372 179.663 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' ILE . . . . . 0.715 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.0 mm -63.24 -47.99 89.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.168 179.23 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -59.33 -43.5 92.73 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.588 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -60.27 -40.4 90.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.814 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' PHE . . . . . 0.58 ' CE1' HG13 ' A' ' 144' ' ' VAL . 18.8 t80 -61.35 -50.07 74.38 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.631 179.727 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' LEU . . . . . 0.718 HD21 ' CG2' ' A' ' 144' ' ' VAL . 37.6 mt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.843 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.839 0.352 . . . . 0.0 111.14 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 1.1 mtp -68.75 160.65 76.32 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.785 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -62.03 -18.18 60.2 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.602 2.201 . . . . 0.0 112.377 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 29.1 t -88.64 -41.37 12.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.994 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.678 HG21 ' HA ' ' A' ' 159' ' ' LEU . 90.9 t -60.02 -40.19 82.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.099 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.627 ' HA ' HG21 ' A' ' 146' ' ' ILE . 4.3 mtm180 -63.11 -43.08 99.45 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 6.7 tttt -62.37 -34.34 76.49 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 178.376 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.75 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.9 OUTLIER -57.5 -60.95 2.89 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.304 179.005 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.78 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -60.73 -30.27 69.88 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.416 -179.708 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.53 -19.78 45.0 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.38 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -93.14 -22.43 19.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.674 0.273 . . . . 0.0 111.14 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . 0.477 ' HD2' HD13 ' A' ' 167' ' ' LEU . 0.2 OUTLIER -102.33 -21.38 14.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.343 -179.812 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.29 5.62 39.98 Favored Glycine 0 CA--C 1.519 0.314 0 C-N-CA 120.49 -0.862 . . . . 0.0 112.818 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.78 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 53.0 t -92.48 159.43 2.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.756 0.313 . . . . 0.0 110.695 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.498 ' N ' HG12 ' A' ' 144' ' ' VAL . 62.6 t0 -109.1 108.34 18.98 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.798 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.644 HG23 ' HB3' ' A' ' 139' ' ' ALA . 0.2 OUTLIER -50.59 -41.52 20.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.519 179.927 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -49.9 -23.11 1.76 Allowed 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.907 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.47 ' CD1' ' CE2' ' A' ' 166' ' ' PHE . 0.6 OUTLIER -120.27 25.69 9.68 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 111.819 0.303 . . . . 0.0 111.819 -179.605 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.501 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 63.2 t -92.64 151.96 3.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.929 0.395 . . . . 0.0 110.87 179.457 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -74.94 79.55 2.16 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.159 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.01 123.75 10.89 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.343 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.329 -0.318 0 CA-C-O 120.757 0.313 . . . . 0.0 111.177 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.45 ' O ' HG21 ' A' ' 135' ' ' VAL . 14.9 t . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.83 0.348 . . . . 0.0 111.066 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.678 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.3 mp -118.61 173.08 7.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.09 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 11.1 tttt -50.37 -45.21 55.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.677 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -59.72 -35.54 74.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.561 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -66.67 -36.84 83.48 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.238 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' ILE . . . . . 0.75 HG21 ' CD1' ' A' ' 138' ' ' TYR . 8.6 mm -63.94 -48.78 84.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.181 179.216 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -58.71 -41.86 87.33 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.594 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.97 -42.03 98.67 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.674 179.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' PHE . . . . . 0.608 ' CE1' HG13 ' A' ' 144' ' ' VAL . 13.6 t80 -59.46 -47.34 85.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.489 179.691 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' LEU . . . . . 0.744 HD21 ' CG2' ' A' ' 144' ' ' VAL . 19.9 mt . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.819 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.196 0 CA-C-O 120.779 0.323 . . . . 0.0 111.105 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . 0.462 ' HB2' HG23 ' A' ' 135' ' ' VAL . 1.0 OUTLIER -129.65 161.38 59.55 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.846 179.969 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -61.99 -24.69 77.06 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.613 2.208 . . . . 0.0 112.225 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.3 m -92.36 -42.02 10.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.854 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.691 HG21 ' HA ' ' A' ' 159' ' ' LEU . 59.2 t -62.03 -37.31 78.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.943 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.67 ' HD3' HD12 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -63.94 -47.54 80.09 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.303 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.22 -40.86 78.36 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 178.36 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.722 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.9 OUTLIER -51.86 -61.1 2.47 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.491 178.973 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.805 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -59.89 -28.11 67.29 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.575 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 11.0 tpt180 -79.95 -24.45 40.98 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.623 0.249 . . . . 0.0 111.373 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 16.8 mm-40 -89.25 -26.34 21.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.047 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 13.9 mptt -96.55 -22.28 17.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.251 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 101.27 8.61 46.7 Favored Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.667 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.805 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 45.1 t -92.73 159.26 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.775 0.321 . . . . 0.0 110.86 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.811 ' HB3' HD11 ' A' ' 148' ' ' LEU . 66.5 t0 -112.67 111.39 22.16 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.807 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.67 HD12 ' HD3' ' A' ' 136' ' ' ARG . 0.0 OUTLIER -49.53 -37.25 11.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.145 0.498 . . . . 0.0 111.726 -179.884 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 4.0 mtm-85 -48.59 -24.02 1.19 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.463 -0.79 . . . . 0.0 112.697 -179.231 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.871 ' N ' HD13 ' A' ' 148' ' ' LEU . 0.0 OUTLIER -127.92 31.75 5.05 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 111.893 0.331 . . . . 0.0 111.893 -179.25 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.478 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 76.5 t -94.75 157.08 3.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.841 0.353 . . . . 0.0 110.594 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.443 ' N ' HG12 ' A' ' 149' ' ' VAL . 1.2 mt-30 -74.89 72.17 2.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.854 -179.717 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.95 117.58 6.52 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.385 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.274 0 CA-C-O 120.876 0.37 . . . . 0.0 110.798 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.645 HG12 HG11 ' A' ' 135' ' ' VAL . 23.6 t . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.749 0.309 . . . . 0.0 111.059 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.691 ' HA ' HG21 ' A' ' 135' ' ' VAL . 0.9 OUTLIER -112.19 173.56 6.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.048 -179.867 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 2.0 tttt -49.15 -46.22 44.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.797 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 49.1 mm-40 -60.61 -35.62 76.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.659 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -65.52 -37.35 86.51 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.471 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' ILE . . . . . 0.722 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.0 mm -65.07 -49.48 79.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.207 179.193 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -58.55 -36.88 74.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.638 179.635 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -66.24 -41.98 89.26 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.918 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' PHE . . . . . 0.584 ' CE2' HD23 ' A' ' 148' ' ' LEU . 37.0 t80 -60.21 -50.84 72.06 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.637 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' LEU . . . . . 0.691 HD21 ' CG2' ' A' ' 144' ' ' VAL . 49.7 mt . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.922 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.879 0.371 . . . . 0.0 111.088 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . 0.673 ' HB2' HG23 ' A' ' 135' ' ' VAL . 1.4 mtp -95.33 157.36 36.45 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.9 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.79 -38.36 85.25 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.527 2.151 . . . . 0.0 112.393 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.2 t -80.06 -38.37 31.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.025 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.722 HG21 ' HA ' ' A' ' 159' ' ' LEU . 65.4 t -61.51 -36.49 73.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.051 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.901 ' HD3' HD12 ' A' ' 146' ' ' ILE . 1.4 mmt180 -68.05 -47.26 68.84 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.508 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.14 -36.94 78.63 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.642 ' CD2' HG21 ' A' ' 163' ' ' ILE . 1.2 t80 -55.95 -58.87 6.08 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.461 179.047 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.709 ' HB3' HG23 ' A' ' 146' ' ' ILE . . . -61.03 -28.73 69.26 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.21 -0.905 . . . . 0.0 111.262 -179.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.55 -29.63 46.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.849 0.357 . . . . 0.0 111.161 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 64.7 mm-40 -85.59 -23.65 27.5 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.163 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -95.89 -24.35 16.47 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.398 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.36 4.17 40.81 Favored Glycine 0 CA--C 1.518 0.268 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.684 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.741 ' CG2' HD21 ' A' ' 167' ' ' LEU . 59.2 t -87.59 157.77 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 0.0 110.826 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.667 ' OD2' HD21 ' A' ' 148' ' ' LEU . 62.3 t0 -106.79 105.48 15.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.73 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.901 HD12 ' HD3' ' A' ' 136' ' ' ARG . 4.3 pt -49.8 -42.16 17.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.49 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 80.3 mtp180 -48.65 -27.92 3.17 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.126 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.667 HD21 ' OD2' ' A' ' 145' ' ' ASP . 0.0 OUTLIER -116.8 24.19 11.42 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 111.979 0.363 . . . . 0.0 111.979 -179.515 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.532 HG21 HD13 ' A' ' 163' ' ' ILE . 43.8 t -88.72 150.47 3.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.762 0.315 . . . . 0.0 110.588 179.37 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.97 78.78 2.17 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.994 -179.684 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . 0.591 ' HA3' HG22 ' A' ' 158' ' ' VAL . . . -82.14 118.69 4.68 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.378 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . 0.501 HG22 ' OD1' ' A' ' 162' ' ' ASP . 8.8 t . . . . . 0 C--N 1.329 -0.299 0 CA-C-O 120.823 0.344 . . . . 0.0 111.002 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.681 ' O ' HG11 ' A' ' 135' ' ' VAL . 26.5 t . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.799 0.333 . . . . 0.0 111.112 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.722 ' HA ' HG21 ' A' ' 135' ' ' VAL . 3.2 mt -95.83 172.78 7.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.955 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.7 tttt -49.72 -42.58 46.3 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.783 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 51.7 mm-40 -56.06 -40.56 73.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.48 179.566 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . 0.501 ' OD1' HG22 ' A' ' 152' ' ' THR . 76.7 m-20 -64.76 -43.49 93.12 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.215 179.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' ILE . . . . . 0.658 ' CG1' HG13 ' A' ' 135' ' ' VAL . 10.7 mm -61.73 -38.78 81.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.167 179.152 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -62.37 -45.2 94.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.246 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -59.04 -42.9 91.35 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.418 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' PHE . . . . . 0.704 ' CE1' HG13 ' A' ' 144' ' ' VAL . 7.8 t80 -61.67 -48.99 78.31 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.297 179.308 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' LEU . . . . . 0.741 HD21 ' CG2' ' A' ' 144' ' ' VAL . 40.1 mt . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.859 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.845 ' HB3' ' NE ' ' A' ' 136' ' ' ARG . . . . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.807 0.337 . . . . 0.0 110.987 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 26.8 mtp -99.6 165.21 15.12 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.951 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -58.67 -45.51 29.14 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.575 2.183 . . . . 0.0 112.183 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 66.7 m -69.85 -37.5 76.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.656 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.65 HG21 ' HA ' ' A' ' 159' ' ' LEU . 64.8 t -64.05 -37.73 80.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.919 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.845 ' NE ' ' HB3' ' A' ' 131' ' ' ALA . 0.0 OUTLIER -64.21 -49.04 73.55 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.306 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 6.2 tttt -58.88 -32.9 69.91 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.747 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -58.42 -60.61 3.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.446 179.197 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.69 ' HB3' HG23 ' A' ' 146' ' ' ILE . . . -60.62 -29.52 69.29 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.665 -179.453 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 63.5 mtt180 -79.79 -27.39 40.39 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.271 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -86.6 -28.48 23.25 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.954 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -93.51 -23.58 18.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.097 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 99.53 10.78 46.49 Favored Glycine 0 CA--C 1.52 0.351 0 C-N-CA 120.596 -0.812 . . . . 0.0 112.56 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.705 ' CG2' HD21 ' A' ' 167' ' ' LEU . 48.5 t -89.95 158.67 2.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.757 0.313 . . . . 0.0 110.715 179.723 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.485 ' N ' HG12 ' A' ' 144' ' ' VAL . 62.8 t0 -104.28 104.05 13.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.035 0.445 . . . . 0.0 110.966 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.738 HD12 ' HD2' ' A' ' 136' ' ' ARG . 3.9 pt -47.36 -44.57 9.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.716 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 7.2 mmt180 -50.0 -23.39 2.01 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.786 -0.643 . . . . 0.0 112.195 -179.484 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.516 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.7 OUTLIER -120.99 22.95 10.88 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -179.608 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.485 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 74.4 t -87.68 148.95 4.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.737 0.303 . . . . 0.0 110.497 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.91 79.32 2.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.904 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . 0.672 ' HA3' HG22 ' A' ' 158' ' ' VAL . . . -85.68 115.33 4.15 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.41 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 3.7 t . . . . . 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.368 . . . . 0.0 111.041 -179.851 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.672 HG22 ' HA3' ' A' ' 151' ' ' GLY . 27.7 t . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.778 0.323 . . . . 0.0 110.945 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.65 ' HA ' HG21 ' A' ' 135' ' ' VAL . 5.6 mt -114.24 174.11 6.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.155 -179.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.1 tttm -50.62 -44.39 57.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.734 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -60.43 -35.4 75.71 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.653 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 36.9 m-20 -66.33 -38.82 88.55 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.273 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' ILE . . . . . 0.747 HG21 ' CD1' ' A' ' 138' ' ' TYR . 5.0 mm -62.01 -50.16 81.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.256 179.054 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.6 -41.25 80.85 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.55 179.638 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.07 -41.25 96.29 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.67 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' PHE . . . . . 0.618 ' CE1' HG13 ' A' ' 144' ' ' VAL . 21.5 t80 -60.89 -48.07 83.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.477 179.618 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' LEU . . . . . 0.705 HD21 ' CG2' ' A' ' 144' ' ' VAL . 41.8 mt . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.839 179.761 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.827 0.346 . . . . 0.0 111.173 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . 0.44 ' HB2' HG23 ' A' ' 135' ' ' VAL . 10.6 mtp -120.94 161.86 38.12 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.888 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.2 -56.84 2.52 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.509 2.139 . . . . 0.0 112.413 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -59.49 -40.64 87.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.871 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.631 ' CG1' HD11 ' A' ' 163' ' ' ILE . 96.3 t -60.36 -34.42 57.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.917 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.567 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.9 OUTLIER -65.85 -52.35 51.09 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.474 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -56.39 -32.79 65.13 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.577 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.718 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -59.02 -61.56 2.55 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.358 179.14 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.856 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -63.15 -23.08 67.27 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.364 -179.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -82.74 -26.43 31.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.088 179.829 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -86.66 -26.72 24.18 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.05 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 2.9 mptt -98.05 -24.9 15.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.247 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 100.84 13.27 34.84 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.612 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.856 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 38.9 t -93.97 161.02 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.718 0.294 . . . . 0.0 110.774 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.79 ' HB3' HD11 ' A' ' 148' ' ' LEU . 47.9 t0 -116.06 104.62 11.75 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.89 0.376 . . . . 0.0 110.795 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.567 HD11 ' HD3' ' A' ' 136' ' ' ARG . 6.1 pt -44.55 -36.26 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.222 0.534 . . . . 0.0 111.805 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -47.64 -26.16 1.41 Allowed 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.251 -0.886 . . . . 0.0 112.644 -179.159 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.853 ' N ' HD13 ' A' ' 148' ' ' LEU . 0.0 OUTLIER -125.21 29.87 5.98 Favored 'General case' 0 C--N 1.332 -0.161 0 C-N-CA 121.007 -0.277 . . . . 0.0 111.612 -179.36 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.468 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 54.5 t -94.26 157.73 2.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.839 0.352 . . . . 0.0 110.593 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.433 ' N ' HG12 ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.91 75.1 2.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.906 -179.69 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -74.56 122.09 7.07 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.369 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.306 0 CA-C-O 120.928 0.394 . . . . 0.0 110.861 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.431 ' O ' HG21 ' A' ' 135' ' ' VAL . 28.3 t . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.815 0.34 . . . . 0.0 110.998 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.528 ' HA ' HG21 ' A' ' 135' ' ' VAL . 5.0 mt -110.89 175.93 5.23 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.07 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 6.9 tttt -49.07 -45.75 43.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.816 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 -60.68 -36.12 77.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.696 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 73.3 m-20 -65.54 -36.3 83.39 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.298 179.663 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' ILE . . . . . 0.718 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.5 mm -64.79 -51.32 68.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.302 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.49 -38.03 73.91 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.638 179.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -64.83 -41.95 95.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.81 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' PHE . . . . . 0.552 ' CE1' HG13 ' A' ' 144' ' ' VAL . 50.0 t80 -60.08 -48.88 79.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.622 179.76 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' LEU . . . . . 0.715 HD21 ' CG2' ' A' ' 144' ' ' VAL . 39.6 mt . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.928 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.841 0.353 . . . . 0.0 111.335 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . 0.509 ' HE3' ' O ' ' A' ' 158' ' ' VAL . 0.0 OUTLIER -112.88 157.2 41.25 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.766 -179.991 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.91 -33.14 50.39 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.632 2.221 . . . . 0.0 112.099 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 9.4 p -76.99 -43.31 35.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.619 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.627 HG21 ' HA ' ' A' ' 159' ' ' LEU . 73.0 t -58.5 -34.97 52.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.856 179.813 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.466 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.2 OUTLIER -64.71 -49.78 69.54 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 179.206 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -57.58 -31.09 65.81 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 178.556 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.688 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -61.25 -62.36 1.89 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.369 179.032 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.833 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -59.92 -29.2 68.21 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.413 -179.578 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? -80.11 -26.29 39.58 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.212 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -86.59 -29.48 22.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.995 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 4.9 mptt -95.07 -22.19 18.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.256 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 97.16 12.82 47.83 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.609 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.833 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 54.0 t -94.3 159.32 2.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.706 0.288 . . . . 0.0 110.783 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.495 ' N ' HG12 ' A' ' 144' ' ' VAL . 67.0 t0 -110.06 111.48 22.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.868 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.466 HD11 ' HD3' ' A' ' 136' ' ' ARG . 7.9 pt -53.36 -39.95 37.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.402 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 1.2 mmm180 -49.23 -25.26 2.18 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.792 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.552 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.3 OUTLIER -119.67 27.17 8.89 Favored 'General case' 0 C--N 1.332 -0.186 0 N-CA-C 111.659 0.244 . . . . 0.0 111.659 -179.827 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.447 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 40.5 t -95.04 150.3 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.867 0.365 . . . . 0.0 110.587 179.364 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -74.86 77.49 2.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.922 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -73.03 125.04 9.43 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.471 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . 0.706 HG22 ' OD1' ' A' ' 162' ' ' ASP . 6.3 t . . . . . 0 C--N 1.328 -0.336 0 CA-C-O 120.766 0.317 . . . . 0.0 110.905 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.53 ' O ' HG21 ' A' ' 135' ' ' VAL . 21.9 t . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.691 0.282 . . . . 0.0 110.759 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.627 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.0 OUTLIER -107.06 178.54 4.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.097 0.475 . . . . 0.0 111.371 -179.648 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . 0.457 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 2.8 tptt -50.59 -43.26 56.5 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.852 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -62.97 -34.62 77.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.794 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . 0.706 ' OD1' HG22 ' A' ' 152' ' ' THR . 26.8 m-20 -65.24 -42.69 93.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.407 179.687 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' ILE . . . . . 0.688 HG21 ' CD1' ' A' ' 138' ' ' TYR . 2.5 mm -62.15 -48.01 90.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.15 179.182 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.74 -37.42 73.56 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.472 179.44 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -64.77 -42.23 95.26 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.536 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' PHE . . . . . 0.552 ' CE2' HD12 ' A' ' 148' ' ' LEU . 28.2 t80 -62.3 -38.4 89.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.509 179.617 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' LEU . . . . . 0.709 HD21 ' CG2' ' A' ' 144' ' ' VAL . 26.0 mt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.976 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.837 0.351 . . . . 0.0 111.079 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . 0.414 ' CB ' ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -99.56 166.68 12.44 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.862 179.948 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . 0.414 ' HD2' ' CB ' ' A' ' 132' ' ' MET . 20.8 Cg_endo -60.91 -26.49 83.22 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.512 2.141 . . . . 0.0 112.282 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -81.47 -44.85 16.84 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.752 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.543 HG21 ' HA ' ' A' ' 159' ' ' LEU . 85.5 t -59.92 -31.49 47.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.862 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -67.28 -52.94 34.59 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 8.7 ttpt -56.37 -31.07 63.45 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 178.536 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.736 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -60.86 -62.57 1.76 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.413 179.103 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.857 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -61.78 -24.1 66.62 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.334 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 20.2 mmm-85 -80.52 -32.51 36.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.903 0.383 . . . . 0.0 110.822 179.707 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -83.72 -29.28 27.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.662 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . 0.666 ' HE3' HD13 ' A' ' 167' ' ' LEU . 11.5 mmtt -89.66 -25.74 21.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.05 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 96.33 13.58 47.95 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.439 -179.535 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.857 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 92.8 t -97.84 159.71 3.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.76 0.314 . . . . 0.0 110.783 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.498 ' N ' HG12 ' A' ' 144' ' ' VAL . 68.4 t0 -108.75 111.96 24.0 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.785 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.46 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 8.6 pt -53.6 -40.06 40.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.039 0.447 . . . . 0.0 111.32 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 91.4 mtt-85 -49.34 -25.67 2.61 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.765 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.434 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.1 OUTLIER -118.81 27.32 8.96 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 111.721 0.267 . . . . 0.0 111.721 -179.878 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.46 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 38.8 t -94.0 154.5 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.851 0.358 . . . . 0.0 110.552 179.373 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.93 75.6 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.952 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -70.0 114.9 5.81 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.426 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.327 -0.375 0 CA-C-O 120.699 0.285 . . . . 0.0 111.167 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.441 HG13 ' CG1' ' A' ' 149' ' ' VAL . 30.8 t . . . . . 0 C--O 1.231 0.081 0 CA-C-O 120.748 0.309 . . . . 0.0 110.921 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.543 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.1 mt -113.19 177.42 4.64 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.072 0.463 . . . . 0.0 111.225 -179.719 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . 0.452 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 1.8 tttt -50.68 -44.44 57.77 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.855 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 68.0 mm-40 -61.98 -34.11 75.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.695 179.795 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -67.11 -38.91 86.46 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.407 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' ILE . . . . . 0.736 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.4 mm -64.08 -48.93 83.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.294 179.263 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -58.37 -41.06 83.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.656 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.1 -41.71 99.43 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.921 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 166' ' ' PHE . . . . . 0.547 ' CE1' HG13 ' A' ' 144' ' ' VAL . 32.8 t80 -60.3 -50.45 73.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.827 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 167' ' ' LEU . . . . . 0.691 HD21 ' CG2' ' A' ' 144' ' ' VAL . 50.8 mt . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.861 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.797 0.332 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -69.95 162.75 66.44 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.86 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_endo -57.28 -24.45 59.78 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.627 2.218 . . . . 0.0 112.144 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.3 m -76.76 -44.86 31.34 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.89 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.572 HG21 ' HA ' ' A' ' 159' ' ' LEU . 93.0 t -59.8 -34.95 57.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.79 -51.38 56.39 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.325 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.403 ' HG3' ' HG3' ' A' ' 141' ' ' GLU . 2.5 tttt -56.75 -29.96 63.1 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 178.564 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.722 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -63.39 -62.74 1.48 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.496 179.301 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.861 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -63.11 -24.56 67.96 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.372 -179.648 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.63 -27.17 29.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.739 0.304 . . . . 0.0 110.957 179.746 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.403 ' HG3' ' HG3' ' A' ' 137' ' ' LYS . 8.2 mm-40 -85.82 -28.04 24.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.019 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 1.6 mmtm -97.66 -25.37 15.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.254 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 101.2 14.09 31.69 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.717 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.861 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 42.9 t -93.2 159.43 2.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.733 0.301 . . . . 0.0 110.826 179.731 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.499 ' N ' HG12 ' A' ' 144' ' ' VAL . 67.1 t0 -110.45 107.59 17.32 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.705 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.459 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 9.7 pt -52.05 -40.19 28.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 121.048 0.451 . . . . 0.0 111.217 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 92.0 mtt-85 -48.9 -26.33 2.41 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.931 -179.749 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.447 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.1 OUTLIER -119.24 26.93 9.13 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.663 0.268 . . . . 0.0 111.668 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.459 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 40.5 t -93.97 157.63 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.782 0.325 . . . . 0.0 110.518 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.431 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.95 76.21 2.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.967 -179.767 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -72.52 109.15 2.71 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.421 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.303 0 CA-C-O 120.607 0.241 . . . . 0.0 111.207 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.425 ' O ' HG21 ' A' ' 135' ' ' VAL . 21.5 t . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.795 0.331 . . . . 0.0 110.999 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.572 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.2 mp -116.05 176.93 4.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.058 0.456 . . . . 0.0 111.183 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . 0.439 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 3.4 tttt -50.32 -46.48 55.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.787 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -59.69 -34.27 72.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.705 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 72.1 m-20 -67.69 -37.62 82.56 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.395 179.672 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' ILE . . . . . 0.722 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.9 mm -64.02 -49.01 83.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.339 179.271 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -58.8 -42.21 88.57 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.624 179.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.57 -40.83 96.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.81 179.8 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 166' ' ' PHE . . . . . 0.583 ' CE1' HG13 ' A' ' 144' ' ' VAL . 46.7 t80 -60.55 -51.31 69.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.65 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 167' ' ' LEU . . . . . 0.738 HD21 ' CG2' ' A' ' 144' ' ' VAL . 29.4 mt . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.896 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.779 0.323 . . . . 0.0 111.199 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . 0.4 ' CB ' ' HD2' ' A' ' 133' ' ' PRO . 2.6 mtm -71.98 166.22 42.66 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.816 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . 0.4 ' HD2' ' CB ' ' A' ' 132' ' ' MET . 22.8 Cg_endo -61.24 -32.64 90.59 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.513 2.142 . . . . 0.0 112.219 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -69.93 -45.54 67.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.782 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.654 ' CG1' HD11 ' A' ' 163' ' ' ILE . 84.7 t -60.16 -33.06 52.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.99 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.436 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.5 OUTLIER -65.9 -50.72 63.46 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.21 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.4 tttt -57.71 -31.71 66.67 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.551 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.716 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -60.27 -61.6 2.48 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.402 179.109 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.851 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -63.78 -21.67 66.54 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.299 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.79 -27.61 28.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.042 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -85.94 -25.81 25.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.059 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . 0.493 ' HG2' HD13 ' A' ' 167' ' ' LEU . 2.1 tptt -98.61 -26.72 14.3 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.247 -179.822 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 103.07 13.11 29.91 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.596 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.851 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 35.0 t -93.27 160.59 2.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.794 0.33 . . . . 0.0 110.831 179.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.802 ' HB3' HD11 ' A' ' 148' ' ' LEU . 51.9 t0 -115.22 105.66 13.15 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.952 0.406 . . . . 0.0 110.755 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.479 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 4.0 pt -45.13 -36.3 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.3 0.571 . . . . 0.0 111.867 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -48.24 -25.32 1.48 Allowed 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.332 -0.849 . . . . 0.0 112.643 -179.157 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.845 ' N ' HD13 ' A' ' 148' ' ' LEU . 0.0 OUTLIER -126.82 31.07 5.37 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 111.817 0.303 . . . . 0.0 111.817 -179.33 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.479 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 54.1 t -92.88 157.45 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.821 0.344 . . . . 0.0 110.65 179.372 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.426 ' N ' HG12 ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.84 69.77 1.87 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.999 -179.645 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -68.79 115.83 6.88 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.403 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.273 0 CA-C-O 120.617 0.246 . . . . 0.0 111.325 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.464 ' O ' HG21 ' A' ' 135' ' ' VAL . 31.7 t . . . . . 0 N--CA 1.458 -0.072 0 CA-C-O 120.805 0.336 . . . . 0.0 110.776 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.601 ' HA ' HG21 ' A' ' 135' ' ' VAL . 0.9 OUTLIER -115.13 176.67 4.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.027 0.442 . . . . 0.0 111.263 -179.69 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 14.3 tttm -49.84 -45.72 50.61 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.818 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 -60.03 -35.46 75.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.653 179.742 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -66.23 -37.94 86.73 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.368 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' ILE . . . . . 0.716 HG21 ' CD1' ' A' ' 138' ' ' TYR . 5.4 mm -63.14 -49.16 84.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.909 179.084 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -59.42 -36.49 75.97 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.508 179.459 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.6 -39.84 92.0 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.775 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 166' ' ' PHE . . . . . 0.536 ' CE1' HG13 ' A' ' 144' ' ' VAL . 57.7 t80 -62.98 -47.27 83.88 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.536 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 167' ' ' LEU . . . . . 0.795 HD21 ' CG2' ' A' ' 144' ' ' VAL . 5.8 mt . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.911 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.741 0.305 . . . . 0.0 111.101 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 77.6 mtp -100.8 162.04 21.93 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.953 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.42 -40.48 71.18 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.549 2.166 . . . . 0.0 112.254 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.22 -43.74 70.03 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.912 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.621 HG21 ' HA ' ' A' ' 159' ' ' LEU . 67.4 t -58.98 -36.48 62.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.942 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.453 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.2 OUTLIER -66.14 -51.92 53.3 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 179.469 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.9 ttpt -56.72 -32.64 65.73 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 178.691 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.734 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.9 OUTLIER -59.73 -61.82 2.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.458 179.205 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.745 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -63.45 -23.31 67.34 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.297 -179.772 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -82.04 -28.22 32.58 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.951 179.78 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -86.35 -28.57 23.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.847 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 4.1 mptt -93.96 -24.58 17.61 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.04 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 98.07 13.94 41.03 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.6 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.749 HG21 HD11 ' A' ' 167' ' ' LEU . 45.6 t -92.74 159.11 2.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.799 0.333 . . . . 0.0 110.828 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.488 ' N ' HG12 ' A' ' 144' ' ' VAL . 68.2 t0 -109.3 105.42 14.82 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.839 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.489 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 7.3 pt -49.33 -39.92 13.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.13 0.49 . . . . 0.0 111.389 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 8.4 mtt-85 -49.4 -24.73 2.09 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.746 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.463 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.6 OUTLIER -120.32 27.99 8.28 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.586 0.231 . . . . 0.0 111.596 -179.846 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.545 ' CG1' HG13 ' A' ' 158' ' ' VAL . 43.4 t -95.31 155.56 3.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.934 0.397 . . . . 0.0 110.792 179.594 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.407 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 8.6 tt0 -74.99 77.61 2.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.096 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.65 111.75 3.79 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.455 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.328 -0.333 0 CA-C-O 120.763 0.316 . . . . 0.0 111.042 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.545 HG13 ' CG1' ' A' ' 149' ' ' VAL . 25.9 t . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.89 0.376 . . . . 0.0 111.19 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.621 ' HA ' HG21 ' A' ' 135' ' ' VAL . 3.8 mp -112.96 175.91 5.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.911 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . 0.441 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 0.4 OUTLIER -50.91 -45.52 60.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.642 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 4.2 mm-40 -60.36 -34.25 73.6 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.603 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -67.64 -37.6 82.68 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.436 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' ILE . . . . . 0.734 HG21 ' CD1' ' A' ' 138' ' ' TYR . 5.4 mm -64.01 -47.93 88.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.169 179.164 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -58.76 -42.38 88.79 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.577 179.409 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.01 -40.94 95.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.653 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 166' ' ' PHE . . . . . 0.58 ' CE1' HG13 ' A' ' 144' ' ' VAL . 20.5 t80 -63.51 -38.94 93.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.513 179.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 167' ' ' LEU . . . . . 0.749 HD11 HG21 ' A' ' 144' ' ' VAL . 12.7 mt . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.77 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.786 0.327 . . . . 0.0 111.196 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . 0.549 ' HB2' HG23 ' A' ' 135' ' ' VAL . 3.3 mtp -91.47 160.37 36.97 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.851 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.65 -23.49 76.05 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.591 2.194 . . . . 0.0 112.242 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.2 m -90.65 -41.48 11.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.898 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.772 HG21 ' HA ' ' A' ' 159' ' ' LEU . 59.5 t -59.91 -39.7 80.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.033 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.75 ' HD3' HD12 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -62.48 -43.44 98.8 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.63 -0.508 . . . . 0.0 109.63 179.364 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.3 -33.32 74.43 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 178.331 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.758 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.9 OUTLIER -57.7 -60.87 3.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.375 179.052 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.711 ' HB3' HG23 ' A' ' 146' ' ' ILE . . . -61.29 -29.61 69.97 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.377 -179.649 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 11.3 mmm180 -79.19 -23.03 44.13 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.339 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -89.67 -26.57 20.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.802 0.334 . . . . 0.0 111.032 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -96.06 -22.31 17.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.288 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.46 7.09 46.44 Favored Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.573 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.797 ' CG2' HD21 ' A' ' 167' ' ' LEU . 59.2 t -89.44 155.24 3.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 120.722 0.296 . . . . 0.0 110.67 179.65 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.489 ' HB3' HD11 ' A' ' 148' ' ' LEU . 66.5 t0 -102.34 109.19 20.77 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.14 0.495 . . . . 0.0 110.89 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.75 HD12 ' HD3' ' A' ' 136' ' ' ARG . 5.4 pt -51.07 -43.78 27.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.63 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . 0.418 HH11 ' HD2' ' A' ' 147' ' ' ARG . 11.6 mtt180 -49.72 -24.62 2.4 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.941 -0.572 . . . . 0.0 112.11 -179.437 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.489 HD11 ' HB3' ' A' ' 145' ' ' ASP . 0.1 OUTLIER -119.2 23.97 11.01 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 112.111 0.412 . . . . 0.0 112.111 -179.645 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.539 ' CG1' HG13 ' A' ' 158' ' ' VAL . 48.9 t -86.64 156.18 3.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.733 0.301 . . . . 0.0 110.555 179.209 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.405 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 4.2 tt0 -74.79 74.24 2.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.067 -179.73 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -72.07 107.38 2.17 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.403 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.299 0 CA-C-O 120.871 0.367 . . . . 0.0 110.988 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.539 HG13 ' CG1' ' A' ' 149' ' ' VAL . 21.9 t . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.865 0.364 . . . . 0.0 111.083 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.772 ' HA ' HG21 ' A' ' 135' ' ' VAL . 14.5 mt -112.37 175.12 5.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.05 -179.803 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . 0.44 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 1.0 OUTLIER -50.77 -44.98 58.77 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.673 179.903 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -61.11 -34.41 74.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.637 179.587 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -66.82 -37.22 84.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.457 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' ILE . . . . . 0.758 HG21 ' CD1' ' A' ' 138' ' ' TYR . 8.2 mm -65.11 -49.23 80.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.186 179.167 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -58.82 -38.42 78.6 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.572 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.49 -41.08 93.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.836 179.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 166' ' ' PHE . . . . . 0.593 ' CE1' HG13 ' A' ' 144' ' ' VAL . 24.6 t80 -61.1 -45.69 93.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.591 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 167' ' ' LEU . . . . . 0.797 HD21 ' CG2' ' A' ' 144' ' ' VAL . 16.4 mt . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.805 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.801 0.334 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.42 166.06 11.75 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.864 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -52.89 -37.62 77.73 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.505 2.137 . . . . 0.0 112.381 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.66 -48.25 55.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.88 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.593 ' CG1' HD11 ' A' ' 163' ' ' ILE . 73.9 t -58.06 -33.06 45.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.848 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.12 -52.88 36.29 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 179.341 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 3.8 tttp -55.96 -30.3 61.53 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 178.634 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.725 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -62.86 -62.78 1.49 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.442 179.295 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.834 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -63.71 -23.91 67.56 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.243 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 3.8 tpt180 -82.97 -25.92 31.81 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.943 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -87.55 -26.59 23.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.945 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -97.52 -25.18 15.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.188 -179.779 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 100.85 13.27 34.82 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.674 -0.775 . . . . 0.0 112.584 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.834 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 44.3 t -94.55 160.03 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.788 0.327 . . . . 0.0 110.743 179.716 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.509 ' N ' HG12 ' A' ' 144' ' ' VAL . 42.9 t0 -111.17 109.6 19.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.733 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.461 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 9.7 pt -52.03 -39.84 27.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.389 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . 0.538 ' HG2' HD23 ' A' ' 148' ' ' LEU . 2.2 ptt180 -48.99 -25.92 2.24 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.794 -179.731 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.538 HD23 ' HG2' ' A' ' 147' ' ' ARG . 0.2 OUTLIER -119.43 26.96 9.07 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 111.645 0.239 . . . . 0.0 111.645 -179.809 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.461 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 43.6 t -95.05 157.53 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.837 0.351 . . . . 0.0 110.586 179.305 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.425 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 2.1 tt0 -74.74 77.55 2.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.067 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -72.91 106.11 1.89 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.447 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 120.605 0.24 . . . . 0.0 111.24 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.446 HG13 ' CG1' ' A' ' 149' ' ' VAL . 21.9 t . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.854 0.359 . . . . 0.0 110.949 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.556 ' HA ' HG21 ' A' ' 135' ' ' VAL . 2.1 mt -121.85 172.46 8.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.219 -179.81 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . 0.442 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 4.9 tttm -47.8 -50.41 25.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.053 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -57.18 -35.38 69.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.781 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -67.56 -34.75 77.69 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.38 179.678 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' ILE . . . . . 0.725 HG21 ' CD1' ' A' ' 138' ' ' TYR . 5.7 mm -64.98 -50.65 73.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.068 179.106 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -59.57 -37.72 79.23 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.571 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.9 -40.5 91.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.712 179.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 166' ' ' PHE . . . . . 0.552 ' CE1' HG13 ' A' ' 144' ' ' VAL . 37.2 t80 -60.91 -48.32 82.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.567 179.675 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 167' ' ' LEU . . . . . 0.777 HD21 ' CG2' ' A' ' 144' ' ' VAL . 16.5 mt . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.955 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.912 ' HB3' ' HD3' ' A' ' 136' ' ' ARG . . . . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.897 0.379 . . . . 0.0 111.016 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . 0.564 ' HB2' HG23 ' A' ' 135' ' ' VAL . 24.5 mmm -88.79 161.19 42.27 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.93 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -52.22 -28.18 32.96 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.587 2.191 . . . . 0.0 112.257 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 58.2 m -87.31 -38.6 16.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.906 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.619 HG21 ' HA ' ' A' ' 159' ' ' LEU . 61.4 t -62.68 -40.48 88.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.022 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.912 ' HD3' ' HB3' ' A' ' 131' ' ' ALA . 25.1 mmm-85 -65.52 -47.74 74.9 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.35 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 2.0 tttm -60.72 -29.81 69.58 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.755 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -60.95 -60.66 3.43 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.481 179.213 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.767 ' HB3' HG23 ' A' ' 146' ' ' ILE . . . -62.69 -27.76 69.47 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.78 -0.645 . . . . 0.0 111.516 -179.544 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.4 -21.18 33.08 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.301 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -91.95 -22.22 20.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.069 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 1.1 mmtt -103.22 -24.47 13.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.346 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.58 9.6 32.82 Favored Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.875 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.798 ' CG2' HD21 ' A' ' 167' ' ' LEU . 46.3 t -89.24 155.06 3.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.748 0.309 . . . . 0.0 110.59 179.545 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.445 ' HB3' ' CG ' ' A' ' 148' ' ' LEU . 61.4 t0 -100.79 104.97 16.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.11 0.481 . . . . 0.0 111.023 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.767 HG23 ' HB3' ' A' ' 139' ' ' ALA . 3.1 pt -47.44 -45.51 9.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.73 179.564 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.67 -22.09 1.9 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.332 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.512 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.9 OUTLIER -121.44 22.27 10.77 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 112.053 0.39 . . . . 0.0 112.053 -179.592 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.468 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 76.0 t -85.96 152.49 3.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.864 0.364 . . . . 0.0 110.574 179.251 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.94 78.98 2.16 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.919 -179.776 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -80.92 106.85 2.6 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.42 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.329 -0.286 0 CA-C-O 120.925 0.393 . . . . 0.0 110.879 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.605 HG12 HG11 ' A' ' 135' ' ' VAL . 22.6 t . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.807 0.337 . . . . 0.0 110.977 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.619 ' HA ' HG21 ' A' ' 135' ' ' VAL . 2.3 mt -122.96 170.93 9.63 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.122 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 29.6 tttm -50.61 -44.75 57.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.622 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -60.31 -35.37 75.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.501 179.704 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -66.26 -38.28 87.45 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.328 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' ILE . . . . . 0.755 HG21 ' CD1' ' A' ' 138' ' ' TYR . 6.1 mm -63.22 -49.78 81.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.248 179.351 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -58.08 -41.04 82.58 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.621 179.719 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.13 -40.72 98.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.764 179.704 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 166' ' ' PHE . . . . . 0.63 ' CE1' HG13 ' A' ' 144' ' ' VAL . 17.9 t80 -60.82 -45.57 93.95 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.486 179.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 167' ' ' LEU . . . . . 0.798 HD21 ' CG2' ' A' ' 144' ' ' VAL . 21.1 mt . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.849 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.876 0.37 . . . . 0.0 111.246 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . 0.589 ' HB2' HG23 ' A' ' 135' ' ' VAL . 1.3 mmt -85.97 161.35 50.16 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.822 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_endo -61.15 -30.81 89.53 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.575 2.183 . . . . 0.0 112.221 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -82.1 -37.39 26.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.736 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.643 ' CG1' HD11 ' A' ' 163' ' ' ILE . 62.6 t -61.7 -34.63 63.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.41 ' HD3' HD13 ' A' ' 146' ' ' ILE . 0.4 OUTLIER -65.91 -52.85 46.45 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.439 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.14 -34.34 63.67 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 178.671 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.719 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.9 OUTLIER -59.08 -61.79 2.37 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.442 179.21 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.853 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -62.01 -23.88 66.7 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.517 -179.747 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 3.2 mmm-85 -82.6 -28.81 30.61 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.717 0.294 . . . . 0.0 111.116 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -84.22 -27.69 27.81 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.123 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 2.1 mptp? -96.06 -26.9 15.34 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.124 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.09 13.34 31.63 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.619 -179.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.853 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 47.7 t -94.91 159.88 2.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-O 120.689 0.28 . . . . 0.0 110.738 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.507 ' N ' HG12 ' A' ' 144' ' ' VAL . 66.9 t0 -111.99 111.17 21.91 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.811 179.817 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.448 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 7.8 pt -52.16 -39.77 28.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.457 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -48.94 -25.75 2.12 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.754 -179.762 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.44 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.2 OUTLIER -119.65 28.12 8.34 Favored 'General case' 0 N--CA 1.462 0.138 0 N-CA-C 111.679 0.251 . . . . 0.0 111.679 -179.832 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.448 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 55.6 t -98.25 155.64 3.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.79 0.329 . . . . 0.0 110.659 179.269 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.94 79.3 2.16 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.96 -179.736 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -76.48 114.83 4.24 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.328 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.33 -0.281 0 CA-C-O 120.694 0.283 . . . . 0.0 111.085 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.462 ' O ' HG21 ' A' ' 135' ' ' VAL . 22.2 t . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.749 0.309 . . . . 0.0 110.79 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.619 ' HA ' HG21 ' A' ' 135' ' ' VAL . 0.8 OUTLIER -117.6 174.69 6.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.094 0.474 . . . . 0.0 111.291 -179.621 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . 0.456 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 2.1 tptt -50.16 -45.8 53.6 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.784 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -60.11 -34.86 74.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.681 179.663 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -67.17 -36.69 82.33 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.332 179.57 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' ILE . . . . . 0.719 HG21 ' CD1' ' A' ' 138' ' ' TYR . 5.2 mm -64.01 -50.3 77.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.093 179.179 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -58.62 -39.65 81.08 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.484 179.675 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -62.54 -41.34 98.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.771 179.664 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 166' ' ' PHE . . . . . 0.541 ' CE1' HG13 ' A' ' 144' ' ' VAL . 40.9 t80 -60.61 -51.81 67.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.568 179.659 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 167' ' ' LEU . . . . . 0.766 HD21 ' CG2' ' A' ' 144' ' ' VAL . 23.7 mt . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.833 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.858 0.361 . . . . 0.0 111.304 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . 0.528 ' HB2' HG23 ' A' ' 135' ' ' VAL . 0.7 OUTLIER -114.42 158.88 38.77 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.843 -179.991 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.08 -54.82 4.79 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.682 2.255 . . . . 0.0 112.159 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.1 m -60.33 -40.97 92.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.624 179.736 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.769 ' CG1' HD11 ' A' ' 163' ' ' ILE . 81.6 t -60.53 -34.24 57.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.716 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.525 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.2 OUTLIER -64.04 -53.16 54.28 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.201 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -56.84 -30.71 64.05 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 178.536 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.678 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -62.26 -61.32 2.54 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.581 179.313 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.835 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -62.45 -27.1 68.88 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.49 -179.466 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 31.0 mmm180 -83.18 -24.06 32.63 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.708 0.289 . . . . 0.0 111.084 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -88.71 -22.84 23.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.25 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . 0.46 ' HD2' HD13 ' A' ' 167' ' ' LEU . 4.3 mmtt -102.65 -25.38 13.58 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.288 -179.716 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.75 9.99 31.64 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.64 -179.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.835 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 25.1 t -94.98 162.05 2.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.632 0.253 . . . . 0.0 110.656 179.628 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.815 ' HB3' HD11 ' A' ' 148' ' ' LEU . 55.5 t0 -117.53 109.09 16.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.946 0.403 . . . . 0.0 110.845 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.525 HD11 ' HD3' ' A' ' 136' ' ' ARG . 5.1 pt -46.45 -37.3 3.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.125 0.488 . . . . 0.0 111.807 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -47.58 -25.35 1.11 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.53 -0.759 . . . . 0.0 112.616 -179.196 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.859 ' N ' HD13 ' A' ' 148' ' ' LEU . 0.0 OUTLIER -127.12 30.24 5.46 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 111.736 0.273 . . . . 0.0 111.736 -179.22 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.486 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 58.3 t -93.92 158.57 2.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.804 0.335 . . . . 0.0 110.609 179.514 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.452 ' N ' HG12 ' A' ' 149' ' ' VAL . 0.7 OUTLIER -74.8 77.13 2.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.975 -179.659 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.59 90.64 0.47 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.393 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . 0.779 HG22 ' OD1' ' A' ' 162' ' ' ASP . 11.2 t . . . . . 0 C--N 1.329 -0.295 0 CA-C-O 120.823 0.344 . . . . 0.0 111.058 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 N--CA 1.457 -0.092 0 CA-C-O 120.795 0.331 . . . . 0.0 110.939 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.503 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.0 OUTLIER -124.04 174.02 7.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.121 -179.773 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . 0.443 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 64.5 tttt -48.54 -50.19 33.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.901 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -56.27 -35.37 67.39 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.824 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . 0.779 ' OD1' HG22 ' A' ' 152' ' ' THR . 89.7 m-20 -67.24 -38.22 84.85 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.434 179.769 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' ILE . . . . . 0.769 HD11 ' CG1' ' A' ' 135' ' ' VAL . 4.2 mm -61.98 -47.28 93.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.064 0.459 . . . . 0.0 109.929 179.114 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -60.23 -40.92 91.89 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.475 179.413 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -62.08 -40.89 97.38 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.798 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 166' ' ' PHE . . . . . 0.568 ' CE1' HG13 ' A' ' 144' ' ' VAL . 44.5 t80 -60.49 -50.6 72.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.429 179.62 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 167' ' ' LEU . . . . . 0.798 HD21 ' CG2' ' A' ' 144' ' ' VAL . 14.8 mt . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.855 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.419 ' HB2' ' HB ' ' A' ' 158' ' ' VAL . . . . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.861 0.363 . . . . 0.0 111.112 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.3 mmm -106.72 161.55 22.52 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.884 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -56.15 -23.6 45.65 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.582 2.188 . . . . 0.0 112.126 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 45.9 p -81.05 -46.18 15.39 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.79 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.713 ' CG1' HD11 ' A' ' 163' ' ' ILE . 86.2 t -58.68 -33.25 48.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.986 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.532 ' HD3' HD11 ' A' ' 146' ' ' ILE . 4.8 mmm180 -64.35 -51.21 64.5 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.263 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -53.96 -38.8 65.36 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 178.467 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.708 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -55.02 -62.6 1.55 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.93 179.183 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.895 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -61.09 -23.28 65.37 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.782 -179.33 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 38.2 mtt-85 -84.08 -28.11 27.78 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.765 0.317 . . . . 0.0 111.123 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -84.05 -27.09 28.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.172 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.27 -27.88 13.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.158 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.28 16.01 24.06 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.578 -179.831 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.895 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 46.4 t -95.91 160.67 2.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.772 0.32 . . . . 0.0 110.756 179.766 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.524 ' N ' HG12 ' A' ' 144' ' ' VAL . 67.2 t0 -113.9 108.99 17.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.888 179.665 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.532 HD11 ' HD3' ' A' ' 136' ' ' ARG . 7.1 pt -50.5 -39.83 18.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.433 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -48.9 -24.84 1.62 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.773 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.558 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.4 OUTLIER -120.36 28.09 8.22 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.652 0.263 . . . . 0.0 111.612 -179.715 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.456 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 55.2 t -99.31 153.6 4.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.928 0.394 . . . . 0.0 110.771 179.456 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -74.96 79.16 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.161 -179.629 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -73.64 120.0 6.75 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.399 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.318 0 CA-C-O 120.643 0.259 . . . . 0.0 111.227 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.487 ' O ' HG21 ' A' ' 135' ' ' VAL . 25.9 t . . . . . 0 N--CA 1.457 -0.083 0 CA-C-O 120.844 0.354 . . . . 0.0 110.847 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.649 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.4 mt -111.87 175.98 5.21 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.107 0.479 . . . . 0.0 111.167 -179.744 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 49.5 tttt -49.43 -48.19 47.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.806 179.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -59.03 -34.48 71.96 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.714 179.778 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -67.35 -36.06 80.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.452 179.721 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' ILE . . . . . 0.713 HD11 ' CG1' ' A' ' 135' ' ' VAL . 4.2 mm -65.2 -50.22 74.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.169 179.226 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -58.52 -39.61 80.61 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.601 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.78 -40.57 97.0 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.628 179.737 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 166' ' ' PHE . . . . . 0.576 ' CE1' HG13 ' A' ' 144' ' ' VAL . 26.9 t80 -60.32 -48.98 79.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.425 179.678 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 167' ' ' LEU . . . . . 0.81 HD21 ' CG2' ' A' ' 144' ' ' VAL . 6.1 mt . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.911 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.486 1.357 0 CA-C-O 120.822 0.344 . . . . 0.0 111.21 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.5 mtp180 -175.54 82.64 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.858 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -71.28 147.26 48.32 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.863 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.718 HG21 ' HG2' ' A' ' 147' ' ' ARG . 25.4 t -106.37 150.31 9.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.136 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.613 HG22 ' CG ' ' A' ' 157' ' ' ARG . 20.5 mt -92.34 68.72 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.895 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -126.86 166.85 16.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.173 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 33.7 mtp -103.12 157.95 32.74 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.807 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 10.5 Cg_endo -53.6 -27.42 41.38 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.642 2.228 . . . . 0.0 112.192 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.6 t -80.06 -47.22 15.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.71 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.735 ' CG1' HD11 ' A' ' 163' ' ' ILE . 94.9 t -58.31 -31.31 42.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.822 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.469 ' HD3' HD11 ' A' ' 146' ' ' ILE . 6.6 mmm-85 -65.42 -52.74 51.22 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.281 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 11.0 tppt? -52.88 -39.5 62.71 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.478 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.689 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -54.33 -62.8 1.42 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.027 -0.988 . . . . 0.0 110.796 179.133 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.873 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -60.18 -24.67 64.97 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.601 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 3.3 mmt85 -82.16 -27.6 32.59 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.69 0.281 . . . . 0.0 111.122 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -85.68 -29.39 24.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.973 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 3.7 mptp? -94.96 -24.45 16.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.172 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 98.66 14.27 38.07 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.613 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.873 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 34.4 t -94.19 160.13 2.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.713 0.292 . . . . 0.0 110.81 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.772 ' HB3' HD11 ' A' ' 148' ' ' LEU . 63.8 t0 -114.9 104.99 12.47 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.789 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.469 HD11 ' HD3' ' A' ' 136' ' ' ARG . 4.4 pt -45.5 -36.33 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.26 0.552 . . . . 0.0 111.818 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . 0.718 ' HG2' HG21 ' A' ' 129' ' ' VAL . 6.8 mtt180 -48.29 -25.6 1.63 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.316 -0.856 . . . . 0.0 112.641 -179.253 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.852 ' N ' HD13 ' A' ' 148' ' ' LEU . 0.0 OUTLIER -125.49 30.02 5.87 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.662 0.268 . . . . 0.0 111.715 -179.433 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.46 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 58.1 t -94.63 155.65 3.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.862 0.363 . . . . 0.0 110.683 179.406 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.408 ' N ' HG12 ' A' ' 149' ' ' VAL . 0.5 OUTLIER -74.96 79.51 2.17 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.925 -179.749 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -73.32 110.52 3.16 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.433 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -103.37 -17.8 15.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.585 0.231 . . . . 0.0 111.215 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -52.64 173.89 0.27 Allowed Glycine 0 C--N 1.331 0.291 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.624 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 14.5 tptt -50.31 123.87 9.35 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.791 0.329 . . . . 0.0 111.195 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.552 ' O ' HD13 ' A' ' 130' ' ' ILE . 80.6 m-20 61.25 44.5 9.77 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.876 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 58.8 57.55 19.25 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.398 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.613 ' CG ' HG22 ' A' ' 130' ' ' ILE . 0.0 OUTLIER -98.0 121.16 39.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.77 0.319 . . . . 0.0 111.03 -179.918 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.463 ' O ' HG21 ' A' ' 135' ' ' VAL . 21.8 t -78.04 110.34 13.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.931 179.753 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.608 ' HA ' HG21 ' A' ' 135' ' ' VAL . 5.1 mt -109.45 178.51 4.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.019 0.438 . . . . 0.0 111.311 -179.754 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . 0.452 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 7.9 tttt -50.04 -47.69 53.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.688 179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -59.99 -33.63 72.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.752 179.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . 0.402 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 70.1 m-20 -67.66 -36.65 81.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.396 179.757 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' ILE . . . . . 0.735 HD11 ' CG1' ' A' ' 135' ' ' VAL . 3.5 mm -65.18 -50.09 75.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.174 179.114 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -58.62 -38.91 79.06 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.539 179.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.8 -42.08 97.77 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.787 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' PHE . . . . . 0.571 ' CE1' HG13 ' A' ' 144' ' ' VAL . 45.8 t80 -59.67 -51.26 70.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.608 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . 0.714 HD21 ' CG2' ' A' ' 144' ' ' VAL . 33.7 mt -70.91 -30.31 66.61 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.959 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -87.52 179.35 6.57 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.122 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 120.92 105.99 2.02 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.592 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 114.63 141.78 7.71 Favored Glycine 0 C--O 1.248 1.001 0 CA-C-O 118.377 -1.235 . . . . 0.0 112.573 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.782 0 CA-C-N 118.34 1.07 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 67.6 m-20 . . . . . 0 N--CA 1.486 1.369 0 CA-C-O 120.807 0.337 . . . . 0.0 111.159 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -134.01 145.63 49.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.878 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 51.8 ttt180 -71.35 123.31 22.03 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.955 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.538 HG21 ' HG2' ' A' ' 147' ' ' ARG . 20.1 t -98.77 154.61 3.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.123 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.765 HG22 ' HG3' ' A' ' 157' ' ' ARG . 18.8 mt -97.37 62.82 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.99 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -128.32 177.16 7.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.168 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 14.7 mtp -104.25 166.29 11.87 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.842 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -63.19 -27.59 72.75 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.556 2.171 . . . . 0.0 112.15 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 24.8 m -79.93 -44.92 19.46 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.772 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.637 HG21 ' HA ' ' A' ' 159' ' ' LEU . 59.5 t -59.46 -33.55 51.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.862 179.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.432 ' CD ' ' CD1' ' A' ' 146' ' ' ILE . 9.1 mmm-85 -63.89 -51.26 65.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.948 0.404 . . . . 0.0 109.921 179.312 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.401 ' CE ' ' HG3' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -53.68 -41.89 67.35 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 178.517 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.7 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -51.51 -61.99 1.9 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.755 179.066 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.814 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -62.76 -20.46 64.98 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.502 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 -83.41 -27.88 29.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.526 -0.307 . . . . 0.0 110.968 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.401 ' HG3' ' CE ' ' A' ' 137' ' ' LYS . 14.9 mt-10 -85.63 -29.36 24.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.86 0.362 . . . . 0.0 110.856 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . 0.521 ' HG2' HD13 ' A' ' 167' ' ' LEU . 4.9 tptt -95.26 -25.43 16.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.081 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 97.43 16.98 32.75 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.52 -179.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.814 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 43.9 t -91.1 158.85 2.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.805 0.336 . . . . 0.0 110.877 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.49 ' N ' HG12 ' A' ' 144' ' ' VAL . 62.3 t0 -109.99 102.16 10.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.751 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.475 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 9.7 pt -48.61 -39.79 10.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.263 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . 0.538 ' HG2' HG21 ' A' ' 129' ' ' VAL . 6.0 mtm-85 -48.97 -25.07 1.75 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.749 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.526 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.5 OUTLIER -120.78 27.44 8.51 Favored 'General case' 0 N--CA 1.463 0.186 0 N-CA-C 111.647 0.24 . . . . 0.0 111.647 -179.78 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.475 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 51.2 t -96.01 152.23 3.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.979 0.419 . . . . 0.0 110.906 179.593 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -74.96 79.36 2.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.973 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -75.99 116.48 4.82 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.507 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -114.43 28.35 8.8 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.803 0.335 . . . . 0.0 110.96 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -98.08 -174.28 33.11 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.349 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 7.9 tttt -45.42 111.07 0.3 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.784 0.326 . . . . 0.0 111.433 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 4.9 t30 62.78 52.85 2.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.89 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 57.12 54.15 39.2 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.459 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.765 ' HG3' HG22 ' A' ' 130' ' ' ILE . 28.9 ttm-85 -96.15 139.8 31.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.82 0.343 . . . . 0.0 110.995 -179.812 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.424 ' O ' HG21 ' A' ' 135' ' ' VAL . 24.9 t -89.97 120.59 39.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.952 179.849 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.637 ' HA ' HG21 ' A' ' 135' ' ' VAL . 3.2 mt -117.12 174.79 5.92 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.152 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . 0.442 ' HG2' ' CE2' ' A' ' 138' ' ' TYR . 0.0 OUTLIER -48.38 -48.97 36.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.875 179.946 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -58.03 -35.63 71.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.866 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -65.7 -38.8 90.23 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.35 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' ILE . . . . . 0.7 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.0 mm -62.64 -48.73 86.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.095 179.114 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -58.23 -39.93 80.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.63 179.541 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.5 -39.3 91.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.812 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' PHE . . . . . 0.62 ' CE1' HG13 ' A' ' 144' ' ' VAL . 21.9 t80 -64.15 -38.45 91.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.662 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . 0.779 HD21 ' CG2' ' A' ' 144' ' ' VAL . 19.5 mt -86.88 -76.39 0.36 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.144 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -66.69 -45.06 80.06 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.393 -179.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -59.06 -27.53 62.57 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.511 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -128.09 -91.56 0.71 Allowed Glycine 0 C--O 1.249 1.048 0 CA-C-O 118.407 -1.218 . . . . 0.0 112.494 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.779 0 CA-C-N 118.365 1.082 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.487 1.417 0 CA-C-O 120.853 0.359 . . . . 0.0 111.14 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -66.58 107.01 1.95 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.911 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 4.6 mtt85 -135.57 -178.21 5.02 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.913 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.865 HG21 ' HG2' ' A' ' 147' ' ' ARG . 22.0 t -108.85 155.94 9.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.171 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.567 HG22 ' HA ' ' A' ' 157' ' ' ARG . 6.0 mt -79.97 68.69 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.804 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -139.97 155.21 47.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.217 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . 0.407 ' CB ' ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -88.93 166.32 22.74 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.849 179.947 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . 0.407 ' HD2' ' CB ' ' A' ' 132' ' ' MET . 22.6 Cg_endo -61.44 -42.09 36.37 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.539 2.159 . . . . 0.0 112.227 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.03 -46.29 85.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.865 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.677 HG21 ' HA ' ' A' ' 159' ' ' LEU . 57.9 t -58.48 -35.08 52.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.913 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.625 ' HD3' HD11 ' A' ' 146' ' ' ILE . 1.6 mmm180 -63.18 -48.07 79.92 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.298 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.03 -38.36 70.43 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 178.323 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.679 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -55.43 -63.06 1.28 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.879 179.127 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.85 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -62.79 -20.99 65.55 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.387 -179.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 12.9 tpt180 -83.54 -27.15 29.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.956 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -85.63 -28.86 24.5 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.888 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . 0.444 ' HE2' HD13 ' A' ' 167' ' ' LEU . 0.0 OUTLIER -95.83 -26.21 15.73 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.109 -179.864 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 100.02 15.59 30.47 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.588 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.85 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 49.0 t -93.71 159.28 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.881 0.372 . . . . 0.0 110.758 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.51 ' N ' HG12 ' A' ' 144' ' ' VAL . 41.6 t0 -110.91 107.71 17.25 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.747 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.625 HD11 ' HD3' ' A' ' 136' ' ' ARG . 6.7 pt -51.19 -39.63 20.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.104 0.478 . . . . 0.0 111.437 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . 0.865 ' HG2' HG21 ' A' ' 129' ' ' VAL . 20.8 mtt180 -48.81 -26.19 2.26 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.832 -179.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.447 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.0 OUTLIER -118.64 26.92 9.23 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 111.71 0.263 . . . . 0.0 111.71 -179.889 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.455 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 56.1 t -96.2 156.65 3.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.873 0.368 . . . . 0.0 110.702 179.468 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.42 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.97 73.38 2.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.888 -179.738 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -69.13 133.67 26.57 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.477 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.19 30.09 0.87 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.851 0.358 . . . . 0.0 110.812 -179.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -96.66 105.13 3.17 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.696 -0.764 . . . . 0.0 113.009 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . 0.522 ' HG3' ' N ' ' A' ' 155' ' ' ASN . 0.0 OUTLIER 73.55 -49.73 0.69 Allowed 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 179.509 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.522 ' N ' ' HG3' ' A' ' 154' ' ' LYS . 9.4 m-20 -155.5 27.12 0.4 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.892 0.377 . . . . 0.0 110.338 179.829 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 108.49 16.1 12.59 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.489 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.567 ' HA ' HG22 ' A' ' 130' ' ' ILE . 1.3 ttt180 -68.55 128.92 38.36 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.748 0.309 . . . . 0.0 110.618 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.493 ' O ' HG21 ' A' ' 135' ' ' VAL . 22.8 t -74.97 106.66 4.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.052 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.677 ' HA ' HG21 ' A' ' 135' ' ' VAL . 16.3 mt -106.59 176.36 5.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.017 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . 0.443 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 0.1 OUTLIER -50.19 -45.71 53.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.645 179.784 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 50.5 mm-40 -61.35 -34.52 75.43 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.627 179.694 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . 0.413 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 60.8 m-20 -65.41 -39.55 92.28 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.249 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' ILE . . . . . 0.679 HG21 ' CD1' ' A' ' 138' ' ' TYR . 3.3 mm -64.47 -45.13 96.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.027 179.037 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' ASP . . . . . 0.507 ' O ' ' HB2' ' A' ' 168' ' ' ALA . 4.5 m-20 -60.61 -35.71 76.8 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.284 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -67.83 -39.01 83.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.469 179.541 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' PHE . . . . . 0.458 ' CE1' HG13 ' A' ' 144' ' ' VAL . 20.2 t80 -68.53 -31.3 70.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.605 179.642 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . 0.844 HD21 ' CG2' ' A' ' 144' ' ' VAL . 2.6 mt -105.69 -80.1 0.55 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.978 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . 0.507 ' HB2' ' O ' ' A' ' 164' ' ' ASP . . . 53.41 100.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.314 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -166.19 -94.63 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.494 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -165.75 6.42 0.06 OUTLIER Glycine 0 C--O 1.25 1.108 0 CA-C-O 118.317 -1.268 . . . . 0.0 112.468 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.818 0 CA-C-N 118.432 1.116 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 6.9 m120 . . . . . 0 N--CA 1.485 1.315 0 CA-C-O 120.896 0.379 . . . . 0.0 111.187 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -103.73 157.67 16.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.891 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.0 141.57 33.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.907 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.664 HG21 ' HG2' ' A' ' 147' ' ' ARG . 14.6 t -132.18 161.55 41.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.948 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.489 ' N ' HG12 ' A' ' 129' ' ' VAL . 3.4 mt -79.96 69.78 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.915 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -142.83 153.35 43.12 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.123 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 64.2 mtp -80.07 157.34 73.68 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.946 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_exo -51.66 -42.58 55.8 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.576 2.184 . . . . 0.0 112.302 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.4 p -61.13 -42.64 98.91 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.956 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.621 ' CG1' HD11 ' A' ' 163' ' ' ILE . 59.2 t -59.46 -34.33 54.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.807 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.415 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -66.8 -53.63 30.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.895 0.379 . . . . 0.0 110.034 179.329 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.4 tttt -55.38 -32.08 62.32 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 178.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.715 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -61.93 -61.97 2.12 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.344 179.149 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.867 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -61.46 -24.41 66.54 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.527 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 9.5 mtp-105 -83.65 -29.05 27.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.795 0.331 . . . . 0.0 110.894 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -84.04 -26.94 28.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.112 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 5.4 mptt -97.45 -27.57 14.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.169 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.85 14.0 28.1 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.624 -179.783 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.867 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 47.3 t -95.46 160.8 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.862 0.363 . . . . 0.0 110.75 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.52 ' N ' HG12 ' A' ' 144' ' ' VAL . 45.5 t0 -113.46 107.07 15.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.615 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.48 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 12.7 pt -50.03 -39.98 16.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.355 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . 0.664 ' HG2' HG21 ' A' ' 129' ' ' VAL . 11.9 mtm105 -49.28 -24.06 1.66 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.854 -179.766 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.495 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.5 OUTLIER -120.45 27.15 8.74 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 120.65 0.262 . . . . 0.0 111.569 -179.83 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.48 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 55.6 t -96.4 158.19 3.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.957 0.408 . . . . 0.0 110.888 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.425 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.4 OUTLIER -74.77 79.6 2.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.157 -179.653 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -69.63 96.61 0.51 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.315 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 70.2 p -84.98 -23.25 28.79 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-O 120.785 0.326 . . . . 0.0 111.209 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -54.18 167.88 1.78 Allowed Glycine 0 C--N 1.332 0.307 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.566 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 3.4 tttt -55.0 138.44 43.81 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.82 0.343 . . . . 0.0 111.08 -179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 10.4 m-20 60.5 31.07 20.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 64.56 53.6 34.3 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.379 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.555 ' CZ ' HD21 ' A' ' 159' ' ' LEU . 38.4 ttp180 -95.04 128.13 41.63 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.847 0.356 . . . . 0.0 111.032 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.424 HG13 ' CG1' ' A' ' 149' ' ' VAL . 25.2 t -87.59 118.56 33.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.012 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.555 HD21 ' CZ ' ' A' ' 157' ' ' ARG . 1.3 mt -114.05 176.87 4.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.021 -179.811 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . 0.444 ' HG2' ' CE2' ' A' ' 138' ' ' TYR . 0.0 OUTLIER -49.37 -49.28 45.18 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.752 179.889 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -57.58 -34.48 69.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.796 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . 0.415 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 83.7 m-20 -67.54 -37.39 82.65 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.372 179.663 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' ILE . . . . . 0.715 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.0 mm -63.24 -47.99 89.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.168 179.23 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -59.33 -43.5 92.73 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.588 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -60.27 -40.4 90.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.814 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' PHE . . . . . 0.58 ' CE1' HG13 ' A' ' 144' ' ' VAL . 18.8 t80 -61.35 -50.07 74.38 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.631 179.727 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . 0.718 HD21 ' CG2' ' A' ' 144' ' ' VAL . 37.6 mt -70.72 -33.18 70.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.843 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -83.14 147.02 28.32 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.169 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -151.81 50.78 0.52 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.564 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 58.76 -176.02 2.5 Favored Glycine 0 C--O 1.249 1.064 0 CA-C-O 118.367 -1.24 . . . . 0.0 112.578 -179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.801 0 CA-C-N 118.466 1.133 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 23.5 p30 . . . . . 0 N--CA 1.487 1.381 0 CA-C-O 120.86 0.362 . . . . 0.0 111.198 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.54 104.22 7.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.871 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.99 156.18 3.09 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.16 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.628 HG21 ' HG3' ' A' ' 147' ' ' ARG . 24.2 t -135.09 149.72 29.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.109 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.438 HG22 ' HG2' ' A' ' 157' ' ' ARG . 4.9 mt -79.99 63.09 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.769 179.785 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -141.22 155.78 45.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.14 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 1.1 mtp -68.75 160.65 76.32 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.785 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -62.03 -18.18 60.2 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.602 2.201 . . . . 0.0 112.377 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 29.1 t -88.64 -41.37 12.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.994 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.678 HG21 ' HA ' ' A' ' 159' ' ' LEU . 90.9 t -60.02 -40.19 82.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.099 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.627 ' HA ' HG21 ' A' ' 146' ' ' ILE . 4.3 mtm180 -63.11 -43.08 99.45 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 6.7 tttt -62.37 -34.34 76.49 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 178.376 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.75 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.9 OUTLIER -57.5 -60.95 2.89 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.304 179.005 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.78 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -60.73 -30.27 69.88 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.416 -179.708 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.53 -19.78 45.0 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.38 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -93.14 -22.43 19.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.674 0.273 . . . . 0.0 111.14 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . 0.477 ' HD2' HD13 ' A' ' 167' ' ' LEU . 0.2 OUTLIER -102.33 -21.38 14.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.343 -179.812 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.29 5.62 39.98 Favored Glycine 0 CA--C 1.519 0.314 0 C-N-CA 120.49 -0.862 . . . . 0.0 112.818 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.78 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 53.0 t -92.48 159.43 2.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.756 0.313 . . . . 0.0 110.695 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.498 ' N ' HG12 ' A' ' 144' ' ' VAL . 62.6 t0 -109.1 108.34 18.98 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.798 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.644 HG23 ' HB3' ' A' ' 139' ' ' ALA . 0.2 OUTLIER -50.59 -41.52 20.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.519 179.927 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . 0.628 ' HG3' HG21 ' A' ' 129' ' ' VAL . 0.7 OUTLIER -49.9 -23.11 1.76 Allowed 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.907 -179.853 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.47 ' CD1' ' CE2' ' A' ' 166' ' ' PHE . 0.6 OUTLIER -120.27 25.69 9.68 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 111.819 0.303 . . . . 0.0 111.819 -179.605 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.501 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 63.2 t -92.64 151.96 3.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.929 0.395 . . . . 0.0 110.87 179.457 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -74.94 79.55 2.16 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.159 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.01 123.75 10.89 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.343 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -99.28 -25.3 14.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.757 0.313 . . . . 0.0 111.177 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -52.77 168.9 0.8 Allowed Glycine 0 C--N 1.331 0.264 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.716 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 1.2 ttmm -58.18 142.47 47.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.768 0.318 . . . . 0.0 110.99 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 59.73 31.21 20.71 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.915 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 66.16 55.01 20.87 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.416 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.438 ' HG2' HG22 ' A' ' 130' ' ' ILE . 0.2 OUTLIER -91.28 131.57 36.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.829 0.347 . . . . 0.0 110.926 179.913 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.45 ' O ' HG21 ' A' ' 135' ' ' VAL . 14.9 t -91.6 123.91 43.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.066 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.678 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.3 mp -118.61 173.08 7.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.09 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 11.1 tttt -50.37 -45.21 55.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.677 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -59.72 -35.54 74.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.561 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -66.67 -36.84 83.48 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.238 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' ILE . . . . . 0.75 HG21 ' CD1' ' A' ' 138' ' ' TYR . 8.6 mm -63.94 -48.78 84.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.181 179.216 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -58.71 -41.86 87.33 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.594 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.97 -42.03 98.67 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.674 179.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' PHE . . . . . 0.608 ' CE1' HG13 ' A' ' 144' ' ' VAL . 13.6 t80 -59.46 -47.34 85.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.489 179.691 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . 0.744 HD21 ' CG2' ' A' ' 144' ' ' VAL . 19.9 mt -75.81 -73.6 0.26 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.819 179.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -82.75 118.12 23.15 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.048 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -101.87 -44.78 1.87 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.562 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -100.68 -58.44 0.85 Allowed Glycine 0 C--O 1.249 1.046 0 CA-C-O 118.406 -1.219 . . . . 0.0 112.479 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.25 -3.757 0 CA-C-N 118.349 1.075 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 . . . . . 0 N--CA 1.486 1.356 0 CA-C-O 120.828 0.346 . . . . 0.0 111.163 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.1 ttm180 -152.37 100.4 2.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.927 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -116.45 176.32 5.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.82 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.622 HG21 ' HG2' ' A' ' 147' ' ' ARG . 21.7 t -133.26 159.26 43.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.017 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.583 HG22 ' HG3' ' A' ' 157' ' ' ARG . 3.3 mp -79.9 67.07 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.065 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -113.15 -169.86 1.57 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.105 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . 0.462 ' HB2' HG23 ' A' ' 135' ' ' VAL . 1.0 OUTLIER -129.65 161.38 59.55 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.846 179.969 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -61.99 -24.69 77.06 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.613 2.208 . . . . 0.0 112.225 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.3 m -92.36 -42.02 10.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.854 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.691 HG21 ' HA ' ' A' ' 159' ' ' LEU . 59.2 t -62.03 -37.31 78.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.943 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.67 ' HD3' HD12 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -63.94 -47.54 80.09 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.303 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.22 -40.86 78.36 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 178.36 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.722 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.9 OUTLIER -51.86 -61.1 2.47 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.491 178.973 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.805 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -59.89 -28.11 67.29 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.575 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 11.0 tpt180 -79.95 -24.45 40.98 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.623 0.249 . . . . 0.0 111.373 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 16.8 mm-40 -89.25 -26.34 21.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.047 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 13.9 mptt -96.55 -22.28 17.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.251 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 101.27 8.61 46.7 Favored Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.667 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.805 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 45.1 t -92.73 159.26 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.775 0.321 . . . . 0.0 110.86 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.811 ' HB3' HD11 ' A' ' 148' ' ' LEU . 66.5 t0 -112.67 111.39 22.16 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.807 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.67 HD12 ' HD3' ' A' ' 136' ' ' ARG . 0.0 OUTLIER -49.53 -37.25 11.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.145 0.498 . . . . 0.0 111.726 -179.884 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . 0.622 ' HG2' HG21 ' A' ' 129' ' ' VAL . 4.0 mtm-85 -48.59 -24.02 1.19 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.463 -0.79 . . . . 0.0 112.697 -179.231 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.871 ' N ' HD13 ' A' ' 148' ' ' LEU . 0.0 OUTLIER -127.92 31.75 5.05 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 111.893 0.331 . . . . 0.0 111.893 -179.25 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.478 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 76.5 t -94.75 157.08 3.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.841 0.353 . . . . 0.0 110.594 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.443 ' N ' HG12 ' A' ' 149' ' ' VAL . 1.2 mt-30 -74.89 72.17 2.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.854 -179.717 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.95 117.58 6.52 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.385 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -130.94 31.48 4.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.876 0.37 . . . . 0.0 110.798 -179.835 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . 0.699 ' HA3' HD11 ' A' ' 159' ' ' LEU . . . -91.79 101.97 2.86 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.566 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 11.3 tttp 63.48 -78.69 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.712 0.292 . . . . 0.0 111.143 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 7.3 t30 -113.23 31.42 6.46 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.852 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 92.11 29.57 11.31 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.536 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.583 ' HG3' HG22 ' A' ' 130' ' ' ILE . 61.2 ttm-85 -77.02 130.98 38.18 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.87 0.367 . . . . 0.0 110.884 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.645 HG12 HG11 ' A' ' 135' ' ' VAL . 23.6 t -74.96 112.04 11.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.059 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.699 HD11 ' HA3' ' A' ' 153' ' ' GLY . 0.9 OUTLIER -112.19 173.56 6.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.048 -179.867 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 2.0 tttt -49.15 -46.22 44.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.797 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 49.1 mm-40 -60.61 -35.62 76.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.659 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -65.52 -37.35 86.51 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.471 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' ILE . . . . . 0.722 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.0 mm -65.07 -49.48 79.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.207 179.193 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -58.55 -36.88 74.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.638 179.635 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -66.24 -41.98 89.26 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.918 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' PHE . . . . . 0.584 ' CE2' HD23 ' A' ' 148' ' ' LEU . 37.0 t80 -60.21 -50.84 72.06 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.637 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . 0.691 HD21 ' CG2' ' A' ' 144' ' ' VAL . 49.7 mt -71.95 -75.66 0.13 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.922 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -59.39 149.57 28.86 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.133 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 131.5 63.85 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.513 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -104.06 54.0 0.68 Allowed Glycine 0 C--O 1.249 1.047 0 CA-C-O 118.387 -1.23 . . . . 0.0 112.556 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.774 0 CA-C-N 118.387 1.094 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 9.0 t30 . . . . . 0 N--CA 1.487 1.414 0 CA-C-O 120.826 0.346 . . . . 0.0 111.195 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 2.2 mtt180 -145.14 -178.49 6.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.886 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 10.0 ttm105 -100.49 158.83 15.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.465 HG21 ' HG2' ' A' ' 147' ' ' ARG . 29.2 t -78.06 147.43 7.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.075 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.592 HG22 ' HG2' ' A' ' 157' ' ' ARG . 4.3 mt -108.34 52.98 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.125 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -100.58 168.08 9.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.088 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . 0.673 ' HB2' HG23 ' A' ' 135' ' ' VAL . 1.4 mtp -95.33 157.36 36.45 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.9 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.79 -38.36 85.25 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.527 2.151 . . . . 0.0 112.393 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.2 t -80.06 -38.37 31.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.025 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.722 HG21 ' HA ' ' A' ' 159' ' ' LEU . 65.4 t -61.51 -36.49 73.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.051 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.901 ' HD3' HD12 ' A' ' 146' ' ' ILE . 1.4 mmt180 -68.05 -47.26 68.84 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.508 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.14 -36.94 78.63 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.642 ' CD2' HG21 ' A' ' 163' ' ' ILE . 1.2 t80 -55.95 -58.87 6.08 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.461 179.047 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.709 ' HB3' HG23 ' A' ' 146' ' ' ILE . . . -61.03 -28.73 69.26 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.21 -0.905 . . . . 0.0 111.262 -179.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.55 -29.63 46.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.849 0.357 . . . . 0.0 111.161 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 64.7 mm-40 -85.59 -23.65 27.5 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.163 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -95.89 -24.35 16.47 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.398 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.36 4.17 40.81 Favored Glycine 0 CA--C 1.518 0.268 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.684 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.741 ' CG2' HD21 ' A' ' 167' ' ' LEU . 59.2 t -87.59 157.77 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 0.0 110.826 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.667 ' OD2' HD21 ' A' ' 148' ' ' LEU . 62.3 t0 -106.79 105.48 15.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.73 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.901 HD12 ' HD3' ' A' ' 136' ' ' ARG . 4.3 pt -49.8 -42.16 17.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.49 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . 0.465 ' HG2' HG21 ' A' ' 129' ' ' VAL . 80.3 mtp180 -48.65 -27.92 3.17 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.126 -179.601 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.667 HD21 ' OD2' ' A' ' 145' ' ' ASP . 0.0 OUTLIER -116.8 24.19 11.42 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 111.979 0.363 . . . . 0.0 111.979 -179.515 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.532 HG21 HD13 ' A' ' 163' ' ' ILE . 43.8 t -88.72 150.47 3.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.762 0.315 . . . . 0.0 110.588 179.37 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.97 78.78 2.17 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.994 -179.684 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . 0.591 ' HA3' HG22 ' A' ' 158' ' ' VAL . . . -82.14 118.69 4.68 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.378 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . 0.501 HG22 ' OD1' ' A' ' 162' ' ' ASP . 8.8 t -137.83 34.87 2.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.823 0.344 . . . . 0.0 111.002 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -81.08 92.75 1.48 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.487 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 7.8 tttt 64.83 -75.08 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.716 0.293 . . . . 0.0 111.078 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.4 t30 -110.3 24.88 12.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.102 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 96.82 29.68 7.99 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.72 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.592 ' HG2' HG22 ' A' ' 130' ' ' ILE . 3.2 mtt180 -79.96 121.93 26.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.787 0.327 . . . . 0.0 110.771 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.681 ' O ' HG11 ' A' ' 135' ' ' VAL . 26.5 t -75.02 92.79 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.112 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.722 ' HA ' HG21 ' A' ' 135' ' ' VAL . 3.2 mt -95.83 172.78 7.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.955 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.7 tttt -49.72 -42.58 46.3 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.783 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 51.7 mm-40 -56.06 -40.56 73.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.48 179.566 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . 0.501 ' OD1' HG22 ' A' ' 152' ' ' THR . 76.7 m-20 -64.76 -43.49 93.12 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.215 179.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' ILE . . . . . 0.658 ' CG1' HG13 ' A' ' 135' ' ' VAL . 10.7 mm -61.73 -38.78 81.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.167 179.152 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -62.37 -45.2 94.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.246 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -59.04 -42.9 91.35 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.418 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' PHE . . . . . 0.704 ' CE1' HG13 ' A' ' 144' ' ' VAL . 7.8 t80 -61.67 -48.99 78.31 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.297 179.308 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . 0.741 HD21 ' CG2' ' A' ' 144' ' ' VAL . 40.1 mt -72.52 -76.21 0.12 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.859 180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -67.12 -78.45 0.06 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.104 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 88.87 49.35 3.6 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.525 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -133.82 4.68 4.7 Favored Glycine 0 C--O 1.25 1.097 0 CA-C-O 118.306 -1.274 . . . . 0.0 112.426 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.812 0 CA-C-N 118.394 1.097 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.487 1.384 0 CA-C-O 120.809 0.338 . . . . 0.0 111.172 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 4.4 mtt180 -91.95 161.56 14.76 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.931 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.33 176.06 6.87 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.901 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.489 HG21 ' HG2' ' A' ' 147' ' ' ARG . 18.4 t -101.14 159.63 3.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.127 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.633 HG22 ' HG3' ' A' ' 157' ' ' ARG . 18.1 mt -80.02 59.94 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.022 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.845 ' HB3' ' NE ' ' A' ' 136' ' ' ARG . . . -120.23 169.91 9.82 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.987 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 26.8 mtp -99.6 165.21 15.12 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.951 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -58.67 -45.51 29.14 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.575 2.183 . . . . 0.0 112.183 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 66.7 m -69.85 -37.5 76.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.656 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.65 HG21 ' HA ' ' A' ' 159' ' ' LEU . 64.8 t -64.05 -37.73 80.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.919 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.845 ' NE ' ' HB3' ' A' ' 131' ' ' ALA . 0.0 OUTLIER -64.21 -49.04 73.55 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.306 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 6.2 tttt -58.88 -32.9 69.91 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.747 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -58.42 -60.61 3.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.446 179.197 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.69 ' HB3' HG23 ' A' ' 146' ' ' ILE . . . -60.62 -29.52 69.29 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.665 -179.453 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 63.5 mtt180 -79.79 -27.39 40.39 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.271 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -86.6 -28.48 23.25 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.954 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -93.51 -23.58 18.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.097 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 99.53 10.78 46.49 Favored Glycine 0 CA--C 1.52 0.351 0 C-N-CA 120.596 -0.812 . . . . 0.0 112.56 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.705 ' CG2' HD21 ' A' ' 167' ' ' LEU . 48.5 t -89.95 158.67 2.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.757 0.313 . . . . 0.0 110.715 179.723 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.485 ' N ' HG12 ' A' ' 144' ' ' VAL . 62.8 t0 -104.28 104.05 13.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.035 0.445 . . . . 0.0 110.966 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.738 HD12 ' HD2' ' A' ' 136' ' ' ARG . 3.9 pt -47.36 -44.57 9.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.716 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . 0.489 ' HG2' HG21 ' A' ' 129' ' ' VAL . 7.2 mmt180 -50.0 -23.39 2.01 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.786 -0.643 . . . . 0.0 112.195 -179.484 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.516 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.7 OUTLIER -120.99 22.95 10.88 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -179.608 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.485 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 74.4 t -87.68 148.95 4.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.737 0.303 . . . . 0.0 110.497 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.91 79.32 2.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.904 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . 0.672 ' HA3' HG22 ' A' ' 158' ' ' VAL . . . -85.68 115.33 4.15 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.41 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 3.7 t -140.67 42.81 1.86 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.368 . . . . 0.0 111.041 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -114.05 101.27 1.1 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.494 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 12.9 tttm 55.69 102.62 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.864 0.364 . . . . 0.0 111.074 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 65.64 14.22 9.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.345 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 81.61 46.99 6.54 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.792 179.789 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.633 ' HG3' HG22 ' A' ' 130' ' ' ILE . 0.3 OUTLIER -96.92 130.97 44.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.781 0.324 . . . . 0.0 110.752 179.903 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.672 HG22 ' HA3' ' A' ' 151' ' ' GLY . 27.7 t -74.95 116.67 17.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.945 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.65 ' HA ' HG21 ' A' ' 135' ' ' VAL . 5.6 mt -114.24 174.11 6.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.155 -179.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.1 tttm -50.62 -44.39 57.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.734 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -60.43 -35.4 75.71 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.653 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 36.9 m-20 -66.33 -38.82 88.55 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.273 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' ILE . . . . . 0.747 HG21 ' CD1' ' A' ' 138' ' ' TYR . 5.0 mm -62.01 -50.16 81.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.256 179.054 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.6 -41.25 80.85 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.55 179.638 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.07 -41.25 96.29 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.67 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' PHE . . . . . 0.618 ' CE1' HG13 ' A' ' 144' ' ' VAL . 21.5 t80 -60.89 -48.07 83.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.477 179.618 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . 0.705 HD21 ' CG2' ' A' ' 144' ' ' VAL . 41.8 mt -74.61 -71.9 0.32 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.839 179.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -60.11 141.88 55.1 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.071 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 126.01 91.74 0.84 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.534 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 127.88 -33.67 3.17 Favored Glycine 0 C--O 1.249 1.047 0 CA-C-O 118.396 -1.224 . . . . 0.0 112.49 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.791 0 CA-C-N 118.386 1.093 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 . . . . . 0 N--CA 1.486 1.334 0 CA-C-O 120.851 0.358 . . . . 0.0 111.21 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.89 163.15 14.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.84 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.95 170.1 17.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.783 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.445 HG21 ' HG3' ' A' ' 147' ' ' ARG . 27.6 t -83.07 136.13 23.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.053 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.664 HG22 ' HG3' ' A' ' 157' ' ' ARG . 2.6 mt -83.42 64.43 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.064 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -116.72 -177.7 3.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.173 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . 0.44 ' HB2' HG23 ' A' ' 135' ' ' VAL . 10.6 mtp -120.94 161.86 38.12 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.888 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.2 -56.84 2.52 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.509 2.139 . . . . 0.0 112.413 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -59.49 -40.64 87.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.871 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.631 ' CG1' HD11 ' A' ' 163' ' ' ILE . 96.3 t -60.36 -34.42 57.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.917 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.567 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.9 OUTLIER -65.85 -52.35 51.09 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.474 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -56.39 -32.79 65.13 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.577 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.718 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -59.02 -61.56 2.55 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.358 179.14 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.856 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -63.15 -23.08 67.27 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.364 -179.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -82.74 -26.43 31.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.088 179.829 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -86.66 -26.72 24.18 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.05 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 2.9 mptt -98.05 -24.9 15.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.247 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 100.84 13.27 34.84 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.612 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.856 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 38.9 t -93.97 161.02 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.718 0.294 . . . . 0.0 110.774 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.79 ' HB3' HD11 ' A' ' 148' ' ' LEU . 47.9 t0 -116.06 104.62 11.75 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.89 0.376 . . . . 0.0 110.795 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.567 HD11 ' HD3' ' A' ' 136' ' ' ARG . 6.1 pt -44.55 -36.26 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.222 0.534 . . . . 0.0 111.805 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . 0.445 ' HG3' HG21 ' A' ' 129' ' ' VAL . 0.0 OUTLIER -47.64 -26.16 1.41 Allowed 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.251 -0.886 . . . . 0.0 112.644 -179.159 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.853 ' N ' HD13 ' A' ' 148' ' ' LEU . 0.0 OUTLIER -125.21 29.87 5.98 Favored 'General case' 0 C--N 1.332 -0.161 0 C-N-CA 121.007 -0.277 . . . . 0.0 111.612 -179.36 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.468 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 54.5 t -94.26 157.73 2.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.839 0.352 . . . . 0.0 110.593 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.433 ' N ' HG12 ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.91 75.1 2.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.906 -179.69 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -74.56 122.09 7.07 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.369 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -137.79 31.36 2.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.928 0.394 . . . . 0.0 110.861 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -92.27 106.05 3.36 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.622 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 5.0 tptp 67.16 -70.88 0.11 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.686 0.279 . . . . 0.0 111.204 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -131.73 36.69 3.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.821 0.343 . . . . 0.0 111.006 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 96.58 27.52 9.71 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.603 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.664 ' HG3' HG22 ' A' ' 130' ' ' ILE . 13.9 ttm180 -80.11 125.1 29.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.77 0.319 . . . . 0.0 110.833 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.431 ' O ' HG21 ' A' ' 135' ' ' VAL . 28.3 t -75.03 111.9 11.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.998 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.528 ' HA ' HG21 ' A' ' 135' ' ' VAL . 5.0 mt -110.89 175.93 5.23 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.07 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 6.9 tttt -49.07 -45.75 43.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.816 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 -60.68 -36.12 77.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.696 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 73.3 m-20 -65.54 -36.3 83.39 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.298 179.663 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' ILE . . . . . 0.718 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.5 mm -64.79 -51.32 68.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.302 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.49 -38.03 73.91 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.638 179.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -64.83 -41.95 95.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.81 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' PHE . . . . . 0.552 ' CE1' HG13 ' A' ' 144' ' ' VAL . 50.0 t80 -60.08 -48.88 79.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.622 179.76 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . 0.715 HD21 ' CG2' ' A' ' 144' ' ' VAL . 39.6 mt -74.98 -31.54 61.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.928 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -91.32 102.62 15.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.03 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 93.82 -46.27 2.3 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.544 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 129.45 138.19 4.39 Favored Glycine 0 C--O 1.249 1.073 0 CA-C-O 118.379 -1.234 . . . . 0.0 112.554 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.785 0 CA-C-N 118.446 1.123 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 8.2 m120 . . . . . 0 N--CA 1.486 1.362 0 CA-C-O 120.806 0.336 . . . . 0.0 111.154 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 5.5 mtt180 -66.24 159.53 26.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.904 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -114.06 114.89 26.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.807 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.404 HG12 ' N ' ' A' ' 130' ' ' ILE . 19.5 t -139.67 154.18 24.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.241 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.661 HG22 ' CG ' ' A' ' 157' ' ' ARG . 20.3 mt -93.37 67.17 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.863 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -129.8 -173.16 2.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.335 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . 0.489 ' SD ' HD23 ' A' ' 159' ' ' LEU . 0.0 OUTLIER -112.88 157.2 41.25 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.766 -179.991 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.91 -33.14 50.39 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.632 2.221 . . . . 0.0 112.099 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 9.4 p -76.99 -43.31 35.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.619 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.627 HG21 ' HA ' ' A' ' 159' ' ' LEU . 73.0 t -58.5 -34.97 52.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.856 179.813 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.466 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.2 OUTLIER -64.71 -49.78 69.54 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 179.206 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -57.58 -31.09 65.81 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 178.556 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.688 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -61.25 -62.36 1.89 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.369 179.032 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.833 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -59.92 -29.2 68.21 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.413 -179.578 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? -80.11 -26.29 39.58 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.212 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -86.59 -29.48 22.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.995 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 4.9 mptt -95.07 -22.19 18.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.256 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 97.16 12.82 47.83 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.609 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.833 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 54.0 t -94.3 159.32 2.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.706 0.288 . . . . 0.0 110.783 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.495 ' N ' HG12 ' A' ' 144' ' ' VAL . 67.0 t0 -110.06 111.48 22.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.868 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.466 HD11 ' HD3' ' A' ' 136' ' ' ARG . 7.9 pt -53.36 -39.95 37.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.402 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 1.2 mmm180 -49.23 -25.26 2.18 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.792 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.552 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.3 OUTLIER -119.67 27.17 8.89 Favored 'General case' 0 C--N 1.332 -0.186 0 N-CA-C 111.659 0.244 . . . . 0.0 111.659 -179.827 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.447 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 40.5 t -95.04 150.3 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.867 0.365 . . . . 0.0 110.587 179.364 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -74.86 77.49 2.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.922 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -73.03 125.04 9.43 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.471 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . 0.706 HG22 ' OD1' ' A' ' 162' ' ' ASP . 6.3 t -135.52 28.36 3.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.766 0.317 . . . . 0.0 110.905 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . 0.541 ' HA3' HD11 ' A' ' 159' ' ' LEU . . . -84.04 97.27 2.05 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.507 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 42.72 -90.55 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 122.451 0.301 . . . . 0.0 111.765 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.431 ' N ' ' O ' ' A' ' 153' ' ' GLY . 4.0 t-20 -89.14 51.16 2.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.993 0.425 . . . . 0.0 111.083 -179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 58.96 56.48 25.09 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.465 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.661 ' CG ' HG22 ' A' ' 130' ' ' ILE . 0.0 OUTLIER -111.57 125.96 54.48 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.797 0.332 . . . . 0.0 110.98 179.971 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.53 ' O ' HG21 ' A' ' 135' ' ' VAL . 21.9 t -80.02 109.41 14.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.759 179.789 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.627 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.0 OUTLIER -107.06 178.54 4.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.097 0.475 . . . . 0.0 111.371 -179.648 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . 0.457 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 2.8 tptt -50.59 -43.26 56.5 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.852 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -62.97 -34.62 77.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.794 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . 0.706 ' OD1' HG22 ' A' ' 152' ' ' THR . 26.8 m-20 -65.24 -42.69 93.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.407 179.687 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' ILE . . . . . 0.688 HG21 ' CD1' ' A' ' 138' ' ' TYR . 2.5 mm -62.15 -48.01 90.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.15 179.182 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.74 -37.42 73.56 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.472 179.44 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -64.77 -42.23 95.26 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.536 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' PHE . . . . . 0.552 ' CE2' HD12 ' A' ' 148' ' ' LEU . 28.2 t80 -62.3 -38.4 89.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.509 179.617 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . 0.709 HD21 ' CG2' ' A' ' 144' ' ' VAL . 26.0 mt -90.44 -77.8 0.39 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.976 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -73.33 -80.71 0.07 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.192 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 169.62 -32.02 0.16 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.571 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 136.95 -24.97 3.09 Favored Glycine 0 C--O 1.249 1.053 0 CA-C-O 118.396 -1.224 . . . . 0.0 112.475 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.25 -3.758 0 CA-C-N 118.377 1.089 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 5.5 m-80 . . . . . 0 N--CA 1.486 1.369 0 CA-C-O 120.869 0.366 . . . . 0.0 111.24 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -139.94 140.23 36.31 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.91 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 9.6 mtt180 -87.56 149.2 24.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.861 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.467 HG21 ' HG2' ' A' ' 147' ' ' ARG . 21.4 t -82.52 151.64 4.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.171 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.679 HG22 ' HG3' ' A' ' 157' ' ' ARG . 3.3 mp -98.82 66.09 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.858 179.804 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -122.61 164.26 18.52 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.079 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . 0.414 ' CB ' ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -99.56 166.68 12.44 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.862 179.948 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . 0.414 ' HD2' ' CB ' ' A' ' 132' ' ' MET . 20.8 Cg_endo -60.91 -26.49 83.22 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.512 2.141 . . . . 0.0 112.282 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -81.47 -44.85 16.84 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.752 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.543 HG21 ' HA ' ' A' ' 159' ' ' LEU . 85.5 t -59.92 -31.49 47.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.862 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -67.28 -52.94 34.59 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 8.7 ttpt -56.37 -31.07 63.45 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 178.536 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.736 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -60.86 -62.57 1.76 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.413 179.103 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.857 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -61.78 -24.1 66.62 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.334 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 20.2 mmm-85 -80.52 -32.51 36.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.903 0.383 . . . . 0.0 110.822 179.707 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -83.72 -29.28 27.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.662 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . 0.666 ' HE3' HD13 ' A' ' 167' ' ' LEU . 11.5 mmtt -89.66 -25.74 21.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.05 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 96.33 13.58 47.95 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.439 -179.535 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.857 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 92.8 t -97.84 159.71 3.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.76 0.314 . . . . 0.0 110.783 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.498 ' N ' HG12 ' A' ' 144' ' ' VAL . 68.4 t0 -108.75 111.96 24.0 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.785 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.46 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 8.6 pt -53.6 -40.06 40.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.039 0.447 . . . . 0.0 111.32 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . 0.467 ' HG2' HG21 ' A' ' 129' ' ' VAL . 91.4 mtt-85 -49.34 -25.67 2.61 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.765 -179.777 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.434 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.1 OUTLIER -118.81 27.32 8.96 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 111.721 0.267 . . . . 0.0 111.721 -179.878 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.46 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 38.8 t -94.0 154.5 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.851 0.358 . . . . 0.0 110.552 179.373 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.93 75.6 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.952 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -70.0 114.9 5.81 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.426 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -102.66 -21.01 14.19 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.699 0.285 . . . . 0.0 111.167 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -55.15 172.13 1.22 Allowed Glycine 0 C--N 1.332 0.33 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.629 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 16.0 tttp -52.91 134.72 37.31 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.798 0.332 . . . . 0.0 111.141 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.9 m-20 59.35 34.75 22.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.732 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 63.99 45.15 94.72 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.304 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.679 ' HG3' HG22 ' A' ' 130' ' ' ILE . 10.9 ttm-85 -82.95 128.14 34.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.86 0.362 . . . . 0.0 110.976 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.441 HG13 ' CG1' ' A' ' 149' ' ' VAL . 30.8 t -87.87 117.98 32.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.921 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.543 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.1 mt -113.19 177.42 4.64 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.072 0.463 . . . . 0.0 111.225 -179.719 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . 0.452 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 1.8 tttt -50.68 -44.44 57.77 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.855 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 68.0 mm-40 -61.98 -34.11 75.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.695 179.795 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -67.11 -38.91 86.46 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.407 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' ILE . . . . . 0.736 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.4 mm -64.08 -48.93 83.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.294 179.263 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -58.37 -41.06 83.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.656 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.1 -41.71 99.43 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.921 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' PHE . . . . . 0.547 ' CE1' HG13 ' A' ' 144' ' ' VAL . 32.8 t80 -60.3 -50.45 73.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.827 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . 0.691 HD21 ' CG2' ' A' ' 144' ' ' VAL . 50.8 mt -73.45 -33.8 65.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.861 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -102.15 86.35 2.84 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.088 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -96.3 28.05 14.61 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.488 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 176.33 98.49 0.11 Allowed Glycine 0 C--O 1.248 1.028 0 CA-C-O 118.347 -1.252 . . . . 0.0 112.497 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.815 0 CA-C-N 118.342 1.071 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 62.3 t30 . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 120.751 0.31 . . . . 0.0 111.219 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.31 175.68 9.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.862 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -94.88 -178.47 4.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.483 HG12 ' N ' ' A' ' 130' ' ' ILE . 21.5 t -98.55 159.51 3.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.04 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.483 ' N ' HG12 ' A' ' 129' ' ' VAL . 28.2 mm -79.9 68.87 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.791 179.81 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -141.6 142.67 33.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.123 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -69.95 162.75 66.44 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.86 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_endo -57.28 -24.45 59.78 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.627 2.218 . . . . 0.0 112.144 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.3 m -76.76 -44.86 31.34 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.89 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.572 HG21 ' HA ' ' A' ' 159' ' ' LEU . 93.0 t -59.8 -34.95 57.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.79 -51.38 56.39 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.325 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.403 ' HG3' ' HG3' ' A' ' 141' ' ' GLU . 2.5 tttt -56.75 -29.96 63.1 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 178.564 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.722 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -63.39 -62.74 1.48 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.496 179.301 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.861 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -63.11 -24.56 67.96 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.372 -179.648 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.63 -27.17 29.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.739 0.304 . . . . 0.0 110.957 179.746 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.403 ' HG3' ' HG3' ' A' ' 137' ' ' LYS . 8.2 mm-40 -85.82 -28.04 24.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.019 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 1.6 mmtm -97.66 -25.37 15.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.254 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 101.2 14.09 31.69 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.717 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.861 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 42.9 t -93.2 159.43 2.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.733 0.301 . . . . 0.0 110.826 179.731 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.499 ' N ' HG12 ' A' ' 144' ' ' VAL . 67.1 t0 -110.45 107.59 17.32 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.705 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.459 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 9.7 pt -52.05 -40.19 28.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 121.048 0.451 . . . . 0.0 111.217 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 92.0 mtt-85 -48.9 -26.33 2.41 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.931 -179.749 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.447 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.1 OUTLIER -119.24 26.93 9.13 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.663 0.268 . . . . 0.0 111.668 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.459 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 40.5 t -93.97 157.63 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.782 0.325 . . . . 0.0 110.518 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.431 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.95 76.21 2.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.967 -179.767 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -72.52 109.15 2.71 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.421 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -97.65 -18.99 18.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.607 0.241 . . . . 0.0 111.207 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -56.36 168.13 3.48 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.508 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.13 136.95 41.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.925 0.393 . . . . 0.0 111.144 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 59.33 33.63 22.56 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.817 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 66.15 42.03 94.62 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.404 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 49.9 ttp180 -82.25 121.63 26.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.853 0.359 . . . . 0.0 110.878 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.425 ' O ' HG21 ' A' ' 135' ' ' VAL . 21.5 t -85.38 122.94 38.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.999 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.572 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.2 mp -116.05 176.93 4.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.058 0.456 . . . . 0.0 111.183 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . 0.439 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 3.4 tttt -50.32 -46.48 55.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.787 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -59.69 -34.27 72.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.705 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 72.1 m-20 -67.69 -37.62 82.56 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.395 179.672 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' ILE . . . . . 0.722 HG21 ' CD1' ' A' ' 138' ' ' TYR . 4.9 mm -64.02 -49.01 83.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.339 179.271 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -58.8 -42.21 88.57 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.624 179.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.57 -40.83 96.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.81 179.8 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' PHE . . . . . 0.583 ' CE1' HG13 ' A' ' 144' ' ' VAL . 46.7 t80 -60.55 -51.31 69.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.65 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . 0.738 HD21 ' CG2' ' A' ' 144' ' ' VAL . 29.4 mt -70.44 -30.95 67.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.896 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -75.14 176.61 7.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.08 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -81.39 -30.64 36.31 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.5 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 79.79 66.59 1.65 Allowed Glycine 0 C--O 1.248 1.03 0 CA-C-O 118.472 -1.182 . . . . 0.0 112.477 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.768 0 CA-C-N 118.309 1.054 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 38.2 t30 . . . . . 0 N--CA 1.486 1.344 0 CA-C-O 120.86 0.362 . . . . 0.0 111.205 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 18.2 ttm-85 -114.73 156.38 24.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.912 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -117.38 172.43 7.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.845 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.552 HG21 ' HG3' ' A' ' 147' ' ' ARG . 21.4 t -132.42 145.45 34.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.173 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.576 HG22 ' HG3' ' A' ' 157' ' ' ARG . 2.6 mp -83.75 65.86 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.997 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -132.74 142.24 48.94 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.199 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . 0.406 ' HE2' ' HD3' ' A' ' 157' ' ' ARG . 2.6 mtm -71.98 166.22 42.66 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.816 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . 0.4 ' HD2' ' CB ' ' A' ' 132' ' ' MET . 22.8 Cg_endo -61.24 -32.64 90.59 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.513 2.142 . . . . 0.0 112.219 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -69.93 -45.54 67.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.782 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.654 ' CG1' HD11 ' A' ' 163' ' ' ILE . 84.7 t -60.16 -33.06 52.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.99 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.436 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.5 OUTLIER -65.9 -50.72 63.46 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.21 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.4 tttt -57.71 -31.71 66.67 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.551 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.716 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -60.27 -61.6 2.48 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.402 179.109 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.851 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -63.78 -21.67 66.54 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.299 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.79 -27.61 28.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.042 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -85.94 -25.81 25.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.059 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . 0.493 ' HG2' HD13 ' A' ' 167' ' ' LEU . 2.1 tptt -98.61 -26.72 14.3 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.247 -179.822 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 103.07 13.11 29.91 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.596 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.851 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 35.0 t -93.27 160.59 2.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.794 0.33 . . . . 0.0 110.831 179.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.802 ' HB3' HD11 ' A' ' 148' ' ' LEU . 51.9 t0 -115.22 105.66 13.15 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.952 0.406 . . . . 0.0 110.755 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.479 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 4.0 pt -45.13 -36.3 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.3 0.571 . . . . 0.0 111.867 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . 0.552 ' HG3' HG21 ' A' ' 129' ' ' VAL . 0.0 OUTLIER -48.24 -25.32 1.48 Allowed 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.332 -0.849 . . . . 0.0 112.643 -179.157 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.845 ' N ' HD13 ' A' ' 148' ' ' LEU . 0.0 OUTLIER -126.82 31.07 5.37 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 111.817 0.303 . . . . 0.0 111.817 -179.33 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.479 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 54.1 t -92.88 157.45 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.821 0.344 . . . . 0.0 110.65 179.372 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.426 ' N ' HG12 ' A' ' 149' ' ' VAL . 0.0 OUTLIER -74.84 69.77 1.87 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.999 -179.645 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -68.79 115.83 6.88 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.403 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -116.79 13.81 15.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.617 0.246 . . . . 0.0 111.325 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -83.06 175.2 52.93 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.298 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.27 117.9 2.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.789 0.328 . . . . 0.0 111.147 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 3.5 m120 62.49 52.72 2.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.938 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 56.66 48.55 76.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.536 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.576 ' HG3' HG22 ' A' ' 130' ' ' ILE . 5.9 ttm180 -90.6 114.94 27.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.781 0.325 . . . . 0.0 110.982 -179.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.464 ' O ' HG21 ' A' ' 135' ' ' VAL . 31.7 t -81.29 118.19 28.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.776 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.601 ' HA ' HG21 ' A' ' 135' ' ' VAL . 0.9 OUTLIER -115.13 176.67 4.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.027 0.442 . . . . 0.0 111.263 -179.69 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 14.3 tttm -49.84 -45.72 50.61 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.818 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 -60.03 -35.46 75.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.653 179.742 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -66.23 -37.94 86.73 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.368 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' ILE . . . . . 0.716 HG21 ' CD1' ' A' ' 138' ' ' TYR . 5.4 mm -63.14 -49.16 84.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.909 179.084 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' ASP . . . . . 0.504 ' O ' ' HB3' ' A' ' 168' ' ' ALA . 4.4 m-20 -59.42 -36.49 75.97 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.508 179.459 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.6 -39.84 92.0 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.775 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' PHE . . . . . 0.536 ' CE1' HG13 ' A' ' 144' ' ' VAL . 57.7 t80 -62.98 -47.27 83.88 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.536 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . 0.795 HD21 ' CG2' ' A' ' 144' ' ' VAL . 5.8 mt -82.33 -69.79 0.6 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.911 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . 0.504 ' HB3' ' O ' ' A' ' 164' ' ' ASP . . . -58.12 -74.39 0.06 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.256 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 119.33 86.51 1.03 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.54 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 166.49 -41.03 0.26 Allowed Glycine 0 C--O 1.249 1.072 0 CA-C-O 118.407 -1.219 . . . . 0.0 112.521 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.818 0 CA-C-N 118.382 1.091 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 120.802 0.334 . . . . 0.0 111.188 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 5.8 ttm180 -118.26 108.4 15.08 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.874 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.16 174.18 5.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.911 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.502 HG21 ' HG3' ' A' ' 147' ' ' ARG . 33.9 t -114.9 158.56 15.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.019 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.734 HG22 ' HG2' ' A' ' 157' ' ' ARG . 3.5 mp -80.01 64.27 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.996 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -135.76 176.53 8.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.101 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 77.6 mtp -100.8 162.04 21.93 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.953 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.42 -40.48 71.18 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.549 2.166 . . . . 0.0 112.254 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.22 -43.74 70.03 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.912 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.621 HG21 ' HA ' ' A' ' 159' ' ' LEU . 67.4 t -58.98 -36.48 62.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.942 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.453 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.2 OUTLIER -66.14 -51.92 53.3 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 179.469 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 13.9 ttpt -56.72 -32.64 65.73 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 178.691 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.734 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.9 OUTLIER -59.73 -61.82 2.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.458 179.205 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.745 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -63.45 -23.31 67.34 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.297 -179.772 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -82.04 -28.22 32.58 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.951 179.78 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -86.35 -28.57 23.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.847 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 4.1 mptt -93.96 -24.58 17.61 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.04 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 98.07 13.94 41.03 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.6 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.749 HG21 HD11 ' A' ' 167' ' ' LEU . 45.6 t -92.74 159.11 2.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.799 0.333 . . . . 0.0 110.828 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.488 ' N ' HG12 ' A' ' 144' ' ' VAL . 68.2 t0 -109.3 105.42 14.82 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.839 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.489 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 7.3 pt -49.33 -39.92 13.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.13 0.49 . . . . 0.0 111.389 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . 0.502 ' HG3' HG21 ' A' ' 129' ' ' VAL . 8.4 mtt-85 -49.4 -24.73 2.09 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.746 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.463 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.6 OUTLIER -120.32 27.99 8.28 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.586 0.231 . . . . 0.0 111.596 -179.846 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.545 ' CG1' HG13 ' A' ' 158' ' ' VAL . 43.4 t -95.31 155.56 3.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.934 0.397 . . . . 0.0 110.792 179.594 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.407 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 8.6 tt0 -74.99 77.61 2.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.096 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.65 111.75 3.79 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.455 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -87.38 -27.09 23.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.763 0.316 . . . . 0.0 111.042 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -57.73 173.19 2.72 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.556 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 3.9 tttp -57.78 140.06 52.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.839 0.352 . . . . 0.0 110.944 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 59.83 30.93 20.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.831 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 69.87 42.34 69.98 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.482 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.734 ' HG2' HG22 ' A' ' 130' ' ' ILE . 0.0 OUTLIER -70.45 127.23 32.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.772 0.32 . . . . 0.0 110.844 -179.993 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.545 HG13 ' CG1' ' A' ' 149' ' ' VAL . 25.9 t -94.41 117.2 37.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.19 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.621 ' HA ' HG21 ' A' ' 135' ' ' VAL . 3.8 mp -112.96 175.91 5.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.911 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . 0.441 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 0.4 OUTLIER -50.91 -45.52 60.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.642 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 4.2 mm-40 -60.36 -34.25 73.6 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.603 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -67.64 -37.6 82.68 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.436 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' ILE . . . . . 0.734 HG21 ' CD1' ' A' ' 138' ' ' TYR . 5.4 mm -64.01 -47.93 88.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.169 179.164 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -58.76 -42.38 88.79 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.577 179.409 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -61.01 -40.94 95.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.653 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' PHE . . . . . 0.58 ' CE1' HG13 ' A' ' 144' ' ' VAL . 20.5 t80 -63.51 -38.94 93.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.513 179.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . 0.749 HD11 HG21 ' A' ' 144' ' ' VAL . 12.7 mt -96.33 -83.18 0.38 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.77 179.861 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . 50.45 -177.64 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.377 179.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -169.2 -61.62 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.452 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 85.74 12.5 71.84 Favored Glycine 0 C--O 1.249 1.077 0 CA-C-O 118.338 -1.257 . . . . 0.0 112.469 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.832 0 CA-C-N 118.387 1.094 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 34.4 m120 . . . . . 0 N--CA 1.487 1.385 0 CA-C-O 120.772 0.32 . . . . 0.0 111.205 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.87 149.3 40.74 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.797 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 11.8 ttt180 -58.64 168.54 1.16 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.014 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.452 HG21 ' HG3' ' A' ' 147' ' ' ARG . 21.2 t -77.42 139.98 17.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.066 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.775 HG22 ' HG3' ' A' ' 157' ' ' ARG . 6.4 mt -80.11 68.22 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.987 0.423 . . . . 0.0 110.974 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -130.19 171.31 13.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.196 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . 0.549 ' HB2' HG23 ' A' ' 135' ' ' VAL . 3.3 mtp -91.47 160.37 36.97 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.851 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.65 -23.49 76.05 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.591 2.194 . . . . 0.0 112.242 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.2 m -90.65 -41.48 11.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.898 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.772 HG21 ' HA ' ' A' ' 159' ' ' LEU . 59.5 t -59.91 -39.7 80.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.033 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.75 ' HD3' HD12 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -62.48 -43.44 98.8 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.63 -0.508 . . . . 0.0 109.63 179.364 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.3 -33.32 74.43 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 178.331 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.758 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.9 OUTLIER -57.7 -60.87 3.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.375 179.052 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.711 ' HB3' HG23 ' A' ' 146' ' ' ILE . . . -61.29 -29.61 69.97 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.377 -179.649 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 11.3 mmm180 -79.19 -23.03 44.13 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.339 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -89.67 -26.57 20.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.802 0.334 . . . . 0.0 111.032 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -96.06 -22.31 17.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.288 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.46 7.09 46.44 Favored Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.573 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.797 ' CG2' HD21 ' A' ' 167' ' ' LEU . 59.2 t -89.44 155.24 3.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 120.722 0.296 . . . . 0.0 110.67 179.65 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.489 ' HB3' HD11 ' A' ' 148' ' ' LEU . 66.5 t0 -102.34 109.19 20.77 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.14 0.495 . . . . 0.0 110.89 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.75 HD12 ' HD3' ' A' ' 136' ' ' ARG . 5.4 pt -51.07 -43.78 27.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.63 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . 0.452 ' HG3' HG21 ' A' ' 129' ' ' VAL . 11.6 mtt180 -49.72 -24.62 2.4 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.941 -0.572 . . . . 0.0 112.11 -179.437 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.489 HD11 ' HB3' ' A' ' 145' ' ' ASP . 0.1 OUTLIER -119.2 23.97 11.01 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 112.111 0.412 . . . . 0.0 112.111 -179.645 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.539 ' CG1' HG13 ' A' ' 158' ' ' VAL . 48.9 t -86.64 156.18 3.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.733 0.301 . . . . 0.0 110.555 179.209 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.405 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 4.2 tt0 -74.79 74.24 2.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.067 -179.73 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -72.07 107.38 2.17 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.403 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -129.06 27.8 5.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.871 0.367 . . . . 0.0 110.988 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . 0.406 ' HA3' ' CD1' ' A' ' 159' ' ' LEU . . . -106.09 107.03 2.68 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.426 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 14.5 tptm 56.17 97.94 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.756 0.313 . . . . 0.0 110.809 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 70.16 -66.15 0.29 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.784 -179.767 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 178.54 58.71 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.429 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.775 ' HG3' HG22 ' A' ' 130' ' ' ILE . 43.2 ttm-85 -108.98 138.87 44.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.861 0.363 . . . . 0.0 110.894 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.539 HG13 ' CG1' ' A' ' 149' ' ' VAL . 21.9 t -82.76 114.39 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.083 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.772 ' HA ' HG21 ' A' ' 135' ' ' VAL . 14.5 mt -112.37 175.12 5.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.05 -179.803 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . 0.44 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 1.0 OUTLIER -50.77 -44.98 58.77 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.673 179.903 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -61.11 -34.41 74.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.637 179.587 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -66.82 -37.22 84.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.457 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' ILE . . . . . 0.758 HG21 ' CD1' ' A' ' 138' ' ' TYR . 8.2 mm -65.11 -49.23 80.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.186 179.167 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -58.82 -38.42 78.6 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.572 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.49 -41.08 93.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.836 179.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' PHE . . . . . 0.593 ' CE1' HG13 ' A' ' 144' ' ' VAL . 24.6 t80 -61.1 -45.69 93.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.591 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . 0.797 HD21 ' CG2' ' A' ' 144' ' ' VAL . 16.4 mt -78.68 -65.56 0.97 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.805 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -85.51 131.82 34.3 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.038 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -93.06 -103.64 1.6 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.539 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -177.99 128.16 1.26 Allowed Glycine 0 C--O 1.249 1.091 0 CA-C-O 118.389 -1.228 . . . . 0.0 112.493 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.77 0 CA-C-N 118.369 1.084 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 . . . . . 0 N--CA 1.487 1.417 0 CA-C-O 120.737 0.303 . . . . 0.0 111.253 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.9 mtt85 -141.8 153.36 44.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.841 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -64.7 -177.35 0.32 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.846 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.3 t -124.88 149.16 29.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.169 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.604 HG22 ' HG3' ' A' ' 157' ' ' ARG . 28.4 mt -87.41 68.93 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.048 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -133.5 -177.11 4.39 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.123 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.42 166.06 11.75 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.864 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -52.89 -37.62 77.73 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.505 2.137 . . . . 0.0 112.381 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.66 -48.25 55.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.88 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.593 ' CG1' HD11 ' A' ' 163' ' ' ILE . 73.9 t -58.06 -33.06 45.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.848 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.12 -52.88 36.29 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 179.341 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 3.8 tttp -55.96 -30.3 61.53 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 178.634 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.725 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -62.86 -62.78 1.49 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.442 179.295 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.834 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -63.71 -23.91 67.56 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.243 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 3.8 tpt180 -82.97 -25.92 31.81 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.943 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -87.55 -26.59 23.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.945 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -97.52 -25.18 15.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.188 -179.779 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 100.85 13.27 34.82 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.674 -0.775 . . . . 0.0 112.584 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.834 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 44.3 t -94.55 160.03 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.788 0.327 . . . . 0.0 110.743 179.716 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.509 ' N ' HG12 ' A' ' 144' ' ' VAL . 42.9 t0 -111.17 109.6 19.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.733 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.461 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 9.7 pt -52.03 -39.84 27.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.389 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . 0.538 ' HG2' HD23 ' A' ' 148' ' ' LEU . 2.2 ptt180 -48.99 -25.92 2.24 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.794 -179.731 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.538 HD23 ' HG2' ' A' ' 147' ' ' ARG . 0.2 OUTLIER -119.43 26.96 9.07 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 111.645 0.239 . . . . 0.0 111.645 -179.809 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.461 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 43.6 t -95.05 157.53 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.837 0.351 . . . . 0.0 110.586 179.305 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.425 ' N ' ' CG1' ' A' ' 149' ' ' VAL . 2.1 tt0 -74.74 77.55 2.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.067 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -72.91 106.11 1.89 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.447 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -93.03 -17.52 23.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.605 0.24 . . . . 0.0 111.24 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -53.25 161.84 2.94 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.649 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.2 138.19 26.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.795 0.331 . . . . 0.0 111.168 -179.897 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 61.68 31.64 18.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.802 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 61.57 68.22 1.76 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.482 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.604 ' HG3' HG22 ' A' ' 130' ' ' ILE . 34.7 ttm180 -112.04 133.7 54.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.813 0.339 . . . . 0.0 110.987 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.446 HG13 ' CG1' ' A' ' 149' ' ' VAL . 21.9 t -85.3 124.18 39.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.949 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.556 ' HA ' HG21 ' A' ' 135' ' ' VAL . 2.1 mt -121.85 172.46 8.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.219 -179.81 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . 0.442 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 4.9 tttm -47.8 -50.41 25.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.053 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -57.18 -35.38 69.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.781 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -67.56 -34.75 77.69 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.38 179.678 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' ILE . . . . . 0.725 HG21 ' CD1' ' A' ' 138' ' ' TYR . 5.7 mm -64.98 -50.65 73.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.068 179.106 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -59.57 -37.72 79.23 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.571 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -65.9 -40.5 91.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.712 179.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' PHE . . . . . 0.552 ' CE1' HG13 ' A' ' 144' ' ' VAL . 37.2 t80 -60.91 -48.32 82.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.567 179.675 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . 0.777 HD21 ' CG2' ' A' ' 144' ' ' VAL . 16.5 mt -75.06 -30.5 61.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.955 179.813 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -106.4 103.44 12.9 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.038 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -176.98 41.54 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.516 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -106.32 -159.45 22.16 Favored Glycine 0 C--O 1.249 1.04 0 CA-C-O 118.348 -1.251 . . . . 0.0 112.447 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.25 -3.745 0 CA-C-N 118.402 1.101 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 . . . . . 0 N--CA 1.487 1.396 0 CA-C-O 120.711 0.291 . . . . 0.0 111.272 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.45 149.85 50.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.982 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -115.41 -175.46 2.71 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.832 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.642 HG22 ' HG2' ' A' ' 147' ' ' ARG . 21.5 t -127.21 137.0 59.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.17 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.559 HG22 ' HG2' ' A' ' 157' ' ' ARG . 32.2 mt -87.29 60.05 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.082 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.912 ' HB3' ' HD3' ' A' ' 136' ' ' ARG . . . -120.47 163.44 17.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.016 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . 0.564 ' HB2' HG23 ' A' ' 135' ' ' VAL . 24.5 mmm -88.79 161.19 42.27 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.93 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -52.22 -28.18 32.96 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.587 2.191 . . . . 0.0 112.257 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 58.2 m -87.31 -38.6 16.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.906 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.619 HG21 ' HA ' ' A' ' 159' ' ' LEU . 61.4 t -62.68 -40.48 88.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.022 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.912 ' HD3' ' HB3' ' A' ' 131' ' ' ALA . 25.1 mmm-85 -65.52 -47.74 74.9 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.35 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 2.0 tttm -60.72 -29.81 69.58 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.755 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -60.95 -60.66 3.43 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.481 179.213 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.767 ' HB3' HG23 ' A' ' 146' ' ' ILE . . . -62.69 -27.76 69.47 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.78 -0.645 . . . . 0.0 111.516 -179.544 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.4 -21.18 33.08 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.301 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -91.95 -22.22 20.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.069 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 1.1 mmtt -103.22 -24.47 13.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.346 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.58 9.6 32.82 Favored Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.875 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.798 ' CG2' HD21 ' A' ' 167' ' ' LEU . 46.3 t -89.24 155.06 3.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.748 0.309 . . . . 0.0 110.59 179.545 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.445 ' HB3' ' CG ' ' A' ' 148' ' ' LEU . 61.4 t0 -100.79 104.97 16.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.11 0.481 . . . . 0.0 111.023 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.767 HG23 ' HB3' ' A' ' 139' ' ' ALA . 3.1 pt -47.44 -45.51 9.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.73 179.564 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . 0.642 ' HG2' HG22 ' A' ' 129' ' ' VAL . 0.0 OUTLIER -50.67 -22.09 1.9 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.332 -179.266 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.512 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.9 OUTLIER -121.44 22.27 10.77 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 112.053 0.39 . . . . 0.0 112.053 -179.592 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.468 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 76.0 t -85.96 152.49 3.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.864 0.364 . . . . 0.0 110.574 179.251 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.94 78.98 2.16 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.919 -179.776 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -80.92 106.85 2.6 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.42 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -112.12 31.14 6.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.925 0.393 . . . . 0.0 110.879 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . 0.426 ' O ' ' N ' ' A' ' 155' ' ' ASN . . . -86.59 95.48 2.05 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.519 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . 0.421 ' N ' ' CD ' ' A' ' 154' ' ' LYS . 0.0 OUTLIER 38.97 -90.9 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 122.606 0.362 . . . . 0.0 111.861 179.92 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.426 ' N ' ' O ' ' A' ' 153' ' ' GLY . 3.2 m-20 -87.49 54.67 3.22 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.887 0.375 . . . . 0.0 111.028 -179.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 57.63 52.46 51.82 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.508 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.559 ' HG2' HG22 ' A' ' 130' ' ' ILE . 0.0 OUTLIER -106.75 121.46 44.41 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.804 0.335 . . . . 0.0 110.892 -179.98 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.605 HG12 HG11 ' A' ' 135' ' ' VAL . 22.6 t -74.96 129.09 37.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.977 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.619 ' HA ' HG21 ' A' ' 135' ' ' VAL . 2.3 mt -122.96 170.93 9.63 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.122 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 29.6 tttm -50.61 -44.75 57.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.622 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -60.31 -35.37 75.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.501 179.704 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -66.26 -38.28 87.45 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.328 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' ILE . . . . . 0.755 HG21 ' CD1' ' A' ' 138' ' ' TYR . 6.1 mm -63.22 -49.78 81.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.248 179.351 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -58.08 -41.04 82.58 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.621 179.719 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.13 -40.72 98.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.764 179.704 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' PHE . . . . . 0.63 ' CE1' HG13 ' A' ' 144' ' ' VAL . 17.9 t80 -60.82 -45.57 93.95 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.486 179.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . 0.798 HD21 ' CG2' ' A' ' 144' ' ' VAL . 21.1 mt -75.69 -31.85 59.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.849 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -91.42 -177.68 4.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.042 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 88.33 29.37 19.77 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.517 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -161.81 88.35 0.11 Allowed Glycine 0 C--O 1.25 1.126 0 CA-C-O 118.399 -1.223 . . . . 0.0 112.513 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.837 0 CA-C-N 118.42 1.11 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 . . . . . 0 N--CA 1.486 1.332 0 CA-C-O 120.78 0.324 . . . . 0.0 111.226 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -119.43 63.12 0.8 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.857 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 1.6 mtm-85 -134.43 -178.58 5.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.888 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.528 HG21 ' CG ' ' A' ' 147' ' ' ARG . 17.0 t -124.51 151.73 30.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.177 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.763 HG22 ' HG2' ' A' ' 157' ' ' ARG . 3.0 mp -81.6 70.73 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.847 179.819 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -124.85 158.05 34.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.246 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . 0.589 ' HB2' HG23 ' A' ' 135' ' ' VAL . 1.3 mmt -85.97 161.35 50.16 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.822 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_endo -61.15 -30.81 89.53 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.575 2.183 . . . . 0.0 112.221 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -82.1 -37.39 26.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.736 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.643 ' CG1' HD11 ' A' ' 163' ' ' ILE . 62.6 t -61.7 -34.63 63.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.41 ' HD3' HD13 ' A' ' 146' ' ' ILE . 0.4 OUTLIER -65.91 -52.85 46.45 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.439 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.14 -34.34 63.67 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 178.671 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.719 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.9 OUTLIER -59.08 -61.79 2.37 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.442 179.21 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.853 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -62.01 -23.88 66.7 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.517 -179.747 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 3.2 mmm-85 -82.6 -28.81 30.61 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.717 0.294 . . . . 0.0 111.116 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -84.22 -27.69 27.81 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.123 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 2.1 mptp? -96.06 -26.9 15.34 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.124 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.09 13.34 31.63 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.619 -179.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.853 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 47.7 t -94.91 159.88 2.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-O 120.689 0.28 . . . . 0.0 110.738 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.507 ' N ' HG12 ' A' ' 144' ' ' VAL . 66.9 t0 -111.99 111.17 21.91 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.811 179.817 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.448 ' HA ' ' CG2' ' A' ' 149' ' ' VAL . 7.8 pt -52.16 -39.77 28.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.457 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . 0.528 ' CG ' HG21 ' A' ' 129' ' ' VAL . 0.1 OUTLIER -48.94 -25.75 2.12 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.754 -179.762 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.44 ' HG ' ' O ' ' A' ' 145' ' ' ASP . 0.2 OUTLIER -119.65 28.12 8.34 Favored 'General case' 0 N--CA 1.462 0.138 0 N-CA-C 111.679 0.251 . . . . 0.0 111.679 -179.832 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.448 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 55.6 t -98.25 155.64 3.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.79 0.329 . . . . 0.0 110.659 179.269 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.94 79.3 2.16 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.96 -179.736 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -76.48 114.83 4.24 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.328 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -110.74 26.17 10.99 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.694 0.283 . . . . 0.0 111.085 -179.866 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -99.05 179.56 31.2 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.354 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -51.27 118.28 3.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.782 0.325 . . . . 0.0 111.178 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 59.72 54.62 4.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.936 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 57.22 48.76 77.62 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.361 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.763 ' HG2' HG22 ' A' ' 130' ' ' ILE . 0.0 OUTLIER -87.93 120.04 28.88 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.808 0.337 . . . . 0.0 111.024 -179.808 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.462 ' O ' HG21 ' A' ' 135' ' ' VAL . 22.2 t -84.0 122.84 38.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.79 179.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.619 ' HA ' HG21 ' A' ' 135' ' ' VAL . 0.8 OUTLIER -117.6 174.69 6.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.094 0.474 . . . . 0.0 111.291 -179.621 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . 0.456 ' HG3' ' CE2' ' A' ' 138' ' ' TYR . 2.1 tptt -50.16 -45.8 53.6 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.784 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -60.11 -34.86 74.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.681 179.663 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -67.17 -36.69 82.33 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.332 179.57 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' ILE . . . . . 0.719 HG21 ' CD1' ' A' ' 138' ' ' TYR . 5.2 mm -64.01 -50.3 77.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.093 179.179 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -58.62 -39.65 81.08 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.484 179.675 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -62.54 -41.34 98.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.771 179.664 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' PHE . . . . . 0.541 ' CE1' HG13 ' A' ' 144' ' ' VAL . 40.9 t80 -60.61 -51.81 67.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.568 179.659 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . 0.766 HD21 ' CG2' ' A' ' 144' ' ' VAL . 23.7 mt -71.15 -72.53 0.21 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.833 179.847 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -66.68 168.62 9.11 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.03 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -173.79 57.69 0.14 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.498 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -78.2 -60.74 2.63 Favored Glycine 0 C--O 1.25 1.109 0 CA-C-O 118.432 -1.204 . . . . 0.0 112.518 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.762 0 CA-C-N 118.419 1.109 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 8.5 m-80 . . . . . 0 N--CA 1.486 1.358 0 CA-C-O 120.788 0.327 . . . . 0.0 111.214 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.39 55.52 1.27 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.854 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.06 175.8 0.11 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.835 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.606 HG22 ' HG2' ' A' ' 147' ' ' ARG . 35.1 t -121.23 115.35 46.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.13 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.539 HG22 ' O ' ' A' ' 130' ' ' ILE . 4.4 mt -93.79 50.03 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.726 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -97.48 178.24 5.26 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.304 -179.799 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . 0.528 ' HB2' HG23 ' A' ' 135' ' ' VAL . 0.7 OUTLIER -114.42 158.88 38.77 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.843 -179.991 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.08 -54.82 4.79 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.682 2.255 . . . . 0.0 112.159 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.1 m -60.33 -40.97 92.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.624 179.736 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.769 ' CG1' HD11 ' A' ' 163' ' ' ILE . 81.6 t -60.53 -34.24 57.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.716 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.525 ' HD3' HD11 ' A' ' 146' ' ' ILE . 0.2 OUTLIER -64.04 -53.16 54.28 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.201 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -56.84 -30.71 64.05 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 178.536 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.678 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -62.26 -61.32 2.54 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.581 179.313 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.835 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -62.45 -27.1 68.88 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.49 -179.466 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 31.0 mmm180 -83.18 -24.06 32.63 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.708 0.289 . . . . 0.0 111.084 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -88.71 -22.84 23.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.25 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . 0.46 ' HD2' HD13 ' A' ' 167' ' ' LEU . 4.3 mmtt -102.65 -25.38 13.58 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.288 -179.716 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 105.75 9.99 31.64 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.64 -179.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.835 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 25.1 t -94.98 162.05 2.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.632 0.253 . . . . 0.0 110.656 179.628 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.815 ' HB3' HD11 ' A' ' 148' ' ' LEU . 55.5 t0 -117.53 109.09 16.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.946 0.403 . . . . 0.0 110.845 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.525 HD11 ' HD3' ' A' ' 136' ' ' ARG . 5.1 pt -46.45 -37.3 3.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.125 0.488 . . . . 0.0 111.807 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . 0.606 ' HG2' HG22 ' A' ' 129' ' ' VAL . 0.1 OUTLIER -47.58 -25.35 1.11 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.53 -0.759 . . . . 0.0 112.616 -179.196 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.859 ' N ' HD13 ' A' ' 148' ' ' LEU . 0.0 OUTLIER -127.12 30.24 5.46 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 111.736 0.273 . . . . 0.0 111.736 -179.22 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.486 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 58.3 t -93.92 158.57 2.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.804 0.335 . . . . 0.0 110.609 179.514 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.452 ' N ' HG12 ' A' ' 149' ' ' VAL . 0.7 OUTLIER -74.8 77.13 2.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.975 -179.659 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -71.59 90.64 0.47 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.393 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . 0.779 HG22 ' OD1' ' A' ' 162' ' ' ASP . 11.2 t -99.14 26.9 5.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.823 0.344 . . . . 0.0 111.058 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -92.45 170.9 33.03 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.429 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -49.95 122.58 6.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.864 0.364 . . . . 0.0 111.081 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 62.0 t30 64.87 40.44 5.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.837 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 59.78 56.76 23.02 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.484 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 17.3 ttm180 -106.05 135.5 47.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.754 0.312 . . . . 0.0 110.999 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 21.8 t -89.27 126.64 42.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.939 179.783 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.503 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.0 OUTLIER -124.04 174.02 7.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.121 -179.773 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . 0.443 ' HG3' ' CD2' ' A' ' 138' ' ' TYR . 64.5 tttt -48.54 -50.19 33.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.901 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -56.27 -35.37 67.39 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.824 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . 0.779 ' OD1' HG22 ' A' ' 152' ' ' THR . 89.7 m-20 -67.24 -38.22 84.85 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.434 179.769 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' ILE . . . . . 0.769 HD11 ' CG1' ' A' ' 135' ' ' VAL . 4.2 mm -61.98 -47.28 93.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.064 0.459 . . . . 0.0 109.929 179.114 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -60.23 -40.92 91.89 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.475 179.413 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -62.08 -40.89 97.38 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.798 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' PHE . . . . . 0.568 ' CE1' HG13 ' A' ' 144' ' ' VAL . 44.5 t80 -60.49 -50.6 72.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.429 179.62 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . 0.798 HD21 ' CG2' ' A' ' 144' ' ' VAL . 14.8 mt -71.92 -29.72 64.6 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.855 179.856 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -91.0 96.51 10.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.111 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 149.73 44.73 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.489 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -113.93 146.5 18.61 Favored Glycine 0 C--O 1.249 1.09 0 CA-C-O 118.349 -1.251 . . . . 0.0 112.485 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.248 -3.805 0 CA-C-N 118.377 1.089 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.488 1.427 0 CA-C-O 120.775 0.321 . . . . 0.0 111.147 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.35 126.28 36.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.901 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 6.4 mtt180 -176.38 166.42 2.78 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.796 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.778 HG22 ' HG2' ' A' ' 147' ' ' ARG . 21.4 t -101.67 146.21 10.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.134 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.918 HG22 ' HG2' ' A' ' 157' ' ' ARG . 24.0 mt -84.24 62.87 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.035 179.823 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.419 ' HB2' ' HB ' ' A' ' 158' ' ' VAL . . . -133.3 -174.71 3.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.112 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.3 mmm -106.72 161.55 22.52 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.884 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -56.15 -23.6 45.65 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.582 2.188 . . . . 0.0 112.126 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 45.9 p -81.05 -46.18 15.39 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.79 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.713 ' CG1' HD11 ' A' ' 163' ' ' ILE . 86.2 t -58.68 -33.25 48.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.986 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.532 ' HD3' HD11 ' A' ' 146' ' ' ILE . 4.8 mmm180 -64.35 -51.21 64.5 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.263 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -53.96 -38.8 65.36 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 178.467 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.708 ' CD1' HG21 ' A' ' 163' ' ' ILE . 0.8 OUTLIER -55.02 -62.6 1.55 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.93 179.183 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.895 ' HB1' ' O ' ' A' ' 144' ' ' VAL . . . -61.09 -23.28 65.37 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.782 -179.33 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 38.2 mtt-85 -84.08 -28.11 27.78 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.765 0.317 . . . . 0.0 111.123 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -84.05 -27.09 28.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.172 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.27 -27.88 13.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.158 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 102.28 16.01 24.06 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.578 -179.831 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.895 ' O ' ' HB1' ' A' ' 139' ' ' ALA . 46.4 t -95.91 160.67 2.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.772 0.32 . . . . 0.0 110.756 179.766 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.524 ' N ' HG12 ' A' ' 144' ' ' VAL . 67.2 t0 -113.9 108.99 17.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.888 179.665 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.532 HD11 ' HD3' ' A' ' 136' ' ' ARG . 7.1 pt -50.5 -39.83 18.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.433 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . 0.778 ' HG2' HG22 ' A' ' 129' ' ' VAL . 0.5 OUTLIER -48.9 -24.84 1.62 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.773 -179.89 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.558 HD12 ' CE2' ' A' ' 166' ' ' PHE . 0.4 OUTLIER -120.36 28.09 8.22 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.652 0.263 . . . . 0.0 111.612 -179.715 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.456 ' CG2' ' HA ' ' A' ' 146' ' ' ILE . 55.2 t -99.31 153.6 4.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.928 0.394 . . . . 0.0 110.771 179.456 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -74.96 79.16 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.161 -179.629 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -73.64 120.0 6.75 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.399 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -104.55 -21.26 13.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.643 0.259 . . . . 0.0 111.227 -179.848 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -50.13 176.21 0.04 OUTLIER Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.729 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 16.5 tptt -53.72 125.01 16.81 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.806 0.336 . . . . 0.0 111.13 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 60.46 47.45 8.68 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.859 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 58.8 55.14 32.52 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.418 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.918 ' HG2' HG22 ' A' ' 130' ' ' ILE . 0.0 OUTLIER -90.87 120.97 32.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.864 0.364 . . . . 0.0 110.922 -179.86 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.487 ' O ' HG21 ' A' ' 135' ' ' VAL . 25.9 t -79.99 111.93 17.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.847 179.791 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.649 ' HA ' HG21 ' A' ' 135' ' ' VAL . 1.4 mt -111.87 175.98 5.21 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.107 0.479 . . . . 0.0 111.167 -179.744 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 49.5 tttt -49.43 -48.19 47.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.806 179.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -59.03 -34.48 71.96 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.714 179.778 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -67.35 -36.06 80.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.452 179.721 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' ILE . . . . . 0.713 HD11 ' CG1' ' A' ' 135' ' ' VAL . 4.2 mm -65.2 -50.22 74.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.169 179.226 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -58.52 -39.61 80.61 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.601 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -63.78 -40.57 97.0 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.628 179.737 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' PHE . . . . . 0.576 ' CE1' HG13 ' A' ' 144' ' ' VAL . 26.9 t80 -60.32 -48.98 79.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.425 179.678 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' LEU . . . . . 0.81 HD21 ' CG2' ' A' ' 144' ' ' VAL . 6.1 mt -72.63 -31.17 64.93 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.911 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -75.71 149.37 38.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.158 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 109.08 29.83 3.88 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.499 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 150.82 109.83 0.47 Allowed Glycine 0 C--O 1.249 1.07 0 CA-C-O 118.385 -1.231 . . . . 0.0 112.526 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.249 -3.782 0 CA-C-N 118.371 1.086 . . . . 0.0 . . . . . . . . . . 0 0 . 1 stop_ save_